2011 ASH Program Book - American Society of Hypertension
2011 ASH Program Book - American Society of Hypertension
2011 ASH Program Book - American Society of Hypertension
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc.<br />
<strong>2011</strong> Annual Scientific Meeting<br />
and Exposition<br />
<strong>Program</strong> <strong>Book</strong><br />
Hilton New York<br />
Saturday, May 21, <strong>2011</strong> – Tuesday, May 24, <strong>2011</strong>
8More than<br />
References: 1. Pepine CJ, Handberg EM, Cooper-DeH<strong>of</strong>f RM, et al; INVEST Investigators. A calcium<br />
antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery<br />
disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA.<br />
2003;290(21):2805-2816. 2. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention<br />
<strong>of</strong> cardiovascular events with an antihypertensive regimen <strong>of</strong> amlodipine adding perindopril as required<br />
versus atenolol adding bendr<strong>of</strong>lumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes<br />
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet.<br />
2005;366(9489):895-906. 3. Black HR, Elliott WJ, Grandits G, et al; CONVINCE Research Group. Principal<br />
results <strong>of</strong> the Controlled Onset Verapamil Investigation <strong>of</strong> Cardiovascular End Points (CONVINCE) trial. JAMA.<br />
2003;289(16):2073-2082. 4. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular<br />
morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a<br />
randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.<br />
Novartis Pharmaceuticals Corporation<br />
East Hanover, New Jersey 07936<br />
©<strong>2011</strong> Novartis
Visit booth<br />
#1100<br />
to find out more<br />
out <strong>of</strong><br />
10<br />
patients may need more than<br />
1 agent to get to BP goal 1-4<br />
Printed in USA 4/11 DIO-1052602
About the <strong>American</strong> <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong>, Inc.<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc., (<strong>ASH</strong>) is the largest<br />
organization <strong>of</strong> hypertension researchers and health care providers<br />
in the United States committed to eliminating hypertension and its<br />
consequences. <strong>ASH</strong> has a domestic and international membership <strong>of</strong><br />
basic science and clinical investigators, physicians, physician assistants,<br />
nurse practitioners and pharmacists, as well as other individuals<br />
with a scientific interest in hypertension.<br />
The <strong>Society</strong> was founded in 1985 in order to provide a forum for the<br />
exchange <strong>of</strong> information among basic scientists, clinical investigators<br />
and others involved in the study or management <strong>of</strong> high blood pressure.<br />
The specific focus <strong>of</strong> the <strong>Society</strong> is to translate current research<br />
findings in hypertension into effective treatment strategies, in order<br />
to better address the needs <strong>of</strong> hypertensive patients. The primary mission<br />
<strong>of</strong> the <strong>Society</strong> is to improve the care <strong>of</strong> patients with hypertension<br />
and associated disorders by:<br />
• Enhancing the education and treatment <strong>of</strong> patients with hypertension<br />
• Educating health care pr<strong>of</strong>essionals regarding hypertension and<br />
current prevention and treatment strategies<br />
• Assisting health care pr<strong>of</strong>essionals in addressing the challenges <strong>of</strong><br />
the modern-day care <strong>of</strong> patients with hypertension<br />
• Advocating public policy that ensures patient access to high<br />
quality hypertension care and supports increased hypertension<br />
research<br />
• Facilitating communication and collaboration among providers,<br />
investigators, policymakers, and patients in areas relating to hypertension<br />
and vascular health<br />
• Promoting the career development <strong>of</strong> researchers in hypertension<br />
and associated disorders, including research in the pathobiology,<br />
prevention, diagnosis, treatment, and psychosocial aspects <strong>of</strong><br />
hypertension<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. is an accredited provider<br />
<strong>of</strong> Continuing Medical Education (CME) by the Accreditation Council<br />
for Continuing Medical Education (ACCME) to sponsor continuing<br />
medical education for physicians.<br />
For more information contact the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>,<br />
Inc. at:<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc.<br />
148 Madison Avenue<br />
Fifth Floor<br />
New York, NY 10016<br />
Telephone: 212-696-9099<br />
Fax: 212-696-0711<br />
E-mail: ash@ash-us.org<br />
Website: www.ash-us.org
Past Presidents <strong>of</strong> the <strong>American</strong><br />
<strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc.<br />
John H. Laragh, MD<br />
First President<br />
Edward G. Biglieri, MD President 1988 – 1990<br />
Jay N. Cohn, MD President 1990 – 1992<br />
Louis Tobian, MD President 1992 – 1994<br />
Barry M. Brenner, MD President 1994 – 1995<br />
Lawrence R. Krak<strong>of</strong>f, MD President 1995 – 1996<br />
Michael H. Alderman, MD President 1996 – 1998<br />
Michael A. Weber, MD President 1998 – 2000<br />
Theodore W. Kurtz, MD President 2000 – 2002<br />
Haralambos Gavras, MD President 2002 – 2004<br />
Thomas D. Giles, MD President 2004 – 2006<br />
Jean E. Sealey, DSC President May 19, 2006<br />
Suzanne Oparil, MD President 2006 – 2008<br />
Henry R. Black, MD President 2008 – 2010
Table <strong>of</strong> Contents<br />
General Information.................................................................... 9<br />
Continuing Education................................................................ 9<br />
Hilton New York Floor Layout................................................ 10<br />
Corporate Members.................................................................... 16<br />
Meeting Sponsors........................................................................ 17<br />
<strong>ASH</strong> Leadership.............................................................................. 18<br />
<strong>2011</strong> <strong>Program</strong> Committee....................................................... 19<br />
Robert Tigerstedt Award Lecture........................................ 20<br />
Young Scholar Award Lectures............................................ 22<br />
Marvin Moser Clinical <strong>Hypertension</strong><br />
Award Lecture................................................................................. 24<br />
<strong>2011</strong> Abstract Reviewers.......................................................... 26<br />
Poster Category Presentation by Day .............................. 30<br />
<strong>ASH</strong> Faculty....................................................................................... 32<br />
<strong>Program</strong> at a Glance.................................................................... 35<br />
<strong>Hypertension</strong> Highlights <strong>2011</strong>, May 21........................... 40<br />
<strong>ASH</strong> <strong>Program</strong>, May 21................................................................. 41<br />
Primary Care Clinician <strong>Program</strong>, May 22......................... 49<br />
<strong>ASH</strong> <strong>Program</strong>, May 22................................................................. 51<br />
<strong>ASH</strong> <strong>Program</strong>, May 23................................................................. 64<br />
<strong>ASH</strong> <strong>Program</strong>, May 24................................................................. 78<br />
<strong>ASH</strong> <strong>Program</strong> Posters, May 21............................................... 86<br />
<strong>ASH</strong> <strong>Program</strong> Posters, May 22............................................... 104<br />
<strong>ASH</strong> <strong>Program</strong> Posters, May 23............................................... 125<br />
<strong>ASH</strong> <strong>Program</strong> Late-Breaking Posters, May 23.............. 144<br />
Faculty Disclosure Listing......................................................... 145<br />
<strong>ASH</strong> Exhibitor Floor Plan........................................................... 154<br />
<strong>ASH</strong> Innovations Theater.......................................................... 157<br />
<strong>ASH</strong> Exhibitors ................................................................................ 158<br />
Author Index.................................................................................... 168<br />
Hilton New York Floor Plans................................................... 181<br />
5
<strong>Program</strong> Color Key<br />
The pages <strong>of</strong> this <strong>Program</strong> <strong>Book</strong> are color-coded to match the<br />
<strong>Program</strong> at a Glance (pages 35–36) and serve as a quick, identifiable<br />
reference <strong>of</strong> the type <strong>of</strong> educational activity or event taking place.<br />
Scientific Sessions*<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
<strong>Hypertension</strong> Highlights <strong>2011</strong><br />
Special Event<br />
Meet the Pr<strong>of</strong>essor Sessions<br />
<strong>Hypertension</strong> for the Primary Care Clinician<br />
Debates<br />
Poster Sessions<br />
Satellite Symposia<br />
<strong>Hypertension</strong> Resource Pavilion<br />
The <strong>ASH</strong> Twenth-Sixth Annual Scientific Meeting is<br />
organized around three (3) concurrent themes:<br />
• Pathobiology <strong>of</strong> <strong>Hypertension</strong><br />
• Translational Issues in <strong>Hypertension</strong><br />
• Therapy <strong>of</strong> <strong>Hypertension</strong><br />
Sessions in each <strong>of</strong> the three (3) themes (or tracks) are labeled<br />
throughout the <strong>Program</strong> <strong>Book</strong> to be easily identifiable.<br />
Future Meeting Dates<br />
Saturday, May 19, 2012 to Tuesday, May 22, 2012<br />
Hilton New York, New York, NY<br />
Wednesday, May 15, 2013 to Saturday, May 18, 2013<br />
San Francisco Marriott, San Francisco, CA
Letter from the President<br />
and <strong>Program</strong> Committee Chair<br />
Dear Colleague,<br />
On behalf <strong>of</strong> the Board <strong>of</strong> Directors <strong>of</strong> the<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc.<br />
(<strong>ASH</strong>), we are pleased to welcome you to<br />
the Twenty-Sixth Annual Scientific Meeting<br />
and Exposition <strong>of</strong> <strong>ASH</strong>. The theme <strong>of</strong><br />
this year’s Scientific Meeting is Adolescent<br />
Obesity and Cardiovascular Risk Reduction:<br />
The Expanding Epidemic.<br />
The <strong>2011</strong> Annual Scientific meeting topics<br />
are organized around three (3) concurrent<br />
George L. Bakris, MD, F<strong>ASH</strong><br />
themes:<br />
— Pathobiology <strong>of</strong> <strong>Hypertension</strong><br />
— Translational Issues in <strong>Hypertension</strong><br />
— Therapy <strong>of</strong> <strong>Hypertension</strong><br />
The Scientific Sessions feature several innovative<br />
components designed to enhance the<br />
translation <strong>of</strong> basic and applied research<br />
into effective hypertension prevention and<br />
treatment strategies.<br />
• <strong>Hypertension</strong> Highlights <strong>2011</strong> –<br />
Saturday, May 21, <strong>2011</strong><br />
<strong>Hypertension</strong> Highlights is a full-day William B. White, MD, F<strong>ASH</strong><br />
program dedicated to educating clinicians<br />
and scientists about some <strong>of</strong> the most interesting, controversial<br />
and evolving topics in the field. It is an ideal update for<br />
<strong>Hypertension</strong> Specialists and those wishing to become specialists<br />
in the field.<br />
• Plenary Session I – Sunday, May 22, <strong>2011</strong><br />
The Keynote speaker for the opening session will be F. Xavier<br />
Pi-Sunyer, MD, MPH, Pr<strong>of</strong>essor <strong>of</strong> Medicine, Chief <strong>of</strong> Endocrinology,<br />
Diabetes, and Nutrition, Director <strong>of</strong> the New York Obesity<br />
Research Center, St. Luke’s/Roosevelt Hospital Center, New York,<br />
New York. Dr. Pi-Sunyer will speak on “Blood Pressure in Obesity.”<br />
Following Dr. Pi-Sunyer’s lecture will be Dr. Rae-Ellen Kavey<br />
presenting a lecture on “Cardiovascular Risk and Risk Reduction<br />
in Children and Adolescents,” Dr. Sadaf Farooqi, PhD, presenting a<br />
lecture on “Mechanisms from Studies <strong>of</strong> Human Obesity” and Dr.<br />
Joseph Flynn addressing the topic <strong>of</strong> “Evaluation and Treatment <strong>of</strong><br />
<strong>Hypertension</strong> in Childhood.”<br />
• Plenary Session II – Monday, May 23, <strong>2011</strong><br />
This session will include the Awards Session as well as state-<strong>of</strong>-theart<br />
topics. Dr. Oscar Carretero will present the Robert Tigerstedt<br />
Award Lecture on “Acetyl-Ser-Asp-Lys-Pro, an Endogenous Tetrapeptide:<br />
Role in Target Organ Damage in <strong>Hypertension</strong>, and Autoimmune<br />
Myocarditis.” Young Scholar Awards will be presented to<br />
Drs. Michael Ryan and Alessandro Cataliotti. Dr. Murray Epstein<br />
will receive the Marvin Moser Clinical <strong>Hypertension</strong> Award.<br />
7
Letter continued<br />
Following the Awards Session, Dr. Abraham Aviv will present a<br />
lecture on the “Leukocyte Telomere Length Genetics and Cardiovascular<br />
Disease” and Dr. Joseph Hill will discuss “Development <strong>of</strong><br />
Cardiac Hypertrophy.”<br />
• Young Investigator-in-Training Abstract Competition<br />
Saturday, May 21, <strong>2011</strong><br />
Trainees submitting the highest ranking abstracts to the meeting<br />
will present their work orally in a special session and compete for<br />
cash prizes. This highlighted session is consistent with <strong>ASH</strong>’s goal<br />
to foster and facilitate the training <strong>of</strong> young and new investigators<br />
in hypertension.<br />
• <strong>Hypertension</strong> for the Primary Care Clinician –<br />
Sunday, May 22, <strong>2011</strong><br />
This program will address commonplace questions that face clinicians<br />
in day-to-day care <strong>of</strong> hypertension including peri-operative<br />
hypertension management, clinical partners in ambulatory care<br />
management <strong>of</strong> hypertension and the resistant hypertensive<br />
patient.<br />
• Debates – Saturday, May 21 – Sunday, May 22, <strong>2011</strong><br />
This year there are five debates on controversial topics <strong>of</strong> relevance<br />
to <strong>Hypertension</strong> Specialists.<br />
• Joint <strong>Society</strong> Symposia<br />
Interactions with other societies, both national and international,<br />
focused on the topic <strong>of</strong> hypertension and cardiovascular and<br />
kidney disease risk as it relates to obesity will be covered. This year<br />
we have a record number <strong>of</strong> joint society sessions that include:<br />
AHA Council for High Blood Pressure Research (HBPR), the<br />
Association for Research into Arterial Structure and Physiology<br />
(ARTERY), the China Social Worker’s Association Vascular Protection<br />
Committee, the European <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> (ESH),<br />
<strong>Hypertension</strong> Canada, the International Pediatric <strong>Hypertension</strong><br />
Association (IPHA), the International <strong>Society</strong> on <strong>Hypertension</strong><br />
in Blacks (ISHIB), the Inter-<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong><br />
(I<strong>ASH</strong>), the National Lipid Association/<strong>American</strong> <strong>Society</strong><br />
for Preventive Cardiology (NLA/ASPC), the National Kidney<br />
Foundation (NKF) and the Preventive Cardiovascular Nurses<br />
Association (PCNA).<br />
The <strong>Society</strong> will also sponsor a small number <strong>of</strong> industry-supported<br />
Satellite Symposia which will introduce novel approaches to antihypertensive<br />
therapy. The Pavilion will host many informative scientific,<br />
technical, periodical and book exhibits designed to support you in<br />
your mission <strong>of</strong> providing the latest in care for your hypertensive<br />
patients.<br />
We look forward to seeing you in New York.<br />
Sincerely,<br />
George L. Bakris, MD, F<strong>ASH</strong><br />
President, 2010 – 2012<br />
William B. White, MD, F<strong>ASH</strong><br />
Chair, <strong>2011</strong> Scientific <strong>Program</strong><br />
Committee<br />
8
General Information<br />
This program book has been underwritten by Novartis<br />
Pharmaceuticals Corporation.<br />
Education<br />
<strong>Program</strong> Objectives<br />
In keeping with the purpose <strong>of</strong> the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>,<br />
Inc. (<strong>ASH</strong>), the Twenty-Sixth Annual Scientific Meeting is designed to<br />
encourage and promote the development, advancement, and exchange<br />
<strong>of</strong> fair and balanced and evidence-based information regarding the<br />
research, diagnosis and treatment <strong>of</strong> hypertension and related cardiovascular<br />
diseases, with the goal <strong>of</strong> improved patient care and health.<br />
The sessions will:<br />
• Present and examine new findings on the physiology, pathophysiology,<br />
epidemiology, diagnosis, and management <strong>of</strong> hypertension<br />
and related conditions.<br />
• Review current state-<strong>of</strong>-the-art advances in managing particular<br />
groups <strong>of</strong> patients.<br />
• Evaluate specific treatment modalities and pharmacological<br />
agents.<br />
Target Audience<br />
Physicians, scientists, pharmacists, physician assistants, nurses and<br />
other health care pr<strong>of</strong>essionals with an interest in the mechanisms or<br />
management <strong>of</strong> hypertension and related diseases will benefit from<br />
attending Scientific Sessions, Satellite Symposia, Embedded Symposia,<br />
Meet the Pr<strong>of</strong>essor Sessions, Case Discussions, Poster Sessions and<br />
the Scientific Exposition.<br />
Continuing Education Credit<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. is accredited by the<br />
Accreditation Council for Continuing Medical Education to provide<br />
continuing medical education for physicians. The <strong>American</strong> <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong>, Inc. designates this educational activity for a maximum<br />
<strong>of</strong> 30 AMA PRA Category 1 Credits. Each physician should claim<br />
credit commensurate with the extent <strong>of</strong> their participation in the<br />
activity.<br />
Conflict <strong>of</strong> Interest Disclosure<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. strives to ensure balance,<br />
independence, objectivity, and scientific rigor in all <strong>of</strong> its educational<br />
programs. All faculty members participating in this program have<br />
been required to disclose any real or apparent conflict(s) <strong>of</strong> interest<br />
that may have a direct bearing on the subject matter <strong>of</strong> the session in<br />
which they are participating. This includes relationships in place at<br />
the time <strong>of</strong> the meeting or in the twelve (12) months preceding the<br />
meeting, with pharmaceutical companies, biomedical device manufacturers,<br />
or other corporations whose products or services are related<br />
to the subject matter <strong>of</strong> the presentation topic.<br />
The intent <strong>of</strong> the policy is to identify openly any conflict <strong>of</strong> interest so<br />
that the listeners may form their own judgments about the presentations<br />
with the full disclosure <strong>of</strong> the facts. All Conflict <strong>of</strong> Interest Disclosure<br />
Statements are available to meeting attendees in the program<br />
book on pages 145–153 and at the <strong>ASH</strong> Information/Membership<br />
Booth located at the entrance <strong>of</strong> the <strong>Hypertension</strong> Resource Pavilion<br />
on the third Floor.<br />
9
General Information continued<br />
Disclosures not available at the time the program book was printed<br />
are included as a separate listing in the registrant bags.<br />
Dagger (†) denotes that the abstract presenting author has related<br />
disclosure information. Please reference the full Disclosure Index at<br />
the <strong>ASH</strong> Information /Membership Booth, located at the entrance<br />
<strong>of</strong> the <strong>Hypertension</strong> Resource Pavilion on the third Floor and in the<br />
Author Index <strong>of</strong> The Journal <strong>of</strong> Clinical <strong>Hypertension</strong> <strong>2011</strong> Abstract<br />
Supplement.<br />
Hilton New York Floor Layout<br />
For detailed floor plans <strong>of</strong> Exhibition and Poster Areas, see pages 154 & 155.<br />
For detailed floor plans <strong>of</strong> Hilton New York, see pages 181 – 183.<br />
10
General Information continued<br />
Meeting Venue/Headquarters Hotel<br />
Hilton NY<br />
1335 Avenue <strong>of</strong> the Americas<br />
New York, NY 10019<br />
Phone: 1-212-586-7000<br />
Fax: 1-212-315-1374<br />
Meeting Registration<br />
Registration for the Meeting will be held on the<br />
Third Floor Promenade.<br />
Registration Desk Hours<br />
Groups<br />
Friday, May 20<br />
Individuals<br />
Friday, May 20<br />
Saturday, May 21<br />
Sunday, May 22<br />
Monday, May 23<br />
Tuesday, May 24<br />
4:00 PM to 6:00 PM<br />
6:00 PM to 9:00 PM<br />
7:00 AM to 7:00 PM<br />
7:00 AM to 6:00 PM<br />
5:30 AM to 5:00 PM<br />
7:00 AM to 9:30 AM<br />
<strong>ASH</strong> Information/Membership Booth<br />
The <strong>ASH</strong> Information/Membership booth will be located at the<br />
entrance <strong>of</strong> the <strong>Hypertension</strong> Resource Pavilion on the Third Floor.<br />
Information/Membership Booth Hours<br />
Friday, May 20<br />
Saturday, May 21<br />
Sunday, May 22<br />
Monday, May 23<br />
Tuesday, May 24<br />
4:00 PM to 9:00 PM<br />
8:30 AM to 5:00 PM<br />
8:30 AM to 5:00 PM<br />
8:30 AM to 5:00 PM<br />
8:30 AM to 12:00 PM<br />
<strong>Program</strong> Information<br />
<strong>Hypertension</strong> Highlights <strong>2011</strong><br />
<strong>Hypertension</strong> Highlights is a full-day program dedicated to educating<br />
clinicians and scientists about some <strong>of</strong> the most interesting,<br />
controversial and evolving topics in the field. It is an ideal update for<br />
<strong>Hypertension</strong> Specialists and those wishing to become specialists in<br />
the field.<br />
Saturday, May 21, <strong>2011</strong><br />
8:30 AM to 3:00 PM<br />
<strong>ASH</strong> Plenary Sessions<br />
Plenary Sessions feature engaging lectures by keynote speakers. The<br />
topics are <strong>of</strong> broad general interest.<br />
Sunday, May 22, <strong>2011</strong><br />
1:15 PM to 3:00 PM<br />
Monday, May 23, <strong>2011</strong><br />
1:30 PM to 4:00 PM<br />
11
General Information continued<br />
<strong>ASH</strong> Scientific Sessions<br />
The Scientific Sessions will address basic and clinical science issues<br />
over a wide range <strong>of</strong> topics.<br />
Saturday, May 21, <strong>2011</strong><br />
4:30 PM to 6:00 PM<br />
Sunday, May 22, <strong>2011</strong><br />
3:30 PM to 5:15 PM<br />
Monday, May 23, <strong>2011</strong><br />
8:00 AM to 10:00 AM<br />
10:30 AM to 12:00 PM<br />
Tuesday, May 24, <strong>2011</strong><br />
8:15 AM to 9:30 AM<br />
10:00 AM to 11:30 AM<br />
<strong>Hypertension</strong> for the Primary Care Clinician<br />
The <strong>Hypertension</strong> for the Primary Care Clinician program will address<br />
commonplace questions that face clinicians in day-to-day care<br />
<strong>of</strong> hypertension.<br />
Sunday, May 22, <strong>2011</strong><br />
8:00 AM to 12:30 PM<br />
Joint Sessions<br />
Special Sessions jointly sponsored by <strong>Society</strong>-related organizations<br />
will enrich the knowledge base and foster new interactions between<br />
attendees.<br />
Saturday, May 21, <strong>2011</strong><br />
4:30 PM to 6:00 PM<br />
Sunday, May 22, <strong>2011</strong><br />
9:00 AM to 10:30 AM<br />
3:30 PM to 5:15 PM<br />
Monday, May 23, <strong>2011</strong><br />
8:30 AM to 10:00 AM<br />
10:30 AM to 12:00 PM<br />
Meet the Pr<strong>of</strong>essor Sessions<br />
Distinguished faculty will provide valuable instructions on (1) writing<br />
a grant; (2) developing an abstract and lecture and (3) understanding<br />
statistics in clinical research.<br />
Attendees will be admitted on a first-come, first-served basis.<br />
Sunday, May 22, <strong>2011</strong><br />
11:00 AM to 12:00 PM<br />
Clinical Debates<br />
Clinical Debates will provide for lively discussion on controversial<br />
topics.<br />
Sunday, May 22, <strong>2011</strong><br />
Monday, May 23, <strong>2011</strong><br />
11:00 AM to 12:00 PM<br />
11:45 AM to 12:15 PM<br />
4:30 PM to 5:00 PM<br />
Abstract Presentations<br />
Authors will showcase their research in oral or poster format.<br />
Saturday, May 21, <strong>2011</strong><br />
6:00 PM to 7:00 PM<br />
Sunday, May 22, <strong>2011</strong><br />
5:30 PM to 6:30 PM<br />
Monday, May 23, <strong>2011</strong><br />
4:30 PM to 5:30 PM<br />
12
General Information continued<br />
Satellite Symposia<br />
The latest information regarding new concepts, treatments, devices<br />
and techniques will be addressed in Satellite Symposia supported by<br />
educational grants.<br />
Monday, May 23, <strong>2011</strong><br />
6:00 AM to 7:30 AM<br />
<strong>ASH</strong> <strong>Hypertension</strong> Resource Pavilion - Technical Exhibits<br />
Technical Exhibits will be located in the <strong>Hypertension</strong> Resource<br />
Pavilion at the Hilton NY. <strong>ASH</strong> will host a welcome reception,<br />
lunches, and high teas in the exhibit hall.<br />
Saturday, May 21, <strong>2011</strong><br />
4:30 PM to 7:30 PM<br />
Opening Reception<br />
6:00 PM to 7:30 PM<br />
Sunday, May 22, <strong>2011</strong><br />
High Tea<br />
10:00 AM to 1:00 PM<br />
and 3:30 PM to 6:30 PM<br />
5:30 PM to 6:30 PM<br />
Monday, May 23, <strong>2011</strong><br />
High Tea<br />
10:00 AM to 1:30 PM<br />
and 4:00 PM to 5:30 PM<br />
4:30 PM to 5:30 PM<br />
Innovations Theater – Rhinelander Gallery<br />
Saturday, May 21, <strong>2011</strong><br />
6:30 PM to 7:30 PM<br />
Sunday, May 22, <strong>2011</strong><br />
12:00 PM to 1:00 PM<br />
5:30 PM to 6:30 PM<br />
<strong>2011</strong> <strong>ASH</strong> <strong>Hypertension</strong> Community Outreach<br />
<strong>ASH</strong> is proud to present its 4th Annual <strong>Hypertension</strong> Community<br />
Outreach Initiative in conjunction with the Twenty-Sixth Annual<br />
Scientific Meeting & Exposition. In 2008, <strong>ASH</strong> began the<br />
<strong>Hypertension</strong> Community Outreach Initiative in New Orleans with<br />
great success. We continued the Outreach Initiative in San Francisco<br />
in 2009 and in New York once again, in 2010.<br />
In <strong>2011</strong>, the Outreach Initiative will provide hypertension screening<br />
and education targeting local New York underinsured and uninsured<br />
population segments. <strong>ASH</strong> will educate the residents <strong>of</strong> the New York<br />
City, Long Island and New Jersey about hypertension and provide<br />
them with products and tools to take home.<br />
Visit the <strong>ASH</strong> <strong>Hypertension</strong> Community Outreach Booth #1600 in<br />
the Pavilion, learn more about the Outreach program and check your<br />
blood pressure.<br />
Multimedia CD-ROM <strong>of</strong> Scientific Meeting<br />
Audio recordings on CD-ROM including select speaker presentations<br />
in PDF format <strong>of</strong> the Scientific Sessions and Satellite Symposium will<br />
be for sale through AVMG in the Second Flood Promenade. You may<br />
also download the individual sessions in MP3 format to your computer<br />
post-conference. Visit our e-commerce store at www.ash-us.org.<br />
13
General Information continued<br />
<strong>ASH</strong> Policy Regarding Videotaping, Photography and<br />
Audio Taping<br />
No individual is permitted to film, videotape, photograph and/or<br />
audiotape meeting symposia, scientific sessions, posters or exhibits<br />
without prior written approval from the <strong>American</strong> <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong>, Inc.<br />
<strong>ASH</strong> Information/Membership Booth<br />
The On-Site <strong>ASH</strong> Information/Membership Booth will be located<br />
at the entrance <strong>of</strong> the <strong>Hypertension</strong> Resource Pavilion on the Third<br />
Floor.<br />
<strong>ASH</strong> Staff Members<br />
Executive Office<br />
Torry Mark Sansone, Executive Director<br />
Mary Trifault, Executive Associate<br />
Scientific Meetings & Pr<strong>of</strong>essional Affairs<br />
Melissa Levine, Associate Executive Director<br />
Ashley Buron, <strong>Program</strong> Coordinator<br />
Meeting and Exhibit Services, <strong>Hypertension</strong> Community Outreach Services<br />
Gilda C. Caputo Hansen, Director<br />
Education Services<br />
Kathleen Sheridan, Director <strong>of</strong> Education<br />
Nicole Rabin, Associate Manager, Continuing Education (CE)<br />
Services<br />
Olivia Carr, <strong>Program</strong> Manager, Educational Services<br />
Membership & Marketing Services<br />
Angel Loayza, Manager<br />
Barbara E. Escobar, Associate Manager<br />
Financial Services<br />
Kevin Lee, Manager<br />
Kereyne A. Bishop, Associate Accounting Manager<br />
Journal <strong>of</strong> the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> (J<strong>ASH</strong>)<br />
Ashley Buron, Managing Editor<br />
14
<strong>ASH</strong> EDUCATION AND RESEARCH<br />
FOUNDATION announces its<br />
<strong>ASH</strong> EDUCATION AND RESEARCH<br />
FOUNDATION announces its<br />
[New Logo]<br />
[New Logo]<br />
Inaugural <strong>ASH</strong> Foundation<br />
5K & 10K Run/Walk<br />
Inaugural <strong>ASH</strong> Foundation<br />
5K & 10K Run/Walk<br />
Registration:<br />
Registration:<br />
Monday, May 23 rd , <strong>2011</strong><br />
NYC Central Park<br />
7:00 AM<br />
Monday, May 23 rd , <strong>2011</strong><br />
NYC Central Park<br />
7:00 AM<br />
Daiichi Sankyo, Inc.<br />
Booth # 1200<br />
<strong>Hypertension</strong> Resource<br />
Pavilion<br />
Daiichi Sankyo, Inc.<br />
Booth # 1200<br />
<strong>Hypertension</strong> Resource<br />
Pavilion<br />
Running Shirt, Water bottle, and Course Maps<br />
will be provided upon registration.<br />
Please consider supporting the Foundation with a<br />
registration donation.<br />
Running Shirt, Water bottle, and Course Maps<br />
will be provided upon registration.<br />
Please consider supporting the Foundation with a<br />
registration donation.<br />
The Foundation thanks Daiichi Sankyo, Inc. for<br />
their generous supporting donation.
<strong>2011</strong> <strong>ASH</strong> Corporate Members<br />
Boehringer Ingelheim Pharmaceuticals, Inc.<br />
Daiichi Sankyo, Inc.<br />
Forest Laboratories, Inc.<br />
Merck & Co., Inc.<br />
Novartis Pharmaceuticals Corporation<br />
Pfizer Inc<br />
Takeda Pharmaceuticals North America, Inc.<br />
16
<strong>ASH</strong> Sponsors<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. wishes<br />
to acknowledge the following Corporate Sponsors<br />
for their generous support <strong>of</strong> the <strong>ASH</strong> Twenty-Sixth<br />
Annual Scientific Meeting.<br />
<strong>2011</strong> Annual Scientific Meeting<br />
Sponsors<br />
Daiichi Sankyo, Inc.<br />
Novartis Pharmaceuticals Corporation<br />
SERVIER<br />
Takeda Pharmaceuticals North America, Inc.<br />
<strong>2011</strong> <strong>Hypertension</strong> Community<br />
Outreach<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. wishes<br />
to acknowledge and thank our Community Partners<br />
for their generous support <strong>of</strong> this program.<br />
<strong>American</strong> Kidney Fund<br />
Association <strong>of</strong> Black Cardiologists, Spirit <strong>of</strong> the Heart<br />
AVMG, Inc.<br />
Boomer Esiason Foundation<br />
Forest Pharmacueticals, Inc.<br />
Foundation <strong>of</strong> National Lipid Association<br />
Hilton NY<br />
HoMedics, Inc.<br />
Institute for Health Equity at Nassau University Medical Center<br />
Metropolitan Exposition, Inc.<br />
MR CHAMMPS at St. Joseph’s Regional Medical Center<br />
Novartis Pharmaceuticals Corporation<br />
Omron Healthcare, Inc.<br />
PepsiCo, Inc.<br />
<strong>Society</strong> for Cardiovascular Angiography and Interventions (SCAI)<br />
17
<strong>ASH</strong> Leadership<br />
2010-<strong>2011</strong> Board <strong>of</strong> Directors<br />
Officers<br />
President: George L. Bakris, MD, F<strong>ASH</strong><br />
President-Elect: William B. White, MD, F<strong>ASH</strong><br />
Vice President: Sandra J. Taler, MD, F<strong>ASH</strong><br />
Secretary: John D. Bisognano, MD, PhD, F<strong>ASH</strong><br />
Treasurer: Franz H. Messerli, MD, F<strong>ASH</strong><br />
Immediate Past President: Henry R. Black, MD, F<strong>ASH</strong><br />
Directors-At-Large<br />
Keith C. Ferdinand, MD, F<strong>ASH</strong><br />
Alan H. Gradman, MD, F<strong>ASH</strong><br />
Daniel T. Lackland, DrPH, F<strong>ASH</strong><br />
Robert A. Phillips, MD, PhD, F<strong>ASH</strong><br />
Addison A. Taylor, MD, PhD, F<strong>ASH</strong><br />
Mattew R. Weir, MD, F<strong>ASH</strong><br />
Ex Officio Non-Voting Members<br />
Thomas D. Giles, MD, F<strong>ASH</strong>, Chair, <strong>ASH</strong> Specialists <strong>Program</strong> Inc.<br />
Michael A. Weber, MD, F<strong>ASH</strong>, Editor-In-Chief,<br />
The Journal <strong>of</strong> Clinical <strong>Hypertension</strong> (JCH)<br />
Myron H. Weinberger, MD, Editor-In-Chief,<br />
Journal <strong>of</strong> the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> (J<strong>ASH</strong>)<br />
Torry Mark Sansone, Executive Director<br />
18
<strong>2011</strong> Scientific <strong>Program</strong><br />
Committee<br />
George L. Bakris, MD, F<strong>ASH</strong>, President<br />
William B. White, MD, F<strong>ASH</strong>, Chair<br />
Pathobiology <strong>of</strong> <strong>Hypertension</strong><br />
David G. Harrison, MD, Co-Chair<br />
Nancy J. Brown, MD<br />
Michael W. Brands, PhD<br />
Joey P. Granger, PhD<br />
Allyn L. Mark, MD<br />
Susanne B. Nicholas, MD, PhD, MPH<br />
J. Howard Pratt, MD<br />
Translational Issues in <strong>Hypertension</strong><br />
Brent M. Egan, MD, F<strong>ASH</strong>, Co-Chair<br />
Donald L. Batisky, MD<br />
John D. Bisognano, MD, PhD, F<strong>ASH</strong><br />
Stephen R. Daniels, MD, PhD, F<strong>ASH</strong><br />
Daniel Duprez, MD, PhD, F<strong>ASH</strong><br />
Keith C. Ferdinand, MD, F<strong>ASH</strong><br />
Joel Handler, MD<br />
Nancy Houston Miller, RN, BSN<br />
Therapy <strong>of</strong> <strong>Hypertension</strong><br />
Robert A. Phillips, MD, PhD, F<strong>ASH</strong>, Co-Chair<br />
Jan N. Basile, MD, F<strong>ASH</strong>*<br />
Michael J. Bloch, MD, F<strong>ASH</strong>*<br />
Lynne T. Braun, PhD, CNP<br />
Barry L. Carter, PharmD<br />
Joseph A. Diamond, MD, F<strong>ASH</strong><br />
F. Wilford Germino, MD, F<strong>ASH</strong>*<br />
David S. Kountz, MD<br />
Louis Kuritzky, MD*<br />
Gbenga Ogedegbe, MD, MPH, MS, F<strong>ASH</strong>*<br />
Aldo J. Peixoto, MD, F<strong>ASH</strong><br />
C. Venkata S. Ram, MD, F<strong>ASH</strong><br />
Scott D. Solomon, MD<br />
*Indicates Primary Care<br />
19
Special Lecture<br />
Monday, May 23, <strong>2011</strong>, 1:30 PM – 4:00 PM • East Ballroom • Third Floor<br />
Robert Tigerstedt Award Lecture<br />
Oscar A. Carretero, MD, F<strong>ASH</strong><br />
Oscar A. Carretero, MD was born in<br />
Mendoza, Argentina and received his<br />
degree from the School <strong>of</strong> Medicine at the<br />
University <strong>of</strong> Cuyo, Mendoza, Argentina.<br />
Dr. Carretero has contributed greatly to<br />
our understanding <strong>of</strong> the role <strong>of</strong> vasoactive<br />
hormones in the regulation <strong>of</strong> blood<br />
pressure and renal function, as well as the<br />
pathogenesis <strong>of</strong> hypertension and target<br />
organ damage (TOD). His research has<br />
resulted in over 360 publications. His<br />
fundamental contributions began with<br />
his initial hypothesis in 1972 that renal<br />
kinins may be involved in the regulation<br />
<strong>of</strong> sodium and water excretion, acting as natriuretic and diuretic hormones.<br />
His work has contributed uniquely to the understanding <strong>of</strong> the<br />
role <strong>of</strong> the renal kallikrein-kinin system, ranging from the development<br />
<strong>of</strong> methods to measure the components <strong>of</strong> the system and its localization<br />
to demonstrating that the renal kallikrein-kinin system is natriuretic and<br />
diuretic not only in high mineralocorticoid situations but also in the basal<br />
state. This work culminated with the demonstration that animals lacking<br />
the main kinin receptor (B2) develop hypertension when they are fed a<br />
high sodium diet. As a pioneer in the field <strong>of</strong> kinin research, where his<br />
contributions have been fundamental, numerous, and <strong>of</strong> high quality,<br />
we now understand that kinins act as paracrine hormones, regulating<br />
organ blood flow and renal function, and also participate on the chronic<br />
cardiovascular protective effect <strong>of</strong> angiotensin-converting enzyme (ACE)<br />
and angiotensin resector blockers. He and his colleagues demonstrated<br />
that kallikrein in the kidney is produced mainly in the connecting tubule<br />
(CNT) and in collaboration with Luciano Barajas they demonstrated that<br />
the CNT returns to the glomerulus and makes contact with the afferent<br />
arteriole. Recently he demonstrated that there is a crosstalk between the<br />
CNT and the afferent arteriole, showing that when sodium is increased<br />
in the perfusate <strong>of</strong> the CNT, the afferent arteriole dilates. They call this<br />
cross talk between the CNT and the afferent arteriole connecting tubuloglomerular<br />
feedback. This seminal contribution explains why during<br />
a sodium load, renal blood flow increases.<br />
Recently he has made another seminal contribution by demonstrating<br />
that the endogenous tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP);<br />
that is destroyed mainly by ACE; has anti-inflammatory and anti-fibrotic<br />
effects, and also contributes to the cardiovascular and renal protective effect<br />
<strong>of</strong> ACE inhibitors. Furthermore, he discovered that the enzyme prolyl<br />
oligopeptidase is involved in the release <strong>of</strong> Ac-SDKP from the protein<br />
thymosin β-4. He has shown that inhibition <strong>of</strong> this enzyme promotes<br />
vascular and renal fibrosis. He and his group have demonstrated that<br />
this peptide inhibits fibrosis by a) decreasing inflammation, b) fibroblast<br />
proliferation and collagen synthesis, c) TGF expression and d) its TGF<br />
signaling (Smad phosphorylation).<br />
20<br />
continued…
Special Lecture continued<br />
In addition, Dr. Carretero has trained numerous investigators in the<br />
field <strong>of</strong> hypertension. Among his distinguished and well-known students<br />
are Alberto Nasjletti, Pr<strong>of</strong>essor <strong>of</strong> Pharmacology at the Medical College<br />
<strong>of</strong> New York; A Guillermo Scicli, Pr<strong>of</strong>essor <strong>of</strong> Medicine Henry Ford<br />
Health Sciences, Wayne State University; and Sadayoshi Ito, Chairman<br />
and Pr<strong>of</strong>essor <strong>of</strong> Medicine, Tohoku University; Luis Juncos, Division<br />
Director, Nephrology, University <strong>of</strong> Mississippi. These are among many<br />
who have become important investigators in the field <strong>of</strong> cardiovascular<br />
or renal physiology and medicine.<br />
Dr. Carretero is an active invited international lecturer, and has received<br />
many awards including a Lifetime Achievement Award from the Inter-<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> and the Novartis award from the<br />
Council <strong>of</strong> High Blood Pressure Research, <strong>American</strong> Heart Association.<br />
He also received a Dr. Honoris Causa from University <strong>of</strong> Cordoba and a<br />
Pr<strong>of</strong>essor Honoris Causa from the University <strong>of</strong> Mendoza. He has been<br />
Chairman, Council for High Blood Pressure Research <strong>of</strong> the AHA, and<br />
President <strong>of</strong> the Inter-<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>. He also serves<br />
in various NIH study sections and committees and serves on the editorial<br />
boards <strong>of</strong> several scientific journals.<br />
21
Young Scholar Award*<br />
Monday, May 23, <strong>2011</strong>, 1:30 PM – 4:00 PM • East Ballroom • Third Floor<br />
Alessandro Cataliotti, MD, PhD<br />
Alessandro Cataliotti, MD, PhD, is an<br />
associate consultant in the Division <strong>of</strong><br />
Cardiovascular Diseases and Internal<br />
Medicine at Mayo Clinic Rochester. He<br />
holds the academic rank <strong>of</strong> associate<br />
pr<strong>of</strong>essor <strong>of</strong> medicine.<br />
Dr. Cataliotti obtained his medical degree<br />
with the highest score cum laude from<br />
the University <strong>of</strong> Catania, Italy where he<br />
also pursued residency and fellowship<br />
in internal medicine, as well as a PhD<br />
program in cardiovascular science. Dr.<br />
Cataliotti began a research fellowship at<br />
Mayo Clinic under the supervision <strong>of</strong> Dr. Burnett in 1998. Throughout<br />
his research career, Dr. Cataliotti has been the recipient <strong>of</strong> numerous<br />
awards, including competitive travel awards from the <strong>American</strong> <strong>Society</strong><br />
<strong>of</strong> <strong>Hypertension</strong> in 2000 and 2003; Heart Failure <strong>Society</strong> <strong>of</strong> America in<br />
1999, 2000, 2001 and 2003; European <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> in 2001;<br />
and International <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> in 2002; and many more in<br />
the following years. Of note, Dr. Cataliotti received a two-year grant<br />
from Bristol-Myers Squibb in 1999 in support for his research here at<br />
Mayo Clinic. Dr. Cataliotti was also a recipient <strong>of</strong> a Beginning Grant in<br />
Aid from the <strong>American</strong> Heart Association in 2003-2004. From 2005 to<br />
2009, he was awarded a Ministry <strong>of</strong> Education, University and Research <strong>of</strong><br />
Italy (MIUR), Rientro dei Cervelli Project. Underscoring Dr. Cataliotti’s<br />
outstanding research achievements and again recognition by his scientific<br />
peers was the awarding <strong>of</strong> one <strong>of</strong> twelve 2006 Doris Duke Clinical Scientist<br />
Development Grants. He has been funded by the National Institutes <strong>of</strong><br />
Health and currently is the principal investigator <strong>of</strong> two RO1s.<br />
Dr. Cataliotti’s research has focused on humoral integration <strong>of</strong> the heart<br />
and kidney in heart failure and hypertension with a special emphasis<br />
upon the natriuretic peptide system. He has published over 70 publications<br />
in leading peer-reviewed journals, including the Circulation,<br />
Lancet, Proceedings <strong>of</strong> The National Academy <strong>of</strong> Science, <strong>American</strong><br />
Journal <strong>of</strong> Physiology, Kidney International, Journal <strong>of</strong> <strong>American</strong> <strong>Society</strong><br />
<strong>of</strong> Nephrology, <strong>American</strong> Journal <strong>of</strong> Kidney Disease, Peptide, Journal <strong>of</strong><br />
<strong>Hypertension</strong>, Regulatory Peptides, European Journal <strong>of</strong> Heart Failure,<br />
<strong>Hypertension</strong>, Circulation Research, <strong>American</strong> Journal <strong>of</strong> <strong>Hypertension</strong><br />
and the Mayo Clinic Proceedings.<br />
Dr. Cataliotti has been active in the discovery <strong>of</strong> novel drug delivery<br />
strategies for cardiac peptides in cardiovascular disease and in hypertension.<br />
He was the first to report feasibility <strong>of</strong> oral delivery <strong>of</strong> human<br />
B-type natriuretic peptide in experimental hypertension, and has<br />
pioneered the cardiac gene delivery strategy for natriuretic peptides in<br />
hypertensive heart disease.<br />
*Supported by an educational grant from SERVIER.<br />
22
Young Scholar Award*<br />
Monday, May 23, <strong>2011</strong>, 1:30 PM – 4:00 PM • East Ballroom • Third Floor<br />
Michael J. Ryan, PhD<br />
Dr. Ryan is an Associate Pr<strong>of</strong>essor <strong>of</strong><br />
Physiology & Biophysics at the University<br />
<strong>of</strong> Mississippi Medical Center in Jackson,<br />
MS. He earned his doctorate from the<br />
State University <strong>of</strong> New York at Buffalo<br />
in 1999 and received his post-doctoral<br />
training at the University <strong>of</strong> Iowa from<br />
1999-2004. In 2004, he was recruited as<br />
an Assistant Pr<strong>of</strong>essor <strong>of</strong> Physiology &<br />
Biophysics at the University <strong>of</strong> Mississippi<br />
Medical Center where he rose to his current<br />
rank <strong>of</strong> Associate Pr<strong>of</strong>essor in 2009.<br />
Dr. Ryan’s research focuses on the<br />
mechanistic role that chronic inflammation has in the development <strong>of</strong><br />
hypertension. In order to examine this link, he studies an animal model<br />
that develops the chronic autoimmune inflammatory disorder systemic<br />
lupus erythematosus (SLE). <strong>Hypertension</strong> is prevalent and cardiovascular<br />
disease is a leading cause <strong>of</strong> death in individuals with SLE. Dr. Ryan is<br />
specifically interested in the effect <strong>of</strong> immune and inflammatory mediators<br />
on renal function, renal injury and vascular physiology as it pertains to<br />
the development <strong>of</strong> hypertension. His work has been continuously funded<br />
by the <strong>American</strong> Heart Association and National Institutes <strong>of</strong> Health.<br />
Dr. Ryan currently sits on the editorial board <strong>of</strong> <strong>Hypertension</strong>, the <strong>American</strong><br />
Journal <strong>of</strong> Physiology: Regulatory, Integrative and Comparative Physiology,<br />
the Journal <strong>of</strong> <strong>Hypertension</strong> and Frontiers in Vascular Physiology.<br />
He is an active member <strong>of</strong> the <strong>American</strong> Heart Association peer review<br />
system serving as a co-chair <strong>of</strong> the Vascular Biology & Blood Pressure<br />
II peer review committee. Dr. Ryan is a Fellow <strong>of</strong> the <strong>American</strong> Heart<br />
Association and serves on the Leadership Committee <strong>of</strong> the Council<br />
for High Blood Pressure as well as on the Greater Southeast Affiliate<br />
Research Committee. Ryan is also an active member <strong>of</strong> the <strong>American</strong><br />
Physiological <strong>Society</strong>. He has served on the Porter Physiology Development<br />
Committee and currently serves on the Education Committee <strong>of</strong><br />
the <strong>American</strong> Physiological <strong>Society</strong> where he actively contributes to the<br />
educational missions <strong>of</strong> the society.<br />
*Supported by an educational grant from SERVIER.<br />
23
Special Lecture<br />
Monday, May 23, <strong>2011</strong>, 1:30 PM – 4:00 PM • East Ballroom • Third Floor<br />
Marvin Moser Clinical <strong>Hypertension</strong> Award Lecture<br />
Murray Epstein, MD<br />
Dr. Murray Epstein is Pr<strong>of</strong>essor <strong>of</strong> Medicine<br />
at the University <strong>of</strong> Miami, School<br />
<strong>of</strong> Medicine. He was a recipient <strong>of</strong> the<br />
1990 Distinguished Scientist Award <strong>of</strong> the<br />
National Kidney Foundation. He served<br />
as a member <strong>of</strong> the National High Blood<br />
Pressure Education <strong>Program</strong> Coordinating<br />
Committee and is a contributor to the 6th<br />
Report <strong>of</strong> the Joint National Committee.<br />
Dr. Epstein is listed in Who’s Who in<br />
America (59th, 60th and 61st edition) and<br />
Who’s Who in Medicine.<br />
Dr. Epstein has authored over 400 journal<br />
articles and book chapters. Many <strong>of</strong> these have related to 1) the pathogenesis<br />
and management <strong>of</strong> hypertension, 2) renal function in diseases<br />
characterized by abnormal volume regulation, and 3) the role <strong>of</strong> the<br />
renin angiotensin aldosterone system. He has also written extensively<br />
on head out water immersion, a unique clinical investigational model<br />
that he has defined and applied to the study <strong>of</strong> a wide range <strong>of</strong> disease<br />
states. The unique attributes <strong>of</strong> this clinical investigative model include<br />
a prompt redistribution <strong>of</strong> circulating blood volume with a consequent<br />
relative central hypervolemia, in the absence <strong>of</strong> concomitant changes in<br />
plasma composition. Dr. Epstein has successfully applied the immersion<br />
model as a clinical investigative tool to characterize the determinants<br />
<strong>of</strong> deranged volume homeostasis and renin-aldosterone, eicosanoid,<br />
kallikrein, vasopressin and ANF responsiveness in diverse edematous<br />
disorders including advanced liver diseases, chronic renal failure and<br />
hypertension. He has also utilized the immersion model to define the<br />
relative roles <strong>of</strong> volume and the renin-angiotensin axis as determinants<br />
<strong>of</strong> aldosterone responsiveness in anephric humans.<br />
Dr. Epstein has also defined the effects <strong>of</strong> calcium antagonists on renal<br />
hemodynamics and renal function At the preclinical level Dr. Epstein,<br />
in collaboration with his co-investigator Dr. Rodger Loutzenhiser, developed<br />
and used the isolated perfused hydronephrotic kidney model to<br />
visualize the renal microvasculature and define the effect <strong>of</strong> interventions<br />
with calcium antagonists and a wide array <strong>of</strong> vasoconstrictors including<br />
angiotensin II and endothelin on the afferent and efferent arterioles. He<br />
extended these studies to the clinical arena in order to define the effect <strong>of</strong><br />
calcium antagonists on renal hemodynamics and as prophylactic agents<br />
to obviate acute renal failure in diverse clinical settings. Most recently<br />
Dr. Epstein has focused his clinical and investigative attention on the<br />
role <strong>of</strong> aldosterone as a pivotal determinant <strong>of</strong> cardiovascular and renal<br />
injury, and the use <strong>of</strong> aldosterone blockade to reverse these adverse<br />
effects. Currently his major investigative focus is on mineralocorticoid<br />
receptor blockade as an intervention to abrogate progressive kidney disease,<br />
and as an intervention to confer cardiovascular and renal benefits<br />
in patients with chronic kidney disease, and in ESRD patients who are<br />
being treated by hemodialysis.<br />
24<br />
continued…
Special Lecture continued<br />
A member <strong>of</strong> several editorial boards, Dr. Epstein also serves as a<br />
reviewer for numerous prominent journals and for study sections for<br />
granting agencies.<br />
Dr. Epstein has served as the editor <strong>of</strong> 4 editions <strong>of</strong> THE KIDNEY IN<br />
LIVER DISEASE (Hanley & Belfus, Philadelphia, 1996), the premier<br />
book in the field, which surveys the wide spectrum <strong>of</strong> renal functional<br />
abnormalities in liver disease. Dr. Epstein has also co authored HYPER-<br />
TENSION: PRACTICAL MANAGEMENT (1988), which has subsequently<br />
been published in Spanish and Portuguese editions. He has also edited<br />
CALCIUM ANTAGONISTS AND THE KIDNEY (Hanley & Belfus, 1990),<br />
the first comprehensive book to survey the diverse effects <strong>of</strong> calcium<br />
antagonists on renal function, and the clinical applicability <strong>of</strong> these findings,<br />
including renal protection. Most recently, Dr. Epstein has edited<br />
3 editions <strong>of</strong> CALCIUM ANTAGONISTS IN CLINICAL MEDICINE<br />
(Hanley and Belfus, 1992, 1997, and 2002), the first comprehensive book<br />
to survey the effects <strong>of</strong> calcium antagonists on both cardiovascular and<br />
renal function. In addition, this book considers the effects <strong>of</strong> calcium<br />
antagonists on other organ systems including the management <strong>of</strong> gastrointestinal<br />
disorders, and disorders <strong>of</strong> the cerebral circulation.<br />
Dr. Epstein has also co-edited ANGIOTENSIN II RECEPTOR ANTAGO-<br />
NISTS (Hanley & Belfus 2001), the first comprehensive book to survey<br />
the effects <strong>of</strong> AT1 receptor antagonists on both cardiovascular and renal<br />
function. In addition, this book considers the effects <strong>of</strong> these novel agents<br />
in elucidating the pr<strong>of</strong>ound physiological effects <strong>of</strong> angiotensin II.<br />
Dr. Epstein, who is a 1963 graduate <strong>of</strong> Columbia University College <strong>of</strong><br />
Physicians and Surgeons, did his postgraduate medical training at University<br />
Hospital in Madison, Wisconsin and at the Cleveland MetroHealth<br />
Medical Center <strong>of</strong> Western Reserve University from 1966 to 1968, he<br />
was a Research Fellow in Nephrology in the Kidney Laboratory <strong>of</strong> Peter<br />
Bent Brigham Hospital in Boston, under Pr<strong>of</strong>essor John P. Merrill. Dr.<br />
Epstein was also an Established Investigator <strong>of</strong> the Howard Hughes<br />
Medical Institute. He is ABIM-certified in internal medicine and nephrology,<br />
and is a Fellow <strong>of</strong> both the <strong>American</strong> College <strong>of</strong> Physicians and the<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> Nephrology. Dr Epstein has also been designated<br />
a <strong>Hypertension</strong> Specialist by the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>.<br />
25
<strong>2011</strong> Abstract Reviewers<br />
Lawrence J. Appel, MD, MPH,<br />
F<strong>ASH</strong><br />
Baltimore, MD<br />
Steven A. Atlas, MD, F<strong>ASH</strong><br />
Bronx, NY<br />
George L. Bakris, MD, F<strong>ASH</strong><br />
Chicago, IL<br />
Jan N. Basile, MD, F<strong>ASH</strong><br />
Charleston, SC<br />
Donald L. Batisky, MD<br />
Atlanta, GA<br />
Dan R. Berlowitz, MD, MPH<br />
Bedford, MA<br />
John D. Bisognano, MD, PhD,<br />
F<strong>ASH</strong><br />
Rochester, NY<br />
Henry R. Black, MD, F<strong>ASH</strong><br />
New York, NY<br />
Michael J. Bloch, MD, F<strong>ASH</strong><br />
Reno, NV<br />
Michael W. Brands, PhD<br />
Augusta, GA<br />
Lynne T. Braun, PhD, CNP<br />
Chicago, IL<br />
Robert D. Brook, MD, F<strong>ASH</strong><br />
Ann Arbor, MI<br />
Angela L. Brown, MD<br />
St. Louis, MO<br />
David A. Calhoun, MD<br />
Birmingham, AL<br />
Oscar A. Carretero, MD, F<strong>ASH</strong><br />
Detroit, MI<br />
Barry L. Carter, PharmD<br />
Iowa City, IA<br />
John R. Cockcr<strong>of</strong>t, MD<br />
Cardiff, United Kingdom<br />
Stephen R. Daniels, MD, PhD,<br />
F<strong>ASH</strong><br />
Aurora, CO<br />
Prakash C. Deedwania, MD,<br />
F<strong>ASH</strong><br />
Fresno, CA<br />
Joseph A. Diamond, MD, F<strong>ASH</strong><br />
New Hyde Park, NY<br />
Daniel Duprez, MD, PhD,<br />
F<strong>ASH</strong><br />
Minneapolis, MN<br />
Brent M. Egan, MD, F<strong>ASH</strong><br />
Charleston, SC<br />
Gilbert M. Eisner, MD, F<strong>ASH</strong><br />
Washington, DC<br />
William J. Elliott, MD, PhD,<br />
F<strong>ASH</strong><br />
Yakima, WA<br />
Michael Ernst, PharmD<br />
Iowa City, IA<br />
Bonita Falkner, MD, F<strong>ASH</strong><br />
Philadelphia, PA<br />
Pamela J. Fall, MD, F<strong>ASH</strong><br />
Augusta, GA<br />
Daniel I. Feig, MD, PhD<br />
Houston, TX<br />
John M. Flack, MD, MPH<br />
Detroit, MI<br />
Joseph T. Flynn, MD, F<strong>ASH</strong><br />
Seattle, WA<br />
Philip B. Gorelick, MD, MPH<br />
Lincoln, IL<br />
Alan H. Gradman, MD, F<strong>ASH</strong><br />
Pittsburgh, PA<br />
Joey P. Granger, PhD<br />
Jackson, MS<br />
Richard H. Grimm, Jr., MD, PhD<br />
Minneapolis, MN<br />
John E. Hall, PhD<br />
Jackson, MS<br />
Joel Handler, MD<br />
Anaheim, CA<br />
Willa A. Hsueh, MD<br />
Houston, TX<br />
David J. Hyman, MD, MPH<br />
Houston, TX<br />
Kenneth A. Jamerson, MD, F<strong>ASH</strong><br />
Ann Arbor, MI<br />
Richard J. Johnson, MD<br />
Denver, CO<br />
John B. Kostis, MD, F<strong>ASH</strong><br />
New Brunswick, NJ<br />
David S. Kountz, MD<br />
Neptune, NJ<br />
Louis Kuritzky, MD<br />
Gainesville, FL<br />
Theodore W. Kurtz, MD<br />
San Francisco, CA<br />
Daniel T. Lackland, DrPH, F<strong>ASH</strong><br />
Charleston, SC<br />
Lewis Landsberg, MD<br />
Chicago, IL<br />
26
<strong>2011</strong> Abstract Reviewers continued<br />
Friedrich C. Luft, MD<br />
Berlin, Germany<br />
Giuseppe Mancia, MD<br />
Milan, Italy<br />
Samuel J. Mann, MD<br />
New York, NY<br />
Allyn L. Mark, MD<br />
Iowa City, IA<br />
Nancy Houston Miller, RN,<br />
BSN<br />
Palo Alto, CA<br />
Gary Mitchell, MD<br />
Norwood, MA<br />
Michael A. Moore, MD, F<strong>ASH</strong><br />
Winston Salem, NC<br />
L. Gabriel Navar, PhD<br />
New Orleans, LA<br />
Shawna D. Nesbitt, MD, MS,<br />
F<strong>ASH</strong><br />
Dallas, TX<br />
Susanne B. Nicholas, MD, PhD,<br />
MPH<br />
Los Angeles, CA<br />
Daniel T. O’Connor, MD<br />
San Diego, CA<br />
Gbenga Ogedegbe, MD, MPH,<br />
MS, F<strong>ASH</strong><br />
New York, NY<br />
Suzanne Oparil, MD, F<strong>ASH</strong><br />
Birmingham, AL<br />
Vasilios Papademetriou, MD,<br />
F<strong>ASH</strong><br />
Washington, DC<br />
Aldo J. Peixoto, MD, F<strong>ASH</strong><br />
West Haven, CT<br />
Robert A. Phillips, MD, PhD,<br />
F<strong>ASH</strong><br />
Worcester, MA<br />
Bertram Pitt, MD<br />
Ann Arbor, MI<br />
J. Howard Pratt, MD<br />
Indianapolis, IN<br />
L. Michael Prisant, MD, F<strong>ASH</strong><br />
Augusta, GA<br />
Clive Rosendorff, MD, PhD,<br />
F<strong>ASH</strong><br />
Bronx, NY<br />
Gary E. Sander, MD, PhD,<br />
F<strong>ASH</strong><br />
Metairie, LA<br />
Ernesto L. Schiffrin, MD, PhD<br />
Montreal, Canada<br />
Alan B. Schwartz, MD, F<strong>ASH</strong><br />
Philadelphia, PA<br />
Scott D. Solomon, MD<br />
Boston, MA<br />
James R. Sowers, MD, F<strong>ASH</strong><br />
Columbia, MO<br />
Jan A. Staessen, MD, PhD<br />
Leuven, Belgium<br />
Sandra J. Taler, MD, F<strong>ASH</strong><br />
Rochester, MN<br />
Addison A. Taylor, MD, PhD,<br />
F<strong>ASH</strong><br />
Houston, TX<br />
Sheldon W. Tobe, MD, F<strong>ASH</strong><br />
Toronto, Canada<br />
Peter P. Toth, MD, PhD<br />
Sterling, IL<br />
Rhian M. Touyz, MD, PhD<br />
Ottawa, Canada<br />
Raymond R. Townsend, MD<br />
Philadelphia, PA<br />
Jason G. Umans, MD, PhD<br />
Bethesda, MD<br />
Alan B. Weder, MD<br />
Ann Arbor, MI<br />
Myron H. Weinberger, MD<br />
Indianapolis, IN<br />
Howard Weintraub, MD<br />
New York, NY<br />
Matthew R. Weir, MD, F<strong>ASH</strong><br />
Baltimore, MD<br />
William B. White, MD, F<strong>ASH</strong><br />
Farmington, CT<br />
Peter W. F. Wilson, MD<br />
Atlanta, GA<br />
Nathan D. Wong, PhD, MPH<br />
Irvine, CA<br />
Jackson T. Wright, Jr., MD,<br />
PhD, F<strong>ASH</strong><br />
Cleveland, OH<br />
Steven A. Yarows, MD, F<strong>ASH</strong><br />
Chelsea, MI<br />
27
More than half <strong>of</strong><br />
hypertensive patients need<br />
3 or more<br />
agents<br />
to help them get to BP GOAL 1-4<br />
References: 1. Pepine CJ, Handberg EM, Cooper-DeH<strong>of</strong>f RM, et al; INVEST Investigators. A calcium antagonist vs<br />
a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International<br />
Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816. 2. Wright<br />
JT Jr, Bakris G, Greene T, et al; African <strong>American</strong> Study <strong>of</strong> Kidney Disease and <strong>Hypertension</strong> Study Group. Effect <strong>of</strong><br />
blood pressure lowering and antihypertensive drug class on progression <strong>of</strong> hypertensive kidney disease: results from<br />
the AASK trial. JAMA. 2002;288(19):2421-2431. 3. Cushman WC, Ford CE, Cutler JA, et al; ALLHAT Collaborative<br />
Research Group. Success and predictors <strong>of</strong> blood pressure control in diverse North <strong>American</strong> settings: the<br />
Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393-<br />
404. 4. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or<br />
hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428. 5. Flack JM,<br />
Calhoun DA, Satlin L, Barbier M, Hilkat R, Brunel P. Efficacy and safety <strong>of</strong> initial combination therapy with amlodipine/<br />
valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.<br />
J Hum Hypertens. 2009;23(7):479-489. 6. Flack JM, Sica DA, Bakris G, et al. Management <strong>of</strong> high blood pressure<br />
in blacks: an update <strong>of</strong> the International <strong>Society</strong> on <strong>Hypertension</strong> in Blacks consensus statement. <strong>Hypertension</strong>.<br />
2010;56(5):780-800.<br />
Novartis Pharmaceuticals Corporation<br />
East Hanover, New Jersey 07936<br />
©<strong>2011</strong> Novartis
Looking for<br />
antihypertensive<br />
EFFICACY<br />
in African <strong>American</strong><br />
patients 5,6, *<br />
Visit booth<br />
#1100<br />
to find out more<br />
* Patients with stage 2/severe hypertension, including African <strong>American</strong> patients with moderate-to-severe<br />
hypertension. Stage 2 hypertension is defined as ≥160/100 mm Hg.<br />
Printed in USA 4/11 EXR-1052006
Poster Category Presentation<br />
Posters will be displayed in the Second Floor Promenade.<br />
Saturday, May 21, <strong>2011</strong><br />
Posters on Display: 4:30 PM – 7:30 PM • Poster Viewing: 6:00 PM – 7:00 PM<br />
Adolescent <strong>Hypertension</strong> and Obesity.............................. (PO-1 – PO-5)<br />
Antiatherosclerotic Drugs................................................... (PO-6 – PO-7)<br />
Cardiac Structure and Function/Imaging....................... (PO-8 – PO-10)<br />
Comprehensive Multi-Level Interventions for<br />
<strong>Hypertension</strong> Management in High-Risk Groups......(PO-11 – PO-30)<br />
Endothelial Function.......................................................(PO-31 – PO-45)<br />
Epidemiology/Special Populations................................(PO-46 – PO-78)<br />
Immune Mechanisms in <strong>Hypertension</strong>........................(PO-79 – PO-82)<br />
Metabolic Syndrome (Diabetes/Glycemic Control;<br />
Dysglycemic Drugs; Insulin Resistance).....................(PO-83 – PO-102)<br />
New Insights into the Role <strong>of</strong> Uric Acid<br />
in <strong>Hypertension</strong>............................................................(PO-103 – PO-104)<br />
Pediatric <strong>Hypertension</strong>...............................................(PO-105 – PO-111)<br />
Risk Factors (Lipids)....................................................(PO-112 – PO-115)<br />
Stroke.............................................................................(PO-117 – PO-119)<br />
Vascular Injury/Inflammation and Remodeling......(PO-120 – PO-123)<br />
Sunday, May 22, <strong>2011</strong><br />
Posters on Display: 10:00 AM – 6:30 PM • Poster Viewing: 5:30 PM – 6:30 PM<br />
Featured Posters<br />
Blood Pressure Measurement/Monitoring......................(FP-1 – FP-4)<br />
Adolescent <strong>Hypertension</strong>..................................................(FP-5 – FP-8)<br />
Aldosterone and Anti-Aldosterone Agents..............(PO-124 – PO-130)<br />
Antihypertensive Drugs and Pharmacology............(PO-131 – PO-157)<br />
Clinical Trials................................................................(PO-158 – PO-184)<br />
Coronary Artery Disease............................................(PO-185 – PO-191)<br />
Genetics/Gene Therapy/Proteomics..........................(PO-192 – PO-198)<br />
Heart Failure/Hypertrophy<br />
(Diastolic Dysfunction)...............................................(PO-199 – PO-216)<br />
<strong>Hypertension</strong> in Patients with Chronic<br />
Kidney Disease.............................................................(PO-217 – PO-226)<br />
Kidney and <strong>Hypertension</strong>...........................................(PO-227 – PO-242)<br />
Off-Target Cardiovascular Effects <strong>of</strong><br />
Non-Cardiovascular Drugs........................................(PO-243 – PO-244)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
30
Poster Category Presentation<br />
Monday, May 23, <strong>2011</strong><br />
Posters on Display: 10:00 AM – 5:30 PM • Poster Viewing: 4:30 PM – 5:30 PM<br />
Featured Posters<br />
Cardiac Structure and Function.................................... (FP-9 – FP-13)<br />
Arterial Structure and Compliance...........................(PO-245 – PO-259)<br />
Blood Pressure Measurement/Monitoring............(PO-260 – PO-305A)<br />
Cellular Mechanisms (Cell Biology;<br />
Cell Membrane Transport/Ion Channels;<br />
Coagulation/Thrombosis; Growth Factors).............(PO-306 – PO-308)<br />
Lipid Metabolism...........................................................................(PO-309)<br />
Neural Hormonal Mechanisms (Renin; Neural Control; Vasoactive<br />
Autacoids).....................................................................(PO-310 – PO-312)<br />
Non – Pharmacological Therapy (Alternative<br />
Medicine; Diet; Physical Activity).............................(PO-313 – PO-322)<br />
Nutrition and Cardiovascular Prevention................(PO-323 – PO-330)<br />
Obesity...........................................................................(PO-331 – PO-339)<br />
Patient – Provider-Healthcare System Issues...........(PO-340 – PO-355)<br />
Preclinical Models/Experimental <strong>Hypertension</strong>.....(PO-357 – PO-358)<br />
Pregnancy......................................................................(PO-359 – PO-361)<br />
Salt-Sensitive Mechanisms <strong>of</strong> <strong>Hypertension</strong>............(PO-362 – PO-364)<br />
Secondary <strong>Hypertension</strong>.............................................(PO-365 – PO-367)<br />
Late-Breaking Posters.........................................(LB-PO-01 – LB-PO-03)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
31
<strong>2011</strong> <strong>ASH</strong> Faculty<br />
Rajiv Agarwal, MD<br />
Indianapolis, IN<br />
Lawrence J. Appel, MD, MPH,<br />
F<strong>ASH</strong><br />
Baltimore, MD<br />
Nancy Artinian, PhD, RN<br />
Detroit, MI<br />
Phyllis August, MD, MPH<br />
New York, NY<br />
Abraham Aviv, MD<br />
Newark, NJ<br />
George L. Bakris, MD, F<strong>ASH</strong><br />
Chicago, IL<br />
Jan N. Basile, MD, F<strong>ASH</strong><br />
Charleston, SC<br />
Donald L. Batisky, MD<br />
Atlanta, GA<br />
John D. Bisognano, MD, PhD,<br />
F<strong>ASH</strong><br />
Rochester, NY<br />
Henry R. Black, MD, F<strong>ASH</strong><br />
New York, NY<br />
Michael J. Bloch, MD, F<strong>ASH</strong><br />
Reno, NV<br />
William E. Boden, MD<br />
Buffalo, NY<br />
Michael W. Brands, PhD<br />
Augusta, GA<br />
Lynne T. Braun, PhD, CNP<br />
Chicago, IL<br />
Emmanuel Bravo, MD<br />
Cleveland, OH<br />
Angela L. Brown, MD<br />
St. Louis, MO<br />
Nancy J. Brown, MD<br />
Nashville, TN<br />
David A. Bushinsky, MD<br />
Rochester, NY<br />
Norman R. C. Campbell, MD<br />
Calgary, Canada<br />
Oscar A. Carretero, MD<br />
Detroit, MI<br />
Barry L. Carter, PharmD<br />
Iowa City, IA<br />
Alessandro Cataliotti, MD, PhD<br />
Rochester, MN<br />
John R. Cockcr<strong>of</strong>t, MD<br />
Cardiff, United Kingdom<br />
Jay N. Cohn, MD<br />
Minneapolis, MN<br />
Steven D. Crowley, PhD<br />
Durham, NC<br />
William C. Cushman, MD,<br />
F<strong>ASH</strong><br />
Memphis, TN<br />
Stephen R. Daniels, MD, PhD,<br />
F<strong>ASH</strong><br />
Aurora, CO<br />
Michael H. Davidson, MD<br />
Chicago, IL<br />
Daniel Duprez, MD, PhD,<br />
F<strong>ASH</strong><br />
Minneapolis, MN<br />
Lance D. Dworkin, MD<br />
Providence, RI<br />
Brent M. Egan, MD, F<strong>ASH</strong><br />
Charleston, SC<br />
Paula T. Einhorn, MD, MS<br />
Bethesda, MD<br />
William J. Elliott, MD, PhD,<br />
F<strong>ASH</strong><br />
Yakima, WA<br />
Murray Epstein, MD<br />
Miami, FL<br />
Murray D. Esler, MBBS, PhD<br />
Melbourne, Australia<br />
Bonita Falkner, MD, F<strong>ASH</strong><br />
Philadelphia, PA<br />
Sadaf Farooqi, PhD<br />
Cambridge, United Kingdom<br />
Daniel I. Feig, MD, PhD<br />
Houston, TX<br />
Ross Feldman, MD<br />
London, Canada<br />
Keith C. Ferdinand, MD, F<strong>ASH</strong><br />
Atlanta, GA<br />
John M. Flack, MD, MPH<br />
Detroit, MI<br />
Joseph T. Flynn, MD, F<strong>ASH</strong><br />
Seattle, WA<br />
Stanley S. Franklin, MD, F<strong>ASH</strong><br />
Los Angeles, CA<br />
William H. Frishman, MD<br />
Valhalla, NY<br />
James B. Froehlich, MD, MPH<br />
Ann Arbor, MI<br />
Leonard M. Fromer, MD<br />
Los Angeles, CA<br />
Jeffrey L. Garvin, PhD<br />
Detroit, MI<br />
32
<strong>2011</strong> <strong>ASH</strong> Faculty continued<br />
Haralambos Gavras, MD<br />
Boston, MA<br />
F. Wilford Germino, MD, F<strong>ASH</strong><br />
Orland Park, IL<br />
Ali G. Gharavi, MD<br />
New York, NY<br />
Thomas D. Giles, MD, F<strong>ASH</strong><br />
New Orleans, LA<br />
Alan S. Go, MD<br />
Oakland, CA<br />
Alan H. Gradman, MD, F<strong>ASH</strong><br />
Pittsburgh, PA<br />
Joey P. Granger, PhD<br />
Jackson, MS<br />
Richard H. Grimm, Jr., MD,<br />
PhD<br />
Minneapolis, MN<br />
Yuan Guo, MD, MS<br />
Beijing, China<br />
John E. Hall, PhD<br />
Jackson, MS<br />
Joel Handler, MD<br />
Anaheim, CA<br />
David Harder, MD, PhD<br />
Milwaukee, WI<br />
Raymond C. Harris, MD<br />
Nashville, TN<br />
David G. Harrison, MD<br />
Atlanta, GA<br />
Joseph A. Hill, MD, PhD<br />
Dallas, TX<br />
Norman K. Hollenberg, MD,<br />
PhD<br />
Boston, MA<br />
Suzanne Hughes, RN, MSN<br />
Akron, OH<br />
Joseph L. Izzo, Jr., MD, F<strong>ASH</strong><br />
Buffalo, NY<br />
Edgar A. Jaimes, MD<br />
Birmingham, AL<br />
Kenneth A. Jamerson, MD,<br />
F<strong>ASH</strong><br />
Ann Arbor, MI<br />
Julie A. Johnson, PharmD<br />
Gainesville, FL<br />
Richard J. Johnson, MD<br />
Denver, CO<br />
Pedro A. Jose, MD<br />
Washington, DC<br />
Luis Juncos, MD<br />
Córdoba, Argentina<br />
Rae-Ellen W. Kavey, MD, MPH<br />
Rochester, NY<br />
Donald E. Kohan, MD, PhD<br />
Salt Lake City, UT<br />
David S. Kountz, MD<br />
Neptune, NJ<br />
Lawrence R. Krak<strong>of</strong>f, MD<br />
New York, NY<br />
Henry Krum, MBBS, PhD<br />
Melbourne, Australia<br />
Louis Kuritzky, MD<br />
Gainesville, FL<br />
Theodore W. Kurtz, MD<br />
San Francisco, CA<br />
Robert F. Kushner, MD<br />
Chicago, IL<br />
Daniel T. Lackland, DrPH,<br />
F<strong>ASH</strong><br />
Charleston, SC<br />
Edward G. Lakatta, MD<br />
Baltimore, MD<br />
Babbette LaMarca, PhD<br />
Jackson, MS<br />
Marc B. Lande, MD, MPH<br />
Rochester, NY<br />
Daniel Levy, MD<br />
Framingham, MA<br />
Nita A. Limdi, PharmD, PhD,<br />
MSPH<br />
Birmingham, AL<br />
Tianhu Liu, MD<br />
Chengdu, China<br />
Charles J. Lowenstein, MD<br />
Rochester, NY<br />
Jianfang Luo, MD<br />
Guangzhou, China<br />
James M. Luther, MD<br />
Nashville, TN<br />
Guiseppe Mancia, MD<br />
Milan, Italy<br />
Samuel J. Mann, MD<br />
New York, NY<br />
Athanasios J. Manolis, MD,<br />
PhD<br />
Athens, Greece<br />
Allyn L. Mark, MD<br />
Iowa City, IA<br />
Barry J. Materson, MD, MBA,<br />
F<strong>ASH</strong><br />
Miami, FL<br />
33
<strong>2011</strong> <strong>ASH</strong> Faculty continued<br />
David L. Mattson, PhD<br />
Milwaukee, WI<br />
Richard J. McManus, MD<br />
Birmingham, United Kingdom<br />
John Merenich, MD<br />
Denver, CO<br />
Franz H. Messerli, MD, F<strong>ASH</strong><br />
New York, NY<br />
Nancy Houston Miller, RN,<br />
BSN<br />
Palo Alto, CA<br />
Mark E. Molitch, MD<br />
Chicago, IL<br />
Krzyszt<strong>of</strong> Narkiewicz, MD,<br />
PhD<br />
Gdánsk, Poland<br />
L. Gabriel Navar, PhD<br />
New Orleans, LA<br />
Shawna D. Nesbitt, MD, MS,<br />
F<strong>ASH</strong><br />
Dallas, TX<br />
Joel M. Neutel, MD, F<strong>ASH</strong><br />
Tustin, CA<br />
Susanne B. Nicholas, MD, PhD,<br />
MPH<br />
Los Angeles, CA<br />
Eoin O’Brien, MD<br />
Dublin, Ireland<br />
Gbenga Ogedegbe, MD, MPH,<br />
MS, F<strong>ASH</strong><br />
New York, NY<br />
Suzanne Oparil, MD, F<strong>ASH</strong><br />
Birmingham, AL<br />
Julio A. Panza, MD<br />
Washington, DC<br />
Vasilios Papademetriou, MD,<br />
F<strong>ASH</strong><br />
Washington, DC<br />
Gianfranco Parati, MD<br />
Milan, Italy<br />
Aldo J. Peixoto, MD, F<strong>ASH</strong><br />
West Haven, CT<br />
Robert A. Phillips, MD, PhD,<br />
F<strong>ASH</strong><br />
Worcester, MA<br />
Thomas A. Pearson, MD, PhD,<br />
MPH<br />
Rochester, NY<br />
F. Xavier Pi-Sunyer, MD, MPH<br />
New York, NY<br />
Bertram Pitt, MD<br />
Ann Arbor, MI<br />
Velvie A. Pogue, MD<br />
New York, NY<br />
David M. Pollock, PhD<br />
Augusta, GA<br />
J. Howard Pratt, MD<br />
Indianapolis, IN<br />
Henry A. Punzi, MD<br />
Carrollton, TX<br />
Leopoldo Raij, MD, F<strong>ASH</strong><br />
Miami, FL<br />
C. Venkata S. Ram, MD, F<strong>ASH</strong><br />
Dallas, TX<br />
James Rippe, MD<br />
Shrewsbury, MA<br />
Talma Rosenthal, MD<br />
Tel Aviv, Israel<br />
Peter M. Rothwell, MD<br />
Oxford, United Kingdom<br />
Luis M. Ruilope, MD<br />
Madrid, Spain<br />
Michael J. Ryan, PhD<br />
Jackson, MS<br />
Elijah Saunders, MD, F<strong>ASH</strong><br />
Baltimore, MD<br />
Ernesto L. Schiffrin, MD, PhD<br />
Montreal, Canada<br />
Roland E. Schmieder, MD<br />
Erlangen, Germany<br />
Antoinette Schoenthaler, EdD<br />
New York, NY<br />
Domenic A. Sica, MD<br />
Richmond, VA<br />
Sidney Smith, Jr., MD<br />
Chapel Hill, NC<br />
Matthew Sorrentino, MD<br />
Chicago, IL<br />
Thomas A. Sos, MD<br />
New York, NY<br />
James R. Sowers, MD, F<strong>ASH</strong><br />
Columbia, MO<br />
Lesley A. Stevens, MD, MS<br />
Boston, MA<br />
Allan D. Struthers, MD<br />
Dundee, United Kingdom<br />
Laura P. Svetkey, MD<br />
Durham, NC<br />
Sandra J. Taler, MD, F<strong>ASH</strong><br />
Rochester, MN<br />
Ting Tao, MD<br />
Shanghai, China<br />
34
<strong>2011</strong> <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> Annual Meeting & Expostion – <strong>Program</strong> at a Glance<br />
Day – Date – Time Pathobiology Translational Therapy Special Sessions Joint Sessions Debates/Meet the Pr<strong>of</strong>essor Innovations Theater Satellite Symposia<br />
Saturday, May 21, <strong>2011</strong><br />
8:30 AM to 3:00 PM<br />
Saturday, May 21, <strong>2011</strong> Pavilion Hours – Open 4:30 PM to 7:30 PM Posters on Display – 4:30 PM to 7:30 PM; Poster Viewing – 6:00 PM to 7:00 PM<br />
Americas Hall, 3rd Floor<br />
<strong>Hypertension</strong><br />
Highlights <strong>2011</strong><br />
East Ballroom, 3rd Floor<br />
Saturday, May 21, <strong>2011</strong><br />
3:15 PM to 4:15 PM<br />
Membership Meeting<br />
<strong>ASH</strong> Members Only<br />
Saturday, May 21, <strong>2011</strong><br />
4:30 PM to 6:00 PM<br />
Trianon Rendezvous, 3rd Floor<br />
Young Investigator<br />
Competition Award<br />
Joint Session – <strong>American</strong><br />
Heart Association’s Council for<br />
High Blood Pressure Research<br />
Saturday, May 21, <strong>2011</strong><br />
6:30 PM to 7:30 PM<br />
Sunday, May 22, <strong>2011</strong><br />
8:00 AM to 12:30 PM<br />
Trianon Rendezvous, 3rd Floor<br />
Genomics and <strong>Hypertension</strong><br />
Beekman Parlor, 2nd Floor<br />
Joint Session – Preventive<br />
Cardiovascular Nurses<br />
Association<br />
Sutton South, 2nd Floor<br />
Joint Session – Association for<br />
Research into Atterial Structure<br />
and Physiology and North<br />
<strong>American</strong> Artery<br />
Regent Parlor, 2nd Floor<br />
Joint Session – National Lipid<br />
Association/<strong>American</strong> <strong>Society</strong><br />
<strong>of</strong> Preventive Cardiology<br />
Sutton Center, 2nd Floor<br />
Saturday, May 21, <strong>2011</strong> 6:00 PM to 7:30 PM Opening Reception – <strong>Hypertension</strong> Resource Pavilion<br />
Americas Hall, 3rd Floor<br />
Sunday, May 22, <strong>2011</strong> 10:00 AM to 1:00 PM <strong>Hypertension</strong> Resource Pavilion Opens – 11:30 AM to 1:00 PM Brunch<br />
Americas Hall, 3rd Floor<br />
<strong>Hypertension</strong> for the<br />
Primary Care Clinician <strong>2011</strong><br />
Sutton North, 2nd Floor<br />
Innovations Theater<br />
Rhinelander Gallery, 2nd Floor<br />
Sunday, May 22, <strong>2011</strong><br />
9:30 AM to 11:00 AM<br />
Joint Session – International<br />
Pediatric <strong>Hypertension</strong><br />
Association<br />
Sutton North, 2nd Floor<br />
Joint Session – China Social<br />
Worker’s Association Vascular<br />
Protection Committee<br />
Sutton Center, 2nd Floor<br />
Joint Session –<br />
<strong>Hypertension</strong> Canada<br />
Sutton South, 2nd Floor<br />
Sunday, May 22, <strong>2011</strong><br />
11:00 AM to 12:00 PM<br />
Joint Session –<br />
Inter-<strong>American</strong> <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong><br />
Regent Parlor, 2nd Floor<br />
Meet the Pr<strong>of</strong>essor –<br />
How to Write a 12 Page Grant<br />
Beekman Parlor, 2nd Floor<br />
Meet the Pr<strong>of</strong>essor –<br />
Understanding Statistics in<br />
Clinical Research<br />
Sutton North, 2nd Floor<br />
Meet the Pr<strong>of</strong>essor –<br />
How to Develop an Abstract/<br />
Lecture<br />
Sutton Center, 2nd Floor<br />
Debate –<br />
Is it Blood Pressure Variablility<br />
or Average Daily Blood<br />
Pressure that Best Predicts<br />
Stroke<br />
Sutton South, 2nd Floor<br />
Debate –<br />
Surgical Intervention for Renal<br />
Artery Stenosis is Indicated<br />
Regent Parlor, 2nd Floor<br />
Sunday, May 22, <strong>2011</strong><br />
12:00 PM to 1:00 PM<br />
West Ballroom, 3rd Floor<br />
Innovations Theater<br />
Rhinelander Gallery, 2nd Floor<br />
Sunday, May 22, <strong>2011</strong><br />
1:15 PM to 3:00 PM<br />
Plenary Session I<br />
East Ballroom, 3rd Floor<br />
Sunday, May 22, <strong>2011</strong><br />
3:30 PM to 5:15 PM<br />
Aldosterone<br />
Mercury Ballroom, 3rd Floor<br />
<strong>Hypertension</strong> in Patients<br />
With Chronic Kidney<br />
Disease<br />
East Ballroom, 3rd Floor<br />
Comprehensive Multi-<br />
Level Interventions for<br />
<strong>Hypertension</strong> Management<br />
in High-Risk Groups<br />
West Ballroom, 3rd Floor<br />
Control <strong>of</strong> <strong>Hypertension</strong> is<br />
Leaving the Office: The Role<br />
<strong>of</strong> Home Blood Pressure and<br />
Telemedicine<br />
Trianon Ballroom, 3rd Floor<br />
Joint Session –<br />
International <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong> in Blacks<br />
Trianon Rendezvous, 3rd Floor<br />
Sunday, May 22, <strong>2011</strong> 5:30 PM to 6:30 PM High Tea and Poster Viewing<br />
Americas Hall, 3rd Floor<br />
Sunday, May 22, <strong>2011</strong><br />
5:30 PM to 6:30 PM<br />
Innovations Theater<br />
Rhinelander Gallery, 2nd Floor<br />
Monday, May 23, <strong>2011</strong> 10:00 AM to 1:30 PM <strong>Hypertension</strong> Resource Pavilion Opens – Lunch in Pavilion 12:00 PM to 1:15 PM<br />
Americas Hall, 3rd Floor<br />
Monday, May 23, <strong>2011</strong><br />
6:00 AM to 7:30 AM<br />
Symposia<br />
Trianon Ballroom, 3rd Floor<br />
Monday, May 23, <strong>2011</strong><br />
8:00 AM to 10:00 AM<br />
Off-Target Cardiovascular<br />
Effects <strong>of</strong> Non-<br />
Cardiovascular Drugs<br />
New Insights into the Role<br />
<strong>of</strong> Uric Acid in <strong>Hypertension</strong><br />
Devices and Surgical<br />
Ablation for Refractory<br />
<strong>Hypertension</strong><br />
Joint Session –<br />
National Kidney Foundation<br />
Mercury Ballroom, 3rd Floor<br />
East Ballroom, 3rd Floor<br />
West Ballroom, 3rd Floor<br />
Trianon Rendezvous, 3rd Floor<br />
Monday, May 23, <strong>2011</strong><br />
10:30 AM to 12:00 PM<br />
Immune Mechanisms in<br />
<strong>Hypertension</strong><br />
Management <strong>of</strong> Elevated<br />
Blood Pressure in the<br />
Hospital Setting<br />
Management <strong>of</strong><br />
<strong>Hypertension</strong> in Diabetics<br />
and Chronic Kidney Disease<br />
Hyperkalemia Management<br />
in High Risk Patients: New<br />
Evidence-Based Approaches<br />
Joint Session –<br />
European <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong><br />
Mercury Ballroom, 3rd Floor<br />
East Ballroom, 3rd Floor<br />
West Ballroom, 3rd Floor<br />
Trianon Ballroom, 3rd Floor<br />
Trianon Rendezvous, 3rd Floor<br />
Monday, May 23, <strong>2011</strong><br />
11:45 AM to 12:15 PM<br />
Debate<br />
Are Elevated Potassium Levels<br />
Really a Concern<br />
Trianon Ballroom, 3rd Floor<br />
Monday, May 23, <strong>2011</strong><br />
1:30 PM to 4:00 PM<br />
Monday, May 23, <strong>2011</strong><br />
4:30 PM to 5:00 PM<br />
Tuesday, May 24, <strong>2011</strong><br />
8:15 AM to 9:30 AM<br />
Tuesday, May 24, <strong>2011</strong><br />
10:00 AM to 11:30 AM<br />
Salt-Sensitive Mechanisms<br />
<strong>of</strong> <strong>Hypertension</strong><br />
Plenary Session II<br />
Monday, May 23, <strong>2011</strong> 4:00 PM to 5:30 PM <strong>Hypertension</strong> Resource Pavilion Opens – High Tea and Poster Viewing 4:30 PM to 5:30 PM<br />
Americas Hall, 3rd Floor<br />
Integrated Cardiovascular<br />
Disease Guidelines and<br />
Implementation<br />
Nutrition and<br />
Cardiovascular Prevention<br />
East Ballroom, 3rd Floor<br />
Late-Breaking Clinical Trials<br />
West Ballroom, 3rd Floor<br />
Debate<br />
The Dominant Contributor<br />
to Systemic <strong>Hypertension</strong> is:<br />
Sympathetic Nervous System<br />
not the RAAS; or Activation<br />
<strong>of</strong> the Intrarenal RAAS not<br />
the SNS<br />
Beekman Parlor, 2nd Floor<br />
Debate<br />
<strong>Hypertension</strong> is a Disorder <strong>of</strong><br />
the Kidney<br />
Sutton North, 2nd Floor<br />
Sutton North, 2nd Floor<br />
Sutton Center, 2nd Floor<br />
Beekman Parlor, 2nd Floor
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc.<br />
<strong>2011</strong> Annual Scientific Meeting and Exposition<br />
<strong>2011</strong> <strong>Program</strong><br />
at a Glance<br />
Hilton New York<br />
Saturday, May 21, <strong>2011</strong> – Tuesday, May 24, <strong>2011</strong>
<strong>2011</strong> <strong>ASH</strong> Faculty continued<br />
Addison A. Taylor, MD, PhD,<br />
F<strong>ASH</strong><br />
Houston, TX<br />
Jens Titze, MD<br />
Erlangen, Germany<br />
Sheldon W. Tobe, MD, F<strong>ASH</strong><br />
Toronto, Canada<br />
Robert D. Toto, MD<br />
Dallas, TX<br />
Rhian M. Touyz, MD, PhD<br />
Ottawa, Canada<br />
Raymond R. Townsend, MD<br />
Philadelphia, PA<br />
Joseph A. Vassalotti, MD<br />
New York, NY<br />
Ronald G. Victor, MD<br />
Los Angeles, CA<br />
Hongyu Wang, MD, PhD<br />
Beijing, China<br />
R. Clinton Webb, PhD<br />
Augusta, GA<br />
David J. Webb, MD<br />
Edinburgh, United Kingdom<br />
Michael A. Weber, MD, F<strong>ASH</strong><br />
New York, NY<br />
Alan B. Weder, MD<br />
Ann Arbor, MI<br />
Myron H. Weinberger, MD<br />
Indianapolis, IN<br />
Matthew R. Weir, MD, F<strong>ASH</strong><br />
Baltimore, MD<br />
Adam Whaley-Connell, DO,<br />
F<strong>ASH</strong><br />
Columbia, MO<br />
Andrew Whelton, MD<br />
Baltimore, MD<br />
William B. White, MD, F<strong>ASH</strong><br />
Farmington, CT<br />
Ian B. Wilkinson, MD<br />
Cambridge, United Kingdom<br />
Bryan Williams, MD<br />
Leicester, United Kingdom<br />
Gordon H. Williams, MD<br />
Boston, MA<br />
Peter W. F. Wilson, MD<br />
Atlanta, GA<br />
Nathan D. Wong, PhD, MPH<br />
Irvine, CA<br />
Martin S. Zand, MD<br />
Rochester, NY<br />
37
<strong>Program</strong> Color Key<br />
The pages <strong>of</strong> this <strong>Program</strong> <strong>Book</strong> are color-coded to match the<br />
<strong>Program</strong> at a Glance (pages 35–36) and serve as a quick, identifiable<br />
reference <strong>of</strong> the type <strong>of</strong> educational activity or event taking place.<br />
Scientific Sessions*<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
<strong>Hypertension</strong> Highlights <strong>2011</strong><br />
Special Event<br />
Meet the Pr<strong>of</strong>essor Sessions<br />
<strong>Hypertension</strong> for the Primary Care Clinician<br />
Debates<br />
Poster Sessions<br />
Satellite Symposia<br />
<strong>Hypertension</strong> Resource Pavilion<br />
The <strong>ASH</strong> Twenth-Sixth Annual Scientific Meeting is<br />
organized around three (3) concurrent themes:<br />
• Pathobiology <strong>of</strong> <strong>Hypertension</strong><br />
• Translational Issues in <strong>Hypertension</strong><br />
• Therapy <strong>of</strong> <strong>Hypertension</strong><br />
Sessions in each <strong>of</strong> the three (3) themes (or tracks) are labeled<br />
throughout the <strong>Program</strong> <strong>Book</strong> to be easily identifiable.
<strong>2011</strong><br />
<strong>American</strong> <strong>Society</strong><br />
<strong>of</strong> <strong>Hypertension</strong><br />
<strong>Program</strong>
MAY 21<br />
Saturday Morning<br />
<strong>Hypertension</strong> Highlights <strong>2011</strong><br />
8:00 AM – 3:00 PM • East Ballroom • Third Floor<br />
Part I:<br />
Co-Chairs: Henry R. Black, MD, F<strong>ASH</strong>, New York, NY and<br />
Michael A. Weber, MD, F<strong>ASH</strong>, New York, NY<br />
8:00 AM Breakfast<br />
8:30 AM Cardiovascular Effects <strong>of</strong> Anti-Diabetic Drugs<br />
Nancy J. Brown, MD, Nashville, TN<br />
9:00 AM Role <strong>of</strong> the Kidney in Angiotensin II <strong>Hypertension</strong><br />
Steven D. Crowley, PhD, Durham, NC<br />
9:30 AM Neurohormonal Assessment in the Diagnosis and<br />
Management <strong>of</strong> <strong>Hypertension</strong><br />
Ronald G. Victor, MD, Los Angeles, CA<br />
10:00 AM Break<br />
Part II:<br />
10:30 AM Panel Discussion: <strong>Hypertension</strong> and Obesity in<br />
Adolescence: Epidemiology, Nutritional Aspects,<br />
Evaluation and Management<br />
Moderator: Bonita Falkner, MD, F<strong>ASH</strong>, Philadelphia,<br />
PA<br />
Panel Discussion Participants:<br />
Donald L. Batisky, MD, Atlanta, GA<br />
Joseph T. Flynn, MD, F<strong>ASH</strong>, Seattle, WA and<br />
Robert F. Kushner, MD, Chicago, IL<br />
11:15 AM Partnership with the Patient to Improve Blood<br />
Pressure Control and the Role <strong>of</strong> the <strong>Hypertension</strong><br />
Specialist in the “Medical Home”<br />
Moderator: Elijah Saunders, MD, F<strong>ASH</strong>, Baltimore,<br />
MD<br />
Joel Handler, MD, Anaheim, CA and<br />
Nancy Houston Miller, RN, BSN, Palo Alto, CA<br />
12:15 PM Lunch<br />
Part III:<br />
1:00 PM Panel Discussion: Resistant <strong>Hypertension</strong>:<br />
Pathophysiology, Evaluation, and New/Old<br />
Treatment Considerations<br />
Moderator: C. Venkata S. Ram, MD, F<strong>ASH</strong>, Dallas, TX<br />
Panel Discussion Participants:<br />
Michael W. Brands, PhD, Augusta, GA<br />
John D. Bisognano, MD, PhD, F<strong>ASH</strong>, Rochester, NY<br />
Domenic A. Sica, MD, Richmond, VA and<br />
Gordon H. Williams, MD, Boston, MA<br />
2:15 PM Complementary and Alternative Therapies in<br />
<strong>Hypertension</strong><br />
Moderator: Robert A. Phillips, MD, PhD, F<strong>ASH</strong>,<br />
Worcester, MA<br />
Panel Discussion Participants:<br />
Brent M. Egan, MD, F<strong>ASH</strong>, Charleston, SC and<br />
Matthew Sorrentino, MD, Chicago, IL<br />
40
Saturday Afternoon MAY 21<br />
<strong>ASH</strong> Membership Meeting<br />
3:15 PM – 4:15 PM • Trianon Rendezvous • Third Floor<br />
<strong>ASH</strong> Annual Membership Meeting<br />
41
MAY 21<br />
Sessions<br />
Saturday Afternoon<br />
4:30 PM – 6:00 PM • Beekman Parlor • Second Floor<br />
Genomics and <strong>Hypertension</strong><br />
Co-Chairs: Theodore W. Kurtz, MD, San Francisco, CA and<br />
Alan B. Weder, MD, Ann Arbor, MI<br />
4:30 PM Pharmacogenetics and Cardiovascular Disease<br />
Nita A. Limdi, PharmD, PhD, MSPH, Birmingham, AL<br />
5:00 PM Genomics <strong>of</strong> Experimental <strong>Hypertension</strong>:<br />
Translation to Humans<br />
Theodore W. Kurtz, MD<br />
5:30 PM Antihypertensive Drug Pharmacogenomics<br />
Julie A. Johnson, PharmD, Gainesville, FL<br />
42
Saturday Afternoon MAY 21<br />
Sessions<br />
4:30 PM – 6:00 PM • Sutton North • Second Floor<br />
Advancements in the Pathophysiology <strong>of</strong><br />
<strong>Hypertension</strong>: Some Novel Concepts<br />
Held in Partnership with the <strong>American</strong> Heart Association’s Council<br />
for High Blood Pressure Research (HBPR)<br />
Co-Chairs: Phyllis August, MD, MPH, New York, NY and<br />
Rhian M. Touyz, MD, PhD, Ottawa, Canada<br />
4:30 PM Overview<br />
Rhian M. Touyz, MD, PhD<br />
4:40 PM Pathophysiology <strong>of</strong> <strong>Hypertension</strong> in Preeclampsia:<br />
Novel Concepts<br />
Joey P. Granger, PhD, Jackson, MS<br />
5:06 PM Vascular Function, <strong>Hypertension</strong> and Erectile<br />
Dysfunction: Novel Mechanisms<br />
R. Clinton Webb, PhD, Augusta, GA<br />
5:32 PM Obesity-Related <strong>Hypertension</strong>: Basic Concepts and<br />
Clinical Implications<br />
John E. Hall, PhD, Jackson, MS<br />
43
MAY 21<br />
Sessions<br />
Saturday Afternoon<br />
4:30 PM – 6:00 PM • Sutton Center • Second Floor<br />
Cardiovascular Risk Prevention<br />
Held in Partnership with the <strong>American</strong> <strong>Society</strong> <strong>of</strong> Preventive<br />
Cardiology (ASPC) and the National Lipid Association (NLA)<br />
Co-Chairs: George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL and<br />
Peter W. F. Wilson, MD, Atlanta, GA<br />
4:30 PM Welcoming Remarks<br />
Peter W. F. Wilson, MD<br />
4:40 PM Prevention Strategy and National Healthcare<br />
Thomas A. Pearson, MD, PhD, MPH, Rochester, NY<br />
5:00 PM National Health Forum Initiatives: Dollars and<br />
Cents<br />
Keith C. Ferdinand, MD, F<strong>ASH</strong>, Atlanta, GA<br />
5:20 PM Aggressive Medical Management versus<br />
Intervention: An Uphill Road to Policy Change<br />
William E. Boden, MD, Buffalo, NY<br />
5:40 PM Leadership Panel Discussion<br />
George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL, Michael H.<br />
Davidson, MD, Chicago, IL and Nathan D. Wong, PhD,<br />
MPH, Irvine, CA<br />
Questions and Answers<br />
44
Saturday Afternoon MAY 21<br />
Sessions<br />
4:30 PM – 6:00 PM • Sutton South • Second Floor<br />
Advocating for Adherence to Better Control<br />
<strong>Hypertension</strong><br />
Held in Partnership with the Preventive Cardiovascular Nurses<br />
Association (PCNA)<br />
Co-Chairs: Nancy Artinian, PhD, RN, Detroit, MI and<br />
Barry L. Carter, PharmD, Iowa City, IA<br />
4:30 PM Enhancing Adherence in Ethically-Diverse<br />
Populations<br />
Gbenga Ogedegbe, MD, MPH, MS, F<strong>ASH</strong>, New York,<br />
NY and Antoinette Schoenthaler, EdD, New York, NY<br />
4:52 PM From Adherence to Advocacy: The Need to Reduce<br />
Sodium<br />
Suzanne Hughes, RN, MSN, Akron, OH<br />
5:14 PM Adherence and Persistence with Medications:<br />
The <strong>ASH</strong> Position<br />
Nancy Houston Miller, RN, BSN, Palo Alto, CA<br />
5:36 PM Practical Tips to Assess and Promote Adherence in<br />
Clinical Practice<br />
Lynne T. Braun, PhD, CNP, Chicago, IL<br />
45
MAY 21<br />
Sessions<br />
Saturday Afternoon<br />
4:30 PM – 6:00 PM • Regent Parlor • Second Floor<br />
Arterial Stiffness: A Paradigm Shift in<br />
Understanding the Increased Cardiovascular Risk<br />
Associated with Aging and Chronic Disease<br />
Held in Partnership with the Association for Research into Arterial<br />
Structure and Physiology (ARTERY) and North <strong>American</strong> Artery<br />
(NAA)<br />
Co-Chairs: John R. Cockcr<strong>of</strong>t, MD, Cardiff, United Kingdom and<br />
Stanley S. Franklin, MD, F<strong>ASH</strong>, Los Angeles, CA<br />
4:30 PM Chronic Obstructive Pulmonary Disease Arterial<br />
Stiffness and Cardiovascular Disease<br />
John R. Cockcr<strong>of</strong>t, MD<br />
4:52 PM Vasculitides Arterial Stiffness and Cardiovascular<br />
Disease<br />
Ian B. Wilkinson, MD, Cambridge, United Kingdom<br />
5:14 PM Is Vascular Aging Inevitable<br />
Edward G. Lakatta, MD, Baltimore, MD<br />
5:36 PM Pulse Wave Analysis in Subjects with Chronic<br />
Kidney Disease<br />
Raymond R. Townsend, MD, Philadelphia, PA<br />
46
Saturday Afternoon MAY 21<br />
Sessions<br />
4:30 PM – 6:00 PM • Trianon Rendezvous • Third Floor<br />
Young Investigator-in-Training Abstract<br />
Competition<br />
Moderator:<br />
Judges:<br />
Addison A. Taylor, MD, PhD, F<strong>ASH</strong>, Houston, TX<br />
Stephen R. Daniels, MD, PhD, F<strong>ASH</strong>, Aurora, CO,<br />
Thomas D. Giles, MD, F<strong>ASH</strong>, New Orleans, LA,<br />
Lawrence R. Krak<strong>of</strong>f, MD, New York, NY,<br />
Susanne B. Nicholas, MD, PhD, MPH, Los Angeles, CA,<br />
and Myron H. Weinberger, MD, Indianapolis, IN<br />
4:30 PM OR-1: Waist Hip Ratio vs Body Mass Index as<br />
Predictors <strong>of</strong> Endothelial Dysfunction<br />
Arantxa Rodriguez, Rosa Fabregate, Martin Fabregate,<br />
Susana Tello, Angelica Fernandez, Asuncion Guerri,<br />
Nuria De la Torre, Jose Saban‐Ruiz. Ramon y Cajal<br />
Hospital, Madrid, ES.<br />
4:42 PM OR-2: M-Atrial Natriuretic Peptide, a Novel Anti-<br />
Hypertensive Therapeutic Peptide, Is Markedly<br />
Resistant to In Vitro Degradation<br />
Paul M. McKie, Alessandro Cataliotti, Tomoko Ichiki,<br />
S. Jeson Sangaralingham, Valentina Cannone, John C.<br />
Burnett, Jr. Mayo Clinic, Rochester, MN, US.<br />
4:54 PM OR-3: Outcomes with Atenolol or Other β-Blockers:<br />
Network and Bayesian Meta-Analyses <strong>of</strong> Clinical<br />
Trials in <strong>Hypertension</strong><br />
W. Kurtis Childers†, 1 William J. Elliott, 1 Sanjib Basu, 2<br />
Peter M. Meyer. 2 1 Pacific Northwest University <strong>of</strong><br />
Health Sciences, Yakima, WA, US; 2 RUSH Medical<br />
College, Chicago, IL, US.<br />
5:06 PM OR-4: Role <strong>of</strong> Renal DJ-1 in the Regulation <strong>of</strong><br />
Oxidative Stress<br />
Santiago Cuevas Gonzalez, Yanrong Zhang, Yu Yang,<br />
Laureano D. Asico, Pedro A. Jose, Ines Armando.<br />
Children’s National Medical Center, George<br />
Washington University, Washington, DC, US.<br />
5:18 PM OR-5: Adiposity, Metabolic and Dietary Risk Factors<br />
Associated with Prehypertension in Black and White<br />
Adolescent Males: A Cross-Sectional Study<br />
Samip J. Parikh, Haidong Zhu, Norman K. Pollock,<br />
Inger Stallmann-Jorgensen, Gutin Bernard, Yanbin<br />
Dong. Medical College <strong>of</strong> Georgia, Augusta, GA, US.<br />
47
MAY 21<br />
Posters<br />
Saturday Evening<br />
Posters will be displayed in the Second Floor Promenade.<br />
Saturday, May 21, <strong>2011</strong><br />
Posters on Display: 4:30 PM – 7:30 PM • Poster Viewing: 6:00 PM – 7:00 PM<br />
Adolescent <strong>Hypertension</strong> and Obesity.............................. (PO-1 – PO-5)<br />
Antiatherosclerotic Drugs................................................... (PO-6 – PO-7)<br />
Cardiac Structure and Function/Imaging....................... (PO-8 – PO-10)<br />
Comprehensive Multi-Level Interventions for<br />
<strong>Hypertension</strong> Management in High-Risk Groups......(PO-11 – PO-30)<br />
Endothelial Function.......................................................(PO-31 – PO-45)<br />
Epidemiology/Special Populations................................(PO-46 – PO-78)<br />
Immune Mechanisms in <strong>Hypertension</strong>........................(PO-79 – PO-82)<br />
Metabolic Syndrome (Diabetes/Glycemic Control;<br />
Dysglycemic Drugs; Insulin Resistance).....................(PO-83 – PO-102)<br />
New Insights into the Role <strong>of</strong> Uric Acid<br />
in <strong>Hypertension</strong>............................................................(PO-103 – PO-104)<br />
Pediatric <strong>Hypertension</strong>...............................................(PO-105 – PO-111)<br />
Risk Factors (Lipids)....................................................(PO-112 – PO-115)<br />
Stroke.............................................................................(PO-117 – PO-119)<br />
Vascular Injury/Inflammation and Remodeling......(PO-120 – PO-123)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
48
Sunday Morning MAY 22<br />
Sessions<br />
8:00 AM – 12:30 PM • West Ballroom • Third Floor<br />
<strong>Hypertension</strong> for the Primary Care Clinician <strong>2011</strong><br />
7:30 AM Breakfast<br />
8:00 AM to 9:00 AM<br />
The Management <strong>of</strong> the Hypertensive Patient<br />
Before and After Surgery<br />
Co-Chairs: Jan N. Basile, MD, F<strong>ASH</strong>, Charleston, SC and<br />
F. Wilford Germino, MD, F<strong>ASH</strong>, Orland Park, IL<br />
8:00 AM Case Presentation<br />
F. Wilford Germino, MD, F<strong>ASH</strong><br />
8:10 AM Pre-operative Evaluation <strong>of</strong> the Patient with<br />
<strong>Hypertension</strong><br />
James B. Froehlich, MD, MPH, Ann Arbor, MI<br />
8:35 AM Peri-operative Management <strong>of</strong> the Hospitalized<br />
Patient with <strong>Hypertension</strong><br />
John D. Bisognano, MD, PhD, F<strong>ASH</strong>, Rochester, NY<br />
9:00 AM to 10:00 AM<br />
A Systems Approach to Optimize Blood Pressure<br />
Control<br />
Co-Chairs: Paula T. Einhorn, MD, MS, Bethesda, MD and Gbenga<br />
Ogedegbe, MD, MPH, MS, F<strong>ASH</strong>, New York, NY<br />
9:00 AM Exporting Lifestyle Modification into Your Practice<br />
Laura P. Svetkey, MD, Durham, NC<br />
9:20 AM Electronic Medical Records and the <strong>Hypertension</strong><br />
Initiative in the Carolinas<br />
Brent M. Egan, MD, F<strong>ASH</strong>, Charleston, SC<br />
9:40 AM A Team Based Approach to Blood Pressure Control<br />
Barry L. Carter, PharmD, Iowa City, IA<br />
10:00 AM Break<br />
10:15 AM to 11:15 AM<br />
Evaluation <strong>of</strong> Resistant <strong>Hypertension</strong><br />
Co-Chairs: Louis Kuritzky, MD, Gainesville, FL and<br />
Samuel J. Mann, MD, New York, NY<br />
10:15 AM Out <strong>of</strong> Office Monitoring to Rule Out Resistant<br />
<strong>Hypertension</strong><br />
Angela L. Brown, MD, St. Louis, MO<br />
continued…<br />
49
MAY 22<br />
Sunday morning<br />
Sessions continued<br />
10:30 AM Outpatient Evaluation for Secondary Causes <strong>of</strong><br />
Resistant <strong>Hypertension</strong><br />
Emmanuel Bravo, MD, Cleveland, OH<br />
10:55 AM Treatment <strong>of</strong> Resistant <strong>Hypertension</strong>:<br />
Tricks <strong>of</strong> the Trade<br />
William J. Elliott, MD, PhD, F<strong>ASH</strong>, Yakima, WA<br />
11:15 AM Panel Discussion:<br />
How Has the Management <strong>of</strong> <strong>Hypertension</strong> in<br />
Primary Care Changed Since JNC 7<br />
Chair: Michael J. Bloch, MD, F<strong>ASH</strong>, Reno, NV<br />
Panel Discussion Participants:<br />
George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL,<br />
Jan N. Basile, MD, F<strong>ASH</strong>, Charleston, SC,<br />
Angela L. Brown, MD, St. Louis, MO and<br />
Leonard M. Fromer, MD, Los Angeles, CA<br />
This Live activity, <strong>Hypertension</strong> for the Primary Care Clinician <strong>2011</strong>,<br />
has been reviewed and is acceptable for up to 4.25 Prescriptive credits by<br />
the <strong>American</strong> Academy <strong>of</strong> Family Physicians. Physicians should claim<br />
only the credit commensurate with the extent <strong>of</strong> their participation in<br />
the activity.<br />
50
Sunday Morning MAY 22<br />
Sessions<br />
9:00 AM – 10:30 AM • Sutton North • Second Floor<br />
The Role <strong>of</strong> Neurohumoral and Vasoactive<br />
Substances in <strong>Hypertension</strong><br />
Held in Partnership with the International Pediatric <strong>Hypertension</strong><br />
Association (IPHA)<br />
Co-Chairs: Donald L. Batisky, MD, Atlanta, GA and<br />
Jay N. Cohn, MD, Minneapolis, MN<br />
9:00 AM Effects <strong>of</strong> Endothelin Blockade on Blood Pressure:<br />
Pro and Con<br />
David M. Pollock, PhD, Augusta, GA<br />
9:30 AM The Interplay <strong>of</strong> Race/Ethnicity, Inflammation<br />
and Elevated Blood Pressure in Children and<br />
Adolescents<br />
Marc B. Lande, MD, MPH, Rochester, NY<br />
10:00 AM Dopamine, the Kidney and <strong>Hypertension</strong><br />
Pedro A. Jose, MD, Washington, DC<br />
51
MAY 22<br />
Sessions<br />
Sunday Morning<br />
9:00 AM – 10:30 AM • Regent Parlor • Second Floor<br />
Renin-Angiotensin System in <strong>Hypertension</strong>:<br />
Regulation and Consequences<br />
Held in Partnership with the Inter-<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong><br />
(I<strong>ASH</strong>)<br />
Co-Chairs: Haralambos Gavras, MD, Boston, MA and<br />
L. Gabriel Navar, PhD, New Orleans, LA<br />
9:00 AM Introduction: The Intratubular RAS in <strong>Hypertension</strong><br />
L. Gabriel Navar, PhD<br />
9:22 AM Role <strong>of</strong> the Transcription Factor ETS-1 as Mediator<br />
<strong>of</strong> Angiotensin II Induced End-Organ Injury<br />
Edgar A. Jaimes, MD, Birmingham, AL<br />
9:44 AM <strong>Hypertension</strong>, Insulin Resistance and Oxidative<br />
Stress<br />
Leopoldo Raij, MD, F<strong>ASH</strong>, Miami, FL<br />
10:06 AM Therapeutic Efficacy <strong>of</strong> New Renin Inhibitors<br />
Luis Juncos, MD, Córdoba, Argentina<br />
52
Sunday Morning MAY 22<br />
Sessions<br />
9:00 AM – 10:40 AM • Sutton Center • Second Floor<br />
The 3rd <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>/China<br />
Social Worker’s Association Vascular Protection<br />
Committee Session on Early Vascular Disease<br />
Detection and Management: Experience from China<br />
Co-Chairs: Suzanne Oparil, MD, F<strong>ASH</strong>, Birmingham, AL and<br />
Hongyu Wang, MD, PhD, Beijing, China<br />
9:00 AM Chinese Guidelines for Early Vascular Disease<br />
Detection <strong>2011</strong>: Experience from China<br />
Hongyu Wang, MD, PhD<br />
9:20 AM Role <strong>of</strong> Cardiometabolic Syndrome and Related<br />
Vascular Disease in Chinese Elderly<br />
Ting Tao, MD, Shanghai, China<br />
9:40 AM Epidemiology <strong>of</strong> <strong>Hypertension</strong> and Peripheral<br />
Vascular Disease in China<br />
Jianfang Luo, MD, Guangzhou, China<br />
10:00 AM Carotid IMT Examination for Atherosclerosis<br />
Screening in Diabetes<br />
Yuan Guo, MD, MS, Beijing, China<br />
10:20 AM Arterial Stiffness Parameters Integrated for Vascular<br />
Health Evaluation in Hypertensive Patients<br />
Tianhu Liu, MD, Chengdu, China<br />
53
MAY 22<br />
Sessions<br />
Sunday Morning<br />
9:00 AM – 10:30 AM • Sutton South • Second Floor<br />
Overcoming Clinical Inertia: Changing Practice<br />
Paradigms on Both Sides <strong>of</strong> the 49th Parallel<br />
Held in Partnership with <strong>Hypertension</strong> Canada<br />
Co-Chairs: Ross Feldman, MD, London, Canada and<br />
Alan H. Gradman, MD, F<strong>ASH</strong>, Pittsburgh, PA<br />
9:00 AM Introduction: Definitions and Scope <strong>of</strong> the Issue<br />
Joel M. Neutel, MD, F<strong>ASH</strong>, Tustin, CA<br />
9:10 AM Clinic Focused Educational Interventions to<br />
Improve Blood Pressure Control: Using the Heart<br />
and Stroke <strong>Hypertension</strong> Clinic Model as the<br />
Paradigm<br />
Sheldon W. Tobe, MD, F<strong>ASH</strong>, Toronto, Canada<br />
9:35 AM Simplifying Treatment Algorithms as a Means <strong>of</strong><br />
Reducing Clinical Inertia<br />
Ross Feldman, MD<br />
10:00 AM US Approaches for Guidelines Implementation<br />
William C. Cushman, MD, F<strong>ASH</strong>, Memphis, TN<br />
10:10 AM Implementation and Impact <strong>of</strong> the Canadian<br />
<strong>Hypertension</strong> Education <strong>Program</strong><br />
Norman R.C. Campbell, MD, Calgary, Canada<br />
10:20 AM Questions and Answers<br />
54
Sunday Morning MAY 22<br />
Posters<br />
Posters will be displayed in the Second Floor Promenade.<br />
Sunday, May 22, <strong>2011</strong><br />
Posters on Display: 10:00 AM – 6:30 PM • Poster Viewing: 5:30 PM – 6:30 PM<br />
Featured Posters<br />
Blood Pressure Measurement/Monitoring......................(FP-1 – FP-4)<br />
Adolescent <strong>Hypertension</strong>..................................................(FP-5 – FP-8)<br />
Aldosterone and Anti-Aldosterone Agents..............(PO-124 – PO-130)<br />
Antihypertensive Drugs and Pharmacology............(PO-131 – PO-157)<br />
Clinical Trials................................................................(PO-158 – PO-184)<br />
Coronary Artery Disease............................................(PO-185 – PO-191)<br />
Genetics/Gene Therapy/Proteomics..........................(PO-192 – PO-198)<br />
Heart Failure/Hypertrophy<br />
(Diastolic Dysfunction)...............................................(PO-199 – PO-216)<br />
<strong>Hypertension</strong> in Patients with Chronic<br />
Kidney Disease.............................................................(PO-217 – PO-226)<br />
Kidney and <strong>Hypertension</strong>...........................................(PO-227 – PO-242)<br />
Off-Target Cardiovascular Effects <strong>of</strong><br />
Non-Cardiovascular Drugs........................................(PO-243 – PO-244)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
55
MAY 22<br />
Debates<br />
Sunday Morning<br />
11:00 AM – 12:00 PM<br />
Sutton South • Second Floor<br />
Debate: Is it Blood Pressure Variability or Average<br />
Daily Blood Pressure that Best Predicts Stroke<br />
Moderator: William B. White, MD, F<strong>ASH</strong>, Farmington, CT<br />
11:00 AM Blood Pressure Variability<br />
Peter M. Rothwell, MD, Oxford, United Kingdom<br />
11:20 AM Average Daily Blood Pressure<br />
Eoin O’Brien, MD, Dublin, Ireland<br />
11:40 AM Rebuttal<br />
11:55 AM Questions and Answers<br />
Regent Parlor • Second Floor<br />
Debate: Surgical Intervention for Renal Artery<br />
Stenosis is Indicated<br />
Moderator: Bryan Williams, MD, Leicester, United Kingdom<br />
11:00 AM Yes: Thomas A. Sos, MD, New York, NY<br />
11:20 AM No: Lance D. Dworkin, MD, Providence, RI<br />
11:40 AM Rebuttal<br />
11:55 AM Questions and Answers<br />
56
Sunday Morning MAY 22<br />
Special Sessions<br />
11:00 AM – 12:00 PM<br />
Meet the Pr<strong>of</strong>essor Sessions<br />
Beekman Parlor • Second Floor<br />
How to Write a 12 Page Grant<br />
David Harder, MD, PhD, Milwaukee, WI<br />
Sutton North • Second Floor<br />
Understanding Statistics in Clinical Research<br />
Richard H. Grimm, Jr., MD, PhD, Minneapolis, MN<br />
Sutton Center • Second Floor<br />
How to Develop an Abstract/Lecture<br />
David G. Harrison, MD, Atlanta, GA<br />
57
MAY 22<br />
Plenary Session I<br />
Sunday Afternoon<br />
1:15 PM – 3:00 PM • East Ballroom • Third Floor<br />
Plenary Session I<br />
Co-Chairs: George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL and<br />
William B. White, MD, F<strong>ASH</strong>, Farmington, CT<br />
1:15 PM President’s Opening Address<br />
1:30 PM Keynote Lecture: Blood Pressure in Obesity<br />
F. Xavier Pi‐Sunyer, MD, MPH, New York, NY<br />
2:00 PM Cardiovascular Risk and Risk Reduction in Children<br />
and Adolescents<br />
Rae‐Ellen W. Kavey, MD, MPH, Rochester, NY<br />
2:20 PM Mechanisms from Studies <strong>of</strong> Human Obesity<br />
Sadaf Farooqi, PhD, Cambridge, United Kingdom<br />
2:40 PM Evaluation and Treatment <strong>of</strong> <strong>Hypertension</strong> in<br />
Childhood<br />
Joseph T. Flynn, MD, F<strong>ASH</strong>, Seattle, WA<br />
58
Sunday Afternoon MAY 22<br />
Sessions<br />
3:30 PM – 5:15 PM • Mercury Ballroom • Third Floor<br />
1 Aldosterone<br />
Co-Chairs: J. Howard Pratt, MD, Indianapolis, IN and<br />
Gordon H. Williams, MD, Boston, MA<br />
3:30 PM Non-Renal Effects <strong>of</strong> Aldosterone<br />
James M. Luther, MD, Nashville, TN<br />
3:50 PM Interactions Between Aldosterone and<br />
Nitric Oxide<br />
Charles J. Lowenstein, MD, Rochester, NY<br />
4:10 PM Role <strong>of</strong> Aldosterone and Mineralocorticoid Receptor<br />
Activation in Obesity Related <strong>Hypertension</strong><br />
John E. Hall, PhD, Jackson, MS<br />
Original Communications<br />
4:30 PM OR-6: Spironolactone Reverses Chlorthalidone-<br />
Induced Sympathetic Activation in Hypertensive<br />
Patients<br />
Prafull Raheja, Debbie Arbique, Zhijun Wang, Wanpen<br />
Vongpatanasin. UT Southwestern Medical Center,<br />
Dallas, TX, US.<br />
4:45 PM OR-7: Plasma Aldosterone Levels Affect Calcium<br />
Metabolism in Patients with Essential <strong>Hypertension</strong><br />
Gian Luca Colussi, Cristiana Catena, GianLuca Colussi,<br />
Leonardo A. Sechi. University <strong>of</strong> Udine, Udine, IT.<br />
5:00 PM OR-8: Inappropriately Intense Salt Restriction,<br />
Which Causes Elevation <strong>of</strong> Plasma Aldosterone<br />
Level, Might Augment Myocardial Fibrosis in<br />
Animal Model <strong>of</strong> Renal Tubular Injury<br />
Tatsuhiko Mori, 1 Kenichi Hasegawa, 2 Hirohisa<br />
Matsuda, 1 Yasuo Matsumura, 2 Nobukazu Ishizaka. 1<br />
1 Osaka Medical College, Takatsuki, JP; 2 Osaka<br />
University <strong>of</strong> Pharmaceutical Sciences, Takatsuki, JP.<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
59
MAY 22<br />
Special Sessions<br />
Sunday Afternoon<br />
3:30 PM – 5:15 PM • East Ballroom • Third Floor<br />
2 <strong>Hypertension</strong> in Patients with Chronic Kidney<br />
Disease<br />
Co-Chairs: Rajiv Agarwal, MD, Indianapolis, IN and<br />
Aldo J. Peixoto, MD, F<strong>ASH</strong>, West Haven, CT<br />
3:30 PM Clinical Epidemiology <strong>of</strong> <strong>Hypertension</strong> and Chronic<br />
Kidney Disease<br />
Rajiv Agarwal, MD<br />
3:50 PM <strong>Hypertension</strong> in Advanced Kidney Disease<br />
Luis M. Ruilope, MD, Madrid, Spain<br />
4:10 PM <strong>Hypertension</strong> in Renal Transplant Patients<br />
Martin S. Zand, MD, Rochester, NY<br />
Original Communications<br />
4:30 PM OR-9: Administration-Time-Dependent Effects <strong>of</strong><br />
Angiotensin Receptor Blockers in Hypertensive<br />
Patients with Chronic Kidney Disease<br />
Ramon C. Hermida, Diana E. Ayala, Artemio Mojon,<br />
Maria J. Fontao, Luisa Chayan, Jose R. Fernandez.<br />
University <strong>of</strong> Vigo, Vigo, ES.<br />
4:45 PM OR-10: Carvedilol for the Treatment <strong>of</strong> Intradialytic<br />
<strong>Hypertension</strong>: The Mechanisms and Treatment <strong>of</strong><br />
Intradialytic <strong>Hypertension</strong> (MATCH) Study<br />
Jula K. Inrig, Peter Van Buren, Catherine Kim, Robert<br />
Toto. UT Southwestern, Dallas, TX, US.<br />
5:00 PM OR-11: Cardiovascular Risk Assessment – Addition<br />
<strong>of</strong> CKD and Race to the Framingham Equation<br />
Paul E. Drawz, 1,2 Sarah Baraniuk, 3 Barry R. Davis, 3<br />
Mahboob Rahman. 2,4 1 MetroHealth Medical Center,<br />
Cleveland, OH, US; 2 Case Western Reserve University,<br />
Cleveland, OH, US; 3 University <strong>of</strong> Texas School <strong>of</strong><br />
Public Health, Houston, TX, US; 4 University Hospitals<br />
Case Medical Center, Cleveland, OH, US.<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
60
Sunday Afternoon MAY 22<br />
Sessions<br />
3:30 PM – 5:15 PM • West Ballroom • Third Floor<br />
3 Comprehensive Multi-Level Interventions for<br />
<strong>Hypertension</strong> Management in High-Risk Groups<br />
Co-Chairs: Daniel Levy, MD, Framingham, MA and<br />
Robert A. Phillips, MD, PhD, F<strong>ASH</strong>, Worcester, MA<br />
3:30 PM <strong>Hypertension</strong> in Minorities: A New York State<br />
Clinical Guidance Statement<br />
Joseph L. Izzo, Jr., MD, F<strong>ASH</strong>, Buffalo, NY<br />
3:50 PM Clinical Trial Interventions: Where Have We Gone<br />
Right or Wrong<br />
Bryan Williams, MD, Leicester, United Kingdom<br />
4:10 PM Integrated and Alternate Approaches to Treatment<br />
William J. Elliott, MD, PhD, F<strong>ASH</strong>, Yakima, WA<br />
Original Communications<br />
4:30 PM OR-12: Influence <strong>of</strong> Inflammatory and<br />
Prothrombotic Factors in Left Ventricular Structure<br />
and Function in Essential Hypertensive Patients<br />
Gregory Vyssoulis, 1 Eva Karpanou, 2 Stella Maria<br />
Kyvelou, 1 I. Barbetseas, 1 C. Stefanadis. 1 1 1st Cardiology<br />
Clinic Athens University Hippokration Hospital, GR;<br />
2 1st Cardiology Clinic Onassis Cardiosurgery Center,<br />
GR.<br />
4:45 PM OR-13: The Kaiser Permanente Northern California<br />
<strong>Hypertension</strong> Project 2001-2009: How an Integrated<br />
Care Delivery System Increased Blood Pressure<br />
Control Rates from 44% to 80% in 8 Years<br />
Marc G. Jaffe, Joseph D. Young. The Permanente<br />
Medical Group, Oakland, CA, US.<br />
5:00 PM OR-14: Intensive Blood Pressure Control Does Not<br />
Increase Falls and Fractures in Patients with Type 2<br />
Diabetes:The ACCORD Trial<br />
Karen Margolis, 1 Lisa Palermo, 2 Eric Vittingh<strong>of</strong>f, 2 Hal<br />
Atkinson, 3 Gregory Evans, 3 Bruce Hamilton, 4 Robert<br />
Josse, 5 Patrick O’Connor, 1 Debra Simmons, 6 Margaret<br />
Tiktin, 7 Ann Schwartz. 2 1 HealthPartners Research<br />
Foundation, US; 2 U <strong>of</strong> CA-SF, US; 3 Wake Forest SOM,<br />
US; 4 Baltimore VAMC, US; 5 University <strong>of</strong> Toronto,<br />
CA; 6 Central Arkansas Veterans Healthcare System,<br />
US; 7 Case Western Research University, US.<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
61
MAY 22<br />
Sessions<br />
Sunday Afternoon<br />
3:30 PM – 5:15 PM • Trianon Rendezvous • Third Floor<br />
New Perspectives in ISHIB Consensus Statement:<br />
Is Clinical Judgment Medically Appropriate<br />
Held in Partnership with the International <strong>Society</strong> on <strong>Hypertension</strong><br />
in Blacks (ISHIB)<br />
Co-Chairs: Kenneth A. Jamerson, MD, F<strong>ASH</strong>, Ann Arbor, MI and<br />
Daniel T. Lackland, DrPH, F<strong>ASH</strong>, Charleston, SC<br />
3:30 PM Is There a Role for Opinion in Guidelines or<br />
Consensus Reports A Perspective<br />
Keith C. Ferdinand, MD, F<strong>ASH</strong>, Atlanta, GA<br />
3:45 PM Highlights <strong>of</strong> the New Consensus Statement<br />
Shawna D. Nesbitt, MD, MS, F<strong>ASH</strong>, Dallas, TX<br />
Debate<br />
4:00 PM Supporting Perspective<br />
John M. Flack MD, MPH, Detroit, MI<br />
4:20 PM Opposing Perspective<br />
William C. Cushman, MD, F<strong>ASH</strong>, Memphis, TN<br />
4:40 PM Rebuttal<br />
62
Sunday Afternoon MAY 22<br />
Sessions<br />
3:30 PM – 5:00 PM • Trianon Ballroom • Third Floor<br />
Control <strong>of</strong> <strong>Hypertension</strong> is Leaving the Office:<br />
The Role <strong>of</strong> Home Blood Pressure and Telemedicine<br />
Co-Chairs: Lawrence R. Krak<strong>of</strong>f, MD, New York, NY and<br />
William B. White, MD, F<strong>ASH</strong>, Farmington, CT<br />
3:30 PM Home Blood Pressure and Cardiovascular Risk<br />
Gianfranco Parati, MD, Milan, Italy<br />
3:52 PM Using Home Blood Pressure in Clinical Practice<br />
Gbenga Ogedegbe, MD, MPH, MS, F<strong>ASH</strong>, New York,<br />
NY<br />
4:14 PM Home Blood Pressure and Telemetry to Improve<br />
<strong>Hypertension</strong> Control<br />
Richard J. McManus, MD, Birmingham, United<br />
Kingdom<br />
4:36 PM The Future <strong>of</strong> Telemedicine in the Management <strong>of</strong><br />
<strong>Hypertension</strong><br />
Lawrence R. Krak<strong>of</strong>f, MD<br />
Supported by an educational grant from Omron Healthcare, Inc.<br />
63
MAY 23<br />
Satellite Symposium<br />
6:00 AM – 7:30 AM • Trianon Ballroom • Third Floor<br />
Monday morning<br />
The Role <strong>of</strong> Beta-Blockers in <strong>Hypertension</strong>:<br />
A Healthy Debate<br />
Chairman: Jan N. Basile, MD, F<strong>ASH</strong>, Charleston, SC<br />
Learning Objectives:<br />
• Describe the differences and similarities<br />
among agents within the beta-blocker class <strong>of</strong><br />
antihypertensive agents<br />
• Summarize the results <strong>of</strong> key clinical trials<br />
investigating beta blockade in African <strong>American</strong>,<br />
Hispanic, and Asian patient populations<br />
• List reasons why beta-blockers should or should<br />
not be used as first line or second step therapy for<br />
hypertension<br />
<strong>Program</strong> Agenda:<br />
6:00 AM Welcome<br />
Overview <strong>of</strong> <strong>Program</strong> Learning Objectives<br />
Audience Response System (ARS)<br />
Jan N. Basile, MD, F<strong>ASH</strong>, Chairman<br />
6:05 AM The Class Effect With Beta-Blockers: Does One Size<br />
Fit All<br />
Addison A. Taylor, MD, PhD, F<strong>ASH</strong>,<br />
Houston, TX<br />
6:25 AM Beta-Blockers and Ethnicity: What Do We Really<br />
Know<br />
Henry A. Punzi, MD, Dallas, TX<br />
6:45 AM Debate: Beta-Blockers Are Appropriate for First<br />
Line or Second Step Therapy in Patients With<br />
<strong>Hypertension</strong><br />
AGREE: William H. Frishman, MD,<br />
Valhalla, NY<br />
DISAGREE: Franz H. Messerli, MD, F<strong>ASH</strong>,<br />
New York, NY<br />
7:15 AM Faculty Panel Discussion With Questions From the<br />
Audience<br />
Jan N. Basile, MD, F<strong>ASH</strong>, Moderator<br />
7:30 AM Review <strong>of</strong> <strong>Program</strong> Learning Objectives and Closing<br />
Remarks<br />
Jan N. Basile, MD, F<strong>ASH</strong>, Moderator<br />
A Breakfast will be held at 5:30 AM in the<br />
Trianon Ballroom.<br />
Supported by an educational grant from Forest Laboratories, Inc.<br />
64
Monday Morning MAY 23<br />
Sessions<br />
8:00 AM – 10:05 AM • Mercury Ballroom • Third Floor<br />
1 Off-Target Cardiovascular Effects <strong>of</strong> Non-<br />
Cardiovascular Drugs<br />
Co-Chairs: Franz H. Messerli, MD, F<strong>ASH</strong>, New York, NY and<br />
Suzanne Oparil, MD, F<strong>ASH</strong>, Birmingham, AL<br />
8:00 AM Anti-VEGF and Other Chemotherapeutic Agents<br />
Rhian M. Touyz, MD, PhD, Ottawa, Canada<br />
8:20 AM Non-Steroidal Anti-Inflammatory Drugs<br />
Raymond C. Harris, MD, Nashville, TN<br />
8:40 AM PDE5 Inhibitors and Organic Nitrates<br />
David J. Webb, MD, Edinburgh, United Kingdom<br />
9:00 AM PPAR Agents<br />
Julio A. Panza, MD, Washington, DC<br />
Original Communications<br />
9:20 AM OR-15: Effects on Ambulatory Blood Pressure <strong>of</strong><br />
Adding Low-Dose Aspirin at Bedtime in Subjects<br />
with Treated <strong>Hypertension</strong><br />
Ramon C. Hermida, University <strong>of</strong> Vigo, Vigo, ES.<br />
9:35 AM OR-16: Cardio-Metabolic Effects <strong>of</strong> Acute and<br />
Sub-Acute Exposures to Ambient Levels <strong>of</strong> Fine<br />
Particulate Matter Air Pollution<br />
Robert D. Brook, 1 Robert L. Bard, 1 J. Timothy<br />
Dvonch, 1 Masako Morishita, 1 Niko Kaciroti, 1 Sanjay<br />
Rajagopalan. 2 1 University <strong>of</strong> Michigan, US; 2 Ohio State<br />
University, US.<br />
9:50 AM OR-17: Impact <strong>of</strong> Nonsteroidal Anti-Inflammatory<br />
Drugs on Nocturnal Blood Pressure<br />
W. B. White†, 1 L. Lavange, 2 A. Marquis. 2 1 University <strong>of</strong><br />
Connecticut School <strong>of</strong> Medicine, Farmington, CT, US;<br />
2 University <strong>of</strong> North Carolina at Chapel Hill, Chapel<br />
Hill, NC, US.<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
65
MAY 23<br />
Sessions<br />
Monday morning<br />
8:00 AM – 10:00 AM • East Ballroom • Third Floor<br />
2 New Insights into the Role <strong>of</strong> Uric Acid in<br />
<strong>Hypertension</strong><br />
Co-Chairs: Richard J. Johnson, MD, Denver, CO and<br />
Andrew Whelton, MD, Baltimore, MD<br />
8:00 AM Fructose-Obesity-Uric Acid Link<br />
Richard J. Johnson, MD<br />
8:25 AM Oxidative Stress and Impact <strong>of</strong> Uric Acid<br />
Allan D. Struthers, MD, Dundee, United Kingdom<br />
8:40 AM Urate-Lowering and Blood Pressure Response<br />
Daniel I. Feig, MD, PhD, Houston, TX<br />
Original Communications<br />
9:00 AM OR-18: Associations <strong>of</strong> Uric Acid with Asymmetric<br />
Dimethylarginine, L-arginine and Arterial Stiffening<br />
in <strong>Hypertension</strong><br />
K. Dimitriadis, C. Tsioufis, A. Aggelis, S. Kyvelou,<br />
E. Stefanadi, L. Lioni, D. Flessas, C. Stefanadis.<br />
Hippokration Hospital, Athens, GR.<br />
9:15 AM OR-19: Epoxyeicosatrienoic Acid Agonist Attenuates<br />
Adipogenesis Derived from Mesenchymal Stem Cells<br />
Via Heme Oxygenase-PPARg Pathways<br />
DongHyun Kim, 1 Luca Vanella, 1 Nitin Puri, 1 Michal L.<br />
Schwartzman, 2 John R. Falck, 3 Komal Sodhi, 1 Nader G.<br />
Abraham. 1 1 University <strong>of</strong> Toledo College <strong>of</strong> Medicine,<br />
Toledo, OH, US; 2 New York Medical College, Valhalla,<br />
NY, US; 3 University <strong>of</strong> Texas Southwestern Medical<br />
Center, Dallas, TX, US.<br />
9:30 AM OR-20: Effect <strong>of</strong> Allopurinol on Blood Pressure:<br />
A Systematic Review<br />
Vikram Agarwal, 1 Nidhi Hans, 2 Franz Messerli. 1 1 St.<br />
Luke’s-Roosevelt Hospital Center, NY, US; 2 Harvard<br />
School <strong>of</strong> Public Health, MA, US.<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
66
Monday Morning MAY 23<br />
Sessions<br />
8:00 AM – 10:00 AM • West Ballroom • Third Floor<br />
3 Devices and Surgical Ablation for Refractory<br />
<strong>Hypertension</strong><br />
Co-Chairs: Domenic A. Sica, MD, Richmond, VA and<br />
Ronald G. Victor, MD, Los Angeles, CA<br />
8:00 AM How to Evaluate and Choose the Appropriate<br />
Patient<br />
Henry Krum, MBBS, PhD, Melbourne, Australia<br />
8:20 AM Renal Nerve Ablation<br />
Roland E. Schmieder, MD, Erlangen, Germany<br />
8:40 AM Carotid Baroreceptor Manipulation<br />
John D. Bisognano, MD, PhD, F<strong>ASH</strong>, Rochester, NY<br />
Original Communications<br />
9:00 AM OR-21: True Resistant <strong>Hypertension</strong>: Optimal Cut-<br />
Off Ambulatory Blood Pressure Level for Diagnosis<br />
and Effect <strong>of</strong> Spironolactone<br />
Jose A. Garcia‐Donaire, Julian Segura, Cesar Cerezo,<br />
Luis M. Ruilope. Hospital 12 de Octubre, Madrid, ES.<br />
9:15 AM OR-22: Individualized <strong>Program</strong>ming Demonstrates<br />
Feasibility <strong>of</strong> Unilateral Approach to Delivery <strong>of</strong><br />
Baroreflex Activation Therapy®<br />
Domenic Sica†, 1 John Bisognano, 2 Mitra Nadim, 3 Luis<br />
Sanchez, 4 George Bakris. 5 1 Virginia Commonwealth<br />
University, Richmond, VA, US; 2 University <strong>of</strong><br />
Rochester, Rochester, NY, US; 3 University <strong>of</strong> Southern<br />
California, Los Angeles, CA, US; 4 Washington<br />
University, St. Louis, MO, US; 5 University <strong>of</strong> Chicago,<br />
Chicago, IL, US.<br />
9:30 AM OR-23: The Efficacy <strong>of</strong> Adding the Direct Renin<br />
Inhibitor Aliskiren on the Patients with Resistant<br />
<strong>Hypertension</strong> (55% Had Chronic Kidney Disease)<br />
– Subgroup Analysis on Different Levels <strong>of</strong> Plasma<br />
Renin Activity<br />
Fumitoshi Satoh, Ryo Morimoto, Masataka Kudo,<br />
Yoshitugu Iwakura, Yoshikiyo Ono, Sadayoshi Ito.<br />
Tohoku University Hospital, Sendai, JP<br />
9:45 AM OR-24: Exploring the Prevalence <strong>of</strong> Resistant<br />
<strong>Hypertension</strong> in a Large Ethnically Diverse<br />
Hypertensive Population<br />
Simran Bhandari, In Lu Liu, Jiaxiao Shi, Federico<br />
Calara, Scott Rasgon, John Sim. Kaiser Permanente<br />
Los Angeles Medical Center, Los Angeles, CA, US.<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
67
MAY 23<br />
Sessions<br />
Monday morning<br />
8:30 AM – 10:00 AM • Trianon Rendezvous • Third Floor<br />
The Kidney Early Evaluation <strong>Program</strong> (KEEP):<br />
A New Longitudinal Dimension for a New Decade<br />
Held in Partnership with the National Kidney Foundation (NKF)<br />
Co-Chairs: George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL and<br />
Joseph A. Vassalotti, MD, New York, NY<br />
8:30 AM KEEP: CKD Screening <strong>Program</strong> Overview<br />
George L. Bakris, MD, F<strong>ASH</strong><br />
8:52 AM KEEP: Longitudinal Preliminary Results<br />
Joseph A. Vassalotti, MD<br />
9:14 AM KEEP: Experience with the CKD-EPI Equation<br />
Lesley A. Stevens, MD, MS Boston, MA<br />
9:36 AM Where Do We Stand on Blood Pressure Control<br />
in KEEP<br />
Adam Whaley‐Connell, DO, F<strong>ASH</strong>, Columbia, MO<br />
68
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
Posters will be displayed in the Second Floor Promenade.<br />
Monday, May 23, <strong>2011</strong><br />
Posters on Display: 10:00 AM – 5:30 PM • Poster Viewing: 4:30 PM – 5:30 PM<br />
Featured Posters<br />
Cardiac Structure and Function.................................... (FP-9 – FP-13)<br />
Arterial Structure and Compliance...........................(PO-245 – PO-259)<br />
Blood Pressure Measurement/Monitoring............(PO-260 – PO-305A)<br />
Cellular Mechanisms (Cell Biology;<br />
Cell Membrane Transport/Ion Channels;<br />
Coagulation/Thrombosis; Growth Factors).............(PO-306 – PO-308)<br />
Lipid Metabolism...........................................................................(PO-309)<br />
Neural Hormonal Mechanisms (Renin; Neural Control; Vasoactive<br />
Autacoids).....................................................................(PO-310 – PO-312)<br />
Non – Pharmacological Therapy (Alternative<br />
Medicine; Diet; Physical Activity).............................(PO-313 – PO-322)<br />
Nutrition and Cardiovascular Prevention................(PO-323 – PO-330)<br />
Obesity...........................................................................(PO-331 – PO-339)<br />
Patient – Provider-Healthcare System Issues...........(PO-340 – PO-355)<br />
Preclinical Models/Experimental <strong>Hypertension</strong>.....(PO-357 – PO-358)<br />
Pregnancy......................................................................(PO-359 – PO-361)<br />
Salt-Sensitive Mechanisms <strong>of</strong> <strong>Hypertension</strong>............(PO-362 – PO-364)<br />
Secondary <strong>Hypertension</strong>.............................................(PO-365 – PO-367)<br />
Late-Breaking Posters.........................................(LB-PO-01 – LB-PO-03)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
69
MAY 23<br />
Sessions<br />
Monday morning<br />
10:05 AM – 11:35 AM • Trianon Ballroom • Third Floor<br />
Hyperkalemia Management in High Risk Patients:<br />
New Evidence-Based Approaches<br />
Co-Chairs: Murray Epstein, MD, Miami, FL and<br />
Luis M. Ruilope, MD, Madrid, Spain<br />
10:05 AM The Spectrum <strong>of</strong> Cardiovascular Risk Associated<br />
with Potassium Abnormalities<br />
Domenic A. Sica, MD, Richmond, VA<br />
10:35 AM Use <strong>of</strong> RAAS Inhibitors for Cardio-Renal Risk<br />
Reduction and Potassium Management<br />
Luis M. Ruilope, MD<br />
11:05 AM Conventional versus Novel Approaches to the<br />
Management <strong>of</strong> Hyperkalemia<br />
David A. Bushinsky, MD, Rochester, NY<br />
Supported by an educational grant from Relypsa, Inc.<br />
70
Monday Morning MAY 23<br />
Debate<br />
11:45 AM – 12:15 PM • Trianon Ballroom • Third Floor<br />
Debate: Are Elevated Potassium Levels Really a<br />
Concern<br />
Moderator: Barry J. Materson, MD, MBA, F<strong>ASH</strong>, Miami, FL<br />
11:35 AM Yes: Vasilios Papademetriou, MD, F<strong>ASH</strong>,<br />
Washington, DC<br />
11:45 AM No: Bertram Pitt, MD, Ann Arbor, MI<br />
11:55 AM Rebuttal<br />
71
MAY 23<br />
Sessions<br />
Monday morning<br />
10:30 AM – 12:00 PM • Mercury Ballroom • Third Floor<br />
1 Immune Mechanisms in <strong>Hypertension</strong><br />
Co-Chairs: Michael W. Brands, PhD, Augusta, GA and<br />
David G. Harrison, MD, Atlanta, GA<br />
10:30 AM The Role <strong>of</strong> Inflammatory Cytokines in Pregnancy-<br />
Induced <strong>Hypertension</strong><br />
Babbette LaMarca, PhD, Jackson, MS<br />
10:52 AM T-Regulatory Cells in <strong>Hypertension</strong><br />
Ernesto L. Schiffrin, MD, PhD, Montreal, Canada<br />
11:14 AM Novel Mechanisms <strong>of</strong> Renal Injury in <strong>Hypertension</strong><br />
David L. Mattson, PhD, Milwaukee, WI<br />
11:36 AM Adaptive Immune Response in <strong>Hypertension</strong><br />
David G. Harrison, MD<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
72
Monday Morning MAY 23<br />
Sessions<br />
10:30 AM – 12:00 PM • East Ballroom • Third Floor<br />
2 Management <strong>of</strong> Elevated Blood Pressure in the<br />
Hospital Setting<br />
Co-Chairs: William J. Elliott, MD, PhD, F<strong>ASH</strong>, Yakima, WA and<br />
Sandra J. Taler, MD, F<strong>ASH</strong>, Rochester, MN<br />
10:30 AM <strong>Hypertension</strong> in the Emergency Department<br />
C. Venkata S. Ram, MD, F<strong>ASH</strong>, Dallas, TX<br />
10:52 AM <strong>Hypertension</strong> in the Inpatient Unit<br />
Alan B. Weder, MD, Ann Arbor, MI<br />
11:14 AM <strong>Hypertension</strong> in the Peri-operative Period<br />
Daniel Duprez, MD, PhD, F<strong>ASH</strong>, Minneapolis, MN<br />
11:36 AM <strong>Hypertension</strong> in the Dialysis Unit<br />
Aldo J. Peixoto, MD, F<strong>ASH</strong>, West Haven, CT<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
73
MAY 23<br />
Sessions<br />
Monday morning<br />
10:30 AM – 12:00 PM • West Ballroom • Third Floor<br />
3 Management <strong>of</strong> <strong>Hypertension</strong> in Diabetics and<br />
Chronic Kidney Disease<br />
Co-Chairs: James R. Sowers, MD, F<strong>ASH</strong>, Columbia, MO and<br />
Bryan Williams, MD, Leicester, United Kingdom<br />
10:30 AM Is There an Optimal Blood Pressure Goal in the<br />
Patient with Type-2 Diabetes<br />
Matthew R. Weir, MD, F<strong>ASH</strong>, Baltimore, MD<br />
10:52 AM Prevention <strong>of</strong> Renal Disease in the Hypertensive,<br />
Type-2 Diabetic<br />
Robert D. Toto, MD, Dallas, TX<br />
11:14 AM Prevention <strong>of</strong> Renal Disease in the African-<br />
<strong>American</strong> Patient with <strong>Hypertension</strong><br />
Velvie A. Pogue, MD, New York, NY<br />
11:36 AM Management <strong>of</strong> Metabolic Co-Morbidities in the<br />
Hypertensive Patient<br />
Mark E. Molitch, MD, Chicago, IL<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
74
Monday Morning MAY 23<br />
Sessions<br />
10:30 AM – 12:00 PM • Trianon Rendezvous • Third Floor<br />
Blood Pressure Variability and Treatment Goals<br />
Held in Partnership with the European <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong><br />
(ESH)<br />
Co-Chairs: George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL and<br />
Krzyszt<strong>of</strong> Narkiewicz, MD, PhD, Gdánsk, Poland<br />
10:30 AM Short and Long-Term Blood Pressure Variability<br />
Giuseppe Mancia, MD, Milan, Italy<br />
10:52 AM J-Curve Revisited<br />
Athanasios J. Manolis, MD, PhD, Athens, Greece<br />
11:14 AM Target Blood Pressure in Nephropatic Patients<br />
George L. Bakris, MD, F<strong>ASH</strong><br />
11:36 AM Ambulatory and Home Blood Pressure Targets<br />
William B. White, MD, F<strong>ASH</strong>, Farmington, CT<br />
75
MAY 23<br />
Plenary Session II<br />
Monday Afternoon<br />
1:30 PM – 4:00 PM • East Ballroom • Third Floor<br />
Award Presentations<br />
Co-Chairs:<br />
George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL and<br />
Norman K. Hollenberg, MD, PhD, Boston, MA<br />
1:30 PM Robert Tigerstedt Award Lecture<br />
Acetyl-Ser-Asp-Lys-Pro, an Endogenous<br />
Tetrapeptide: Role in Target Organ Damage in<br />
<strong>Hypertension</strong>, and Autoimmune Myocarditis<br />
Oscar A. Carretero, MD, F<strong>ASH</strong>, Detroit, MI<br />
2:00 PM Young Scholar Award Lecture*<br />
Novel Mechanisms Linking Chronic Inflammation<br />
and <strong>Hypertension</strong> in Systemic Lupus Erythematosus<br />
Michael J. Ryan, PhD, Jackson, MS<br />
2:20 PM Young Scholar Award Lecture*<br />
State Rescued with Innovative BNP Based<br />
Technologies<br />
Alessandro Cataliotti, MD, PhD, Rochester, MN<br />
2:40 PM Marvin Moser Clinical Award Lecture<br />
Water Immersion: A Model <strong>of</strong> Volume Expansion<br />
for Assessing Renin-Aldosterone Responsiveness<br />
and Renal Sodium Handling in Humans<br />
Murray Epstein, MD, Miami, FL<br />
State-<strong>of</strong>-the-Art Lectures<br />
Co-Chairs: George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL and<br />
David G. Harrison, MD, Atlanta, GA<br />
3:00 PM Leukocyte Telomere Length Genetics and<br />
Cardiovascular Disease<br />
Abraham Aviv, MD, Newark, NJ<br />
3:30 PM Development <strong>of</strong> Cardiac Hypertrophy<br />
Joseph A. Hill, MD, PhD, Dallas, TX<br />
*Supported by an educational grant from SERVIER.<br />
76
Monday Afternoon MAY 23<br />
Debates<br />
4:30 PM – 5:00 PM<br />
Beekman Parlor • Second Floor<br />
Debate: The Dominant Contributor to Systemic<br />
<strong>Hypertension</strong> is<br />
Moderator: Murray Epstein, MD, Miami, FL<br />
4:30 PM Sympathetic Nervous System not the RAAS<br />
Murray D. Esler, MBBS, PhD, Melbourne, Australia<br />
4:40 PM Activation <strong>of</strong> the Intrarenal RAAS not the SNS<br />
L. Gabriel Navar, PhD, New Orleans, LA<br />
4:50 PM Rebuttal<br />
Sutton North • Second Floor<br />
Debate: <strong>Hypertension</strong> is a Disorder <strong>of</strong> the Kidney<br />
Moderator: Jens Titze, MD, Erlangen, Germany<br />
4:30 PM Yes: Joey P. Granger, PhD, Jackson, MS<br />
4:40 PM No: Allyn L. Mark, MD, Iowa City, IA<br />
4:50 PM Rebuttal<br />
77
MAY 24<br />
Sessions<br />
Tuesday Morning<br />
8:15 AM – 9:30 AM • West Ballroom • Third Floor<br />
Late-Breaking Clinical Trials<br />
Co-Chairs: George L. Bakris, MD, F<strong>ASH</strong>, Chicago, IL and<br />
William B. White, MD, F<strong>ASH</strong>, Farmington, CT<br />
8:15 AM LB-OR-01: Evaluation <strong>of</strong> Cardiovascular Effects in<br />
Three Double-Blind, Placebo-Controlled Clinical<br />
Trials with Controlled-Release Phentermine/<br />
Topiramate<br />
Suzanne Oparil†, 1 Wesley Day, 2 Charles Bowden. 2<br />
1 University <strong>of</strong> Alabama, Birmingham, AL, US; 2 Vivus,<br />
Mountain View, CA, US.<br />
8:30 AM LB-OR-02: Longterm (3 – 5 Months) Spaceflight<br />
Promotes a Sustained Decrease in Blood Pressure<br />
and Systemic Vascular Resistance in Astronauts<br />
Peter Norsk, 1 Ali Asmar, 1 Niels Juel Christensen. 2<br />
1 University <strong>of</strong> Copenhagen, Copenhagen, DK; 2 Herlev<br />
University Hospital, Herlev, DK.<br />
8:45 AM LB-OR-03: Azilsartan Medoxomil Plus<br />
Chlorthalidone Reduces BP More Effectively<br />
Than Olmesartan Plus HCTZ in Stage 2 Systolic<br />
<strong>Hypertension</strong><br />
William C. Cushman†, 1 George Bakris, 2 William B.<br />
White, 3 Michael Weber, 4 Domenic Sica, 5 Andrew<br />
Roberts, 6 Eric Lloyd, 6 Stuart Kupfer. 6 1 University <strong>of</strong><br />
TN College <strong>of</strong> Medicine, US; 2 U <strong>of</strong> Chicago Pritzker<br />
School <strong>of</strong> Medicine, US; 3 U <strong>of</strong> CT School <strong>of</strong> Medicine,<br />
US; 4 New York, NY, US; 5 VA Commonwealth U Health<br />
System, US; 6 Takeda Global Research & Development,<br />
US.<br />
9:00 AM LB-OR-04: Common Blood Pressure Genetic<br />
Variants and Their Relations to <strong>Hypertension</strong>,<br />
Target-Organ Damage, and Cardiovascular Disease<br />
Risk: The International Collaboration for Blood<br />
Pressure Genome-Wide Association Studies (ICBP)<br />
Georg Ehret, 1 Patricia Munroe, 4 Christopher Newton-<br />
Cheh, 5 Kenneth Rice, 3 Cornelia van Duin, 6 Aravinda<br />
Chakravarti, 1 Daniel Levy, 2 Mark Caulfield, 4 Toby<br />
Johnson. 4 1 Johns Hopkins, Baltimore, MD, US;<br />
2 NHLBI, Framingham, MA, US; 3 University <strong>of</strong><br />
Washington, Seattle, WA, US; 4 London School <strong>of</strong><br />
Medicine, London, GB; 5 Broad Institute, Cambridge,<br />
MA, US; 6 The Rotterdam Study, Rotterdam, NL.<br />
continued…<br />
78
Tuesday Morning MAY 24<br />
Sessions continued<br />
9:15 AM LB-OR-05: Sixteen Novel Loci Influence Blood<br />
Pressure in Diverse Populations<br />
Georg B. Ehret, 1 Patricia B. Munroe, 2 Kenneth M.<br />
Rice, 3 Murielle Bochud, 4 Andrew D. Johnson, 5<br />
Daniel I. Chasman, 6 Albert V. Smith, 7 Bruce M.<br />
Pstay, 3 Goncalo R. Abecasis, 8 Aravinda Chakravarti, 1<br />
Paul Elliott, 9 Cornelia M. van Duijn, 10 Christopher<br />
Newton Cheh, 11 Daniel Levy, 5 Mark J. Caulfield, 2<br />
Toby Johnson. 2 1 Johns Hopkins University School <strong>of</strong><br />
Medicine, US; 2 Queen Mary University <strong>of</strong> London,<br />
GB; 3 University <strong>of</strong> Washington, Seattle, US; 4 University<br />
<strong>of</strong> Lausanne, CH; 5 National Heart Lung, and Blood<br />
Institute, Bethesda, US; 6 Brigham and Women’s<br />
Hospital, Boston, US; 7 University <strong>of</strong> Iceland, Reykajvik,<br />
IS; 8 University <strong>of</strong> Michigan School <strong>of</strong> Public Health,<br />
Ann Arbor, US; 9 Imperial College, GB; 10 Erasmus<br />
Medical Center, NL; 11 Massachusetts General Hospital,<br />
US.<br />
79
MAY 24<br />
Sessions<br />
Tuesday Morning<br />
10:00 AM – 11:30 AM • Sutton North • Second Floor<br />
1 Salt-Sensitive Mechanisms <strong>of</strong> <strong>Hypertension</strong><br />
Co-Chairs: Allyn L. Mark, MD, Iowa City, IA and<br />
Jens Titze, MD, Erlangen, Germany<br />
10:00 AM Renal Sodium Handling, Endothelin, and<br />
Genetic Models<br />
Donald E. Kohan, MD, PhD, Salt Lake City, UT<br />
10:30 AM Significance <strong>of</strong> Non-Osmotic Sodium<br />
Jens Titze, MD<br />
11:00 AM Nitric Oxide, Superoxide and Renal Sodium<br />
Handling<br />
Jeffrey L. Garvin, PhD, Detroit, MI<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
80
Tuesday Morning MAY 24<br />
Sessions<br />
10:00 AM – 11:30 AM • Sutton Center • Second Floor<br />
2 Integrated Cardiovascular Disease Guidelines<br />
and Implementation<br />
Co-Chairs: Henry R. Black, MD, F<strong>ASH</strong>, New York, NY and<br />
Sidney Smith, Jr., MD, Chapel Hill, NC<br />
10:00 AM Rationale for the NHLBI Integrated Cardiovascular<br />
Risk Reduction Guidelines<br />
Sidney Smith, Jr., MD<br />
10:30 AM Implementation <strong>of</strong> the Integrated Cardiovascular<br />
Risk Reduction Guidelines<br />
John Merenich, MD, Denver, CO<br />
11:00 AM Results <strong>of</strong> the Integrated Cardiovascular Risk<br />
Reduction Guidelines Implementation in Northern<br />
California<br />
Alan S. Go, MD, Oakland, CA<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
81
MAY 24<br />
Sessions<br />
Tuesday Morning<br />
10:00 AM – 11:30 AM • Beekman Parlor • Second Floor<br />
3 Nutrition and Cardiovascular Prevention<br />
Co-Chairs: Lawrence J. Appel, MD, MPH, F<strong>ASH</strong>, Baltimore, MD<br />
and David S. Kountz, MD, Neptune, NJ<br />
10:00 AM High Fructose Corn Syrup, Sucrose and Fructose:<br />
What Do We Really Know<br />
James Rippe, MD, Shrewsbury, MA<br />
10:30 AM Cations and Blood Pressure Control<br />
Lawrence J. Appel, MD, MPH, F<strong>ASH</strong><br />
11:00 AM Low Protein and Renal Protection<br />
Robert D. Toto, MD, Dallas, TX<br />
1 Pathobiology Track 2 Translational Track 3 Therapy Track<br />
82
<strong>Hypertension</strong> Awareness Campaign for Your Patients<br />
ARE YOU 1 IN 3<br />
GET THE FACTS. KNOW YOUR RISKS.<br />
Help spread the word by visiting 1in3people.com.<br />
As per the <strong>American</strong> Heart Association, 1 in 3 US adults has high blood pressure. 1<br />
1. Roger VL, Go AS, Lloyd-Jones DM, et al; for the <strong>American</strong> Heart Association Statistics Committee and Stroke<br />
Statistics Subcommittee. Heart disease and stroke statistics—<strong>2011</strong> update: a report from the <strong>American</strong><br />
Heart Association. Circulation. <strong>2011</strong>;123;e18-e209.<br />
Novartis Pharmaceuticals Corporation<br />
East Hanover, New Jersey 07936<br />
© <strong>2011</strong> Novartis Printed in USA 4/11 CVF-1058015 Printed on Recycled Paper
<strong>2011</strong><br />
<strong>American</strong> <strong>Society</strong><br />
<strong>of</strong> <strong>Hypertension</strong><br />
<strong>Program</strong><br />
Posters
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
Posters will be displayed in the Second Floor Promenade.<br />
Saturday, May 21, <strong>2011</strong><br />
Posters on Display: 4:30 PM – 7:30 PM • Poster Viewing: 6:00 PM – 7:00 PM<br />
Adolescent <strong>Hypertension</strong> and Obesity.............................. (PO-1 – PO-5)<br />
Antiatherosclerotic Drugs................................................... (PO-6 – PO-7)<br />
Cardiac Structure and Function/Imaging....................... (PO-8 – PO-10)<br />
Comprehensive Multi-Level Interventions for<br />
<strong>Hypertension</strong> Management in High-Risk Groups......(PO-11 – PO-30)<br />
Endothelial Function.......................................................(PO-31 – PO-45)<br />
Epidemiology/Special Populations................................(PO-46 – PO-78)<br />
Immune Mechanisms in <strong>Hypertension</strong>........................(PO-79 – PO-82)<br />
Metabolic Syndrome (Diabetes/Glycemic Control;<br />
Dysglycemic Drugs; Insulin Resistance).....................(PO-83 – PO-102)<br />
New Insights into the Role <strong>of</strong> Uric Acid<br />
in <strong>Hypertension</strong>............................................................(PO-103 – PO-104)<br />
Pediatric <strong>Hypertension</strong>...............................................(PO-105 – PO-111)<br />
Risk Factors (Lipids)....................................................(PO-112 – PO-115)<br />
Stroke.............................................................................(PO-117 – PO-119)<br />
Vascular Injury/Inflammation and Remodeling......(PO-120 – PO-123)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
86
Saturday Afternoon MAY 21<br />
Posters<br />
4:30 PM – 7:30 PM • Second Floor Promenade<br />
Adolescent hypertension and obesity<br />
PO-1:<br />
PO-2:<br />
PO-3:<br />
PO-5:<br />
Common Carotid Artery Intima-Media Thickness<br />
in Patients with Abdominal Obesity and Essential<br />
<strong>Hypertension</strong><br />
Evgeny V. Shlyakhto, 1 Olga D. Belyaeva, 2 Olga O.<br />
Bolshakova, 1 Aelita V. Berezina, 2 Olga O. Berkovich, 2<br />
Elena I. Baranova. 2 1 Almazov Federal Heart, Blood<br />
and Endocrinology Centre, Saint-Petersburg, RU;<br />
2 Saint-Petersburg State Medical University, Saint-<br />
Petersburg, RU.<br />
Prevalence <strong>of</strong> <strong>Hypertension</strong> in Pediatric Oncology<br />
Survivors<br />
Kathy K. Y. Lee‐Son, 1 Sheila L. Pritchard, 2 Douglas<br />
G. Matsell, 1 Josephine X. Chow, 1 Janis M. Dionne. 1<br />
1 BC Children’s Hospital, Vancouver, BC, CA; 2 BC<br />
Children’s Hospital, Vancouver, BC, CA.<br />
Blood Pressure Variability in White Coat<br />
Hypertensive Adolescents<br />
Egle R. Silva, Jose J. Villasmil, Greily A. Bermudez,<br />
Mayela J. Bracho, Carlos E. Esis, Gustavo E. Calmon,<br />
Alicex C. Gonzalez. Instituto de Enfermedades<br />
Cardiovasculares, Universidad del Zulia, Maracaibo,<br />
VE.<br />
Pharmacologic Management <strong>of</strong> Primary<br />
<strong>Hypertension</strong> in Adolescents<br />
Esther Yoon, Lisa Cohn, Albert Rocchini, David<br />
Kershaw, Gary Freed, Frank Ascione, Sarah Clark.<br />
University <strong>of</strong> Michigan, US.<br />
Antiatherosclerotic Drugs<br />
PO-6:<br />
PO-7:<br />
Effects <strong>of</strong> 3-Hydroxy-3-Methylglutaryl Coenzyme A<br />
Reductase Inhibitors on Blood Pressure<br />
Vikram V. Agarwal, Alexandros Briasoulis, Franz H.<br />
Messerli. St. Luke’s-Roosevelt Hospital, Columbia<br />
University College <strong>of</strong> Physicians and Surgeons, New<br />
York, NY, US.<br />
Statin Effect on the Blood Pressure in Young and<br />
Elderly Adults: Meta-Analysis<br />
Camila Hartmann, Manuela S. Baldo, Talita R.<br />
Strano, Tariane F. Foiato, Emilton Lima, Jr.. Pontifícia<br />
Universidade Católica do Paraná, Curitiba, PR, BR.<br />
Cardiac Structure and Function/Imaging<br />
PO-8:<br />
Effect <strong>of</strong> Telmisartan on Paroxymal Atrial<br />
Fibrillation in Hypertensive Patients with Different<br />
Left Atrial Size<br />
Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi,<br />
Gianluigi Marasi, Pierangelo Lazzari. University <strong>of</strong><br />
Pavia, Pavia, IT.<br />
87
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-9:<br />
PO-10:<br />
Effect <strong>of</strong> Aliskiren on QT Dispersion in Diabetic and<br />
Non Diabetic Hypertensive Patients<br />
Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi,<br />
Gianluigi Marasi, Pierangelo Lazzari. University <strong>of</strong><br />
Pavia, IT.<br />
Impact <strong>of</strong> Antihypertensive Therapy on<br />
Dyssynchrony in Patients with Never-Treated<br />
<strong>Hypertension</strong><br />
Beom‐June Kwon, Sung‐Won Jang, Kyu‐Young Choi,<br />
Dong‐Bin Kim, Eun‐Joo Cho, Ho‐Joong Youn, Tae‐Ho<br />
Rho, Jae‐Hyung Kim. The Catholic University <strong>of</strong><br />
Korea, Seoul, KR.<br />
Comprehensive multi-level interventions<br />
for hypertension management in highrisk<br />
groups<br />
PO-11:<br />
PO-12:<br />
PO-13:<br />
PO-14:<br />
PO-15:<br />
Refractory <strong>Hypertension</strong> Characterized by<br />
Heightened Sympathetic Tone<br />
Maria Czarina Acelajado, 1 Roberto Pisoni, 2 Tanja<br />
Dudenbostel, 3 Suzanne Oparil, 3 David A. Calhoun. 3<br />
1 Philippine General Hospital, Manila, PH; 2 Medical<br />
University <strong>of</strong> South Carolina, Charleston, SC, US;<br />
3 University <strong>of</strong> Alabama at Birmingham, Birmingham,<br />
AL, US.<br />
Prehypertension has Increased Peripheral Resistance<br />
in Patients with Obesity<br />
Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1 Erik<br />
Luepke, 2 Santiago Garcia Ruiz, 1 Santos J. Martinez. 1<br />
1 University General Hospital <strong>of</strong> Albacete, Albacete, ES;<br />
2 University General Hospital “La Paz”, Madrid, ES.<br />
Some Fixed Combinations are Better Reducing<br />
Central Blood Pressure and Hypertensive Time than<br />
Others<br />
Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1<br />
Santiago Garcia Ruiz, 1 Ana Galdamez Nuñez, 2 Erik<br />
Luepke, 3 Manuel Aguilera Saldaña. 1 1 University<br />
General Hospital <strong>of</strong> Albacete, Albacete, ES; 2 Health<br />
Center <strong>of</strong> Villacerrada, Albacete, ES; 3 University<br />
General Hospital “La Paz”, Madrid, ES.<br />
Prevalence <strong>of</strong> Orthostatic Hypotension among Very<br />
Elderly Persons with <strong>Hypertension</strong><br />
Elaine Ku, 1 Yee Lu, 1 Edward Schneider, 1 Rick Smith, 2<br />
Vito M. Campese. 1 1 USC/Keck School <strong>of</strong> Medicine, Los<br />
Angeles, CA, US; 2 Los Angeles Jewish Home for the<br />
Aging, Reseda, CA, US.<br />
Effects <strong>of</strong> Renal Stenting on Renal and Cardiac<br />
Outcomes in Patients with Resistant <strong>Hypertension</strong><br />
Cristiana Catena, GianLuca Colussi, Frine Capobianco,<br />
Stefania Fedrizzi, Leonardo A. Sechi. University <strong>of</strong><br />
Udine, Udine, IT.<br />
88
Saturday Afternoon MAY 21<br />
Posters<br />
PO-16:<br />
PO-17:<br />
PO-18:<br />
PO-19:<br />
PO-20:<br />
PO-21:<br />
PO-22:<br />
Evaluation <strong>of</strong> a Treatment Algorithm Using<br />
Combination Therapy for the Management<br />
<strong>of</strong> Patients with <strong>Hypertension</strong> and<br />
Hypercholesterolemia (STITCH2)<br />
G. K. Dresser†, S. A. E. Nelson, J. L. Mahon, G. Y. Zou,<br />
M. K. Vandervoort, C. J. Wong, B. G. Feagan, R. D.<br />
Feldman. Robarts Research Institute, London, CA.<br />
Sex Differences Impact the Hemodynamics <strong>of</strong><br />
Untreated Essential Hypertensive Subjects<br />
Carlos M. Ferrario, 1,2 Ronald D. Smith. 1 1 Consortium<br />
Southeastern <strong>Hypertension</strong> Control, Winston Salem,<br />
NC, US; 2 Wake Forest University School <strong>of</strong> Medicine,<br />
Winston Salem, NC, US.<br />
Improving Global Vascular Risk Management Using<br />
the COSEHC Cardiovascular Risk Assessment Tool<br />
Carlos M. Ferrario†, 1,2 Michael A. Moore, 1 Debra<br />
Simmons, 1,2 Chris Colby, 3 Alex Exuzides, 3 Sumeet<br />
Panjabi. 4 1 Consortium for Southeastern <strong>Hypertension</strong><br />
Control, Winston Salem, NC, US; 2 Wake Forest<br />
University School <strong>of</strong> Medicine, Winston Salem, NC,<br />
US; 3 ICON Clinical Research, San Francisco, CA, US;<br />
4 Daiichi Sankyo, Inc., Parsippany, NJ, US.<br />
A COSEHC Sponsored Quality Improvement<br />
Initiative Enriches Chronic Disease Practice and<br />
Performance <strong>of</strong> North Carolina Diabetic Patients<br />
Mazen Hamad, 1 Brian Forrest, 2 Michael Moore, 2<br />
Debra Simmons, 2 JaNae Joyner. 2 1 Cary Healthcare<br />
Associates, Cary, NC, US; 2 The Consortium for<br />
Southeastern <strong>Hypertension</strong> Control (COSEHC),<br />
Winston Salem, NC, US.<br />
Cardiovascular Care Disparities in a South Carolina<br />
Primary Care Site Participating in the COSEHC<br />
Customized Model <strong>of</strong> Intervention and Care<br />
(COSMIC) Project<br />
JaNae Joyner, 1 Brian Forrest, 1 Kristina Yu‐Isenberg, 2<br />
Debra Simmons, 1 Daniel Lackland. 1 1 The Consortium<br />
for Southeastern <strong>Hypertension</strong> Control (COSEHC),<br />
Winston Salem, NC, US; 2 Novartis Pharmaceuticals<br />
Corporation, US.<br />
Adherence to Comprehensive Interventions for<br />
Management <strong>of</strong> Uncontrolled <strong>Hypertension</strong><br />
Tessa J. Kerby, Stephen E. Asche, Michael V. Maciosek,<br />
JoAnn M. SperlHillen, Simrandeep K. Tiawana,<br />
Patrick J. O’Connor, Karen L. Margolis. HealthPartners<br />
Research Foundation, Minneapolis, MN, US.<br />
Blood Pressure Control in Spanish Speaking<br />
Patients with Type II Diabetes Mellitus Using a<br />
Group Visit Model<br />
Mateo Levine Ledezma, Marie F. Martinez, Scott A.<br />
Rasgon. Kaiser Permanente, Los Angeles, CA, US.<br />
89
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-23:<br />
PO-25:<br />
PO-26:<br />
PO-27:<br />
PO-28:<br />
PO-29:<br />
PO-30:<br />
A Multi-Level Intervention to Control <strong>Hypertension</strong><br />
in African <strong>American</strong>s<br />
Gbenga Ogedegbe, 1 Jonathan Tobin, 2 Joseph Schwartz, 3<br />
Thomas Pickering. 3 1 NYU School <strong>of</strong> Medicine, NY,<br />
NY, US; 2 Clinical Directors Network, NY, NY, US;<br />
3 Columbia University, NY, NY, US.<br />
Physical Characteristics <strong>of</strong> Salt in the Treatment and<br />
Prevention <strong>of</strong> <strong>Hypertension</strong><br />
Maithri Reddy, 1 Podduturu S. Reddy, 2 Sushma Reddy. 1<br />
1 Endocrinology & Diabetes Center, Fort Gratiot, MI,<br />
US; 2 St.Clair Pulmonary & Critical Care, Port Huron,<br />
MI, US.<br />
Relation between Cardiovascular Risk Score,<br />
Asymptomatic Peripheral Disease and Left<br />
Ventricular Hypertrophy<br />
Juan José Tamarit‐García, 1 Belén Roig‐Espert, 2 Vicente<br />
Navarro‐Ibáñez. 2 1 Dr. Peset Universitary Hospital,<br />
Valencia, ES; 2 Manises Hospital, Manises, Valencia, ES.<br />
A Computer-Mediated Intervention and D<strong>ASH</strong> Diet,<br />
WHEELS-I <strong>Program</strong>, Sustains Improved Blood<br />
Pressure over 8 Weeks in Women from Diverse<br />
Ethnic Backgrounds<br />
Margaret Scisney‐Matlock, 1 Susan Steigerwalt, 2<br />
Kenneth Jamerson, 1 Stephanie Lucas, 3 Susan Pressler, 1<br />
Amanda Sen, 1 Elizabeth Brough. 1 1 University <strong>of</strong><br />
Michigan, Ann Arbor, MI, US; 2 St. John Health<br />
System, Detroit, MI, US; 3 Center Preventative<br />
Medicine, St Clair Shores, MI, US.<br />
Relationships between Aggressive Systolic BP Goals,<br />
Nocturnal BP Dipping, and Carotid Atherosclerosis<br />
in Type 2 Diabetes: The SANDS Study<br />
Angela Silverman, 3 Mihriye Mete, 3 Jerome L. Fleg, 2<br />
Marie Russell, 1 Robert E. Ratner, 3 Mary J. Roman, 4<br />
Mario Stylianou, 2 Jason G. Umans, 3 Matthew R.<br />
Weir, 5 Barbara V. Howard. 3 1 Phoenix Indian Medical<br />
Center, US; 2 National Heart, Lung, and Blood Institute,<br />
US; 3 MedStar Health Research Institute, US; 4 Weill<br />
Medical College <strong>of</strong> Cornell University, US; 5 University<br />
<strong>of</strong> Maryland School <strong>of</strong> Medicine, US.<br />
Improved <strong>Hypertension</strong> Control Rates through a<br />
Multidisciplinary Regional Approach<br />
Ann M. Wells, Stephanie C. Schneider, Jennifer Bajaj,<br />
Susan Schreiner, Beverly Kroner. Kaiser Permanente<br />
Colorado, Denver, CO, US.<br />
Clinical Pharmacist-Physician Team Approach in<br />
Treating Resistant <strong>Hypertension</strong> Cases<br />
Sandra A. Yoo, Joel Handler, Alec V. Does. Kaiser<br />
Permanente, Anaheim, CA, US.<br />
90
Saturday Afternoon MAY 21<br />
Posters<br />
Endothelial Function<br />
PO-31:<br />
PO-32:<br />
PO-33:<br />
PO-34:<br />
PO-35:<br />
PO-37:<br />
PO-38:<br />
PO-39:<br />
A Novel ANP-Like Peptide, ANP1-28RR, Revealed<br />
by a Single Nucleotide Polymorphism <strong>of</strong> the ANP<br />
Gene, rs5065 Codes for a Peptide with Increased<br />
Permeability Properties In Vitro<br />
Valentina Cannone, Brenda K. Huntley, Guido<br />
Boerrigter, Alessandro Cataliotti, Denise M. Heublein,<br />
John C. Burnett. Mayo Clinic, Rochester, MN, US.<br />
Exaggerated Exercise Blood Pressure Response<br />
is Associated with Arterial Stiffness, Asymmetric<br />
Dimethylarginine and Osteoprotegerin in Essential<br />
<strong>Hypertension</strong><br />
K. Dimitriadis, C. Tsioufis, A. Aggelis, A. Michaelides,<br />
S. Aslam, C. Wilcox, V. Papademetriou, C. Stefanadis.<br />
Hippokration Hospital, Athens, GR.<br />
Endothelial Impact <strong>of</strong> Blood Pressure above the<br />
Goals in Hypertensive Patients<br />
Jose Saban‐Ruiz, Martin Fabregate, Rosa Fabregate,<br />
Olivia Sanchez, Susana Tello, Angelica Fernandez,<br />
Nuria De la Torre, Arantxa Rodriguez. Ramon y Cajal<br />
Hospital, Madrid, ES.<br />
Plasma Sodium but Not Sodium to Potassium Ratio<br />
Could be a Simple and Low-Cost Technique to<br />
Predict Vascular Inflammation. Correlation with<br />
Resistin Levels<br />
Martin Fabregate, Rosa Fabregate, Nuria De la Torre,<br />
Cristina Martinez, Arantxa Rodriguez, Ana Alonso,<br />
Carlos Moreno, Jose Saban‐Ruiz. Ramon y Cajal<br />
Hospital, Madrid, ES.<br />
Time for Action. Correlation between Plasma Renin<br />
Activity and Biomarkers. A Mandatory Study as<br />
Result <strong>of</strong> a Recent Heart Outcomes Prevention<br />
Evaluation Analysis<br />
Jose Saban‐Ruiz, Martin Fabregate, Rosa Fabregate,<br />
Elena Tutor, Elena Castresana, Nuria De la Torre,<br />
Juanjo Villafruela, Susana Tello, Arantxa Rodriguez.<br />
Ramon y Cajal Hospital, Madrid, ES.<br />
Variability <strong>of</strong> Flow Mediated Dilation Technique: A<br />
Multicentre Italian Study<br />
Francesco Faita, Lorenzo Ghiadoni, Vincenzo<br />
Gemignani, Elisabetta Bianchini, Almerina Biggi,<br />
Giuseppe Ambrosio, Gaetano A. Lanza, Maria Lorenza<br />
Muiesan, Francesco Cosentino, Stefano Taddei.<br />
Working Group on Endothelium <strong>of</strong> the Italian <strong>Society</strong><br />
<strong>of</strong> <strong>Hypertension</strong>, IT.<br />
Endothelial Dysfunction in Hypertensive Patients<br />
with Metabolic Syndrome<br />
Olga Gonzalez‐Albarran, Sara Calvo, Marta Carrasco,<br />
Marta Cano, Berniza Calderon, Ana Maria Matei.<br />
Hospital Ramón y Cajal, Madrid, ES.<br />
Normative Brachial Artery Diameter Dilatation<br />
Following Reactive Hyperemia<br />
Martha A. Kaeser, Daniel W. Haun, Norman W.<br />
Kettner. Logan College <strong>of</strong> Chiropractic, Chesterfield,<br />
MO, US.<br />
91
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-40:<br />
PO-41:<br />
PO-42:<br />
PO-43:<br />
PO-44:<br />
PO-45:<br />
Severity <strong>of</strong> Obstructive Sleep Apnea and<br />
Atherosclerosis: Multiple Associations in the Setting<br />
<strong>of</strong> <strong>Hypertension</strong><br />
A. Kasiakogias, C. Tsioufis, C. Thomopoulos, I.<br />
Andrikou, M. Almiroudi, I. Mpafakis, K. Kintis, C.<br />
Stefanadis. Hippokration Hospital, Athens, GR.<br />
Modulation <strong>of</strong> Vascular Function and Oxidative<br />
Stress in Type II Diabetes Mellitus: Effects <strong>of</strong> Alpha-<br />
Lipoic Acid<br />
Bobby V. Khan†, 1 Tahir Haque, 1 Desikan Rajagopal, 1<br />
Nadya Merchant, 1 Barry Connell, 2 Tarek M. Saleh. 2<br />
1 Atlanta Vascular Research Foundation, Atlanta,<br />
GA, US; 2 University <strong>of</strong> Prince Edward Island,<br />
Charlottetown, PE, CA.<br />
Atherogenic Index <strong>of</strong> the Plasma as Marker <strong>of</strong><br />
Oxidative Stress and Endothelial Dysfunction<br />
Rosa Fabregate, Arantxa Rodriguez, Martin Fabregate,<br />
Elena Marin, Andres Reyes, Cristina Martinez, Susana<br />
Tello, Nuria De la Torre, Jose Saban‐Ruiz. Ramon y<br />
Cajal Hospital, Madrid, ES.<br />
The Effect <strong>of</strong> Angiotensin Converting Enzyme<br />
Inhibitors and Angiotensin-II Receptor Antagonists<br />
on the Endothelial Dysfunction in Patients<br />
with Chronic Pulmonary Heart with Arterial<br />
<strong>Hypertension</strong><br />
Nestor M. Seredyuk, Igor P. Vakalyuk, Vitaliy N.<br />
Seredyuk, Sergiy V. Fedorov. Ivano-Frankivsk National<br />
Medical University, Ivano-Frankivsk, UA.<br />
Associations <strong>of</strong> Renal Flow Reserve with Endothelial<br />
Dysfunction in Essential Hypertensives<br />
C. Tsioufis, D. Tsiachris, I. Tatsis, K. Dimitriadis, D.<br />
Syrseloudis, I. Kallikazaros, V. Papademetriou, C.<br />
Stefanadis. Hippokration Hospital, Athens, GR.<br />
Increased Endothelin-1 Vasoconstrictor Tone with<br />
Prehypertension<br />
Brian R. Weil, 1 Michael L. Mestek, 1 Jared J. Greiner, 1<br />
Brian L. Stauffer, 2 Christopher A. DeSouza. 1<br />
1 University <strong>of</strong> Colorado at Boulder, Boulder, CO,<br />
US; 2 University <strong>of</strong> Colorado Denver and the Health<br />
Sciences Center, Aurora, CO, US.<br />
Epidemiology/Special Populations<br />
PO-46:<br />
Management <strong>of</strong> Hypertensive Patients in France<br />
as a Function <strong>of</strong> Gender and Cardiovascular Risk:<br />
PARITE Study<br />
Simon Tabassome, 1 Claire Mounier‐Vehier, 2<br />
Dominique Guedj, 3 Assya Achouba, 4 Emmanuel<br />
Ghannad, 5 Stéphane Quéré, 4 Maxime Guenoun. 6<br />
1 CHU Saint-Antoine, Paris, FR; 2 Cardiologic Hospital,<br />
Lille, FR; 3 Cardiologist, Paris, FR; 4 Novartis Pharma<br />
SAS, Paris, FR; 5 Cardiologist, Gif sur Yvette, FR;<br />
6 Cardiologist, Marseille, FR.<br />
92
Saturday Afternoon MAY 21<br />
Posters<br />
PO-47:<br />
PO-48:<br />
PO-49:<br />
PO-50:<br />
PO-51:<br />
PO-52:<br />
PO-53:<br />
PO-54:<br />
The Relationship <strong>of</strong> Resistant <strong>Hypertension</strong> and<br />
Treatment Outcomes with Total Compliance and<br />
Brain Natriuretic Peptide in an African <strong>American</strong><br />
Hypertensive Cohort<br />
Omid Bakhtar, Brian A. Ference, Phillip D. Levy,<br />
Samar A. Nasser, Lowell Hedquist, John M. Flack.<br />
Division <strong>of</strong> Translational Research and Clinical<br />
Epidemiology, Wayne State University, Detroit Medical<br />
Center, Detroit, MI, US.<br />
Which Ambulatory Blood Pressure Monitoring<br />
Parameters Predict Mortality in Elderly Subjects<br />
Iddo Z. Ben‐Dov, 1 Michael Bursztyn. 2 1 The Rockefeller<br />
University, New York, NY, US; 2 Hadassah – Hebrew<br />
University Medical Center, Jerusalem, IL.<br />
Birth Weight, Stimulus Response and Hemodynamic<br />
Variability Implicates Ethnic Contrasts <strong>of</strong><br />
Autonomic Control <strong>of</strong> Heart Rate and Blood<br />
Pressure and an Effect on CV Disease<br />
Wei Chen, Pronabesh DasMahapatra, Camilo<br />
Fernandez, Gerald S. Berenson. Tulane University<br />
Health Sciences Center, New Orleans, LA, US.<br />
Changes in Levels <strong>of</strong> Serum Cholesterol and<br />
Development <strong>of</strong> <strong>Hypertension</strong> in the Brisighella<br />
Heart Study<br />
Claudio Borghi, Ada Dormi, Sergio d’Addato, Arrigo<br />
Cicero, Luca Laghi, Eugenio Roberto Cosentino,<br />
Maddalena Veronesi. St. Orsola-Malpighi Hospital,<br />
Bologna, IT.<br />
Alcohol Consumption and the Risk <strong>of</strong> <strong>Hypertension</strong>:<br />
A Systematic Review and Meta-Analysis<br />
Alex Briasoulis, Vikram Agarwal, Manpreet S.<br />
Sabharwal, George Syros, Girish N. Nadkarni, Franz<br />
H. Messerli. St. Luke’s-Roosevelt Hospital Center,<br />
Columbia University College <strong>of</strong> Physicians and<br />
Surgeons, New York, NY, US.<br />
Trends in Albuminuria under RAS Suppression and<br />
Relationship with Cardiovascular Disease<br />
Cesar Cerezo, 1 Julian Segura, 1 Jose R. Banegas, 2 Juan<br />
J. de la Cruz, 2 Ton J. Rabelink, 3 Luis M. Ruilope. 1<br />
1 Hospital 12 de Octubre, Madrid, ES; 2 Universidad<br />
Autónoma, Madrid, ES; 3 Leiden University Medical<br />
Center, Leiden, NL.<br />
Large Change in the Opinon on Antihypertensive<br />
Drug Treatment among General Practioners in<br />
Sweden between 2002 and 2009<br />
John K. F. Dahlström, Mats Persson, Bo Carlberg,<br />
Lars‐Hjalmar Lindholm. Family Medicine, Umeå, SE.<br />
Novel Method for Assessing the Prevalence <strong>of</strong><br />
<strong>Hypertension</strong> and Cardiovascular Disease Risk in<br />
a Community Screening <strong>Program</strong> in a South East<br />
Region <strong>of</strong> US<br />
Mahfouz El Shahawy, 1 Miglena Entcheva, 1 Susan<br />
Gaida, 1 Joshua Grant. 2 1 Sarasota Memorial Hospital,<br />
Sarasota, FL, US; 2 Lake Erie College <strong>of</strong> Osteopathic<br />
Medicine, US.<br />
93
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-55:<br />
PO-56:<br />
PO-57:<br />
PO-58:<br />
PO-59:<br />
PO-60:<br />
PO-61:<br />
Pre-<strong>Hypertension</strong>: Is it a Disease<br />
Mahfouz El Shahawy, 1 Miglena Entcheva, 1 Susan<br />
Gaida, 1 Joshua Grant. 2 1 Sarasota Memorial Hospital,<br />
Sarasota, FL, US; 2 Lake Erie College <strong>of</strong> Osteopathic<br />
Medicine, US.<br />
Exercise Capacity Predicts Progression from Pre-<br />
<strong>Hypertension</strong> to <strong>Hypertension</strong> in African <strong>American</strong><br />
Men<br />
Charles Faselis, 1,2 Raya Kheirbek, 1 Michael Doumas, 1,2<br />
Ross Fletcher, 1 Vasilios Papademetriou, 1,3 Peter<br />
Kokkinos. 1,2,3 1 Veterans Affairs Medical Center,<br />
Washington, DC, US; 2 George Washington University,<br />
Washington, DC, US; 3 Georgetown University,<br />
Washington, DC, US.<br />
Biracial (Black-White) Divergence and Correlates<br />
<strong>of</strong> Augmentation Index among Younger Adults: The<br />
Bogalusa Heart Study<br />
Camilo Fernandez, Pronabesh DasMahapatra, Wei<br />
Chen, Sathanur R. Srinivasan, Gerald S. Berenson.<br />
Tulane University Health Sciences Center, New<br />
Orleans, LA, US.<br />
Use <strong>of</strong> Electronic Health Records to Evaluate<br />
<strong>Hypertension</strong> Pharmacoepidemiology in a Primary<br />
Care Practice Network<br />
Christopher Hebert†, Rustam Kudyakov, Yahya Daoud,<br />
Dunlei Cheng, Andrew Masica. Baylor Health Care<br />
System, Dallas, TX, US.<br />
Cardiovascular Risk Factors Prevalence in Greek<br />
Hypertensives Stratified by Gender and Age<br />
Gregory Vyssoulis, 1 Eva Karpanou, 2 Stella Maria<br />
Kyvelou, 1 M. Liakos, 1 C. Stefanadis. 1 1 1st Cardiology<br />
Clinic Athens University Hippokration Hospital, GR;<br />
2 1st Cardiology Clinic Onassis Cardiosurgery Center,<br />
GR.<br />
ABO and Rhesus Blood Groups and Cardiovascular<br />
Risk in Essential Hypertensive Patients<br />
Stella Maria Kyvelou, 1 Gregory Vyssoulis, 1 Eva<br />
Karpanou, 2 T. Gialernios, 1 C. Stefanadis. 1 1 1st<br />
Cardology Clinic Athens University Hippokration<br />
Hospital, GR; 2 1st Cardiology Clinic Onassis<br />
Cardiosurgery Center, GR.<br />
Efficacy, Safety and Tolerability <strong>of</strong> Valsartan/<br />
Hydrochlorothiazide Single Pill Combination in<br />
Asian Patients with Essential <strong>Hypertension</strong>: An<br />
Observational Study<br />
Wen‐Ter Lai†, 1 Jeong‐Euy Park, 2 Neelesh Dongre, 3<br />
Jackson Wang. 3 1 Kaohsiung Medical University<br />
Hospital, Kaohsiung, TW; 2 Samsung Medical Center,<br />
Irwon-dong, Gangnam-gu, Seoul, KR; 3 Novartis<br />
Pharma AG, Basel, CH.<br />
94
Saturday Afternoon MAY 21<br />
Posters<br />
PO-62:<br />
PO-63:<br />
PO-64:<br />
PO-65:<br />
PO-66:<br />
PO-67:<br />
PO-68:<br />
PO-69:<br />
PO-70:<br />
Trends in Serum Lipids, <strong>Hypertension</strong>, Physician<br />
Advice and Compliance among Reproductive-<br />
Aged Women: United States National Health and<br />
Nutrition Examination Survey 1999-2008<br />
Tabassum H. Laz, Mahbubur Rahman, Abbey B.<br />
Berenson. University <strong>of</strong> Texas Medical Branch,<br />
Galveston, TX, US.<br />
Excessive Blood Pressure Elevation during Exercise<br />
Correlates with Low Fitness among Normotensive<br />
Firefighters<br />
Adi Leiba, 1,2 Dorothee M. Baur, 1,3 Stefanos N. Kales. 1,3<br />
1 Harvard School <strong>of</strong> Public Health, Boston, MA, US;<br />
2 Sheba Medical Center, Tel Hashomer, IL; 3 Cambridge<br />
Health Alliance, Cambridge, MA, US.<br />
Smoking and <strong>Hypertension</strong>: Do They Follow the<br />
Same Trend<br />
Aurelio Leone. City Hospital, Massa, Ms, IT.<br />
Arterial <strong>Hypertension</strong> and Liver Cirrhosis: The<br />
Experience <strong>of</strong> a Single Liver Unit<br />
Simona Leoni, Serena Flori, Barbara Stagni, Ilaria<br />
Serio, Luigi Bolondi. Malpighi Hospital, Division <strong>of</strong><br />
Internal Medicine Pr<strong>of</strong>. Bolondi, Bologna, IT.<br />
Blood Pressure Control and Age: The Experience <strong>of</strong><br />
a Single Centre<br />
Serena Flori, Simona Leoni, Barbara Stagni, Ilaria<br />
Serio, Luigi Bolondi. Malpighi Hospital, Division <strong>of</strong><br />
Internal Medicine, Bologna, IT.<br />
The Effect <strong>of</strong> C<strong>of</strong>fee on Blood Pressure and<br />
Cardiovascular Disease among Hypertensive<br />
Individuals: Meta-Analysis<br />
Arthur E. Mesas, Luz Leon‐Muñoz, Fernando<br />
Rodriguez‐Artalejo, Esther Lopez‐Garcia. Autonoma<br />
University <strong>of</strong> Madrid, Madrid, ES.<br />
Mechanisms Underlying Increased Aortic BP in<br />
Black Versus White Young Adults: The ENIGMA<br />
Study<br />
Carmel M. McEniery, 1 Andrew T. Garrett, 2 Nigel<br />
Baber, 2 John R. Cockcr<strong>of</strong>t, 3 Ian B. Wilkinson. 1<br />
1 University <strong>of</strong> Cambridge, Cambridge, GB; 2 University<br />
<strong>of</strong> Hertfordshire, GB; 3 Cardiff University, GB.<br />
Diabetes Type 2 and Other Cardiovascular Risk<br />
Factors in an Adult Mediterranean Population<br />
Javier Nieto, 1 Patricio Giralt, 2 Maria Jose Ballesteros, 1<br />
G. Gutierrez, 3 Carmen Mora, 1 Agustin Carreño. 1<br />
1 Hospital General, Ciudad Real, ES; 2 Fundacion<br />
Sociosanitaria, Ciudad Real, Castilla La Mancha, ES;<br />
3 Consejería de Salud, Toledo, ES.<br />
Serum Uric Acid is an Independent Risk Factor for<br />
Cardiovascular Diseases Mortality in Hypertensive<br />
Patients<br />
Mitsuru Ohishi, Yasushi Takeya, Miyuki Onishi, Yuji<br />
Tatara, Kei Kamide, Hiromi Rakugi. Osaka University,<br />
Suita, Osaka, JP.<br />
95
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-71:<br />
PO-72:<br />
PO-73:<br />
PO-74:<br />
PO-75:<br />
PO-76:<br />
PO-77:<br />
Blood Pressure Control and All Cause Mortality in<br />
Old and Very Old Patients with <strong>Hypertension</strong><br />
Vasilios Papademetriou, Richard Amdur, Charles<br />
Faselis, Michael Doumas, Costas Tsioufis, Peter<br />
Kokkinos, Ross D. Fletcher. Veterans Administration<br />
and Georgetown University Medical Centers<br />
Washington DC, Washington, DC, US.<br />
Ambulatory Blood Pressure Monitoring Pr<strong>of</strong>ile in<br />
Untreated African Blacks and Causasians Untreated<br />
Hypertensive Patients Matched for Age and Gender<br />
Albertino Damasceno, 1 C. Mavimbe, 1 Loide Barbosa, 2<br />
Jose A. Silva, 2 Domingos Diogo, 1 T. Madede, 1 Jorge<br />
Polonia. 2 1 Universidade Eduardo Mondlane, Maputo,<br />
MZ; 2 Hospital Pedro Hispano, Matosinhos, PT.<br />
Regional Differences in Hypertensive<br />
Cardiovascular Remodeling between Fishing and<br />
Farming Communities in Japan<br />
Koji Sakata, 1 Yuichiro Yano, 2 Takuro Imamura, 1 Kazuo<br />
Kitamura, 1 Kazuomi Kario. 2 1 University <strong>of</strong> Miyazaki,<br />
JP; 2 Jichi Medical University School <strong>of</strong> Medicine, JP.<br />
Relevance <strong>of</strong> Atrial Fibrillation in a Large Cohort <strong>of</strong><br />
Hypertensive Patients<br />
Julian Segura, 1 Vanesa Moñivas, 1,2 Jose A. Garcia-<br />
Donaire, 1 Cesar Cerezo, 1 Luis M. Ruilope. 1 1 Hospital<br />
12 de Octubre, Madrid, ES; 2 Hospital Puerta de Hierro,<br />
Madrid, ES.<br />
Periodontal Disease Severity and Albumin Excretion<br />
in Hypertensive Patients: A Positive Association<br />
Beyond Systemic Inflammation<br />
C. Tsioufis, A. Kasiakogias, C. Thomopoulos, N.<br />
Soldatos, A. Kordalis, M. Almiroudi, K. Kintis, C.<br />
Stefanadis. Hippokration Hospital, Athens, GR.<br />
Efficacy <strong>of</strong> Amlodipine/Olmesartan Medoxomil with<br />
or without Hydrochlorothiazide in Elderly Patients<br />
Uncontrolled by Monotherapy<br />
Matthew R. Weir†, 1 Henry A. Punzi, 2 Ali Shojaee, 3<br />
William F. Waverczak, 3 Jen‐Fue Maa. 3 1 University<br />
<strong>of</strong> Maryland School <strong>of</strong> Medicine, US; 2 Trinity<br />
<strong>Hypertension</strong> & Metabolic Research Institute, US;<br />
3 Daiichi Sankyo, Inc., US.<br />
Blood Pressure Therapy and Risk <strong>of</strong> CVD:<br />
Framingham Heart Study Experience<br />
Peter W. F. Wilson†, 1 Michael Pencina, 2 Ralph B.<br />
D’Agostino, 2 Asya Lyass, 2 R. S. Vasan, 2 Philip A. Wolf, 2<br />
Daniel Levy. 3 1 Emory University, Atlanta, GA, US;<br />
2 Boston University, Boston, MA, US; 3 Framingham<br />
Heart Study, Framingham, MA, US.<br />
96
Saturday Afternoon MAY 21<br />
Posters<br />
Immune mechanisms in hypertension<br />
PO-79:<br />
PO-80:<br />
PO-81:<br />
PO-82:<br />
Renal Specific Silencing <strong>of</strong> Dopamine D 2 Receptors<br />
in Mice Increases Blood Pressure and Pro-<br />
Inflammatory Factors<br />
Ines Armando, Santiago Cuevas, Yanrong Zhang,<br />
Laureano Asico, Crisanto Escano, Pedro A. Jose.<br />
Children’s National Medical Center, Washington, DC,<br />
US.<br />
Macrophages Regulate Pressor Responses to<br />
Endothelin-1<br />
E. L. Owen, N. Dhaun, M. Bailey, D. J. Webb, D. C.<br />
Kluth. University <strong>of</strong> Edinburgh, GB.<br />
BMI Influences the Association <strong>of</strong> an IL-6<br />
Polymorphism on Increased Insulin Resistance in a<br />
Hypertensive Population<br />
P. Underwood, 1 B. Chamarthi, 1 J. Williams, 1 B. Sun, 1<br />
P. Hopkins, 2 G. Adler, 1 G. Williams. 1 1 Brigham and<br />
Women’s Hospital, US; 2 University <strong>of</strong> Utah, US.<br />
Correlation between Endothelial Dysfunction and<br />
Inflammatory Markers at the Chronic Heart Failure<br />
with Arterial <strong>Hypertension</strong><br />
Roman I. Yatsyshyn, Natalya G. Yatsyshyn. Medical<br />
University, Ivano-Frankivsk, UA.<br />
Metabolic Syndrome (Diabetes/Glycemic<br />
Control; Dysglycemic Drugs; Insulin<br />
Resistance)<br />
PO-83:<br />
PO-84:<br />
PO-85:<br />
Screening for Diabetes in a Developing Country<br />
Olutayo Christopher Alebiosu, 1 Olawale Ogunsemi, 2<br />
Olatunde Odusan, 2 Oluranti Familoni. 2 1 College <strong>of</strong><br />
Health Sciences, Osun State University, Osogbo, Osun,<br />
NG; 2 Olabisi Onabanjo University, Sagamu Campus,<br />
Ogun State, NG.<br />
Metabolic Pr<strong>of</strong>ile and Framingham Heart Scores<br />
among Hypertensives in Turkey from 2003 to 2007<br />
Mustafa Arici, 1 Ulver Derici, 2 Cetin Turgan, 1 Yunus<br />
Erdem, 1 Sukru Sindel, 2 Bulent Altun, 1 Bulent Erbay, 3<br />
Oktay Karatan, 3 Enver Hasanoglu, 2 Sali Caglar. 4<br />
1 Hacettepe University Faculty <strong>of</strong> Medicine, Ankara,<br />
TR; 2 Gazi University Faculty <strong>of</strong> Medicine, Ankara, TR;<br />
3 Ankara University Faculty <strong>of</strong> Medicine, Ankara, TR;<br />
4 Turkish <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> and Renal Diseases,<br />
Ankara, TR.<br />
Gender-Independent Elevation <strong>of</strong> Fasting Glucose<br />
with the Progressive Decrease in Sleep-Time<br />
Relative Blood Pressure Decline: The Hygia Project<br />
Diana E. Ayala, 1 Juan J. Crespo, 2 Ana Moya, 3 Pedro A.<br />
Callejas, 2 Peregrina Eiroa, 2 Alfonso Otero, 4 Artemio<br />
Mojon, 1 Jose R. Fernandez, 1 Ramon C. Hermida, 1<br />
Investigadores Proyecto Hygia. 1 1 University <strong>of</strong> Vigo,<br />
Vigo, ES; 2 Gerencia de Atención Primaria, Vigo, ES;<br />
3 Gerencia de Atención Primaria, Pontevedra, ES;<br />
4 Complejo Hospitalario Universitario, Orense, ES.<br />
97
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-86:<br />
PO-87:<br />
PO-88:<br />
PO-89:<br />
PO-90:<br />
PO-91:<br />
PO-92:<br />
First-Line Aliskiren/HCTZ Lowers BP in Older<br />
Patients with Stage 2 <strong>Hypertension</strong> and Metabolic<br />
Syndrome or Diabetes<br />
Jan Basile†, 1 Simon Babazadeh, 2 Michael Lillestol, 3<br />
Thomas Severin, 4 Cheraz Cherif Papst, 4 Richard<br />
Weitzman. 5 1 Ralph H Johnson VA Medical Center,<br />
Medical University <strong>of</strong> South Carolina, Charleston,<br />
SC, US; 2 Crest Clinical Trials Inc, Santa Ana, CA, US;<br />
3 Lillestol Research LLC, Fargo, ND, US; 4 Novartis<br />
Pharma AG, Basel, CH; 5 Novartis Pharmaceuticals<br />
Corporation, East Hanover, NJ, US.<br />
Effects <strong>of</strong> Time <strong>of</strong> Day <strong>of</strong> <strong>Hypertension</strong> Treatment<br />
on the Ambulatory Blood Pressure Pattern <strong>of</strong><br />
Patients with Diabetes: The Hygia Project<br />
Juan J. Crespo, 1 Manuel Dominguez‐Sardiña, 1<br />
Maria T. Rios, 1 Ana Moya, 2 Sonia M. Gomara, 2 Luis<br />
Meijide, 2 Artemio Mojon, 3 Diana E. Ayala, 3 Ramon C.<br />
Hermida, 3 Investigadores Proyecto Hygia. 3 1 Gerencia<br />
de Atención Primaria, Vigo, ES; 2 Gerencia de Atención<br />
Primaria, Pontevedra, ES; 3 University <strong>of</strong> Vigo, Vigo,<br />
ES.<br />
Overweight and High Blood Pressure as the<br />
Cardiometabolic Risk Factors Most Frequently<br />
Related to Nonalcoholic Fatty Liver Disease<br />
Susana Tello, Angelica Fernandez, Asuncion Guerri,<br />
Rosa Fabregate, Martin Fabregate, Jose Campoy, Arturo<br />
Ugalde, Jose Saban‐Ruiz. Ramon y Cajal Hospital,<br />
Madrid, ES.<br />
Myeloperoxidase, Leptin and Retinol Binding<br />
Protein 4, as Biomarkers <strong>of</strong> Osteopenia and<br />
Atherosclerosis, Two Sister-Diseases<br />
Rosa Fabregate, Olivia Sanchez, Elena Marin, Andres<br />
Reyes, Cristina Martinez, Susana Tello, Martin<br />
Fabregate, Arantxa Rodriguez, Jose Saban‐Ruiz.<br />
Ramon y Cajal Hospital, Madrid, ES.<br />
Unlike Sex, HDL-Cholesterol, Body Mass Index,<br />
Homocysteine and Smoking, Blood Pressure is Not a<br />
Determinant Factor <strong>of</strong> Plasma Leptin Levels<br />
Martin Fabregate, Olivia Sanchez, Rosa Fabregate, Olga<br />
Fernandez, Jose Manuel Del Rey, Susana Tello, Nuria<br />
De la Torre, Elena Tutor, Ana Alonso, Jose Saban‐Ruiz.<br />
Ramon y Cajal Hospital, Madrid, ES.<br />
Salt Sensitive Type 2 Diabetics Have Greater<br />
Metabolic Improvements on a Paleolithic-Type Diet<br />
Compared to an ADA Diet<br />
Lynda A. Frassetto, Olga Schmidlin, Anthony<br />
Sebastian, Umesh Masharani. UCSF, San Francisco,<br />
CA, US.<br />
Impact <strong>of</strong> Gender in Cardiovascular Control in<br />
Hypertensive Patients with Metabolic Syndrome.<br />
OPENMET Survey<br />
Olga Gonzalez, 1 Alberto Galgo, 2 Carlos Alvarez. 3<br />
1 Hospital Ramón y Cajal, Madrid, ES; 2 Primary Care<br />
Center, Madrid, ES; 3 Pfizer Laboratory, Madrid, ES.<br />
98
Saturday Afternoon MAY 21<br />
Posters<br />
PO-93:<br />
PO-94:<br />
PO-95:<br />
PO-96:<br />
PO-97:<br />
PO-98:<br />
PO-99:<br />
Microalbuminuria in Women with Prior Gestational<br />
Diabetes<br />
Olga Gonzalez Albarran, Marta Carrasco, Marta Cano,<br />
Berniza Calderón, Ana Maria Matei. Hospital Ramón y<br />
Cajal, Madrid, ES.<br />
Elevation <strong>of</strong> Blood Suger Changes Glomerular and<br />
Tubular Function in Normotesive Subjects<br />
Shigeo Kakinoki, 1 Tetsuya Fujimoto, 2 Maiko Machida, 2<br />
Shigeru Takechi, 3 Kouichi Kanda, 4 Takeshi Kobayashi, 5<br />
Akikazu Nomura. 2 1 Otaru kyoukai Hospital, Otaru,<br />
Hokkaido, JP; 2 Hokkaido College <strong>of</strong> Pharmacy,<br />
Otaru, Hokkaido, JP; 3 Date Red Cross Hospital, Date,<br />
Hokkaido, JP; 4 Sapporo Kosei General Hospital,<br />
Sapporo, Hokkaido, JP; 5 Hokkaido Social Insurance<br />
Health Care and Research Center, Sapporo, Hokkaido,<br />
JP.<br />
Effects <strong>of</strong> Simvastatin and Rosiglitazone<br />
Combination in Patients with the Metabolic<br />
Syndrome (The SIROCO Study)<br />
Ivana Lazich†, Pantelis A. Sarafidis, Raymond Oliva,<br />
Basil Burney, George Bakris. University <strong>of</strong> Chicago<br />
Pritzker School <strong>of</strong> Medicine, Chicago, IL, US.<br />
Pulse Wave Analysis in Type 2 Diabetic Hypertensive<br />
Patients<br />
Ari L. Lieber, 1 Michel E. Safar, 1 Julie Peroz, 1 Gerard<br />
Slama, 1 Bernard I. Levy, 2 Jacques Blacher. 1 1 Hotel-Dieu<br />
Hospital, Paris, FR; 2 Hopital Lariboisiere, Paris, FR.<br />
Circadian Blood Pressure Pattern and Prevalence<br />
<strong>of</strong> Nocturnal <strong>Hypertension</strong> in Subjects with and<br />
without Type 2 Diabetes: The Hygia Project<br />
Maria C. Castiñeira, 1 Ana Moya, 2 Jesus Perez de Lis, 3<br />
Lorenzo Pousa, 3 Jose L. Salgado, 3 Susana Hernaiz, 3<br />
Artemio Mojon, 4 Jose R. Fernandez, 4 Ramon C.<br />
Hermida, 4 Investigadores Proyecto Hygia. 4 1 Gerencia<br />
de Atención Primaria, Lugo, ES; 2 Gerencia de Atención<br />
Primaria, Pontevedra, ES; 3 Gerencia de Atención<br />
Primaria, Vigo, ES; 4 University <strong>of</strong> Vigo, Vigo, ES.<br />
Influence <strong>of</strong> Sleep-Time Blood Pressure for the<br />
Proper Identification <strong>of</strong> Isolated Office and Masked<br />
<strong>Hypertension</strong> among Patients with Type 2 Diabetes:<br />
The Hygia Project<br />
Ana Moya, 1 Elvira Sineiro, 1 Maria C. Castiñeira, 2<br />
Sonia M. Gomara, 1 Artemio Mojon, 3 Maria J. Fontao, 3<br />
Sonia Lorenzo, 3 Diana E. Ayala, 3 Ramon C. Hermida, 3<br />
Investigadores Proyecto Hygia. 3 1 Gerencia de Atención<br />
Primaria, Pontevedra, ES; 2 Gerencia de Atención<br />
Primaria, Lugo, ES; 3 University <strong>of</strong> Vigo, Vigo, ES.<br />
Suboptimal Control <strong>of</strong> Arterial <strong>Hypertension</strong> in<br />
Patients with Type 2 Diabetes Mellitus<br />
Maria Sarigianni, Eleni Mpekiari, Apostolos Tsapas,<br />
Konstantinos Paletas. Medical School, Aristotle<br />
University <strong>of</strong> Thessaloniki, Thessaloniki, GR.<br />
99
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-100:<br />
PO-101:<br />
PO-102:<br />
Prevalence <strong>of</strong> Metabolic Syndrome According to<br />
Different Definitions in a Mediterranean Cohort <strong>of</strong><br />
Hypertensives<br />
John A. Papadakis, 1 Eirini Lioudaki, 1,2 George E.<br />
Vrentzos, 1 Helen Mavrogeni, 1 Maria‐Helen Zeniodi, 1<br />
Emmanuel S. Ganotakis, 1 Dimitri P. Mikhailidis. 2<br />
1 University Hospital <strong>of</strong> Heraklion, Heraklion, GR;<br />
2 Royal Free Hospital campus, University College<br />
London (UCL) Medical School, London, GB.<br />
Telmisartan Prophylactic Treatment Induces Tissue-<br />
Specific Gene Modulation Favoring Normal Glucose<br />
Homeostasis in CRDH Rats<br />
Firas Younis, 1 Yoram Oron, 1 Rona Limor, 2 Naftali<br />
Stern, 2 Talma Rosenthal. 1 1 Tel Aviv Univeristy, Tel Aviv,<br />
Ramat Aviv, IL; 2 Tel Aviv-Sourasky Medical Center, Tel<br />
Aviv, IL.<br />
Hyperuricemia and the Pathogenesis <strong>of</strong><br />
<strong>Hypertension</strong> and Insulin Resistance in Murine<br />
Model <strong>of</strong> the Metabolic Syndrome<br />
William Baldwin, 1 Steven McRae, 1 George Marek, 1<br />
David Wymer, 1 Varinderpal Pannu, 1 Chris Baylis, 2<br />
Richard J. Johnson, 1,2 Yuri Y. Sautin. 1 1 University <strong>of</strong><br />
Florida, Gainesville, FL, US; 2 University <strong>of</strong> Florida,<br />
Gainesville, FL, US; 3 University <strong>of</strong> Colorado, Denver,<br />
CO, US.<br />
New insights into the role <strong>of</strong> uric acid in<br />
hypertension<br />
PO-103:<br />
PO-104:<br />
Relation <strong>of</strong> Uric Acid with Blood Pressure and<br />
Health Related Quality <strong>of</strong> Life One Year Post<br />
Myocardial Infarction<br />
Antonios Ioannidis, Dimitrios Tsounis. Hellenic Open<br />
University, GR.<br />
<strong>Hypertension</strong> in Hyperuricemic Gout Subjects<br />
Receiving Febuxostat or Allopurinol<br />
Andrew Whelton†, 1,2 Patricia MacDonald, 3 Barbara<br />
Hunt, 3 Lhanoo Gunawardhana. 3 1 Universal Clinical<br />
Research Center, Inc, Hunt Valley, MD, US; 2 Johns<br />
Hopkins University School <strong>of</strong> Medicine, Baltimore,<br />
MD, US; 3 Takeda Global Research & Development<br />
Center, Inc, Deerfield, IL, US.<br />
Pediatric <strong>Hypertension</strong><br />
PO-105:<br />
Systolic and Diastolic Blood Pressures among Sickle<br />
Cell Patients<br />
Guillermo A. De Angulo, 1 Robert J. Adams, 1 Yim<br />
Eunsil, 1 Janet L. Kwiatkowski, 2 Ana C. Xavier, 1 Ellen<br />
Debenham, 1 Jessica A. Peterson, 1 Daniel T. Lackland. 1<br />
1 Medical University <strong>of</strong> South Carolina, Charleston,<br />
SC, US; 2 The Children’s Hospital <strong>of</strong> Philadelphia,<br />
Philadelphia, PA, US.<br />
100
Saturday Afternoon MAY 21<br />
Posters<br />
PO-106:<br />
PO-107:<br />
PO-108:<br />
PO-109:<br />
PO-110:<br />
PO-111:<br />
Antihypertensive Drug Use in Children: Are the<br />
Drugs Labeled and Indicated<br />
Joseph Flynn†, 1 W. Pete Welch, 2 Wenya Yang, 2 Drew<br />
Braucht, 2 Perdita Taylor‐Zapata, 3 Anne Zajicek. 3<br />
1 Seattle Children’s Hospital, Seattle, WA, US; 2 The<br />
Lewin Group, Inc., Falls Church, VA, US; 3 Eunice<br />
Kennedy Shriver National Institute <strong>of</strong> Child Health<br />
and Human Development, Bethesda, MD, US.<br />
Clinical and Demographic Characteristics <strong>of</strong><br />
Children with <strong>Hypertension</strong>: New Multicenter Data<br />
Joseph Flynn†, 1 Ying Zhang, 2 Susan Solar‐Yohay, 2<br />
Victor Shi. 2 1 Seattle Children’s Hospital, Seattle, WA,<br />
US; 2 Novartis Pharma AG, East Hanover, NJ, US.<br />
Cardiovascular Risk Factors in Obese Children and<br />
Adolescents<br />
Isabel Torro, 1,2 Julio Alvarez, 1,2 Francisco Aguilar, 1,2<br />
Jose Alcon, 1,2 Empar Lurbe. 1,2 1 Hospital General<br />
Universitario, University <strong>of</strong> Valencia, Valencia, ES;<br />
2 Health Institute Carlos III, Madrid, ES.<br />
Left Ventricular Geometry in Children with Primary<br />
<strong>Hypertension</strong>: Prevalence and Predictors<br />
Cozumel S. Pruette, 1 Barbara A. Fivush, 1 Joseph T.<br />
Flynn, 2 Tammy M. Brady. 1 1 Johns Hopkins University,<br />
Baltimore, MD, US; 2 Seattle Children’s Hospital,<br />
Seattle, WA, US.<br />
Serum Uric Acid in U.S. Adolescents: Distribution<br />
and Relationship to Demographic Characteristics<br />
and Cardiovascular Risk Factors<br />
Ibrahim F. Shatat, 1 Rany T. Abdallah, 2 David J. Sas, 1<br />
Susan M. Hailpern. 3 1 Medical University <strong>of</strong> South<br />
Carolina Children’s Hospital, Charleston, SC, US;<br />
2 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />
US; 3 Independent Consultant, Katonah, NY, US.<br />
Clinic and Ambulatory Blood Pressure<br />
Measurements and Patterns in Asymptomatic<br />
Children with Sickle Cell Disease<br />
Ibrahim F. Shatat, 1 Ram V. Kalpatthi, 2 Amanda E.<br />
Blue, 1 Katelyn Graeme, 1 Mary A. Johnson, 1 John K.<br />
Orak, 1 Sharron M. Jackson. 1 1 Medical University <strong>of</strong><br />
South Carolina Children’s Hospital, Charleston, SC,<br />
US; 2 Children’s Mercy Hospital, Kansas City, MO, US.<br />
Risk Factors (Lipids)<br />
PO-112:<br />
Evaluating the Effects <strong>of</strong> Hypercholesterolemia<br />
on Vascular Risk Pr<strong>of</strong>ile <strong>of</strong> Treated Hypertensive<br />
Patients. Results <strong>of</strong> a Cross-Sectional National Study<br />
Pedro Aranda, Manuel Gorostidi, Julian Segura,<br />
Alex de la Sierra, Jose Juan de la Cruz, Jose<br />
Carlos Fernandez, Luis Maria Ruilope. Cardiorisk<br />
Investigators Group, Madrid, ES.<br />
101
MAY 21<br />
Posters<br />
Saturday Afternoon<br />
PO-113:<br />
PO-114:<br />
PO-115:<br />
Negative Influence <strong>of</strong> Hypercholesterolemia on<br />
Blood Pressure Control. Results <strong>of</strong> a Spanish<br />
National Survey with ABPM<br />
Pedro Aranda, Jose Carlos Fernandez, Manuel<br />
Gorostidi, Julian Segura, Alejandro de la Sierra, Jose<br />
Juan de la Cruz, Luis Maria Ruilope. Cardiorisk<br />
Investigators Group, Madrid, ES.<br />
Association <strong>of</strong> Weight Misperception with Abnormal<br />
Lipid Levels and <strong>Hypertension</strong> among Overweight<br />
and Obese Reproductive-Age Women<br />
Mahbubur Rahman, Tabassum H. Laz, Abbey B.<br />
Berenson. University <strong>of</strong> Texas Medical Branch,<br />
Galveston, TX, US.<br />
Influence <strong>of</strong> Metabolic Syndrome Components in<br />
Atherosclerotic Disease and Intima Media Thickness<br />
<strong>of</strong> Carotid Artery Assessed by Gray Scale Method<br />
Priscilla Lopes Sarmento, Frida Liane Plavnik, Sérgio<br />
Aron Ajzen. Federal University <strong>of</strong> Sao Paulo, Sao<br />
Paulo, SP, BR.<br />
Stroke<br />
PO-117: <strong>Hypertension</strong> and Other Co-Morbid Conditions are<br />
Not Determinants <strong>of</strong> Treatment in Acute Ischemic<br />
Stroke<br />
Jordan A. Magarik, Robert J. Adams, Christine A.<br />
Holmstedt, Edward C. Jauch, Andrea D. Boan, Aquilla<br />
S. Turk, Daniel T. Lackland. Medical University <strong>of</strong><br />
South Carolina, Charleston, SC, US.<br />
PO-118: Pr<strong>of</strong>ile <strong>of</strong> Incidental Thyroid Nodules in 2996<br />
Patients Undergoing Carotid Ultrasound<br />
Saxena Naveen, 1 Srivastava Vinita, 1 William Bridges, 2<br />
Ricardo Abaunza, 1 Chanda Craft, 1 Nomita Joshi, 1<br />
Govind Rughani. 1 1 Internal Medicine and Cardiology<br />
Center, Greenville, SC, US; 2 Clemson University,<br />
Clemson, SC, US.<br />
PO-119: Additional Impact <strong>of</strong> Morning Haemostatic Factors<br />
and Blood Pressure Surgeon Stroke in Older<br />
Japanese Hypertensives<br />
Yuichiro Yano, Satoshi Hoshide, Kazuyuki Shimada,<br />
Kazuomi Kario. Jichi Medical University School <strong>of</strong><br />
Medicine, Tochigi, JP.<br />
Vascular Injury/Inflammation and<br />
Remodeling<br />
PO-120:<br />
Non-Dipping Status is Accompanied by<br />
Hypoadiponectinemia and Increased Aortic<br />
Stiffness in Essential <strong>Hypertension</strong><br />
I. Andrikou, C. Tsioufis, D. Syrseloudis, A. Kordalis,<br />
M. Almiroudi, I. Mpafakis, K. Kintis, T. Papaioannou,<br />
D. Aragiannis, C. Stefanadis. Hippokration Hospital,<br />
Athens, GR.<br />
102
Saturday Afternoon MAY 21<br />
Posters<br />
PO-121:<br />
PO-122:<br />
PO-123:<br />
Association <strong>of</strong> Retinal Microvascular Caliber with<br />
Blood Pressure Levels<br />
Raz Gibstein, 1 Yosi Rosman, 2 Ehud Rechtman, 1 Nira<br />
Koren‐Morag, 2 Yehonatan Sharabi, 2 Shlomo Segev, 2<br />
Ehud Assia, 1 Ehud Grossman. 2 1 Meir Hospital, IL; 2 The<br />
Chaim Sheba Medical Center, Tel Hashomer, Affiliated<br />
to Sackler School <strong>of</strong> Medicine, IL.<br />
Inhibiting the Renin-Angiotensin System with<br />
Aliskiren and/or Valsartan Protects Against<br />
C-Reactive Protein Mediated Vascular Injury<br />
Response<br />
Fadi G. Hage†, Caleb Pierce, Wei Zhang, Dongqi<br />
Xing, Yiu‐Fai Chen, Mark A. McCrory, Suzanne<br />
Oparil, Alexander J. Szalai. University <strong>of</strong> Alabama at<br />
Birmingham, Birmingham, AL, US.<br />
High Osteopontin N-Terminal/C-Terminal<br />
Fragment Ratio is Associated with Carotid Plaque<br />
Inflammation<br />
Talya Wolak, 1 Netta Sion‐Vrdy, 1 George Grennberg, 1<br />
Gabriel Szendro, 1 Assaf Rudich, 2 Ori Nov, 2 Victor<br />
Novack, 1 Esther Paran. 1 1 Soroka University Medical<br />
Center, Bear Sheva, IL; 2 Faculty <strong>of</strong> Health Sciences,<br />
Ben-Gurion University <strong>of</strong> the Negev Israel, Bear Sheva,<br />
IL.<br />
103
MAY 22<br />
Posters<br />
Sunday Morning<br />
Posters will be displayed in the Second Floor Promenade.<br />
Sunday, May 22, <strong>2011</strong><br />
Posters on Display: 10:00 AM – 6:30 PM • Poster Viewing: 5:30 PM – 6:30 PM<br />
Featured Posters<br />
Blood Pressure Measurement/Monitoring......................(FP-1 – FP-4)<br />
Adolescent <strong>Hypertension</strong>..................................................(FP-5 – FP-8)<br />
Aldosterone and Anti-Aldosterone Agents..............(PO-124 – PO-130)<br />
Antihypertensive Drugs and Pharmacology............(PO-131 – PO-157)<br />
Clinical Trials................................................................(PO-158 – PO-184)<br />
Coronary Artery Disease............................................(PO-185 – PO-191)<br />
Genetics/Gene Therapy/Proteomics..........................(PO-192 – PO-198)<br />
Heart Failure/Hypertrophy<br />
(Diastolic Dysfunction)...............................................(PO-199 – PO-216)<br />
<strong>Hypertension</strong> in Patients with Chronic<br />
Kidney Disease.............................................................(PO-217 – PO-226)<br />
Kidney and <strong>Hypertension</strong>...........................................(PO-227 – PO-242)<br />
Off-Target Cardiovascular Effects <strong>of</strong><br />
Non-Cardiovascular Drugs........................................(PO-243 – PO-244)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
104
Sunday Morning MAY 22<br />
Posters<br />
10:00 AM – 6:30 PM • Second Floor Promenade<br />
Featured Posters – Blood Pressure<br />
Measurement/Monitoring<br />
Moderators:<br />
FP-1:<br />
FP-2:<br />
FP-3:<br />
FP-4:<br />
Suzanne Oparil, MD, Birmingham, AL and<br />
Talma Rosenthal, MD, Tel Aviv, Israel<br />
Ambulatory Blood Pressure Monitoring and<br />
Cardiovascular Events in High-Risk Patients<br />
Alejandro de la Sierra†, 1 Julian Segura, 2 Jose R.<br />
Banegas, 2 Manuel Gorostidi, 2 Felipe Madruga, 2 Xavier<br />
Clar, 2 Teresa Gijon, 2 Luis M. Ruilope. 2 1 Hospital<br />
Mutua Terrassa, Terrassa, ES; 2 Spanish <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong>, Madrid, ES.<br />
A Perfect Replacement for the Mercury<br />
Sphygmomanometer: The Case <strong>of</strong> the Hybrid Blood<br />
Pressure Monitor<br />
George S. Stergiou, Nikos Karpettas, Anastasios Kollias,<br />
Antonis Destounis, Dimitris Tzamouranis. University<br />
<strong>of</strong> Athens, Athens, GR.<br />
Improvement in Blood Pressure Control among<br />
Hypertensive Patients Treated in the Department <strong>of</strong><br />
Veterans Affairs<br />
Ross D. Fletcher, Vasilios Papademetriou, Richard<br />
Amdur, Chris McManus, Ronald Jones, Charles<br />
Faselis. Veterans Affairs and Georgetown University,<br />
Washington, DC, US.<br />
Clinical Characteristics <strong>of</strong> Patients with<br />
Uncontrolled and Apparent Treatment Resistant<br />
<strong>Hypertension</strong>: NHANES 1988-2008<br />
Brent Egan, 1 Yumin Zhao, 1 R. Neal Axon, 1 R. Neal<br />
Axon, 2 Keith Ferdinand. 3 1 Medical University <strong>of</strong><br />
S.C., Charleston, SC, US; 2 Ralph H. Johnson, VAMC,<br />
Charleston, SC, US; 3 Emory University, Atlanta, GA,<br />
US.<br />
105
MAY 22<br />
Posters<br />
Sunday Morning<br />
10:00 AM – 6:30 PM • Second Floor Promenade<br />
Featured Posters – Adolescent<br />
<strong>Hypertension</strong><br />
Moderators:<br />
FP-5:<br />
FP-6:<br />
FP-7:<br />
FP-8:<br />
Daniel I. Feig, MD, PhD, Houston, TX and<br />
Joseph T. Flynn, MD, Seattle, WA<br />
Which BP Measurement Method Best Predicts<br />
Target Organ Damage in Youth<br />
Elaine M. Urbina, 1,2 Philip R. Khoury, 1 Connie E.<br />
McCoy, 1 Stephen R. Daniels, 3 Lawrence M. Dolan, 1,2<br />
Thomas R. Kimball. 1,2 1 Cincinnati Children’s Hospital<br />
Medical Center, Cincinnati, OH, US; 2 University<br />
<strong>of</strong> Cincinnati, Cincinnati, OH, US; 3 University <strong>of</strong><br />
Colorado, Aurora, CO, US.<br />
Effects <strong>of</strong> the D<strong>ASH</strong> Diet on Flow Mediated<br />
Dilation in Adolescents with Pre-<strong>Hypertension</strong> and<br />
<strong>Hypertension</strong><br />
Sarah C. Couch, 1 Linda Levin, 2 Amanda Thopy, 1 Brian<br />
E. Saelens, 3 Mark Mitsnefes, 4 Stephen R. Daniels, 5<br />
Elaine M. Urbina. 4 1 University <strong>of</strong> Cincinnati Medical<br />
Center, Cincinnati, OH, US; 2 University <strong>of</strong> Cincinnati,<br />
Cincinnati, OH, US; 3 Children’s Hospital and<br />
Regional Medical Center, Seattle, WA, US; 4 Cincinnati<br />
Children’s Hospital Medical Center, Cincinnati, OH,<br />
US; 5 University <strong>of</strong> Colorado School <strong>of</strong> Medicine,<br />
Denver, CO, US.<br />
Determinants <strong>of</strong> Arterial Stiffness in Children and<br />
Adolescents<br />
George S. Stergiou, Anastasios Kollias, Periklis Giovas,<br />
Leonidas Roussias. University <strong>of</strong> Athens, Athens, GR.<br />
Prevalence <strong>of</strong> Overweight and Elevated Blood<br />
Pressure in a Large Cohort <strong>of</strong> Children and<br />
Adolescents (Age 3-17 Years) at an Initial Clinic<br />
Examination<br />
Kenneth F. Adams, 1 Karen L. Margolis, 1 David<br />
J. Magid, 2 Joan C. Lo, 3 Alan R. Sinaiko, 4 Elyse<br />
O. Kharbanda, 1 Nancy E. Sherwood, 1 Matt F.<br />
Daley, 2 Emily D. Parker, 1 Patrick J. O’Connor. 1<br />
1 HealthPartners Research Foundation, Minneapolis,<br />
MN, US; 2 Kaiser Permanente Colorado, Denver, CO,<br />
US; 3 Kaiser Permanente Northern California, Oakland,<br />
CA, US; 4 University <strong>of</strong> MN, Minneapolis, MN, US.<br />
106
Sunday Morning MAY 22<br />
Posters<br />
10:00 AM – 6:30 PM • Second Floor Promenade<br />
Aldosterone and anti-aldosterone<br />
agents<br />
PO-124:<br />
PO-125:<br />
PO-126:<br />
PO-127:<br />
PO-128:<br />
PO-129:<br />
Aldosterone Metrics and Their Ability to<br />
Discriminate between Incident Resistant<br />
<strong>Hypertension</strong> during Follow-Up in a Hypertensive<br />
Cohort<br />
Jennifer D. Dochee, Berhane Seyoum, Phillip Levy,<br />
Brain Ference, Shiling Zhang, Lowell Hedquist, John<br />
Flack. Wayne State University, Detroit, MI, US.<br />
Aldosterone-Induced Rise in Blood Pressure in<br />
Normotensive Rats is Due to a Decrease in PGE 2<br />
Levels<br />
Danita Eatman, Aisha Rollins-Hairston, Deborah Lyn,<br />
Mohamed A. Bayorh. Morehouse School <strong>of</strong> Medicine,<br />
Atlanta, GA, US.<br />
Delayed Diagnosis <strong>of</strong> Primary Aldosteronism-<br />
Help from the Web: A Yahoo Support Group for<br />
Patients Struggling with Diagnosis and Long-Term<br />
Management<br />
Clarence E. Grim. High Blood Pressure Consulting,<br />
Milwaukee, US.<br />
Dose Titration <strong>of</strong> the Oral Potassium Binder-<br />
RLY5016 to Maintain Normal Serum Potassium in<br />
Heart Failure and Chronic Kidney Disease Patients<br />
on Aldosterone Antagonists<br />
Bertram Pitt†, 1 David Bushinsky, 2 Sherin Halfon, 3<br />
Dalane Kitzman, 4 Mitja Lainscak, 5 Vandana Mathur, 3<br />
Yuri Stasiv, 3 I.‐Zu Huang. 3 1 U. <strong>of</strong> Michigan, US; 2 U. <strong>of</strong><br />
Rochester, US; 3 Relypsa, US; 4 Wake Forest U., US; 5 U.<br />
Clinic Golnik, SI.<br />
Hyperkalemia with Aldosterone Antagonist<br />
Monotherapy in Essential <strong>Hypertension</strong>. A Meta-<br />
Analysis<br />
Jorge Romero, 1 Harikrishna Makani, 1 Jonathan<br />
Kahan, 1 Omar Wever‐Pinzon, 2 Clinton Colaco, 1 Franz<br />
H. Messerli. 1 1 St Luke’s Roosevelt Medical Center/<br />
Columbia University College <strong>of</strong> Physicians and<br />
Surgeons, New York, NY, US; 2 The University <strong>of</strong> Utah-<br />
Health Sciences Center, US.<br />
Body Mass Index Correlates with Plasma<br />
Aldosterone in Overweight/Obese Hypertensive<br />
Patients Despite Drug Therapy<br />
Riccardo Sarzani, Federico Guerra, Lucia Mancinelli,<br />
Alessia Buglioni, Eliana Franchi, Paolo Dessì‐Fulgheri.<br />
University Politecnica delle Marche, Ancona, IT.<br />
107
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-130:<br />
Aldosterone to Renin Ratio as a Predictor <strong>of</strong><br />
Mortality and Cardiovascular Outcomes<br />
John J. Sim†, 1 Simran K. Bhandari, 1 Jiaxiao M. Shi, 2<br />
Federico B. Calara, 4 Scott A. Rasgon, 1 Kamyar<br />
Kalantar‐Zadeh. 3 1 Kaiser Permanente Los Angeles<br />
Medical Center, Los Angeles, CA, US; 2 Kaiser<br />
Permanente Southern California, US; 3 Harbor UCLA<br />
Medical Center, US; 4 Novartis Corporation, US.<br />
Antihypertensive Drugs and<br />
Pharmacology<br />
PO-131:<br />
PO-132:<br />
PO-133:<br />
PO-134:<br />
PO-135:<br />
PO-136:<br />
Both Morning and Evening Dosing <strong>of</strong> Nebivolol<br />
Reduces Trough to Morning Blood Pressure Surge in<br />
Hypertensive Patients<br />
Maria Czarina Acelajado, 1 Roberto Pisoni, 3 Tanja<br />
Dudenbostel, 2 David A. Calhoun, 2 Stephen P. Glasser. 2<br />
1 Philippine General Hospital, Manila, PH; 2 University<br />
<strong>of</strong> Alabama at Birmingham, Birmingham, AL, US;<br />
3 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />
US.<br />
Administration-Time-Dependent Effects on<br />
Ambulatory Blood Pressure <strong>of</strong> Hydrochlorothiazide<br />
as Added Therapy in Hypertensive Subjects<br />
Uncontrolled with Valsartan<br />
Diana E. Ayala, Ramon C. Hermida, Artemio Mojon,<br />
Jose R. Fernandez. University <strong>of</strong> Vigo, Vigo, ES.<br />
Irbesartan/Amlodipine Fixed Combination<br />
in Patients Uncontrolled on Amlodipine 5 mg<br />
(I-COMBINE Study)<br />
Guillaume Bobrie. European George Pompidou<br />
Hospital, Paris, FR.<br />
Irbesartan/Amlodipine Fixed Combination in<br />
Patients Uncontrolled on Irbesartan 150 mg (I-ADD<br />
Study)<br />
Guillaume Bobrie. European George Pompidou<br />
Hospital, Paris, FR.<br />
Poly(3-Hydroxybutyrate) Nanoparticles Loaded with<br />
Paclitaxel Cause Prolonged Antiproliferative Action<br />
Anton P. Bonartsev, 1 Sergey A. Yakovlev, 2 Elena<br />
A. Filatova, 2 Galina M. Soboleva, 1 Tatiana K.<br />
Mahina, 2 Vera L. Myshkina, 2 Garina A. Bonartseva. 2<br />
1 M.V.Lomonosov Moscow State University, Moscow,<br />
RU; 2 Russian Academy <strong>of</strong> Sciences, Moscow, RU.<br />
The Efficacy and Safety <strong>of</strong> Angiotensin Receptor<br />
Blocker and Calcium Channel Blocker Combination<br />
in <strong>Hypertension</strong><br />
Bulent Boyaci, 1 Mehmet Berktas, 2 Pinar Kizilirmak. 2<br />
1 Gazi University Faculty <strong>of</strong> Medicine, Ankara, TR;<br />
2 Novartis Pharma, Istanbul, TR.<br />
108
Sunday Morning MAY 22<br />
Posters<br />
PO-137:<br />
PO-138:<br />
PO-139:<br />
PO-140:<br />
PO-141:<br />
Better Control <strong>of</strong> Central Pressures and Total<br />
Hypertensive Time in Patients with <strong>Hypertension</strong><br />
Receiving Telmisartan as Monotheraphy. Prospective<br />
Study<br />
Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1<br />
Santiago Garcia Ruiz, 1 Rafael Fernandez, 2 Erik<br />
Luepke. 3 1 University General Hospital <strong>of</strong> Albacete,<br />
Albacete, ES; 2 Health Center <strong>of</strong> Villarrobledo,<br />
Albacete, ES; 3 University General Hospital “La Paz”,<br />
Madrid, ES.<br />
Intravenous Hydralazine for Blood Pressure<br />
Management in the Hospitalized Patient<br />
Patrick T. Campbell, William L. Baker, Bendel D.<br />
Steven, William B. White. University <strong>of</strong> Connecticut<br />
School <strong>of</strong> Medicine, Farmington, CT, US.<br />
Long-Term Efficacy and Safety <strong>of</strong> Combination<br />
Olmesartan Medoxomil/Amlodipine<br />
Besylate+Hydrochlorothiazide in Study Participants<br />
with <strong>Hypertension</strong> Based on Age: The TRINITY<br />
Study<br />
Steven G. Chrysant†, 1 Dean J. Kereiakes, 2 Suzanne<br />
Oparil, 3 Joseph Izzo, 4 Thomas Littlejohn, 5 Michael<br />
Melino, 6 James Lee, 6 Victor Fernandez, 6 Reinilde<br />
Heyrman. 6 1 Oklahoma Cardiovascular and<br />
<strong>Hypertension</strong> Center and University <strong>of</strong> Oklahoma<br />
College <strong>of</strong> Medicine, US; 2 The Christ Hospital Heart<br />
and Vascular Center and The Carl and Edyth Lindner<br />
Center for Research and Education at the Christ<br />
Hospital, US; 3 University <strong>of</strong> Alabama at Birmingham,<br />
US; 4 State University <strong>of</strong> New York at Buffalo, US;<br />
5 Piedmont Medical Research Associates, US; 6 Daiichi<br />
Sankyo, Inc, US.<br />
Long-Term Efficacy and Safety <strong>of</strong> Combination<br />
Olmesartan Medoxomil/Amlodipine<br />
Besylate+Hydrochlorothiazide—The TRINITY<br />
Study: A Subgroup Analysis by Study Participant<br />
Race<br />
Steven G. Chrysant†, 1 Dean J. Kereiakes, 2 Joseph Izzo, 3<br />
Thomas Littlejohn, 4 Suzanne Oparil, 5 Michael Melino, 6<br />
James Lee, 6 Victor Fernandez, 6 Reinilde Heyrman. 6<br />
1 Oklahoma Cardiovascular and <strong>Hypertension</strong> Center<br />
and University <strong>of</strong> Oklahoma College <strong>of</strong> Medicine, US;<br />
2 The Christ Hospital Heart and Vascular Center and<br />
The Carl and Edyth Lindner Center for Research and<br />
Education at the Christ Hospital, US; 3 State University<br />
<strong>of</strong> New York at Buffalo, US; 4 Piedmont Medical<br />
Research Associates, US; 5 University <strong>of</strong> Alabama at<br />
Birmingham, US; 6 Daiichi Sankyo, Inc, US.<br />
Comparison <strong>of</strong> Valsartan/Amlodipine Added to<br />
Diuretic with Losartan Added to Diuretic on BP<br />
Load in <strong>Hypertension</strong><br />
Daniel Duprez†, 1 Keith Ferdinand, 2 Das Purkayastha, 3<br />
Rita Samuel, 3 Richard F. Wright. 4 1 University <strong>of</strong><br />
Minnesota, Minneapolis, MN, US; 2 Emory University,<br />
Atlanta, GA, US; 3 Novartis Pharmaceuticals<br />
Corporation, East Hanover, NJ, US; 4 Pacific Heart<br />
Insitute, Santa Monica, CA, US.<br />
109
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-142:<br />
PO-143:<br />
PO-144:<br />
PO-145:<br />
PO-146:<br />
PO-147:<br />
PO-148:<br />
The Impact <strong>of</strong> Initial Treatment <strong>of</strong> <strong>Hypertension</strong><br />
on Control in the First Year: Comparison <strong>of</strong> Initial<br />
Monotherapy, Free-Dose Combination and Fixed-<br />
Dose Combinations<br />
Brent Egan†, 1 Stephanie Shaftman, 1 Dipankar<br />
Bandyopadhyay, 1 C. Wagner, 1 Daniel Lackland, 1<br />
Kristina Yu‐Isenberg. 2 1 Medical University <strong>of</strong> South<br />
Carolina, SC, US; 2 Novartis Pharmaceuticals, NJ, US.<br />
A Bedtime Dose <strong>of</strong> ARB Reduces Urinary Albumin<br />
Excretion Via the Improvement <strong>of</strong> Baroreflex<br />
Sensitivity – The J-TOP Study<br />
Kazuo Eguchi, Motohiro Shimizu, Satoshi Hoshide,<br />
Kazuyuki Shimada, Shizukiyo Ishikawa, Kazuomi<br />
Kario. Jichi Medical University School <strong>of</strong> Medicine,<br />
Shimotsuke, Tochigi-ken, JP.<br />
Response to Aliskiren in Patients with Non-<br />
Controlled Blood Pressure Seems to be Irrespective<br />
<strong>of</strong> Previous Therapy and Plasma Renin Activity<br />
Angelica Fernandez, Susana Tello, Asuncion Guerri,<br />
Olivia Sanchez, Rosa Fabregate, Martin Fabregate,<br />
Arantxa Rodriguez, Jose Saban‐Ruiz. Ramon y Cajal<br />
Hospital, Madrid, ES.<br />
Impact <strong>of</strong> Initial Combination Therapy vs.<br />
Monotherapy on Major Cardiovascular Events: A<br />
Matched Cohort Study<br />
Alan H. Gradman†, 1 Hélène Parisé, 2 Marie‐Hélène<br />
Lafeuille, 2 Heather Falvey, 3 Patrick Lefebvre, 2 Mei<br />
Sheng Duh. 2 1 Temple University School <strong>of</strong> Medicine<br />
(Clinical Campus), Pittsburgh, PA, US; 2 Analysis<br />
Group, Inc., Boston, MA, US; 3 Novartis Pharma AG,<br />
Basel, CH.<br />
Relationship between Sleep-Time Blood Pressure<br />
Control and Reduction <strong>of</strong> Urinary Albumin<br />
Excretion after Timed-Treatment with Olmesartan<br />
in Essential <strong>Hypertension</strong><br />
Ramon C. Hermida, Diana E. Ayala, Maria J. Fontao,<br />
Artemio Mojon, Jose R. Fernandez. University <strong>of</strong> Vigo,<br />
Vigo, ES.<br />
Nebivolol and Hydrochlorothiazide in African-<br />
<strong>American</strong>s with <strong>Hypertension</strong>: Effects on Diastolic<br />
and Endothelial Function<br />
Bobby V. Khan†, Nadya Merchant, Tahir Haque, Syed<br />
T. Rahman, Sujan Bhaheetharan, Keith C. Ferdinand.<br />
Emory University School <strong>of</strong> Medicine, Atlanta, GA,<br />
US.<br />
Peripheral Edema Associated with Calcium<br />
Antagonists<br />
Harikrishna Makani, Jorge Romero, Nay Htyte,<br />
Ronaldo Sevilla Berrios, Arpit Shah, Waddy Gonzalez,<br />
Franz H. Messerli. St. Luke’s Roosevelt Hospital<br />
and Columbia University College <strong>of</strong> Physicians and<br />
Surgeons, New York, NY, US.<br />
110
Sunday Morning MAY 22<br />
Posters<br />
PO-149:<br />
PO-150:<br />
PO-152:<br />
PO-153:<br />
PO-154:<br />
PO-155:<br />
Efficacy <strong>of</strong> a Simplified Mechanistic Algorithm<br />
for Management <strong>of</strong> Resistant <strong>Hypertension</strong>: A<br />
Retrospective Study<br />
Neal S. Parikh, Samuel J. Mann†. NY Presbyterian<br />
Hospital – Weill Cornell Med Ctr, New York, NY, US.<br />
Long-Term Efficacy and Safety <strong>of</strong> Combination<br />
Olmesartan Medoxomil/Amlodipine<br />
Besylate+Hydrochlorothiazide—The TRINITY<br />
Study: Subgroup Analyses Based on Study<br />
Participant Diabetes Status and BMI<br />
Suzanne Oparil†, 1 Joseph Izzo, 2 Steven G. Chrysant, 3<br />
Dean J. Kereiakes, 4 Thomas Littlejohn, 5 Michael<br />
Melino, 6 James Lee, 6 Victor Fernandez, 6 Reinilde<br />
Heyrman. 6 1 University <strong>of</strong> Alabama at Birmingham,<br />
US; 2 State University <strong>of</strong> New York at Buffalo, US;<br />
3 Oklahoma Cardiovascular and <strong>Hypertension</strong> Center<br />
& University <strong>of</strong> Oklahoma College <strong>of</strong> Medicine, US;<br />
4 The Christ Hospital Heart and Vascular Center &<br />
The Carl and Edyth Lindner Center for Research<br />
and Education, US; 5 Piedmont Medical Research<br />
Associates, US; 6 Daiichi Sankyo, Inc, US.<br />
Differential Cardioprotective Effects <strong>of</strong> Carvedilol<br />
and Valsartan under Different Cardiac Loading<br />
Conditions<br />
Minesh Rajpal†, Shaila Karan, Sirisha Srikakarlapudi,<br />
Peter J. Osmond, Joseph L. Izzo. SUNY at Buffalo, NY,<br />
US.<br />
Effects <strong>of</strong> Time <strong>of</strong> <strong>Hypertension</strong> Treatment on the<br />
Circadian Blood Pressure Pattern <strong>of</strong> Subjects with<br />
Resistant <strong>Hypertension</strong>: The Hygia Project<br />
Maria T. Rios, 1 Manuel Dominguez‐Sardiña, 1 Lorenzo<br />
Pousa, 1 Jesus Perez de Lis, 1 Alfonso Otero, 2 Maria<br />
J. Fontao, 3 Jose R. Fernandez, 3 Diana E. Ayala, 3<br />
Ramon C. Hermida, 3 Investigadores Proyecto Hygia. 3<br />
1 Gerencia de Atención Primaria, Vigo, ES; 2 Complejo<br />
Hospitalario Universitario, Orense, ES; 3 University <strong>of</strong><br />
Vigo, Vigo, ES.<br />
Plasma Renin-Guided Treatment in Young<br />
Untreated <strong>Hypertension</strong>: A Randomized<br />
Comparative Pilot Study<br />
Il‐Suk Sohn, 1 Chang‐Bum Park, 1 Eun‐Sun Jin, 1<br />
Chong‐Jin Kim, 1 Jin‐Man Cho. 2 1 Kyung Hee<br />
University Gangdong Hospital, Seoul, KR; 2 Aab<br />
Cardiovascular Research Institute, Rochester, NY, US.<br />
Angiotensin Converting Enzyme Inhibitors or<br />
Angiotensin Receptor Blockers as First-Line<br />
Treatment in Patients with Uncomplicated<br />
<strong>Hypertension</strong><br />
Konstantinos Tziomalos, Maria Baltatzi, Athinodoros<br />
Pavlidis, Konstantinos Koulousios, Vasiliki Dourliou,<br />
Anastasios Hatzopoulos, Vaia Bougatsa, Lambrini<br />
Kirkineska, Christos Savopoulos, Apostolos I.<br />
Hatzitolios. Medical School, Aristotle University <strong>of</strong><br />
Thessaloniki, AHEPA Hospital, Thessaloniki, GR.<br />
111
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-156:<br />
PO-157:<br />
Amlodipine/Valsartan Single Pill Combination<br />
Treatment <strong>of</strong> Arterial <strong>Hypertension</strong> in a Real Life<br />
Practice in Russia<br />
Irina E. Chazova, 1 Yuri A. Karpov, 1 Alexey V.<br />
Vigdorchik†, 2 Antonina Y. Zazulina. 2 1 Russian<br />
Cardiology Scientific-Industrial Complex, Moscow,<br />
RU; 2 Novartis Pharma LLC, Moscow, RU.<br />
Real Life Safety and Effectiveness <strong>of</strong> Amlodipine/<br />
Valsartan Single Pill Combination in the Treatment<br />
<strong>of</strong> <strong>Hypertension</strong><br />
Irina E. Chazova, 1 Neelesh Dongre, 2 Alexey V.<br />
Vigdorchik†. 3 1 Russian Cardiology Scientific-Industrial<br />
Complex, Moscow, RU; 2 Novartis Pharma AG, Basel,<br />
CH; 3 Novartis Pharma LLC, Moscow, RU.<br />
Clinical Trials<br />
PO-158:<br />
PO-159:<br />
PO-160:<br />
PO-161:<br />
PO-162:<br />
The Influence <strong>of</strong> Antihypertensive Therapy on Blood<br />
Pressure Variability: The X-CELLENT Study<br />
Yi Zhang, 1,2 Davide Agnoletti, 1 Michel E. Safar, 1<br />
Jacques Blacher. 1 1 Paris Descartes University, Paris,<br />
FR; 2 Jiaotong University School <strong>of</strong> Medicine, Shanghai,<br />
CN.<br />
A Double-Dummy Comparison <strong>of</strong> De Novo<br />
Combination vs Sequential Add-On Therapy:<br />
‘ACCELERATE’<br />
Morris Brown, 1,2 Gordon McInnes, 1,3 Cheraz Cherif<br />
Papst, 4 Jack Zhang, 4 Thomas MacDonald. 1,5 1 British<br />
<strong>Hypertension</strong> <strong>Society</strong>, GB; 2 University <strong>of</strong> Cambridge,<br />
GB; 3 University <strong>of</strong> Glasgow, GB; 4 Novartis Pharma<br />
AG, CH; 5 University <strong>of</strong> Dundee, GB.<br />
Amlodipine Plus Telmisartan or Amiloride for<br />
Hypertensive Patients: Focus on Effects on Metabolic<br />
Pr<strong>of</strong>iles<br />
Hong Yuan, Jingjing Cai, Zhijun Huang. The Center <strong>of</strong><br />
Clinical Pharmacology <strong>of</strong> the Third Xiangya Hospital,<br />
Central South University, Changsha, CN.<br />
Amlodipine Plus Telmisartan or Amiloride for<br />
<strong>Hypertension</strong> in Moderate and High-Risk Patients:<br />
A 24-Week Observation<br />
Jingjing Cai, Zhijun Huang, Rong Cui, Hong Yuan. The<br />
Center <strong>of</strong> Clinical Pharmacology <strong>of</strong> the Third Xiangya<br />
Hospital, Central South University, Changsha, CN.<br />
Efficacy and Safety <strong>of</strong> Azilsartan Medoxomil/<br />
Chlorthalidone vs Olmesartan/HCTZ Combinations<br />
in Stage 2 Systolic HTN<br />
William C. Cushman†, 1 Domenic Sica, 2 George L.<br />
Bakris, 3 Michael A. Weber, 4 William B. White, 5<br />
Charlie Cao, 6 Andrew Roberts, 6 Stuart Kupfer. 6 1 U<br />
<strong>of</strong> TN College <strong>of</strong> Medicine, Memphis, TN, US; 2 VA<br />
Commonwealth U Health System, Richmond, VA,<br />
US; 3 U <strong>of</strong> Chicago Pritzker School <strong>of</strong> Medicine,<br />
Chicago, IL, US; 4 New York, NY, US; 5 U <strong>of</strong> CT School<br />
<strong>of</strong> Medicine, Farmington, CT, US; 6 Takeda Global<br />
Research & Development, Deerfield, IL, US.<br />
112
Sunday Morning MAY 22<br />
Posters<br />
PO-163: Effect <strong>of</strong> Aliskiren and Antihypertensive Drugs on<br />
Diastolic Function in Hypertensives with Diastolic<br />
Dysfunction: A Randomised Study<br />
Maria Leonarda De Rosa. University <strong>of</strong> Naples<br />
Federico II, Naples, IT.<br />
PO-164: Effects <strong>of</strong> Add-On Nebivolol on Blood Pressure and<br />
Glucose Parameters in Hypertensive Patients with<br />
Prediabetes<br />
P. Deedwania†, 1 D. G. Cheung, 2 J. Shea, 3 W. Chen, 3 J. J.<br />
Whalen. 3 1 UCSF, US; 2 Long Beach Center for Clinical<br />
Research, US; 3 Forest Research Institute, US.<br />
PO-165: Incident Diabetes with Antihypertensive Drugs:<br />
Updated Network and Bayesian Meta-Analyses <strong>of</strong><br />
Clinical Trial Data<br />
William J. Elliott†, 1 Sanjib Basu, 2 Peter M. Meyer. 2<br />
1 Pacific Northwest University <strong>of</strong> Health Sciences,<br />
Yakima, WA, US; 2 RUSH Medical College, Chicago,<br />
IL, US.<br />
PO-166: Efficacy and Safety <strong>of</strong> Combination DRI/CCB (±<br />
Diuretic) in US Minority Patients with Stage 2<br />
<strong>Hypertension</strong> and Obesity<br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ,<br />
US; 3 The University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, US.<br />
PO-167: Efficacy <strong>of</strong> Combination Aliskiren/Amlodipine with<br />
and without Diuretic on Ambulatory Blood Pressure<br />
in Minorities with <strong>Hypertension</strong><br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corp, East Hanover, NJ, US; 3 The<br />
University <strong>of</strong> Alabama at Birmingham, Birmingham,<br />
AL, US.<br />
PO-168: Role <strong>of</strong> Plasma Renin Activity on BP Response to<br />
Aliskiren-Based Therapy in Stage 2 Hypertensive<br />
African <strong>American</strong>s<br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ,<br />
US; 3 The University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, US.<br />
PO-169: Efficacy and Safety <strong>of</strong> Combination DRI/CCB<br />
(±Diuretic) Therapy in African <strong>American</strong>s with<br />
Stage 2 <strong>Hypertension</strong><br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ,<br />
US; 3 The University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, US.<br />
113
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-170:<br />
PO-171:<br />
PO-172:<br />
PO-173:<br />
PO-174:<br />
PO-175:<br />
PO-176:<br />
PO-177:<br />
PO-178:<br />
Combination Aliskiren/Amlodipine with and<br />
without Diuretic in Minorities with <strong>Hypertension</strong><br />
and Metabolic Syndrome or Diabetes<br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corp, East Hanover, NJ, US; 3 Univ <strong>of</strong><br />
Alabama at Birmingham, Birmingham, AL, US.<br />
Efficacy and Safety <strong>of</strong> Olmesartan Medoxomil<br />
Versus Losartan Potassium in Subjects with Stage 1<br />
or 2 <strong>Hypertension</strong><br />
John M. Flack†, 1 Alan Graff, 2 Wei Li, 3 Kathleen J.<br />
Chavanu, 3 Robert Dubiel. 3 1 Wayne State University<br />
School <strong>of</strong> Medicine, US; 2 Private Practice, US; 3 Daiichi<br />
Sankyo, Inc., US.<br />
Decreasing Sleep-Time Blood Pressure Determined<br />
by Ambulatory Monitoring Reduces Cardiovascular<br />
Risk in Resistant <strong>Hypertension</strong><br />
Ramon C. Hermida, 1 Diana E. Ayala, 1 Artemio<br />
Mojon, 1 Luisa Chayan, 2 Maria J. Dominguez, 3 Maria<br />
J. Fontao, 1 Ignacio Alonso, 1 Jose R. Fernandez. 1<br />
1 University <strong>of</strong> Vigo, Vigo, ES; 2 Urgencias Sanitarias<br />
061 Galicia, Santiago, ES; 3 Policlinica La Rosaleda,<br />
Santiago, ES.<br />
Influence <strong>of</strong> Circadian Time <strong>of</strong> Blood Pressure-<br />
Lowering Treatment on Cardiovascular Risk in<br />
Resistant <strong>Hypertension</strong><br />
Ramon C. Hermida, Diana E. Ayala, Artemio Mojon,<br />
Jose R. Fernandez. University <strong>of</strong> Vigo, Vigo, ES.<br />
Administration-Time Differential Benefit on<br />
Cardiovascular Risk Reduction <strong>of</strong> the Various<br />
Classes <strong>of</strong> <strong>Hypertension</strong> Medications<br />
Ramon C. Hermida, Diana E. Ayala, Artemio Mojon,<br />
Jose R. Fernandez. University <strong>of</strong> Vigo, Vigo, ES.<br />
Influence <strong>of</strong> Number <strong>of</strong> <strong>Hypertension</strong> Medications<br />
and Circadian Time <strong>of</strong> Treatment on Cardiovascular<br />
Morbidity and Mortality<br />
Ramon C. Hermida, Diana E. Ayala, Artemio Mojon,<br />
Jose R. Fernandez. University <strong>of</strong> Vigo, Vigo, ES.<br />
Doppler Measurement <strong>of</strong> Ankle Brachial Index is<br />
Still the Standard in Screening <strong>of</strong> Peripheral Arterial<br />
Disease<br />
Laura Rantamaula, Juha Varis, Ilkka M. Kantola. Turku<br />
University Hospital, Turku, FI.<br />
Comparative Effects <strong>of</strong> Carvedilol and Valsartan on<br />
Cardiac Workload<br />
Shaila Karan†, Sirisha Srikakarlapudi, Minesh Rajpal,<br />
Peter J. Osmond, Joseph L. Izzo, Jr. SUNY at Buffalo,<br />
Buffalo, NY, US.<br />
Olmesartan + CCB vs Olmesartan + Diuretic as<br />
Combination Therapy for Elderly Hypertensive<br />
Patients<br />
Johji Kato, Naoto Yokota, Toshihiro Kita, Tanenao Eto,<br />
Kazuo Kitamura. University <strong>of</strong> Miyazaki, Miyazaki<br />
City, Miyazaki, JP.<br />
114
Sunday Morning MAY 22<br />
Posters<br />
PO-179:<br />
PO-180:<br />
PO-181:<br />
PO-182:<br />
PO-183:<br />
PO-184:<br />
Efficacy and Safety <strong>of</strong> Olmesartan Medoxomil<br />
Versus Losartan Potassium in Antihypertensive<br />
Naïve/Non-Naïve Subjects<br />
Henry A. Punzi†, 1 Andrew Lewin, 2 Wei Li, 3 Kathleen J.<br />
Chavanu, 3 Robert Dubiel. 3 1 Trinity <strong>Hypertension</strong> and<br />
Metabolic Research Institute, US; 2 National Research<br />
Institute, US; 3 Daiichi Sankyo, Inc., US.<br />
Computer-Mediated System, WHEELS-I, Provides<br />
Evidence <strong>of</strong> Feasibility for Momentary Assessment<br />
<strong>of</strong> D<strong>ASH</strong> Diet Adherence over 8 Weeks<br />
Margaret Scisney‐Matlock, 1 Susan Steigerwalt, 2<br />
Kenneth Jamerson, 1 Amanda Sen, 1 Susan Pressler, 1<br />
Elizabeth Brough. 1 1 University <strong>of</strong> Michigan, Ann<br />
Arbor, MI, US; 2 St. John Health System, Detroit, US.<br />
Carvedilol Reduces Aortic Wave Reflection and<br />
Improves Left Ventricular/Vascular Coupling<br />
Compared to Atenolol: The CENTRAL Study<br />
Niren K. Shah†, 1 Benjamin J. Epstein, 1,2 Wilmer W.<br />
Nichols, 2 Steven M. Smith, 2 Julie A. Johnson. 2 1 East<br />
Coast Institute for Research, Jacksonville, FL, US;<br />
2 University <strong>of</strong> Florida, Gainesville, FL, US.<br />
Fixed-Dose Combination <strong>of</strong> Azilsartan Medoxomil/<br />
CLD Provides Superior BP Reduction to<br />
Monotherapies in Stage 2 HTN<br />
D. Sica†, 1 G. L. Bakris, 2 W. B. White, 3 M. A. Weber, 4<br />
W. C. Cushman, 5 A. Roberts, 6 C. Cao, 6 S. Kupfer. 6 1 VA<br />
Commonwealth U Health System, Richmond, VA, US;<br />
2 U <strong>of</strong> Chicago Pritzker School <strong>of</strong> Medicine, Chicago,<br />
IL, US; 3 U <strong>of</strong> CT School <strong>of</strong> Medicine, Farmington,<br />
CT, US; 4 New York, NY, US; 5 U <strong>of</strong> TN College <strong>of</strong><br />
Medicine, Memphis, TN, US; 6 Takeda Global Research<br />
& Development, Deerfield, IL, US.<br />
Efficacy <strong>of</strong> an Amlodipine/Olmesartan Medoxomil<br />
Algorithm in Patients Uncontrolled on Prior ACE<br />
Inhibitor Monotherapy<br />
Matthew R. Weir†, 1 Alan Graff, 2 Ali Shojaee, 3 William<br />
F. Waverczak, 3 Jen‐Fue Maa. 3 1 University <strong>of</strong> Maryland<br />
School <strong>of</strong> Medicine, US; 2 Private Practice, US; 3 Daiichi<br />
Sankyo, Inc., US.<br />
Pilot Randomized Controlled Trial <strong>of</strong> Intensive<br />
Blood Pressure Control in Hemodialysis Dialysis<br />
Patients: The BID Trial<br />
Philip Zager, 1 Dana Miskulin, 2 Jennifer Gassman. 3<br />
1 University <strong>of</strong> New Mexico Health Sciences Center,<br />
Albuquerque, NM, US; 2 Tufts Medical Center, Boston,<br />
MA, US; 3 Cleveland Clinic Research Foundation,<br />
Cleveland, OH, US.<br />
Coronary Artery Disease<br />
PO-185:<br />
Blood Pressure and Heart Related Quality <strong>of</strong> Life<br />
One Year Post Myocardial Infarction<br />
Antonios Ioannidis, Dimitrios Tsounis. Hellenic Open<br />
University, GR.<br />
115
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-186:<br />
PO-187:<br />
PO-188:<br />
PO-189:<br />
PO-190:<br />
PO-191:<br />
False-Positive Stress Testing Results in<br />
Hypertensives with No Coronary Artery Disease<br />
Fei Lu, 1 Gabriele Fragasso, 2 Chunzeng Lu, 1 Vitantonio<br />
Di Bello, 1 Roberto Pedrinelli, 1 Mario Marzilli, 1 Alberto<br />
Balbarini. 1 1 University <strong>of</strong> Pisa, IT; 2 Scientific Institute<br />
<strong>of</strong> H San Raffaele, IT.<br />
Inadequate Blood Pressure Control in Hypertensives<br />
Referred for Cardiac Stress Testing<br />
Tarek M. Mousa, Harmony Leighton, Seema Patel,<br />
Todd Kerwin. New York Hospital Medical Center <strong>of</strong><br />
Queens/Cornell University Weill Medical College,<br />
Flushing, NY, US.<br />
Relationship between Exercise Intolerance and<br />
Plasma Natriuretic Peptide Level in Hypertensives<br />
with Postinfarction Cardiosclerosis<br />
Mariya A. Orynchak, Iryna I. Vakalyuk, Igor P.<br />
Vakalyuk. Ivano-Frankivsk National Medical<br />
University, Ivano-Frankivsk, UA.<br />
Influence <strong>of</strong> a History <strong>of</strong> <strong>Hypertension</strong> with Clinical<br />
Presentation and Prognosis after Admission<br />
with Non ST Segment Elevation Acute Coronary<br />
Syndrome<br />
Joaquin Rueda Soriano, Miguel Angel Arnau Vives,<br />
Ana Osa Saez, Esther Zorio Grima, Luis Martínez<br />
Dolz, Luis Almenar, Miguel Palencia Pérez, Antonio<br />
Salvador Sanz. Hospital La Fe, Valencia, ES.<br />
Characteristics <strong>of</strong> Hypertensive Response during<br />
Exercise Echocardiography in Hypertensive Patients<br />
with No History <strong>of</strong> Coronary Artery Disease<br />
Il‐Suk Sohn, Chang‐Bum Park, Eun‐Sun Jin, Jin‐Man<br />
Cho, Chong‐Jin Kim, Jong‐Hoa Bae. Kyung Hee<br />
University School <strong>of</strong> Medicine, Seoul, KR.<br />
The Ankle-Brachial Index as a Predictor <strong>of</strong> Coronary<br />
Artery Disease<br />
Svetlana Kostic, Dragan Mijalkovic, Ivan Tasic.<br />
Institute for Therapy and Rehabilitation “Niska Banja”,<br />
Niska Banja, RS.<br />
Genetics/Gene Therapy/Proteomics<br />
PO-192:<br />
PO-193:<br />
Cardiac BNP Gene Delivery Prevents Hypertensive<br />
Heart Disease in Spontaneous Hypertensive Rats<br />
Alessandro Cataliotti, 1 Fernando L. Martin, 1 Jason M.<br />
Tonne, 2 Diego Bellavia, 1 John C. Burnett, 1 Yasuhiro<br />
Ikeda. 2 1 Mayo Clinic, Rochester, MN, US; 2 Mayo<br />
Clinic, Rochester, MN, US.<br />
DNA Variants in NOS3 are Associated with<br />
Improved Small Artery Elasticity and Decreased<br />
Systolic Blood Pressure<br />
Daniel Duprez, 1 Natalia Florea, 1 Sara Saul, 1 Ryan<br />
Palaciao, 1 Steven Rich, 2 Jay N. Cohn, 1 Jennifer Hall. 1<br />
1 University <strong>of</strong> Minnesota, Minneapolis, MN, US;<br />
2 University <strong>of</strong> Virginia, Charlottesville, VA, US.<br />
116
Sunday Morning MAY 22<br />
Posters<br />
PO-194:<br />
PO-195:<br />
PO-196:<br />
PO-198:<br />
SNP-SNP Interactions among <strong>Hypertension</strong> Related<br />
Genes<br />
Masahiko Eto, 1 Takanori Aonuma, 1 Masanobu<br />
Okayama, 2 Maki Kumada, 2 Ritei Uehara, 2 Yoshikazu<br />
Nakamura, 2 Eiji Kajii. 2 1 Wakuya Medical and Welfare<br />
Center, Wakuya, Miyagi, JP; 2 Jichi Medical University,<br />
Shimotsuke, Tochigi, JP.<br />
Blood Pressure, Endothelial Dysfunction, Lipid<br />
Pr<strong>of</strong>ile and CYP3A5 Gene Polymorphism in Uzbek<br />
Hypertensive Patients<br />
Amayak Kevorkov, Marietta Eliseyeva. Republican<br />
Specialized Center <strong>of</strong> Cardiology, Tashkent, UZ.<br />
Mitochondrial Polymorphisms are Associated<br />
with Blood Pressure and Metabolic Traits in the<br />
Framingham Heart Study<br />
Chunyu Liu, 1,2 Qiong Yang, 3 Shih‐Jen Hwang, 1,2<br />
Fengzhu Sun, 4 Caroline S. Fox, 1 Ramachandran S.<br />
Vasan, 1,5 Faina Schwartz, 5 Daniel Levy. 1,2 1 National<br />
Heart, Lung, and Blood Institute’s Framingham Heart<br />
Study, Framingham, MA, US; 2 NHLBI, Bethesda,<br />
MD, US; 3 Boston University School <strong>of</strong> Public Health,<br />
Boston, MA, US; 4 University <strong>of</strong> Southern California,<br />
Los Angeles, CA, US; 5 Boston University School <strong>of</strong><br />
Medicine, Boston, MA, US.<br />
Targeted Disruption <strong>of</strong> Npr1 Gene Upregulates<br />
Renin-Angiotensin System and Cardiac<br />
Hypertrophy in Null Mutant Mice<br />
Kailash N. Pandey. Tulane University Health Sciences<br />
School <strong>of</strong> Medicine, New Orleans, LA, US.<br />
Heart Failure/Hypertrophy (Diastolic<br />
Dysfunction)<br />
PO-199:<br />
PO-200:<br />
PO-201:<br />
A Meta-Analysis <strong>of</strong> the Effect <strong>of</strong> Anti-Hypertensive<br />
Treatment on Echocardiogram Parameters in Heart<br />
Failure Patients with Preserved Ejection Fraction<br />
Alex Briasoulis, 1 Vikram Agarwal, 1 Manpreet S.<br />
Sabharwal, 1 Girish N. Nadkarni, 1 Franz H. Messerli. 2<br />
1 St. Luke’s-Roosevelt Hospital Center, Columbia<br />
University College <strong>of</strong> Physicians and Surgeons, New<br />
York, NY, US; 2 St. Luke’s-Roosevelt Hospital Center,<br />
Columbia University College <strong>of</strong> Physicians and<br />
Surgeons, New York, NY, US.<br />
Effects <strong>of</strong> Renin-Angiotensin System Blockade on<br />
Mortality and Rehospitalization in Heart Failure<br />
with Preserved Ejection Fraction<br />
Vikram V. Agarwal, 1 Alexandros Briasoulis, 1 Girish<br />
Nadkarni, 1 Manpreet S. Sabharwal, 1 Nidhi Hans, 2<br />
Franz H. Messerli. 1 1 St. Luke’s-Roosevelt Hospital<br />
Center, New York, NY, US; 2 Harvard School <strong>of</strong> Public<br />
Health, Boston, MA, US.<br />
Socioeconomic Status and Costs in Heart Failure<br />
Billy G. Chacko, Tej K. Atluri, Syed U. Naqvi, Hamza<br />
Rana, Pavel J. Levy, Kimberley J. Hansen. Wake Forest<br />
University Baptist Medical Center, Winston Salem,<br />
NC, US.<br />
117
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-202: Can High Dose <strong>of</strong> Valsartan Improve Ventricular-<br />
Vascular Coupling in Heart Failure<br />
Wook‐Jin Chung†, 1 Hye‐Sun Seo, 2 Sung‐Hee Shin, 3<br />
Young‐Sup Byun, 4 Sung‐Kee Ryu, 5 Wook‐Bum Pyun, 6<br />
Se‐Joong Rim. 7 1 Gachon University Gil Hospital,<br />
Gachon University School <strong>of</strong> Medicine, Incheon,<br />
KR; 2 Inha University Hospital, KR; 3 Soonchunhyang<br />
University School <strong>of</strong> Medicine, KR; 4 Sanggye Paik<br />
Hospital, Inje University College <strong>of</strong> Medicine, KR;<br />
5 Eulji General Hospital, Eulji University School <strong>of</strong><br />
Medicine, KR; 6 Ewha Womans University, School <strong>of</strong><br />
Medicine, KR; 7 Gangnam Severance Hospital, Yonsei<br />
University College <strong>of</strong> Medicine, KR.<br />
PO-203: Can N-Terminal pro-B Type Natriuretic Peptide<br />
Predict LV Diastolic Dysfunction in Hypertensive<br />
Heart Disease<br />
Wook‐Jin Chung, 1 Sung‐Hee Shin, 2 Hye‐Sun Seo, 3<br />
Young‐Sup Byun, 4 Sung‐Kee Ryu, 5 Wook‐Bum<br />
Pyun, 6 Se‐Joong Rim. 7 1 Gachon University Gil<br />
Hospital, Gachon University School <strong>of</strong> Medicine,<br />
Incheon, KR; 2 Inha University Hospital, Incheon,<br />
KR; 3 Soonchunhyang University School <strong>of</strong> Medicine,<br />
Bucheon, KR; 4 Sanggye Paik Hospital, Inje University<br />
College <strong>of</strong> Medicine, KR; 5 Eulji General Hospital, Eulji<br />
University School <strong>of</strong> Medicine, KR; 6 Ewha Womans<br />
University, School <strong>of</strong> Medicine, KR; 7 Gangnam<br />
Severance Hospital, Yonsei University College <strong>of</strong><br />
Medicine, KR.<br />
PO-204: PPARg Agonist Inhibits, and PPARg Antagonist<br />
Exacerbates, Pressure Overload-Induced Cardiac<br />
Fibrosis and Dysfunction<br />
Kaizheng Gong, Yiu‐Fai Chen, Peng Li, Wei Zhang,<br />
Fadi Hage, Namasivayam Ambalavanan, Suzanne<br />
Oparil, Dongqi Xing. University <strong>of</strong> Alabama at<br />
Birmingham, Birmingham, AL, US.<br />
PO-205: Left Ventricular Mass Index is Associated with<br />
Cognitive Impairment Independently <strong>of</strong> Blood<br />
Pressure in the Elderly<br />
Manabu Hayakawa, 1,2 Yuichiro Yano, 2,3 Kazuo<br />
Kuroki, 1 Kazuyuki Shimada, 3 Kazuomi Kario. 3<br />
1 Kushima Shimin Hospital, Miyazaki, JP; 2 University<br />
<strong>of</strong> Miyazaki, Miyazaki, JP; 3 Jichi Medical University<br />
School <strong>of</strong> Medicine, Tochigi, JP.<br />
PO-206: Heart Failure Hospitalization in Tennessee (2006-<br />
2008): Race, Age, and Gender Analyses<br />
Baqar Husaini†, 1 Van Cain, 1 Pamela Hull, 1 Zahid<br />
Samad, 1 H. Okafor, 2 Robert Levine, 2 U. Sampson. 3<br />
1 Tennessee State University, US; 2 Meharry Medical<br />
College, Nashville, TN, US; 3 Vanderbilt University,<br />
Nashville, TN, US.<br />
118
Sunday Morning MAY 22<br />
Posters<br />
PO-207:<br />
PO-208:<br />
PO-209:<br />
PO-210:<br />
PO-211:<br />
PO-212:<br />
Reverse Association <strong>of</strong> Early Relaxation Tissue<br />
Doppler Waves with Left Ventricle Mass in<br />
Hypertensive Non Diabetic Patients<br />
Athanasios N. Kartalis, Nikolaos E. Smyrnioudis,<br />
Stefanos H. Garoufalis, Georgios N. Benetos,<br />
Panagiotis M. Moschouris, Panagiotis D. Sgourakis,<br />
Nikolaos V. Papagiannis, Ioannis V. Georgiadis,<br />
Georgios E. Georgiopoulos. General Hopsital <strong>of</strong> Chios<br />
Island, Chios, GR.<br />
Association <strong>of</strong> Geometric Patterns <strong>of</strong> the Left<br />
Ventricle with Microalbuminuria in Hypertensive<br />
Non-Diabetic Patients<br />
Athanasios N. Kartalis, Nikolaos E. Smyrnioudis,<br />
Stefanos H. Garoufalis, Georgios N. Benetos,<br />
Panagiotis M. Moschouris, Panagiotis D. Sgourakis,<br />
Nikolaos V. Papagiannis, Georgios E. Georgiopoulos.<br />
General Hopsital <strong>of</strong> Chios Island, Chios, GR.<br />
Relation <strong>of</strong> Ventricular Geometry to Brain<br />
Natriuretic Peptide Levels, EF and NYHA Class in<br />
Heart Failure<br />
Sanjay Kumar, 1 Amit Nautiyal, 2 Jason Lazar. 1 1 SUNY<br />
Downstate Medical Center, Brooklyn, NY, US;<br />
2 University <strong>of</strong> Wisconsin, Madison, WI, US.<br />
The Influence <strong>of</strong> Telmisartan on Plasma Potassium<br />
Levels in Hypertensives with Insulin Resistance and<br />
Heart Failure<br />
Mariya A. Orynchak, Oleg M. Sheremeta, Nestor<br />
M. Seredyuk, Nadiya V. Skrypnyk. Ivano-Frankivsk<br />
National Medical University, Ivano-Frankivsk, UA.<br />
The Types <strong>of</strong> Left Ventricular Diastolic Dysfunction<br />
and Plasma NT-pro BNP Levels in Patients with<br />
Metabolic Syndrome<br />
Mariya A. Orynchak, Iryna I. Vakalyuk, Iryna O.<br />
Gaman. Ivano-Frankivsk National Medical University,<br />
Ivano-Frankivsk, UA.<br />
Postoperatiave B-Type Natriuretic Peptide Level<br />
Associates with Prolonged Hospitalization after<br />
Non-Cardiac Surgery in Patients with <strong>Hypertension</strong><br />
Wook Bum Pyun, 1 Jae Hong Park, 2 Sang‐Hak Lee, 3<br />
Wook‐Jin Chung, 4 Young‐Sup Byun, 5 Sung‐Kee Ryu, 6<br />
Se‐Joong Rim, 7 Gil Ja Shin. 1 1 Mokdong Hospital,<br />
School <strong>of</strong> Medicine, Ewha Womans University, Seoul,<br />
KR; 2 Kangnam General Hospital, Yongin, KR; 3 Yonsei<br />
Cardiovascular Center, Yonsei University College<br />
<strong>of</strong> Medicine, Seoul, KR; 4 Heart Center, Gachon<br />
University Gil Medical Center, Incheon, KR; 5 Sanggye<br />
Paik Hospital, Inje University College <strong>of</strong> Medicine,<br />
Seoul, KR; 6 Eulji General Hospital, Eulji University<br />
School <strong>of</strong> Medicine, Seoul, KR; 7 Gangnam Severance<br />
Hospital, Yonsei University College <strong>of</strong> Medicine, Seoul,<br />
KR.<br />
119
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-213:<br />
PO-214:<br />
PO-215:<br />
PO-216:<br />
Treatment Blocking the Renin-Angiotensin System<br />
and Two-Year Mortality in Very Old Patients with<br />
Heart Failure and Preserved Ventricular Ejection<br />
Fraction<br />
Carlos Rodriguez‐Pascual, 1 Emilio Paredes‐Galan, 3<br />
Arturo Vilches‐Moraga, 1 Ana Isabel Ferrero-<br />
Martinez, 1 Marta Torrente‐Carballido, 1 Fernando<br />
Rodríguez‐Artalejo. 2 1 Hospital Meixoeiro, Vigo,<br />
Pontevedra, ES; 2 Universidad Autonoma, Madrid, ES;<br />
3 Hospital Meixoeiro, Vigo, Pontevedra, ES.<br />
Left Ventricular Hypertrophy in Overweight/Obese<br />
Hypertensives with Metabolic Syndrome Depends<br />
on Body Mass Index<br />
Federico Guerra, Lucia Mancinelli, Luca Angelini,<br />
Marco Fortunati, Paolo Dessì-Fulgheri, Riccardo<br />
Sarzani. University Politecnica delle Marche, Ancona,<br />
IT.<br />
The Association <strong>of</strong> Left Ventricular Hypertrophy<br />
with Exercise Induced Intraventricular Asynchrony<br />
Hye‐Sun Seo, 1 Young‐Sup Byun, 2 Sung‐Kee Ryu, 3<br />
Wook‐Bum Pyun, 4 Se‐Joong Rim, 5 Wook‐Jin Chung, 6<br />
Sung‐Hee Shin. 7 1 Soonchunhyang University Hospital,<br />
Bucheon, KR; 2 Sanggye Paik Hospital, Inje University<br />
College <strong>of</strong> Medicine, Seoul, KR; 3 Eulji General<br />
Hospital, Eulji University School <strong>of</strong> Medicine, Seoul,<br />
KR; 4 Ewha Womans University Hospital, Seoul, KR;<br />
5 Gangnam Severance Hospital, Yonsei University<br />
College <strong>of</strong> Medicine, Seoul, KR; 6 Gachon University<br />
Gil Hospital, Gachon University School <strong>of</strong> Medicine,<br />
Incheon, KR; 7 Inha University Hospital, Incheon, KR.<br />
Gender Specific Prognostic Differences in Regard<br />
to the Regression <strong>of</strong> Hypertensive Left Ventricular<br />
Hypertrophy (12 Years Follow-Up Study)<br />
Ivan Tasic, 1 Svetlana Kostic, 1 Dragan Djordjevic, 1<br />
Gordana Lazarevic, 2 Dragan Lovic. 3 1 Institute for<br />
Therapy and Rehabilitation “Niska Banja”, Niska Banja,<br />
RS; 2 Clinic <strong>of</strong> Cardiology, Nis, RS; 3 Clinic for Internal<br />
Disease InterMedica-Dr Lovic, Nis, RS.<br />
<strong>Hypertension</strong> in patients with chronic<br />
kidney disease<br />
PO-217:<br />
PREdictors <strong>of</strong> Adequate Control <strong>of</strong> <strong>Hypertension</strong><br />
among Chronic Kidney Disease Patients (PREACH-<br />
CKD)<br />
Ma Czarlota M. Acelajado‐Valdenor, Angelo Dave C.<br />
Javier, Maria Czarina M. Acelajado. Philippine General<br />
Hospital, Manila, PH.<br />
120
Sunday Morning MAY 22<br />
Posters<br />
PO-218:<br />
PO-219:<br />
PO-220:<br />
PO-221:<br />
PO-222:<br />
PO-223:<br />
Prevalence, Awareness, Treatment and Control <strong>of</strong><br />
<strong>Hypertension</strong> in Chronic Kidney Disease<br />
Bulent Altun, 1 Gultekin Suleymanlar, 2 Cengiz Utas, 3<br />
Turgay Arinsoy, 4 Kenan Ates, 5 Tevfik Ecder, 6 Taner<br />
Camsari, 7 Kamil Serdengecti. 8 1 Hacettepe University<br />
Faculty <strong>of</strong> Medicine, Ankara, TR; 2 Akdeniz University<br />
Medical School, Antalya, TR; 3 Erciyes University<br />
Faculty <strong>of</strong> Medicine, Kayseri, TR; 4 Gazi University<br />
Faculty <strong>of</strong> Medicine, Ankara, TR; 5 Ankara University<br />
Faculty <strong>of</strong> Medicine, Ankara, TR; 6 Istanbul University<br />
Istanbul Faculty <strong>of</strong> Medicine, Istanbul, TR; 7 Dokuz<br />
Eylul University Faculty <strong>of</strong> Medicine, Izmir, TR;<br />
8 Istanbul University Cerrahpasa Faculty <strong>of</strong> Medicine,<br />
Istanbul, TR.<br />
Selective Endothelin-A Receptor Antagonism<br />
Reduces Proteinuria, Blood Pressure and Arterial<br />
Stiffness in Chronic Proteinuric Kidney Disease<br />
N. Dhaun, I. MacIntyre, J. Goddard, D. J. Webb.<br />
University <strong>of</strong> Edinburgh, GB.<br />
Discordant Estimation <strong>of</strong> the Prevalence <strong>of</strong> Masked<br />
<strong>Hypertension</strong> According to Daytime or Nighttime<br />
Blood Pressure in Subjects with Chronic Kidney<br />
Disease. The Hygia Project<br />
Ramon C. Hermida, 1 Alfonso Otero, 2 Luis Piñeiro, 3<br />
Diana E. Ayala, 1 Ana Moya, 4 Elvira Sineiro, 4 Maria<br />
J. Fontao, 1 Artemio Mojon, 1 Jose R. Fernandez, 1<br />
Investigadores Proyecto Hygia. 1 1 University <strong>of</strong> Vigo,<br />
Vigo, ES; 2 Complejo Hospitalario Universitario,<br />
Orense, ES; 3 Complejo Hospitalario Universitario,<br />
Pontevedra, ES; 4 Gerencia de Atención Primaria,<br />
Pontevedra, ES.<br />
Alteration <strong>of</strong> the Circadian Blood Pressure Pattern<br />
in Subjects with Chronic Kidney Disease: The Hygia<br />
Project<br />
Alfonso Otero, 1 Manuel Dominguez‐Sardiña, 2 Maria<br />
C. Castiñeira, 3 Juan J. Crespo, 2 Amelia Ferreras, 2<br />
Artemio Mojon, 4 Diana E. Ayala, 4 Jose R. Fernandez, 4<br />
Ramon C. Hermida, 4 Investigadores Proyecto Hygia. 4<br />
1 Complejo Hospitalario Universitario, Orense, ES;<br />
2 Gerencia de Atención Primaria, Vigo, ES; 3 Gerencia<br />
de Atención Primaria, Pontevedra, ES; 4 University <strong>of</strong><br />
Vigo, Vigo, ES.<br />
Usefulness <strong>of</strong> the Resistive Index in Renal Doppler<br />
Ultrasonography as an Indicator <strong>of</strong> Vascular<br />
Damage in Patients with Risks <strong>of</strong> Atherosclerosis<br />
Tatsuo Kawai, Kei Kamide, Miyuki Onishi, Hiroko<br />
Yamamoto‐Hanasaki, Yoshichika Baba, Kazuhiro<br />
Hongyo, Izumi Shimaoka, Yuji Tatara, Yasushi Takeya,<br />
Mitsuru Ohishi, Hiromi Rakugi. Osaka University<br />
Graduate School <strong>of</strong> Medicine, Suita, Osaka, JP.<br />
Intradialytic <strong>Hypertension</strong> is Not Associated with<br />
Increased Blood Pressure Variability<br />
Catherine Kim, Peter N. Van Buren, Robert Toto, Jula<br />
K. Inrig. University <strong>of</strong> Texas at Southwestern, Dallas,<br />
TX, US.<br />
121
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-224:<br />
PO-225:<br />
PO-226:<br />
Effect <strong>of</strong> Vitamin D Supplementation on Blood<br />
Pressure among HD Patients Undergoing Dialysis<br />
Bharadwaj Cheruvu, 1 Yap Jason, 1,2 Saklayen<br />
Mohammad. 1,2 1 Veterans Medical Center, Dayton, OH,<br />
US; 2 Wright State University, Dayton, OH, US.<br />
Heme Oxygenase Induction Prevents Endothelial<br />
Dysfunction and Renal Damage in ec-SOD KO Mice<br />
Nitin Puri, 1 Tomoko Kawakami, 1 Luca Vanella, 1 Lars<br />
Bellner, 2 Rita Rezzani, 3 Toru Takahashi, 4 Kiyoshi<br />
Morita, 4 Nader G. Abraham. 1 1 University <strong>of</strong> Toledo,<br />
Toledo, OH, US; 2 New York Medical College, Valhalla,<br />
NY, US; 3 University <strong>of</strong> Brescia, IT; 4 Okayama<br />
University Medical School, Okayama, JP.<br />
Mean Hemodialysis-Unit Systolic BP is Similar in<br />
Patients with and without Frequent Intradialytic<br />
<strong>Hypertension</strong><br />
Peter N. Van Buren, Catherine Kim, Robert D. Toto,<br />
Jula K. Inrig. University <strong>of</strong> Texas Southwestern<br />
Medical Center, Dallas, TX, US.<br />
Kidney and <strong>Hypertension</strong><br />
PO-227:<br />
PO-228:<br />
PO-229:<br />
PO-230:<br />
PO-231:<br />
Nighttime Hemodynamics and Arterial Stiffness<br />
Exert a Powerful Additive Predictive Effect on the<br />
Occurrence <strong>of</strong> Microalbuminuria in <strong>Hypertension</strong>:<br />
A 6-year Follow-Up Study<br />
E. Andrikou, C. Tsioufis, C. Thomopoulos, A. Kordalis,<br />
I. Andrikou, M. Giakoumis, L. Lioni, M. Almiroudi, I.<br />
Eleftheriadou, C. Stefanadis. Hippokration Hospital,<br />
Athens, GR.<br />
Learning Nephrology through Mobile Devices: The<br />
Nephrology On-Demand Mobile Experience<br />
Tejas Desai, 1 Maria Ferris. 2 1 East Carolina University<br />
Brody School <strong>of</strong> Medicine, US; 2 The University <strong>of</strong><br />
North Carolina at Chapel Hill, US.<br />
Characteristics <strong>of</strong> Hypertensive Patients Using<br />
Either Aliskiren or Other Antihypertensive<br />
Medications<br />
Debra F. Eisenberg†, 1 Jinhee Park, 2 Christy Fang, 1<br />
Jean Lian, 2 Andrea DeVries. 1 1 HealthCore, Inc.,<br />
Wilmington, DE, US; 2 Novartis Pharmaceuticals, East<br />
Hanover, NJ, US.<br />
The Dopamine D1-Like Receptors Interact with the<br />
a 1A Adrenergic Receptor in Human Renal Epithelial<br />
Tubule Cells<br />
Riley C. Ennis, Van Anthony M. Villar, Julie A. Jurgens,<br />
John E. Jones, Pedro A. Jose. Children National<br />
Medical Center, Washington, DC, US.<br />
Uncoupled NOS is a Major Source <strong>of</strong> Renal<br />
Superoxide in Angiotensin II-Induced <strong>Hypertension</strong><br />
Maria C. Gongora, Li Li, Wei Chen, Kin Lung Siu,<br />
David G. Harrison. Emory University, Atlanta, GA,<br />
US.<br />
122
Sunday Morning MAY 22<br />
Posters<br />
PO-232:<br />
PO-233:<br />
PO-234:<br />
PO-235:<br />
PO-236:<br />
PO-237:<br />
PO-238:<br />
Loss <strong>of</strong> SNX5 Impairs Dopamine D 1 Receptor<br />
Endocytosis and Recycling and Aggravates the<br />
Blood Pressure in SHR<br />
Van Anthony M. Villar, 1,2 Ines Armando, 1,2 Lauren<br />
C. Frazer, 2 Kristen M. Russo, 2 Patricia M. Notario, 2<br />
Hewang Li, 1,2 Hironobo Sanada, 3 Yingjin Luo, 2 Lauren<br />
Comisky, 2 Holly Ann Russell, 2 Yu Yang, 1 Pedro A.<br />
Jose, 1,2 John E. Jones. 1,2 1 Children’s National Medical<br />
Center, Washington, DC, US; 2 Georgetown University<br />
School <strong>of</strong> Medicine, Washington, DC, US; 3 Fukushima<br />
Medical University School <strong>of</strong> Medicine, Fukushima, JP.<br />
Ambulatory Blood Pressure Measurement in<br />
Patients with Chronic Kidney Disease: Outcomes<br />
and Correlation with Clinic BP and BpTRU<br />
Ashok L. Kirpalani, Aditya S. Bhabhe, Dilip A.<br />
Kirpalani, Hardik K. Shah. Bombay Hospital Institute<br />
<strong>of</strong> Medical Sciences, Mumbai, Maharashtra, IN.<br />
Perinatal Dietary Protein and NaCl on Offspring’s<br />
Ambulatory Blood Pressure and Renal Injury<br />
Jong Y. Lee, Silvia H. Azar. Univ <strong>of</strong> MN School <strong>of</strong><br />
Medicine, Minneapolis, MN, US.<br />
Effects <strong>of</strong> a Direct Renin Inhibitor on RRI in<br />
Hypertensive Patients<br />
Francesco Natale, Chiara Cirillo, Chiara Granato,<br />
Claudia Concilio, Alessandro Siciliano, Luigi Aronne,<br />
Maria Credendino, Emanuela Lo Priore, Alessandro<br />
Ranieri, Maria Giovanna Russo, Raffaele Calabrò.<br />
Second University <strong>of</strong> Naples, Monaldi Hospital,<br />
Naples, IT.<br />
Uncontrolled <strong>Hypertension</strong> in CKD Patients is<br />
Associated with Higher Heart Rate<br />
Alexander Kagan, 1,2,3 Hedy Feibel, 3 Ishay Shoval, 3<br />
Jayson Rapoport. 1,2 1 Kaplan Medical Center, Rehovot,<br />
IL; 2 Hebrew University, Jerusalem, IL; 3 ”Meuhedet”<br />
Sick Fund, IL.<br />
Analysis <strong>of</strong> Left Ventricular Function and <strong>of</strong><br />
Coronary Circulation in Relationship to Renal<br />
Function<br />
César S. Rosa, 1,2 Bruno B. Pelazza, 1,2 Sebastião R.<br />
Filho. 1 1 Federal University <strong>of</strong> Uberlândia, Uberlândia,<br />
Minas Gerais, BR; 2 Heart Institute <strong>of</strong> Triangulo<br />
Mineiro, Uberlândia, Minas Gerais, BR.<br />
Discrepancies in <strong>Hypertension</strong> Control Rates<br />
Evaluated by Means <strong>of</strong> Office BP and Ambulatory<br />
BP Monitoring in Hypertensive Patients with and<br />
without Chronic Kidney Disease<br />
Manuel Gorostidi, 1 Julian Segura, 2 Alejandro de la<br />
Sierra, 3 Juan J. de la Cruz, 4 Jose R. Banegas, 4 Luis M.<br />
Ruilope. 2 1 Hospital Central de Asturias, Oviedo, ES;<br />
2 Hospital 12 de Octubre, Madrid, ES; 3 Hospital Mutua<br />
Terrasa, Universidad de Barcelona, Barcelona, ES;<br />
4 Universidad Autónoma, Madrid, ES.<br />
123
MAY 22<br />
Posters<br />
Sunday Morning<br />
PO-239:<br />
PO-240:<br />
PO-241:<br />
PO-242:<br />
Impaired Coronary Microcirculation is Associated<br />
with Increased Urine Albumin Excretion in<br />
Untreated Hypertensives<br />
D. Tsiachris, C. Tsioufis, K. Dimitriadis, D. Rousos,<br />
I. Tatsis, A. Kordalis, A. Kefala, C. Stefanadis.<br />
Hippokration Hospital, Athens, GR.<br />
Associations <strong>of</strong> Renal Hemodynamics with Target<br />
Organ Damage in Untreated Hypertensives. An<br />
Invasive Approach<br />
C. Tsioufis, D. Tsiachris, K. Dimitriadis, D. Rousos, I.<br />
Tatsis, D. Syrseloudis, G. Latsios, V. Papademetriou, C.<br />
Stefanadis. Hippokration Hospital, Athens, GR.<br />
Albuminuria is Related to Circulating Soluble<br />
Receptor for Advanced Glycation End Products<br />
and Biomarkers <strong>of</strong> Endothelial Function in<br />
<strong>Hypertension</strong><br />
C. Tsioufis, K. Dimitriadis, A. Aggelis, M. Poulakis, A.<br />
Kefala, A. Kasiakogias, A. Miliou, M. Almiroudi, C.<br />
Stefanadis. Hippokration Hospital, Athens, GR.<br />
Chronic Kidney Disease Education in the<br />
Community Health Center Setting Improves<br />
Prescription Filling Rates for Antihypertensive<br />
Medications<br />
Paul Bolin, Cindy Christiano, Melanie Hames,<br />
Tejas Desai, Hsiao Lai, Karen Parker, Rachel Ward,<br />
Courtland Winborne, Lacy Dean. East Carolina<br />
University Brody School <strong>of</strong> Medicine, US.<br />
Off-target cardiovascular effects <strong>of</strong><br />
non-cardiovascular drugs<br />
PO-243:<br />
PO-244:<br />
Sitagliptin is Associated with Increased Blood<br />
Pressure in Rats<br />
Dov Gavish, 1,3 Eyal Leibovitz, 1,3 Yonatan Shrabi, 2,3<br />
Ehud Grosman, 2,3 Dror Harats. 2,3 1 Wolfson Hospital,<br />
Holon, IL; 2 Sheba Medical Center, Ramat Gan, IL; 3 Tel<br />
Aviv Univeristy, Tel Aviv, IL.<br />
Blood Pressure Evaluation in Oncology and CNS<br />
Indications: Implementation <strong>of</strong> ABPM and Home<br />
BP Telemonitoring<br />
Jeffrey Heilbraun. Scientific Affairs, Rockville, MD, US.<br />
124
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
Posters will be displayed in the Second Floor Promenade.<br />
Monday, May 23, <strong>2011</strong><br />
Posters on Display: 10:00 AM – 5:30 PM • Poster Viewing: 4:30 PM – 5:30 PM<br />
Featured Posters<br />
Cardiac Structure and Function.................................... (FP-9 – FP-13)<br />
Arterial Structure and Compliance...........................(PO-245 – PO-259)<br />
Blood Pressure Measurement/Monitoring............(PO-260 – PO-305A)<br />
Cellular Mechanisms (Cell Biology;<br />
Cell Membrane Transport/Ion Channels;<br />
Coagulation/Thrombosis; Growth Factors).............(PO-306 – PO-308)<br />
Lipid Metabolism...........................................................................(PO-309)<br />
Neutral Hormonal Mechanisms (Renin; Neutral Control; Vasoactive<br />
Autacoids.......................................................................(PO-310 – PO-312)<br />
Non – Pharmacological Therapy (Alternative<br />
Medicine; Diet; Physical Activity).............................(PO-313 – PO-322)<br />
Nutrition and Cardiovascular Prevention................(PO-323 – PO-330)<br />
Obesity...........................................................................(PO-331 – PO-339)<br />
Patient – Provider-Healthcare System Issues...........(PO-340 – PO-355)<br />
Preclinical Models/Experimental <strong>Hypertension</strong>.....(PO-357 – PO-358)<br />
Pregnancy......................................................................(PO-359 – PO-361)<br />
Salt-Sensitive Mechanisms <strong>of</strong> <strong>Hypertension</strong>............(PO-362 – PO-364)<br />
Secondary <strong>Hypertension</strong>.............................................(PO-365 – PO-367)<br />
Late-Breaking Posters.........................................(LB-PO-01 – LB-PO-03)<br />
Dagger (†) denotes that the presenting author has related disclosure<br />
information.<br />
125
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
10:00 AM – 5:30 PM • Second Floor Promenade<br />
Featured Posters – Cardiac Structure<br />
and Function<br />
Moderators:<br />
FP-9:<br />
FP-10:<br />
FP-11:<br />
FP-12:<br />
FP-13:<br />
John D. Bisognano, MD, PhD, Rochester, NY and<br />
Robert A. Phillips, MD, PhD, Worcester, MA<br />
Parallel Deterioration <strong>of</strong> Albuminuria, Arterial<br />
Stiffness and Left Ventricular Mass in Essential<br />
<strong>Hypertension</strong>: Integrating Target Organ Damage<br />
E. Andrikou, C. Tsioufis, K. Dimitriadis, D. Flessas, K.<br />
Kintis, I. Mpafakis, M. Almiroudi, G. Chlapoutakis, M.<br />
Poulakis, M. Giakoumis, C. Stefanadis. Hippokration<br />
Hospital, Athens, GR.<br />
The Prognostic Value <strong>of</strong> Left Ventricular<br />
Hypertrophy in the Very Elderly: The PROTEGER<br />
Study<br />
Yi Zhang, 1,2 Davide Agnoletti, 1 Julie Peroz, 1 Ari<br />
Lieber, 1 Pierre Iaria, 1 Athanase D. Protogerou, 3 Michel<br />
E. Safar, 1 Jacques Blacher. 1 1 Paris Descartes University,<br />
Paris, FR; 2 Jiaotong University School <strong>of</strong> Medicine,<br />
Shanghai, CN; 3 University <strong>of</strong> Athens, Athens, GR.<br />
Cornell Product Left Ventricular Hypertrophy<br />
in Electrocardiogram and Mortality in a General<br />
Population<br />
Joji Ishikawa, 1 Shizukiyo Ishikawa, 2 Kazunori Kayaba, 3<br />
Kazuomi Kario. 1 1 Jichi Medical University School<br />
<strong>of</strong> Medicine, Tochigi, JP; 2 Jichi Medical University,<br />
Tochigi, JP; 3 Saitama Prefectural University, Saitama,<br />
JP.<br />
Identification <strong>of</strong> Myocardial Viability in<br />
Hypertensive Patients Receiving Beta-Blockers by<br />
Dobutamine Echocardiography<br />
Fei Lu, Vitantonio Di Bello, Chunzeng Lu, Mario<br />
Marzilli, Alberto Balbarini. University <strong>of</strong> Pisa, IT.<br />
Targeted Delivery <strong>of</strong> Endothelial Cells<br />
Overexpressing IL8RA and IL8RB Receptors<br />
Promotes Structural and Functional Recovery <strong>of</strong><br />
the Left Ventricle in Rats Following Myocardial<br />
Infarction<br />
Peng Li, Dongqi Xing, Kaizheng Gong, Fadi Hage,<br />
Onyedika John IIonze, Suzanne Oparil, Yiu‐Fai Chen.<br />
UAB, Birmingham, AL, US.<br />
126
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
10:00 AM – 5:30 PM • Second Floor Promenade<br />
Arterial Structure and Compliance<br />
PO-245:<br />
PO-246:<br />
PO-247:<br />
PO-248:<br />
PO-249:<br />
PO-250:<br />
PO-251:<br />
PO-252:<br />
Vascular Injury in Hypertensive Patients. are Men<br />
and Women Equal PARITE Study<br />
Claire Mounier‐Vehier, 1 Simon Tabassome, 2<br />
Dominique Guedj, 3 Assya Achouba, 4 Emmanuel<br />
Ghannad, 5 Stéphane Quéré, 4 Maxime Guenoun. 6<br />
1 Cardiologic Hospital, Lille, FR; 2 CHU Saint-Antoine,<br />
Paris, FR; 3 Cardiologist, Paris, FR; 4 Novartis Pharma<br />
SAS, Rueil-Malmaison, FR; 5 Cardiologist, Gif sur<br />
Yvette, FR; 6 Cardiologist, Marseille, FR.<br />
Peripheral Pulse Pressure Strongly Correlates with<br />
Central Systolic Blood Pressure in Adults: Bogalusa<br />
Heart Study<br />
Rebecca I. Clark, Camilo Fernandez, Gerald S.<br />
Berenson, Thomas D. Giles, Gary E. Sander. Tulane<br />
University Health and Sciences Center, New Orleans,<br />
LA, US.<br />
Addition <strong>of</strong> Eplerenone to RAAS Blockade in<br />
Patients with CKD and Proteinuria Correlates with<br />
Baseline Vascular Compliance<br />
Debbie L. Cohen†, Kevin A. Sterling, Raymond R.<br />
Townsend. University <strong>of</strong> Pennsylvania, Philadelphia,<br />
PA, US.<br />
Arterial Stiffness Evaluation in HIV Patients<br />
Antonio J. Delgado‐Leon, 1 Zenaida Castillo, 1 Jose M.<br />
Rojas, 1 Susana I. Celis, 2 Jennifer Moreno. 1 1 University<br />
<strong>of</strong> Carabobo, Valencia, Carabobo, VE; 2 Instituto<br />
Docente de Urologia, Valencia, Carabobo, VE.<br />
A New Vibrational Approach for Carotid Pulse Wave<br />
Velocity Assessment<br />
Francesco Faita, 1 Vincenzo Gemignani, 1 Elisabetta<br />
Bianchini, 1 Rosa Maria Bruno, 2 Lorenzo Ghiadoni. 2<br />
1 Institute <strong>of</strong> Clinical Physiology – National Research<br />
Council, Pisa, IT; 2 University <strong>of</strong> Pisa, Pisa, IT.<br />
Central-Peripheral Blood Pressure Differences are<br />
Greater in Hispanics and African-<strong>American</strong>s<br />
Haroon Kamran, Louis Salciccioli, Rinkesh Patel,<br />
Mohamed Munshi, Stephen Littman, Jason Lazar.<br />
SUNY Downstate Medical Center, Brooklyn, NY, US.<br />
The Left Ventricular Septal – Aortic Angle<br />
Relationship with the Augmentation Index and<br />
Central Blood Pressures<br />
Mediha Ibrahim, Kinda Venner-Jones, Haroon<br />
Kamran, Louis Salciccioli, Carl Bastien, Jason Lazar.<br />
SUNY Downstate Medical Center, Brooklyn, NY, US.<br />
Differences in Post-Ischemic Reactive Hyperemia<br />
Tissue Oxygen Saturation between Normals and<br />
Hypertensive Subjects<br />
Revathy Thangaratnavel, Haroon Kamran, Louis<br />
Salciccioli, Wah Wah Htun, Ilir Maraj, Edinrin Rae<br />
Obasare, Jason Lazar. Downstate Medical Center,<br />
Brooklyn, NY, US.<br />
127
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
PO-253:<br />
PO-254:<br />
PO-255:<br />
PO-256:<br />
PO-257:<br />
PO-258:<br />
PO-259:<br />
The Relationship between Impaired Lung Function<br />
and Cardiac Function in Older Individuals<br />
Barry J. McDonnell, 1 Iain Munnery, 2 Margaret M.<br />
Munnery, 2 Charlotte Bolton, 2 Carmel M. McEniery, 3<br />
Ian B. Wilkinson, 3 John R. Cockcr<strong>of</strong>t. 2 1 University<br />
<strong>of</strong> Wales Institute, Cardiff, Cardiff, GB; 2 Cardiff<br />
University, Cardiff, GB; 3 University <strong>of</strong> Cambridge,<br />
Cambridge, GB.<br />
Hyperemia Induced Changes in Carotid-Radial<br />
Pulse Wave Velocity before and after Pre and Post<br />
Ischemic Conditioning<br />
Nwamaka Onuigbo, Haroon Kamran, Louis Salciccioli,<br />
Abhishek Sharma, Jason Lazar. SUNY Downstate<br />
Medical Center, Brooklyn, NY, US.<br />
The Predictive Value <strong>of</strong> Carotid Artery Features over<br />
Traditional Risk Factors and Endothelial Function<br />
Oana Sandu, 1 Iulian Nastac, 2 Jaime Uribarri. 1 1 MSSM,<br />
NY, US; 2 UPB, Bucharest, RO.<br />
Determinants <strong>of</strong> Central Reflected Pressure Waves<br />
Sirisha Srikakarlapudi, Minesh Rajpal, Shaila Karan,<br />
Peter J. Osmond, Joseph L. Izzo. SUNY at Buffalo,<br />
Buffalo, NY, US.<br />
Regular Exercise-Induced Upregulation <strong>of</strong><br />
Circulating Endothelial Progenitor Cells Attenuates<br />
Age-Related Decline in Arterial Elasticity in Healthy<br />
Men<br />
Jun Tao, Zhen Yang. The First Affilaited Hospital. Sun<br />
Yat-Sen University, CN.<br />
Subendocardial Viability Ratio as an Index <strong>of</strong><br />
Impaired Coronary Flow Reserve in Untreated<br />
Hypertensives<br />
D. Tsiachris, C. Tsioufis, K. Dimitriadis, D. Rousos,<br />
A. Kordalis, I. Anastasopoulos, D. Syrseloudis, C.<br />
Stefanadis. Hippokration Hospital, Athens, GR.<br />
Impaired Coronary Microcirculation is Not<br />
Accompanied by Adverse Vascular Remodeling in<br />
Untreated Hypertensives<br />
D. Tsiachris, C. Tsioufis, D. Rousos, C. Thomopoulos,<br />
A. Kasiakogias, A. Kordalis, G. Latsios, C. Stefanadis.<br />
Hippokration Hospital, Athens, GR.<br />
Blood Pressure Measurement/Monitoring<br />
PO-260:<br />
Comparison <strong>of</strong> Central Hemodynamics between<br />
A_PULSE and Other Two Tonometry-Based Devices<br />
Yi Zhang, 1,2 Davide Agnoletti, 1 Julie Peroz, 1 Ari<br />
Lieber, 1 Michel E. Safar, 1 Paolo Salvi, 3,4 Jirar<br />
Topouchian, 1 Jacques Blacher. 1 1 Paris Descartes<br />
University, Paris, FR; 2 Jiaotong University School <strong>of</strong><br />
Medicine, Shanghai, CN; 3 University <strong>of</strong> Nancy, Nancy,<br />
FR; 4 University <strong>of</strong> Bologna, Bologna, IT.<br />
128
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-261:<br />
PO-262:<br />
PO-263:<br />
PO-264:<br />
PO-265:<br />
PO-266:<br />
PO-267:<br />
Two Office Blood Pressure Readings Taken on<br />
Each <strong>of</strong> Two Visits are Not Enough for an Accurate<br />
Estimation and an Adequate <strong>Hypertension</strong><br />
Diagnosis<br />
María M. Martínez, 1 María T. Díaz, 1 María T. Ríos, 1<br />
Rocío Del Tío, 1 Jesús Barros, 1 Victoria Mota, 1 Isabel<br />
Bueno, 1 Moncho Velhas, 1 Javier Pérez, 2 Ignacio<br />
Alonso. 2 1 Sergas (Health Department <strong>of</strong> Galicia), ES;<br />
2 University <strong>of</strong> Vigo, ES.<br />
Prevalence <strong>of</strong> Self-Monitoring Blood Pressure<br />
among Adults – Healthstyles, 2005 and 2008<br />
Carma Ayala, Xin Tong, Nora L. Keenan. CDC/<br />
NCCDPHP/DHDSP, Atlanta, GA, US.<br />
Prognostic Value <strong>of</strong> Clinic and Ambulatory Blood<br />
Pressure Measurements in Resistant <strong>Hypertension</strong><br />
Diana E. Ayala, 1 Ramon C. Hermida, 1 Artemio<br />
Mojon, 1 Luisa Chayan, 2 Maria J. Dominguez, 3 Maria<br />
J. Fontao, 1 Ignacio Alonso, 1 Jose R. Fernandez. 1<br />
1 University <strong>of</strong> Vigo, Vigo, ES; 2 Urgencias Sanitarias<br />
061 Galicia, Santiago, ES; 3 Policlinica La Rosaleda,<br />
Santiago, ES.<br />
Can Personal Exposures to Higher Nighttime<br />
and Early Morning Temperatures Increase Blood<br />
Pressure<br />
Robert D. Brook, 1 Hwashin H. Shin, 2 Robert L. Bard, 1<br />
Richard T. Burnett, 2 Alan Vette, 3 Carry Croghan, 3<br />
Ron Williams. 3 1 University <strong>of</strong> Michigan, US; 2 Health<br />
Canada, CA; 3 USEPA, US.<br />
24-h Ambulatory Blood Pressure and<br />
Cardiovascular Events in Elderly Hypertensive<br />
Patients Followed-Up for Seven Years<br />
Jose Mesquita Bastos, 1 Susana Bertoquini, 2 Jorge<br />
Polonia. 3 1 Universidade de Aveiro, Aveiro, PT;<br />
2 Faculdade Psicologia e Ciências da Educação, PT;<br />
3 Faculdade de Medicina do Porto, PT.<br />
Total Peripheral Resistance and its Relationship with<br />
<strong>Hypertension</strong> in Patients with Severe Sleep Apnea<br />
Ricardo M. Cabrera Sole, 1 Ramon Coloma, 1 Caridad<br />
Turpin Lucas, 1 Ana Galdamez Nuñez, 2 Erik Luepke, 3<br />
Juan Cañas, 4 Manuel Aguilera Saldaña. 1 1 University<br />
General Hospital <strong>of</strong> Albacete, Albacete, ES; 2 Health<br />
Center <strong>of</strong> Villacerrada, Albacete, ES; 3 University<br />
General Hospital “La Paz”, Madrid, ES; 4 Health Center<br />
No. 3, Albacete, ES.<br />
Patients with Hypertensive Crisis Have Higher Risk<br />
Following First Month after the Crisis Compared<br />
with Hypertensive Patients at Similar Blood<br />
Pressure<br />
Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1 Ana<br />
Galdamez Nuñez, 2 Juan Cañas, 3 Manuel Aguilera<br />
Saldaña. 1 1 University General Hospital <strong>of</strong> Albacete,<br />
Albacete, ES; 2 Health Center <strong>of</strong> Villacerrada, Albacete,<br />
ES; 3 Health Center No. 3, Albacete, ES.<br />
129
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
PO-268:<br />
PO-269:<br />
PO-270:<br />
PO-271:<br />
PO-272:<br />
PO-273:<br />
PO-274:<br />
PO-275:<br />
PO-276:<br />
Correlation between Left Ventricular Mass and<br />
Ambulatory or Clinic Blood Pressure in Very Elderly<br />
Subjects<br />
S. Carugo, 1 A. Esposito, 1 D. Solari, 1 M. Maisaidi, 1<br />
G. Mancia. 2 1 ASP IMMeS e PAT, University <strong>of</strong> Milan,<br />
Milan, IT; 2 University Milano-Bicocca, S. Gerardo<br />
Hospital, Monza, IT.<br />
Clinical and Ambulatory Blood Pressure Values in<br />
Centenaries<br />
S. Carugo, 1 A. Esposito, 1 D. Solari, 1 M. Maisaidi, 1<br />
G. Mancia. 2 1 ASP IMMeS e PAT, University <strong>of</strong> Milan,<br />
Milan, IT; 2 University Milano-Bicocca, S. Gerardo<br />
Hospital, Monza, IT.<br />
Usefulness <strong>of</strong> Automated Office Blood Pressure<br />
Measurement by BpTRU for the Diagnosis <strong>of</strong><br />
Resistant <strong>Hypertension</strong><br />
Giuseppe Crippa, 1 Antonino Cassi, 1 Matteo Bosi, 2<br />
Maria Luisa Fares. 1 1 Guglielmo da Saliceto Hospital,<br />
Piacenza, IT; 2 Universita’ Cattolica, Piacenza, IT.<br />
Effects <strong>of</strong> Aliskiren- and Ramipril-Based Treatment<br />
on Central Aortic Blood Pressure in Systolic<br />
<strong>Hypertension</strong><br />
Daniel Duprez†, 1 Fabio Baschiera, 2 Alan Charney, 3<br />
InYoung Baek, 2 Patrick Brunel. 2 1 University <strong>of</strong><br />
Minnesota, Minneapolis, MN, US; 2 Novartis Pharma<br />
AG, Basel, CH; 3 Novartis Pharmaceutical Corporation,<br />
East Hanover, NJ, US.<br />
Apparent Treatment Resistant <strong>Hypertension</strong> in a<br />
Community-Based Practice Network<br />
Brent Egan†, Yumin Zhao, W. Adam Brzezinski,<br />
Benjamin Clyburn, Jan Basile, Daniel Lackland.<br />
Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />
US.<br />
Progression from Pre-<strong>Hypertension</strong> to <strong>Hypertension</strong><br />
is Accelerated in African <strong>American</strong>s<br />
Anbesaw Selassie, C. Shaun Wagner, Brent Egan†.<br />
Medical University <strong>of</strong> South Carolina, Charleston, US.<br />
Clinical Characteristics <strong>of</strong> Patients with<br />
Uncontrolled and Apparent Treatment Resistant<br />
<strong>Hypertension</strong>: NHANES 2005-2008<br />
Brent Egan†, 1 Yumin Zhao, 1 R. Neal Axon, 1 Keith<br />
Ferdinand. 2 1 Medical University <strong>of</strong> South Carolina,<br />
Charleston, SC, US; 2 Emory University, Atlanta, GA,<br />
US.<br />
Impacting Population Cardiovascular Health<br />
through a Community-Based Practice Network:<br />
Update on An-<strong>ASH</strong>-Supportive Collaborative<br />
Brent Egan†, Marilyn Laken, Daniel Lackland. Medical<br />
University <strong>of</strong> S.C., Charleston, SC, US.<br />
Estimation <strong>of</strong> Central Cardiovascular Parameters<br />
from Brachial Cuff Pressure Waveform<br />
Kenji Fujii, 1 Tatsuya Kobayashi, 1 Toshihiko Ogura, 1<br />
Hir<strong>of</strong>umi Tomiyama, 2 Akira Yamashina. 2 1 Omron<br />
Healthcare Co., Ltd, JP; 2 Tokyo Medical University, JP.<br />
130
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-277:<br />
PO-278:<br />
PO-279:<br />
PO-280:<br />
PO-281:<br />
PO-282:<br />
PO-283:<br />
Blood Pressure Measurement-Device and<br />
Calibration Patterns in Home Health Care<br />
F. W. Germino, 1,2 Megan M. Germino. 3 1 Orland<br />
Primary Care Specialists, Orland Park, IL, US; 2 Rush<br />
School <strong>of</strong> Medicine, Chicago, IL, US; 3 Rush University,<br />
Chicago, IL, US.<br />
ABPM in Octogenarians<br />
Eduardo Podjarny, 1 Jacques Bernheim, 1,2 Eliezer<br />
Golan. 1,2 1 Meir Medical Center, Kfar-Saba, IL; 2 Tel-<br />
Aviv University, Tel-Aviv, IL.<br />
Impact <strong>of</strong> Initial Antihypertensive Treatment with<br />
a Single-Pill Combination on Blood Pressure Goal<br />
Attainment: A Matched Cohort Study<br />
Alan H. Gradman†, 1 Hélène Parisé, 2 Marie‐Hélène<br />
Lafeuille, 2 Heather Falvey, 3 Patrick Lefebvre, 2 Mei<br />
Sheng Duh. 2 1 Temple University School <strong>of</strong> Medicine<br />
(Clinical Campus), Pittsburgh, PA, US; 2 Analysis<br />
Group, Inc., Boston, MA, US; 3 Novartis Pharma AG,<br />
Basel, CH.<br />
Influence <strong>of</strong> Dipping Classification on Fasting<br />
Glucose in Subjects with and without Elevated<br />
Ambulatory Blood Pressure: The Hygia Project<br />
Manuel Dominguez‐Sardiña, 1 Pedro A. Callejas, 1<br />
Peregrina Eiroa, 1 Juan J. Crespo, 1 Jose L. Salgado, 1<br />
Alfonso Otero, 2 Maria J. Fontao, 3 Sonia Lorenzo, 3<br />
Ramon C. Hermida, 3 Investigadores Proyecto Hygia. 3<br />
1 Gerencia de Atención Primaria, Vigo, ES; 2 Complejo<br />
Hospitalario Universitario, Orense, ES; 3 University <strong>of</strong><br />
Vigo, Vigo, ES.<br />
Influence <strong>of</strong> Duration <strong>of</strong> Ambulatory Blood Pressure<br />
Monitoring (48 vs. 24 Hours) on Cardiovascular<br />
Risk Assessment<br />
Ramon C. Hermida, Diana E. Ayala, Maria J. Fontao,<br />
Artemio Mojon, Jose R. Fernandez. University <strong>of</strong> Vigo,<br />
Vigo, ES.<br />
Reproducibility <strong>of</strong> Nocturnal Blood Pressure<br />
Dipping is Influenced by Day-to-Day Changes in<br />
Sleep Quality<br />
Alan L. Hinderliter, 1 Faye S. Routledge, 2 James A.<br />
Blumenthal, 2 William K. Wohlgemuth, 3 Andrew<br />
Sherwood. 2 1 University <strong>of</strong> North Carolina School<br />
<strong>of</strong> Medicine, Chapel Hill, NC, US; 2 Duke University<br />
Medical Center, Durham, NC, US; 3 University <strong>of</strong><br />
Miami School <strong>of</strong> Medicine, Miami, FL, US.<br />
Using Telephonic Outreach to Improve Blood<br />
Pressure Control<br />
Timothy Ho, 1 Joel Handler, 1 Michael Kanter, 2 Kristi<br />
Reynolds, 3 Ruthie Goldberg, 2 Joe Kimura. 1 1 Kaiser<br />
Permanente Medical Center, Anaheim, CA, US;<br />
2 Southern California Permanente Medical Group,<br />
Pasadena, CA, US; 3 Kaiser Permanente Southern<br />
California, Pasadena, CA, US.<br />
131
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
PO-284:<br />
PO-285:<br />
PO-287:<br />
PO-288:<br />
PO-289:<br />
PO-290:<br />
PO-291:<br />
Relationship between the Reduction <strong>of</strong> Left<br />
Ventricular Mass Index and the Changes in Sleep<br />
Blood Pressure with Sodium Restriction and/or<br />
Diuretic Treatment<br />
Joji Ishikawa, Kazuo Eguchi, Satoshi Hoshide,<br />
Kazuyuki Shimada, Kazuomi Kario. Jichi Medical<br />
University School <strong>of</strong> Medicine, Tochigi, JP.<br />
BpTRU – A Useful Alternative to 24 Hour<br />
Ambulatory Blood Pressure Monitoring in<br />
Evaluation and Management <strong>of</strong> <strong>Hypertension</strong> in<br />
India<br />
Dilip A. Kirpalani, Hardik K. Shah, Aditya S. Bhabhe,<br />
Ashok L. Kirpalani. Bombay Hospital Institute <strong>of</strong><br />
Medical Sciences, Mumbai, Maharashtra, IN.<br />
Effects <strong>of</strong> Traffic-Related Particles on Blood Pressure<br />
and DNA Methylation<br />
Denise P. Lamoureux, Edgar A. Diaz, Yeonseung<br />
Chung, Mark S. Long, Joy Lawrence, Vasileios<br />
Papapostolou, Phuong‐son Nguyen, John J. Godleski.<br />
Harvard School <strong>of</strong> Public Health, US.<br />
Ambulatory Blood Pressure in the Biological Time<br />
Structures<br />
Mary S. Lee, 1 John S. Lee, 2 Jong Y. Lee, 3 Franz<br />
Halberg. 4 1 Northwestern Univ. School <strong>of</strong> Medicine,<br />
Chicago, IL, US; 2 Univ <strong>of</strong> Minnesota School <strong>of</strong><br />
Medicine, Minneapolis, MN, US.<br />
Ambulatory Blood Pressure Monitoring in<br />
Hypertensive Smokers: Evidence <strong>of</strong> Impaired Night-<br />
Response<br />
Linda Landini, 1 Aurelio Leone. 2 1 University <strong>of</strong> Pisa,<br />
Pisa, Pi, IT; 2 City Hospital, Massa, Ms, IT.<br />
Oscillometric and Auscultatory Blood Pressure<br />
Measurements before and after Acute Exercise and<br />
Rest in the Elderly<br />
Leandra Gonçalves Lima, Iara Felício Anunciato,<br />
Fernanda Jatte, Júlio Cesar Moriguti, Eduardo Ferriolli,<br />
Nereida K. Costa Lima. Ribeirao Preto Medical School<br />
Sao Paulo University, Ribeirao Preto, SP, BR.<br />
Home Blood Pressure Monitoring Requires<br />
Feedback to Patients to Improve Treatment <strong>of</strong><br />
<strong>Hypertension</strong><br />
Alexander G. Logan, 1 Warren McIsaac, 2 Jane Irvine, 3<br />
Andras Tisler, 4 Denice Feig, 5 Joseph Cafazzo. 6 1 Mount<br />
Sinai Hospital, Toronto, ON, CA; 2 Mount Sinai<br />
Hospital, Toronto, ON, CA; 3 York University, Toronto,<br />
ON, CA; 4 Semmelweis University, Budapest, HU;<br />
5 Mount Sinai Hospital, Toronto, ON, CA; 6 Toronto<br />
General Hospital, Toronto, ON, CA.<br />
132
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-292:<br />
PO-293:<br />
PO-294:<br />
PO-295:<br />
PO-297:<br />
PO-298:<br />
PO-299:<br />
Blood Pressure in Firefighters<br />
Steven M. M<strong>of</strong>fatt†, 1,4 Suchita Garg, 2 Michael J.<br />
Epstein, 2 Nandini Hadker, 2 Lora Lex, 1,4 Feride Frech-<br />
Tamas. 3 1 Indianapolis Fire Department, Indianapolis,<br />
IN, US; 2 United BioSource Corporation, Lexington,<br />
MA, US; 3 Novartis Pharmaceuticals, East Hanover, NJ,<br />
US; 4 Public Safety Medical, Indianapolis, IN, US.<br />
Long-Term Effects <strong>of</strong> Telemetric Blood Pressure<br />
Monitoring in Adequately Treated Patients with<br />
Arterial <strong>Hypertension</strong><br />
Claas L. Neumann, Eike M. Rieken, Jan‐Marc Schmidt<br />
Thrun, Egbert G. Schulz. Nephrologisches Zentrum<br />
Göttingen, Göttingen, Niedersachsen, DE.<br />
Relationship between Central and Peripheral Blood<br />
Pressure in Type 2 Diabetic and Prediabetic Patients<br />
Anna Oliveras, 1,3 Julián Segura, 3 Carmen Suárez, 3<br />
Manuel Gómez, 3 Luis García‐Ortiz, 3 Nieves Martell, 3<br />
María Abad, 3 Luis Vigil, 3 David Ferrero, 3 Juan J. de<br />
la Cruz, 2 Luis M. Ruilope, 3 Alejandro de la Sierra. 3<br />
1 Hosp.del Mar. Parc Salut Mar, Barcelona, ES;<br />
2 Autonomous University <strong>of</strong> Madrid, ES; 3 On Behalf <strong>of</strong><br />
the PRESCEN Study, ES.<br />
Clinical Characteristics, Blood Pressure Control,<br />
and Antihypertensive Treatment Patterns among<br />
Elderly Patients with <strong>Hypertension</strong><br />
Sujata P. Sarda, 1 Si‐Tien Wang, 1 Priyanka<br />
Ramamurthy, 1 Robert Wei, 1 Jinhee Park†, 2 L. M.<br />
Andrews, 2 Feride Frech‐Tamas, 2 Mei Sheng Duh. 1<br />
1 Analysis Group, Inc., Boston, MA, US; 2 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ, US.<br />
Antihypertensive Effectiveness <strong>of</strong> Combination<br />
Lercanedipine with Diltiazemi in Patients with Mild<br />
to Moderate Arterial <strong>Hypertension</strong><br />
Oksana L. Rekovets, Yuriy M. Sirenko, Anna S.<br />
Dobrokhod, Galina F. Primak, Alla S. Vaschilko,<br />
Evhenia A. Pavlyuk. Institute <strong>of</strong> Cardiology, Kyiv, UA.<br />
Higher Night-Time Blood Pressure and Cardiac<br />
Damage in 1176 Patients: Effects <strong>of</strong> BMI and Drug<br />
Therapy<br />
Riccardo Sarzani, Federico Guerra, Massimiliano<br />
Fedecostante, Paolo Barbatelli, Elena Giannini, Letizia<br />
Lancioni, Emma Espinosa, Paolo Dessì‐Fulgheri.<br />
University Politecnica delle Marche, Ancona, IT.<br />
Seasonality <strong>of</strong> 24 H, Daytime and Night-Time Blood<br />
Pressure: Summer Does Not Always Mean Lower<br />
Federico Guerra, Massimiliano Fedecostante, Letizia<br />
Lancioni, Elena Giannini, Paolo Barbatelli, Emma<br />
Espinosa, Paolo Dessì‐Fulgheri, Riccardo Sarzani.<br />
University Politecnica delle Marche, Ancona, IT.<br />
133
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
PO-300:<br />
PO-301:<br />
PO-302:<br />
PO-303:<br />
PO-304:<br />
PO-305:<br />
PO-305A:<br />
Improvement in <strong>Hypertension</strong> Control after a 2-Year<br />
Participation in a Web-Based <strong>Program</strong> on High BP<br />
Management<br />
Julian Segura, 1 Manuel Gorostidi, 2 Alejandro de la<br />
Sierra, 3 Jose R. Banegas, 4 Juan J. de la Cruz, 4 Luis<br />
M. Ruilope. 1 1 Hospital 12 de Octubre, Madrid, ES;<br />
2 Hospital Central de Asturias, Oviedo, ES; 3 Hospital<br />
Mutua Terrasa, Universidad de Barcelona, Barcelona,<br />
ES; 4 Universidad Autónoma, Madrid, ES.<br />
Ambulatory Blood Pressure Monitoring in<br />
Prehypertension<br />
Gabor Simonyi, Mihaly Medvegy. Flor Ferenc Hospital<br />
<strong>of</strong> County Pest, Kistarcsa, HU.<br />
Diagnostic Accuracy <strong>of</strong> Home Versus Ambulatory<br />
Blood Pressure Monitoring<br />
George S. Stergiou, Efthimia G. Nasothimiou, Dimitrios<br />
Tzamouranis, Vagia Rarra, Leonidas G. Roussias.<br />
University <strong>of</strong> Athens, Athens, GR.<br />
Patients’ Preference for Out-<strong>of</strong>-Office Blood<br />
Pressure Evaluation Method: Ambulatory or Home<br />
Monitoring<br />
Efthimia G. Nasothimiou, Nikolaos Karpettas,<br />
Antonios Destounis, George S. Stergiou. University <strong>of</strong><br />
Athens, Athens, GR.<br />
Preditive Value <strong>of</strong> Ambulatory Blood Pressure for<br />
Cardiovascular Events in Hypertensive Patients after<br />
a First Event<br />
Tiago Teixeira, 1 José Nuno Figueiredo, 1 Jose Mesquita<br />
Bastos, 1 Jose Nobre Santos, 1 Jorge Polonia. 2 1 Hospital<br />
Infante D.Pedro, EPE, Aveiro, PT; 2 Faculdade de<br />
Medicina do Porto, PT.<br />
Methods for Fast and Accurate Normalization <strong>of</strong><br />
Real-World Prescription Data: A Report from the<br />
O’QUIN <strong>Hypertension</strong> Initiative<br />
C. Shaun Wagner, Brent Egan. Medical University <strong>of</strong><br />
South Carolina, Charleston, SC, US.<br />
High Blood Pressure Treatment among Black and<br />
White Stroke Patients<br />
Andrea D. Boan, David L. Bachman, Robert J. Adams,<br />
Brent M. Egan, Joyce S. Nicholas, Andrew B. Lawson,<br />
Daniel T. Lackland. Medical University <strong>of</strong> South<br />
Carolina, Charleston, SC, US.<br />
Cellular Mechanisms (Cell Biology;<br />
Cell Membrane Transport/Ion Channels;<br />
Coagulation/Thrombosis; Growth<br />
Factors; Ion Channels)<br />
PO-306:<br />
Pharmacological Inhibition <strong>of</strong> PI3Kg Reduces Blood<br />
Pressure by a Vasorelaxant Akt/LTCC Mechanism<br />
Daniela Carnevale, 1 Giada Mascio, 1 Giuseppe Cifelli, 1<br />
Carmine Vecchione, 1 Giuseppe Lembo. 1,2 1 IRCCS<br />
Neuromed, Pozzilli, IT; 2 ”Sapienza” University <strong>of</strong><br />
Rome, Rome, IT.<br />
134
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-307:<br />
PO-308:<br />
<strong>Hypertension</strong> Induces b-Amyloid Deposition and<br />
Cognitive Impairment by Activating RAGE in Brain<br />
Endothelium<br />
Daniela Carnevale, 1 Giada Mascio, 1 Giuseppe Cifelli, 1<br />
Shi Du Yan, 3 Giuseppe Lembo. 1,2 1 IRCCS Neuromed,<br />
Pozzilli, IT; 2 ”Sapienza” University <strong>of</strong> Rome, Rome, IT;<br />
3 Columbia University, New York, US.<br />
Downmodulation <strong>of</strong> Peroxiredoxin-3 Expression in<br />
Cardiac Fibroblasts by Angiotensin II<br />
Paul J. Lijnen, Jos F. van Pelt. University <strong>of</strong> Leuvan<br />
(KULeuven), Leuven, BE.<br />
Lipid Metabolism<br />
PO-309:<br />
Does the Association between Lipid Pr<strong>of</strong>ile and<br />
Obesity Indices Vary through Decades in Essential<br />
Hypertensive Patients<br />
Stella Maria Kyvelou, 1 Gregory Vyssoulis, 1 Eva<br />
Karpanou, 2 I. Skoumas, 1 C. Stefanadis. 1 1 1st<br />
Cardiology Clinic Athens University Hippokration<br />
Hospital Athens Greece, GR; 2 1st Cardiology Clinic<br />
Onassis Cardiosurgery Center Athens, GR.<br />
Neural hormonal Mechanisms (Renin;<br />
Neural Control; Vasoactive Autacoids)<br />
PO-310:<br />
PO-311:<br />
PO-312:<br />
Long Term Follow-Up <strong>of</strong> Patients with Postural<br />
Orthostatic Tachycardia Syndrome<br />
Joao Freitas, 1,2 Alexandra Sousa, 1 Ana Lebreiro, 1 Maria<br />
Julia Maciel, 1,2 Francisco Rocha Goncalves. 2 1 Hospital<br />
de Sao Joao -E.P.E., Porto, PT; 2 Unoversidade do Porto,<br />
Porto, PT.<br />
Resistant <strong>Hypertension</strong> and Intravascular Volume<br />
Expansion<br />
Guilherme Augusto Mariano Pego, João Bernardo Pego,<br />
Maria Fátima Leitão, Helia Martins, Nadia Moreira,<br />
Luis Augusto Providência. University Hospital <strong>of</strong><br />
Coimbra, PT.<br />
Expression <strong>of</strong> the Renin-Angiotensin System in a<br />
Human Placental Cell Line<br />
Nan Pan, 1 Wayne L. Frome, 1 Richard A. Dart, 1 Duane<br />
A. Tewksbury, 1 Jiangming Luo. 2 1 Marshfield Clinic<br />
Research Foundation, Marshfield, WI, US; 2 Marshfield<br />
Clinic, Marshfield, WI, US.<br />
135
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
Non-Pharmacological Therapy<br />
(Alternative Medicine; Diet; Physical<br />
Activity)<br />
PO-313:<br />
PO-314:<br />
PO-315:<br />
PO-316:<br />
PO-317:<br />
PO-318:<br />
PO-319:<br />
The HARMONY Study: <strong>Hypertension</strong> Analysis <strong>of</strong><br />
Stress Reduction Using Mindfulness Meditation and<br />
Yoga<br />
Kimberly C. Blom, 1 Brian Baker, 2 Jane Irvine, 4 Susan<br />
Abbey, 2 Beth Abramson, 3 Martin Myers, 1 Nancy<br />
Perkins, 1 Sheldon W. Tobe. 1 1 Sunnybrook Health<br />
Sciences Centre, Toronto, ON, CA; 2 University Health<br />
Network, Toronto, ON, CA; 3 St. Michael’s Hospital,<br />
Toronto, ON, CA; 4 York University, Toronto, ON, CA.<br />
Impact <strong>of</strong> Smoking Cessation on Nocturnal Blood<br />
Pressure<br />
Patrick T. Campbell, Carla J. Rash, Sheila M. Alessi,<br />
Nancy M. Petry, William B. White. University <strong>of</strong><br />
Connecticut, Farmington, CT, US.<br />
Leisure Physical Activity and Emergent<br />
Cardiovascular Risk Factors in Hypertensive<br />
Patients<br />
Cristiana Catena, GianLuca Colussi, Andrea Russo,<br />
Gabriele Brosolo, Leonardo A. Sechi. University <strong>of</strong><br />
Udine, IT.<br />
Aerobic Exercise Training Improves Renal Function<br />
in African <strong>American</strong>s<br />
Keith M. Diaz, 1 Deborah L. Feairheller, 1 Kathleen<br />
M. Sturgeon, 1 Praveen Veerabhadrappa, 1 Sheara<br />
Williamson, 1 Jan Kretzschmar, 1 Michael D. Brown. 1<br />
1 Temple University, Philadelphia, PA, US; 2 Temple<br />
University, Philadelphia, PA, US.<br />
Actions to Control <strong>Hypertension</strong> among Adults with<br />
<strong>Hypertension</strong><br />
Jing Fang, Nora L. Keenan. CDC, Atlanta, GA, US.<br />
Exercise Capacity is Inversely Related to Mortality<br />
Risk in Hypertensive Individuals with Sleep Apnea<br />
Peter Kokkinos, 1,2,3 Shikha Khosla, 1 Marshal Balish, 1<br />
Raya Kheirbek, 1 Helen Sheriff, 1 Eric Nylen, 1,3<br />
Charles Faselis. 1,3 1 Veterans Affairs Medical Center,<br />
Washington, DC, US; 2 Georgetown University<br />
School <strong>of</strong> Medicine, Washington, DC, US; 3 George<br />
Washington University School <strong>of</strong> Medicine,<br />
Washington, DC, US.<br />
Heart Rate Recovery, Fitness and Mortality Risk in<br />
Hypertensive Individuals<br />
Peter Kokkinos, 1,2,3 Charles Faselis, 1,3 Michael<br />
Doumas, 1,3 Ross Fletcher, 1,2 Andreas Pittaras, 1<br />
Athanasios Manolis, 1 Rhea Kheirbek, 1 Vasilios<br />
Papademetriou. 1,2 1 Veterans Affairs Medical Center,<br />
Washington, DC, US; 2 Georgetown University<br />
School <strong>of</strong> Medicine, Washington, DC, US; 3 George<br />
Washington University, Washington, DC, US.<br />
136
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-321:<br />
PO-322:<br />
The Cost-Effectiveness <strong>of</strong> Interventions Designed to<br />
Reduce Sodium Intake<br />
Guijing Wang, Darwin Labarthe. Centers for Disease<br />
Control and Prevention, Atlanta, GA, US.<br />
Seasonal Effects <strong>of</strong> Blood Pressure in<br />
Postmenopausal Women<br />
Adrian D. Wood, 1 Frank Thies, 1 William D. Fraser, 2<br />
Lorna Aucott, 1 Karen R. Secombes, 1 William G.<br />
Simpson, 3 David M. Reid, 1 Helen M. Macdonald. 1<br />
1 University <strong>of</strong> Aberdeen, Aberdeen, GB; 2 University <strong>of</strong><br />
Liverpool, Liverpool, GB; 3 Aberdeen Royal Infirmary,<br />
Aberdeen, GB.<br />
Nutrition and Cardiovascular<br />
Prevention<br />
PO-323:<br />
PO-324:<br />
PO-325:<br />
PO-325A:<br />
PO-326:<br />
Antihypertensive Effect <strong>of</strong> Dietary Integration with<br />
Grana Padano Cheese in Hypertensive Patients<br />
Giuseppe Crippa, 1 Matteo Bosi, 2 Cassi Antonino, 1<br />
Lucia Fiorentini, 2 Filippo Rossi. 2 1 Guglielmo da<br />
Saliceto Hospital, Piacenza, IT; 2 Universita’ Cattolica<br />
del Sacro Cuore, Piacenza, IT.<br />
Abnormal Circadian Blood Pressure Variability in<br />
Healthy Adults: A Function <strong>of</strong> Weight Gain, Increase<br />
in Waist Circumference and Insulin Resistance<br />
Alok K. Gupta, 1 Germaine G. Cornelissen‐Guillaume, 2<br />
William D. Johnson, 1 Frank L. Greenway, 1 Darcy<br />
Johannsen, 1 Eric Ravussin. 1 1 Pennington Biomedical<br />
Research Center, Louisiana State University System,<br />
Baton Rouge, LA, US; 2 University <strong>of</strong> Minnesota,<br />
Minneapolis, MN, US.<br />
Endothelial Dysfunction in Healthy Adults:<br />
A Function <strong>of</strong> Weight Gain, Increase in Waist<br />
Circumference and Insulin Resistance<br />
Alok K. Gupta, William D. Johnson, Darcy Johannsen,<br />
Eric Ravussin. Pennington Biomedical Research<br />
Center, Louisiana State University System, Baton<br />
Rouge, LA, US.<br />
Dysglycemia Induces Abnormal Circadian<br />
Variability <strong>of</strong> Blood Pressure<br />
Alok K. Gupta, 1 Kathirvel Gopalakrishnan, 2 Sivarajan<br />
Kumarasamy, 2 William D. Johnson, 1 Bina Joe. 2<br />
1 Pennington Biomedical Research Center, Louisiana<br />
State University System, Baton Rouge, LA, US;<br />
2 University <strong>of</strong> Toledo College <strong>of</strong> Medicine, Toledo,<br />
OH, US.<br />
Relationship between Salt Intake and Central<br />
Aortic Hemodynamics in a Cohort <strong>of</strong> Untreated<br />
Hypertensive Patients<br />
Jorge J. Polonia, Jose A. Silva, Susana P. Bertoquini,<br />
Barbosa Loide. Faculdade Medicina Porto, Matosinhos<br />
Porto, PT.<br />
137
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
PO-327:<br />
PO-328:<br />
PO-329:<br />
PO-330:<br />
Effect <strong>of</strong> Lifestyle Modification in Menopausal<br />
Women with Obesity, <strong>Hypertension</strong>, Autonomic and<br />
Endothelial Dysfunction<br />
Rosa M. Santos, 1 Joao Freitas, 1 Agostinho Monteiro, 3<br />
Espiga Macedo, 3 Eduardo Tejera, 2 Irene Rebelo. 2<br />
1 Hospital S Joao, Porto, PT; 2 Faculty Pharmacy, Porto,<br />
PT; 3 Faculty Medicine, Porto, PT.<br />
At Risk Older Latino Men and Women: Blood<br />
Pressure, Body Mass Index and D<strong>ASH</strong> Accordance<br />
Beth A. Staffileno, 1 Christy Tangney, 1 David X.<br />
Marquez, 2 Louis Fogg, 1 Eduardo E. Bustamante, 2<br />
Martha Clare Morris, 1 Ruby Hoyem, 1 Alexis<br />
Manning, 1 JoEllen Wilbur. 1 1 Rush University Medical<br />
Center, Chicago, IL, US; 2 University <strong>of</strong> Illinois at<br />
Chicago, Chicago, IL, US.<br />
Medical Avatar Can Select Patients with<br />
Cardiovascular Risk Factors<br />
Jerzy T. Tyszkiewicz, Bartosz Symonides, Zbigniew<br />
Gaciong. Medical University <strong>of</strong> Warsaw, Warsaw, PL.<br />
Aerobic Exercise Training Improves Endothelial<br />
Function in Pre-Hypertensive African <strong>American</strong>s<br />
Sheara T. Williamson, Deborah L. Feairheller, Kathleen<br />
M. Sturgeon, Praveen Veerabhadrappa, Michael<br />
D. Brown, Jan Kretzschmar. Temple University,<br />
Philadelphia, PA, US.<br />
Obesity<br />
PO-331:<br />
PO-332:<br />
PO-334:<br />
PO-335:<br />
The Effect <strong>of</strong> BMI on the Systemic Catecholamine<br />
and Haemodynamic Response to Increased<br />
Sympathetic Activity in Young Adults: A Pilot Study<br />
James M. Coulson†, John R. Cockcr<strong>of</strong>t. Cardiff<br />
University, Cardiff, Wales, GB.<br />
Aldosterone Release is Positively Correlated with<br />
Increasing Body Weight in Patients with Resistant<br />
<strong>Hypertension</strong><br />
Tanja Dudenbostel, Maria Czarina Acelajado, Roberto<br />
Pisoni, Suzanne Oparil, David A. Calhoun. Vascular<br />
Biology and <strong>Hypertension</strong>, University <strong>of</strong> Alabama at<br />
Birmingham, Birmingham, AL, US.<br />
Beta2-Adrenoceptor Polymorphisms (Arg16Gly)<br />
Accompanying High Plasma Norepinephrine is<br />
Related to Cardiovascular and Renal Complications<br />
in Obese Subjects<br />
Kazuko Masuo, 1 Hiromi Rakugi, 2 Toshio Ogihara, 2<br />
Murray D. Esler, 1 Gavin W. Lambert. 1 1 Baker IDI<br />
Heart & Diabetes Institute, Melbourne, VIC, AU;<br />
2 Osaka University Graduate School <strong>of</strong> Medicine, Suita,<br />
Osaka, JP.<br />
Efficacy <strong>of</strong> an Amlodipine/Olmesartan Medoxomil<br />
Algorithm on BP Control in Obese Patients<br />
Uncontrolled by Monotherapy<br />
Joel M. Neutel†, 1 Willa Hsueh, 2 Ali Shojaee, 3 William F.<br />
Waverczak, 3 Jen‐Fue Maa. 3 1 Orange County Research<br />
Center, US; 2 The Methodist Hospital Research<br />
Institute, US; 3 Daiichi Sankyo, Inc., US.<br />
138
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-336:<br />
PO-337:<br />
PO-338:<br />
PO-339:<br />
Resolution <strong>of</strong> <strong>Hypertension</strong> after Adjustable Gastric<br />
Banding – 1 Year Interim Results <strong>of</strong> the LAP-BAND<br />
AP® EXperience (APEX) Study<br />
John Dixon, 1 Michael Oefelein, 2 Ted Okerson†. 2<br />
1 Monash University, Melbourne, AU; 2 Allergan, Inc,<br />
Irvine, CA, US.<br />
Initial Aliskiren/HCTZ Combination Therapy<br />
Lowers BP in Obese Patients with Stage 2<br />
<strong>Hypertension</strong> and Type 2 Diabetes<br />
Raymond R. Townsend, 1 Alan Forker, 2 Thomas<br />
Severin, 3 Cheraz Cherif Papst, 3 Anthony Yadao. 4<br />
1 University <strong>of</strong> Pennsylvania Medical Center,<br />
Philadelphia, PA, US; 2 St Luke’s Lipid and Diabetes<br />
Research Center, Kansas City, MO, US; 3 Novartis<br />
Pharma AG, Basel, CH; 4 Novartis Pharmaceuticals<br />
Corporation, East Hanover, NJ, US.<br />
Aliskiren/HCTZ Inhibits RAAS Activity in Obese<br />
and Non-Obese Patients with Stage 2 <strong>Hypertension</strong><br />
and Type 2 Diabetes<br />
Raymond R. Townsend, 1 Alan Forker, 2 Thomas<br />
Severin, 3 Cheraz Cherif Papst, 3 Anthony Yadao. 4<br />
1 University <strong>of</strong> Pennsylvania Medical Center,<br />
Philadelphia, PA, US; 2 St Luke’s Lipid and Diabetes<br />
Research Center, Kansas City, MO, US; 3 Novartis<br />
Pharma AG, Basel, CH; 4 Novartis Pharmaceuticals<br />
Corporation, East Hanover, NJ, US.<br />
Aliskiren/Amlodipine Combination Lowers BP in<br />
Obese and Non-Obese Patients with Moderate-to-<br />
Severe <strong>Hypertension</strong><br />
Rudiger C. Braun‐Dullaeus, 1 Sergey B. Shustov, 2<br />
Carmen Alvarez, 3 Gregorio G. Rogelio, 4 Cheraz Cherif<br />
Papst, 5 Jack Zhang†. 6 1 Otto-von-Guericke University,<br />
Magdeburg, DE; 2 State Educational Institution <strong>of</strong><br />
High Pr<strong>of</strong>essional Education, St Petersburg, RU; 3 ABS<br />
Centelles, Barcelona, ES; 4 St Luke’s Medical Center,<br />
Quezon, PH; 5 Novartis Pharma AG, Basel, CH;<br />
6 Novartis Pharmaceuticals Corporation, East Hanover,<br />
NJ, US.<br />
Patient-Provider-Healthcare System<br />
Issues<br />
PO-340:<br />
PO-341:<br />
Clinical Inertia in <strong>Hypertension</strong>: Identifying<br />
Barriers to Improve Quality<br />
Bryan Batson, 1 JaNae Joyner, 2 Philip Mellen, 1 William<br />
Smith. 1 1 Hattiesburg Clinic, Hattiesburg, PA, US; 2 The<br />
Consortium for Southeastern <strong>Hypertension</strong> Control<br />
(COSEHC), Winston-Salem, NC, US.<br />
Renal Artery Stent Management: A Survey <strong>of</strong> Local<br />
Practice Patterns<br />
Frank K. Boateng, Daniel L. Landry, Barbara A. Greco.<br />
Baystate Medical Center, Springfield, MA, US.<br />
139
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
PO-342:<br />
PO-343:<br />
PO-344:<br />
PO-345:<br />
PO-346:<br />
PO-347:<br />
Impact <strong>of</strong> Switching from Valsartan to a Lower-<br />
Tiered Angiotensin Receptor Blocker on Subsequent<br />
Treatment Patterns<br />
E. K. Buysman†, 1 L. M. Andrews, 2 T. J. Bancr<strong>of</strong>t, 1 H.<br />
B. Dastani, 2 J. Zhang, 2 M. L. Monsalvo. 3 1 i3 Innovus,<br />
Eden Prairie, MN, US; 2 Novartis Pharmaceuticals<br />
Corporation, East Hanover, NJ, US; 3 i3 Research,<br />
Buenos Aires, AR.<br />
<strong>Hypertension</strong> Specialists’ Current and Potential<br />
Impact on Resistant <strong>Hypertension</strong> in the Medicare<br />
Population<br />
William J. Elliott†, 1 Brent M. Egan, 2 Thomas D. Giles, 3<br />
George L. Bakris, 4 Torry Mark Sansone. 5 1 Pacific<br />
Northwest University <strong>of</strong> Health Sciences, Yakima, WA,<br />
US; 2 Medical University <strong>of</strong> South Carolina, Charleston,<br />
SC, US; 3 Tulane University School <strong>of</strong> Medicine, New<br />
Orleans, LA, US; 4 The University <strong>of</strong> Chicago, Chicago,<br />
IL, US; 5 The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, New<br />
York, NY, US.<br />
Mitigating Risk – Cardiovascular Health Assessment<br />
for the Men/Ms <strong>of</strong> Paterson and Passaic County –<br />
MR CHAMMP<br />
Robert T. Faillace, Margaret Latrella, Carolyn Strimike,<br />
Deborah Terrone, James Pruden, Ken Morris, Kathleen<br />
Sauter. St. Joseph’s Healthcare System, Paterson, NJ,<br />
US.<br />
Quantification <strong>of</strong> Clinical Inertia during GP’s<br />
Management <strong>of</strong> Uncontrolled Hypertensive Patients<br />
– Clepsydre Study<br />
Xavier Girerd, 1 Béatrice Fiquet, 2 Stéphane Quéré, 2<br />
Alain Francillon. 2 1 Pitié-Salpétrière Hospital, Paris, FR;<br />
2 Novartis Pharma SAS, Rueil-Malmaison, FR.<br />
Time to Talk CARDIO Communication Tool Use<br />
Improves Cardiovascular Disease Management<br />
Behaviors and Satisfaction<br />
Brian Forrest, 1 Stephanie Brinson, 1 Susan Harris<br />
Bavisotto, 1 JaNae Joyner. 2 1 Access Healthcare,<br />
Apex, NC, US; 2 The Consortium for Southeastern<br />
<strong>Hypertension</strong> Control (COSEHC), Winston Salem,<br />
NC, US.<br />
Automated Outreach for Antihypertensive<br />
Medication Refill Reminders<br />
Kelley R. Green, 1 Joel Handler, 2 Southida S.<br />
Vansomphone, 3 Claire Mesirov, 4 Kristi Reynolds. 4<br />
1 Kaiser Permanente Southern California Permanente<br />
Medical Group, Pasadena, CA, US; 2 Kaiser Permanente<br />
Medical Center, Anaheim, CA, US; 3 Kaiser<br />
Permanente, Downey, CA, US; 4 Kaiser Permanente<br />
Southern California, Pasadena, CA, US.<br />
140
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-348:<br />
PO-350:<br />
PO-351:<br />
PO-352:<br />
PO-353:<br />
PO-354:<br />
PO-355:<br />
Impact <strong>of</strong> Non-Medical Switching between Different<br />
Angiotensin Receptor Blockers on Blood Pressure<br />
and Medical Resource Utilization<br />
Khalid M. Kamal†, 1 Christopher Zacker, 2 Louis<br />
Civitarese. 3 1 Duquesne University Mylan School<br />
<strong>of</strong> Pharmacy, Pittsburgh, PA, US; 2 Novartis<br />
Pharmaceuticals Corporation, Emmaus, NJ, US;<br />
3 Preferred Primary Care Physicians, Pittsburgh, PA,<br />
US.<br />
Simple Drug Preference Questions are Predictive <strong>of</strong><br />
Antihypertensive Response: A STITCH2 Substudy<br />
Sigrid A. Nelson, 1 George K. Dresser, 2,3 Jeffrey L.<br />
Mahon, 1,2,3 Brian G. Feagan, 1,2,3 Guang Y. Zou, 1,3<br />
Margaret K. Vandervoort, 1 Cindy J. Wong, 1 Ross D.<br />
Feldman. 1,2,3 1 Robarts Research Institute, CA; 2 London<br />
Health Sciences Centre, CA; 3 University <strong>of</strong> Western<br />
Ontario, CA.<br />
Increased Clinical Outcomes at One Year Follow-Up<br />
Found in a Diabetic Patient-Centered Medical Home<br />
Pilot <strong>Program</strong><br />
Jennifer O’Donnell, 1 Cyndi Shull, 2 Amber Winkler, 1<br />
JaNae Joyner, 3 Laura Long. 2 1 Palmetto Primary Care<br />
Physicians, US; 2 Blue Cross and Blue Shield <strong>of</strong> South<br />
Carolina, US; 3 The Consortium for Southeastern<br />
<strong>Hypertension</strong> Control, Winston-Salem, NC, US.<br />
Single Pill vs Free-Equivalent Combination<br />
Therapies for <strong>Hypertension</strong>: Meta-Analysis <strong>of</strong><br />
Adherence and Costs<br />
Beth Sherrill, 1 Michael Halpern, 2 Sumeet Panjabi†, 3<br />
Shahnaz Khan, 1 Jie Zhang. 1 1 RTI Health Solutions,<br />
Research Triangle Park, NC, US; 2 RTI International,<br />
Washington, DC, US; 3 Daiichi Sankyo, Inc, Parsippany,<br />
NJ, US.<br />
Differences and Similarities in Explanatory Models<br />
<strong>of</strong> <strong>Hypertension</strong> in the U.S., Tanzania and Jamaica<br />
John Purakal, 1 Jean Williams‐Johnson, 2 Eric Williams, 2<br />
Ibtissam Ammary, 3 Senga Pemba, 4 Joseph Kambona, 4<br />
Robert Welch, 1 John Flack, 1 Phillip Levy. 1 1 Wayne<br />
State University School <strong>of</strong> Medicine, Detroit, MI,<br />
US; 2 University Hospital <strong>of</strong> the West Indies, JM;<br />
3 University <strong>of</strong> Michigan School <strong>of</strong> Public Health,<br />
Ann Arbor, MI, US; 4 Tanzanian Training Centre for<br />
International Health, TZ.<br />
Treat to Target using Interactive Voice Messaging<br />
to Enhance Primary Care Physican Management <strong>of</strong><br />
<strong>Hypertension</strong><br />
Graham A. Scott. Kaiser Permanente Medical Center,<br />
Riverside, CA, US.<br />
Is Poor Blood Pressure Control in Patients<br />
Presenting for Elective Surgery Predictable<br />
Patrick E. Benedict, Sachin Kheterpal, Amy M. Shanks,<br />
Alan B. Weder. University <strong>of</strong> Michigan, Ann Arbor,<br />
MI, US.<br />
141
MAY 21 23<br />
Posters<br />
Monday Afternoon<br />
Morning<br />
Preclinical Models/Experimental<br />
<strong>Hypertension</strong><br />
PO-357:<br />
PO-358:<br />
Paraventricular Nucleus <strong>of</strong> the Hypothalamus<br />
Neurons Project to Parasympathetic Brainstem<br />
Neurons that Control Heart Rate<br />
David Mendelowitz, Ramon Pinol. George Washington<br />
University, Washington, DC, US.<br />
Effects <strong>of</strong> Sex on Sympathetic Neural and<br />
Hemodynamic Responses to Head-Up Tilt in<br />
Hypertensive Seniors<br />
Yoshiyuki Okada, 1,2 M. Melyn Galbreath, 1,2 Shigeki<br />
Shibata, 1,2 Sara S. Jarvis, 1,2 Tiffany B. VanGundy, 1<br />
Rhonda L. Meier, 1 Wanpen Vongpatanasin, 2 Benjamin<br />
D. Levine, 1,2 Qi Fu. 1,2 1 Institute for Exercise and<br />
Environmental Medicine, Texas Health Presbyterian<br />
Hospital, Dallas, TX, US; 2 The UT Southwestern<br />
Medical Center at Dallas, Dallas, TX, US.<br />
Pregnancy<br />
PO-359: Autoantibodies to the Angiotensin II Type 1<br />
Receptor in Preeclampsia<br />
Maciej Adamczyk, R. Jeffrey Brashear, Stephen C. Hsu,<br />
Phillip G. Mattingly. Abbott Laboratories, Abbott Park,<br />
IL, US.<br />
PO-360: The Correlation between the Serum Testosterone<br />
Level and Insulin Sensitivity in Pre-Eclampsia –<br />
Eclampsia Syndrome<br />
M. Yousri K. Amin, Ibrahim L. Abdellatifi, Yousri<br />
A. Mohyeldin, Abdelmoneim A. Fawzy, Akram A.<br />
Deghedi, Mohamed A. Harb. Alexandria University,<br />
Alexandria, EG.<br />
PO-361: Effects <strong>of</strong> High Altitude and Ancestry on Uterine<br />
Artery Shear Stress and Blood Pressure in Normal<br />
Pregnant vs. Preeclamptic Women<br />
Ronald Magness, 1 Ira Bernstein, 2 Stacy Zamadio. 3<br />
1 University <strong>of</strong> Wisconsin - Madison, Madison, WI,<br />
US; 2 University <strong>of</strong> Vermont, Vermont, US; 3 New Jersey<br />
Medical School, New Jersey, US.<br />
Salt-Sensitive Mechanisms <strong>of</strong><br />
<strong>Hypertension</strong><br />
PO-362:<br />
PO-363:<br />
Silencing <strong>of</strong> PKG1 Gene Sensitizes Vascular Smooth<br />
Muscle Cells to Marinobufagenin: Impact on Aging,<br />
Fibrosis, and Salt-Sensitivity<br />
Olga V. Fedorova, 1 Victoria Y. Shilova, 1 Joseph I.<br />
Shapiro, 2 Edward G. Lakatta, 1 Alexei Y. Bagrov. 1<br />
1 Intramural Research <strong>Program</strong>, National Institute on<br />
Aging, NIH, Baltimore, MD, US; 2 College <strong>of</strong> Medicine,<br />
University <strong>of</strong> Toledo, Toledo, OH, US.<br />
Heritability <strong>of</strong> Na/K Excretion during the Saline/<br />
Lasix Protocol in African <strong>American</strong> Twins<br />
Clarence E. Grim, Robinson Miguel. High Blood<br />
Pressure Consulting, Milwaukee, WI, US.<br />
142
Monday Morning Afternoon MAY 21 23<br />
Posters<br />
PO-364:<br />
Gender Difference in the Relationship <strong>of</strong><br />
Marinobufagein to Salt-Sensitivity <strong>of</strong> Blood Pressure<br />
Alexei Y. Bagrov, 1 Olga V. Fedorova, 1 Philippe Burri, 2<br />
Edward G. Lakatta, 1 Olle Melander. 2 1 National Institute<br />
on Aging, NIH, Baltimore, MD, US; 2 Lund University,<br />
Malmö, SE.<br />
Secondary <strong>Hypertension</strong><br />
PO-365:<br />
PO-366:<br />
PO-367:<br />
Association <strong>of</strong> Renal Artery Stenosis with Acute<br />
Pulmonary Edema in Hypertensive Patients<br />
Roxana O. Darabont, 1 Alexandru Corlan, 2 Mircea<br />
Cinteza, 1 Dragos Vinereanu. 1 1 University <strong>of</strong> Medicine<br />
and Pharmacy ‘Carol Davila’, Bucharest, RO;<br />
2 University Emergency Hospital, Bucharest, RO.<br />
Big Endothelin-1 and Nitric Oxid Levels in<br />
Hypertensive Elderly with and without Obstructive<br />
Sleep Apnea<br />
Nereida K. C. Lima, Iara F. Anunciato, Romulo R.<br />
Lobo, Alan L. Eckeli, Regina M. R. Fernandes, Paulo<br />
R. B. Evora, Fernando Nobre, Waldiceu A. Verri-<br />
Junior, Julio C. Moriguti, Eduardo Ferriolli, Eduardo B.<br />
Coelho. Ribeirao Preto School <strong>of</strong> Medicine – Sao Paulo<br />
University, Ribeirao Preto, SP, BR.<br />
Pheochromocytoma and Coronary Artery Disease<br />
Galina N. Potapova, 1 L. M. Sergakova, 1 G. V.<br />
Ryabikina, 1 L. N. Lyutikova, 1 I. E. Chazova, 1 N. S.<br />
Kuznetsov, 2 E. G. Popov, 1 I. Y. Gavrilov. 1 1 Cardiology<br />
Research Complex, Moscow, RU; 2 Endocrinology<br />
Research Center, Moscow, RU.<br />
143
MAY 21 23<br />
Posters Late-Breaking Posters<br />
Monday Afternoon<br />
Morning<br />
LB-PO-01:<br />
LB-PO-02:<br />
LB-PO-03:<br />
ANP-cGMP-PKG Activation Inhibits TGF-b-<br />
Induced Smad3 Nuclear Translocation by Increasing<br />
Smad3 Binding to Cytosolic b2-Tubulin in Rat<br />
Pulmonary Arterial Smooth Muscle Cells<br />
Kaizheng Gong, 1,2 Dongqi Xing, 1 Peng Li, 1<br />
Namasivayam Ambalavanan, 3 Suzanne Oparil, 1 Yiu-<br />
Fai Chen. 1 1 University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, US; 2 The Second Medical School <strong>of</strong><br />
Yangzhou University, Yangzhou, CN; 3 University <strong>of</strong><br />
Alabama at Birmingham, Birmingham, AL, US.<br />
Effect <strong>of</strong> Carvedilol CR, Lisinopril and Their<br />
Combination on Markers <strong>of</strong> Early Cardiovascular<br />
Disease in Subjects with High-Normal Blood<br />
Pressure: The DETECT Study<br />
Sara M. Saul, 1 Daniel A. Duprez, 1 Wei Zhong, 2<br />
Gregory A. Grandits, 2 Jay N. Cohn. 1 1 University <strong>of</strong><br />
Minnesota Medical School, Minneapolis, MN, US;<br />
2 University <strong>of</strong> Minnesota School <strong>of</strong> Public Health,<br />
Minneapolis, MN, US.<br />
Consistency <strong>of</strong> Masked <strong>Hypertension</strong> in African<br />
<strong>American</strong>s during Repeat Office Visits<br />
Praveen Veerabhadrappa, Keith M. Diaz, Sheara M.<br />
Williamson, Jan Kretzschmar, Deboarh L. Feairheller,<br />
Kathleen M. Sturgeon, Shannon B. Watkins, Michael<br />
D. Brown. Temple University, Philadephia, PA, US.<br />
144
Faculty Disclosure Listing<br />
Rajiv Agarwal, MD<br />
Advisor/Consultant: Abbott, Merck, Daiichi-Sankyo, Reata, Amgen.<br />
Trustee/Board Member/Committee Member: Abbott. Speakers’ Bureau/Speaking/Teaching:<br />
Abbott, Merck.<br />
Lawrence J. Appel, MD, MPH<br />
I have no relationships to disclose.<br />
Donna K. Arnett, PhD, MSPH<br />
I have no relationships to disclose.<br />
Nancy Artinian, RN, BSN<br />
I have no relationships to disclose.<br />
Phyllis August, MD, MPH<br />
Advisor/Consultant: Otsuka.<br />
Abraham Aviv, MD<br />
Employment Income/Salary: University <strong>of</strong> Medicine and Dentistry,<br />
New Jersey Medical School. Grant/Research Support: National Institutes<br />
<strong>of</strong> Health.<br />
George L. Bakris, MD<br />
Advisor/Consultant: Takeda, Abbott, CVRx, Ardian, Walgreen’s,<br />
Johnson & Johnson, Merck. Trustee, Board Member, Committee<br />
Member: National Kidney Foundation. Grant/Research Support:<br />
Forest Labs, Novartis. Speaker’s Bureau/Speaking/Teaching: Forest<br />
Labs, Novartis. President, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Jan N. Basile, MD<br />
Advisor/Consultant: Boehringer-Ingelheim, Forest Laboratories,<br />
Daiichi-Sankyo, Takeda. Speakers’ Bureau/Speaking/Teaching:<br />
Daiichi-Sankyo, Forest, Takeda.<br />
Donald L. Batisky, MD<br />
I have no relationships to disclose.<br />
John D. Bisognano, MD, PhD<br />
Advisor/Consultant: CVRx. Grant/Research Support: CVRx. Secretary,<br />
<strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Henry R. Black, MD<br />
Advisor/Consultant: Servier, Mitsubushi, Xoma, Ligand, Bristol-Myers<br />
Squibb, Biosante, Novartis. Grant/Research Support: AHRQ/HHS.<br />
Speakers’ Bureau/Speaking/Teaching: Daiichi-Sankyo, Boehringer-<br />
Ingelheim, MSD. Immediate Past President, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Michael J. Bloch, MD<br />
Advisor/Consultant: Takeda. Grant/Research Support: Novartis.<br />
Speakers’ Bureau/Speaking/Teaching: AstraZeneca, Abbott, Boehringer-Ingelheim.<br />
Michael W. Brands, PhD<br />
I have no relationships to disclose.<br />
Lynne T. Braun, PhD, CNP<br />
Royalties (Including Trademarks or Patents): UpToDate, Inc. Grant/<br />
Research Support: National Institutes <strong>of</strong> Health. Speakers’ Bureau/<br />
Speaking/Teaching: <strong>American</strong> Heart Association, Spotlight Speaker.<br />
Other Relevant Financial Benefit or Relationship: National Lipid Association<br />
Web Presentation.<br />
Emmanuel Bravo, MD<br />
I have no relationships to disclose.<br />
145
Faculty Disclosure Listing continued<br />
Angela L. Brown, MD<br />
Advisor/Consultant: Takeda. Speakers’ Bureau/Speaking/Teaching:<br />
Novartis, Forest, Pfizer.<br />
Nancy J. Brown, MD<br />
Advisor/Consultant: Novartis, Merck. Grant/Research Support: Forest,<br />
Shire HGT. Ownership/Partnership or Principal <strong>of</strong> Non-Pr<strong>of</strong>it or<br />
for Pr<strong>of</strong>it Corporation: Protein Discovery.<br />
David A. Bushinksy, MD<br />
Employment Income/Salary: Univeristy <strong>of</strong> Rochester. Advisor/Consultant:<br />
Amgen, Genzyme, Relypsa, Cytochroma. Grant/Research<br />
Support: National Institutes <strong>of</strong> Health, Renal Research Institute. Ownership<br />
Interest (Stocks, Excluding Diversified Mutual Funds): Amgen,<br />
Relypsa. Speakers’ Bureau/Speaking/Teaching: Amgen, Genzyme.<br />
Norman R.C. Campbell, MD<br />
Other Relevant Financial Benefit or Relationship: Boehringer-Ingelheim.<br />
Oscar A. Carretero, MD<br />
Grant/Research Support: National Institutes <strong>of</strong> Health, Roche Pharmaceuticals.<br />
Barry L. Carter, PharmD<br />
I have no relationships to disclose.<br />
Alessandro Cataliotti, MD, PhD<br />
Grant/Research Support: National Institutes <strong>of</strong> Health.<br />
John R. Cockcr<strong>of</strong>t, MD<br />
Advisor/Consultant: Forest, Novartis, Genzyme, GlaxoSmithKline.<br />
Grant/Research Support: GlaxoSmithKline. Speakers’ Bureau/Speaking/Teaching:<br />
Genzyme, Amgen.<br />
Jay N. Cohn, MD<br />
I have no relationships to disclose.<br />
Steven D. Crowley, PhD<br />
I have no relationships to disclose.<br />
William C. Cushman, MD<br />
Advisor/Consultant: Takeda, Novartis.<br />
Stephen R. Daniels, MD, PhD<br />
I have no relationships to disclose.<br />
Michael H. Davidson, MD<br />
Advisor/Consultant: Abbott, Aegerion, Amgen, AstraZeneca, Atherotech,<br />
Daiichi-Sankyo, DTC MD, Esperion, GlaxoSmithKline, iMD<br />
(Intelligent Medical Decisions), Kinemed, LipoScience, Merck, Novo<br />
Nordisk, Roche, San<strong>of</strong>i-Aventis, Synarc, Takeda, Vindico Medical<br />
Education. Trustee/Board Member/Committee Member: DTC MD,<br />
Omthera, Pr<strong>of</strong>essional Education, Inc. Medical Education Company,<br />
Sonogene. Grant/Research Support: Abbott, Daiichi-Sankyo, GlaxoSmithKline,<br />
Merck, Roche.<br />
Daniel Duprez, MD, PhD<br />
Advisor/Consultant: Novartis, Abbott, Pfizer, Merck. Grant/Research<br />
Support: Novartis, Roche, Merck. Speakers’ Bureau/Speaking/Teaching:<br />
Novartis, Pfizer, Merck, Boehringer-Ingelheim, Forest, Abbott.<br />
Lance D. Dworkin, MD<br />
Advisor/Consultant: Questcor. Grant/Research Support: Questcor,<br />
Pfizer, AstraZeneca.<br />
146
Faculty Disclosure Listing continued<br />
Brent M. Egan, MD<br />
Advisor/Consultant: NiCox. Grant/Research Support: Daiichi-Sankyo,<br />
Novartis, Takeda.<br />
Paula T. Einhorn, MD, MS<br />
I have no relationships to disclose.<br />
William J. Elliott, MD, PhD<br />
Royalties (Including Trademarks or Patents): Elsevier, Inc. Grant/<br />
Research Support: Forest Research Institute. Speakers’ Bureau/Speaking/Teaching:<br />
Forest Laboratories, Boehringer-Ingelheim, NiCox,<br />
Inc., <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>.<br />
Murray Epstein, MD<br />
Advisor/Consultant: Bristol-Myers Squibb, AstraZeneca.<br />
Murray D. Esler, MBBS, PhD<br />
Advisor/Consultant: ADRIAN Corporation, Chief Investigator International<br />
Trial. Speakers’ Bureau/Speaking/Teaching: Solvay Australia.<br />
Bonita Falkner, MD<br />
Advisor/Consultant: AstraZeneca, Pfizer, Merck.<br />
Sadaf Farooqi, PhD<br />
I have no relationships to disclose.<br />
Daniel I. Feig, MD, PhD<br />
I have no relationships to disclose.<br />
Ross Feldman, MD<br />
Advisor/Consultant: AstraZeneca, Boehringer-Ingelheim, Bristol-<br />
Myers Squibb, Merck, Forest Canada, Novartis, Pfizer, San<strong>of</strong>i-Aventis,<br />
Servier, Takeda. Trustee/Board Member/Committee Member: Servier,<br />
Takeda.<br />
Keith C. Ferdinand, MD<br />
Advisor/Consultant: AstraZeneca, Merck, Pfizer, Novartis, Takeda,<br />
Forest. Grant/Research Support: Daiichi-Sankyo. Speakers’ Bureau/<br />
Speaking/Teaching: Novartis, AstraZeneca. Member, <strong>ASH</strong> Board <strong>of</strong><br />
Directors.<br />
John M. Flack, MD, MPH<br />
Advisor/Consultant: Novartis, Daiichi-Sankyo. Grant Research/<br />
Support: Novartis. Speakers’ Bureau/Speaking/Teaching: Novartis,<br />
Daiichi-Sankyo, Boehringer-Ingelheim.<br />
Joseph T. Flynn, MD<br />
Advisor/Consultant: Pfizer, Novartis, PTC Therapeutics.<br />
Stanley S. Franklin, MD<br />
I have no relationships to disclose.<br />
William H. Frishman, MD<br />
Ownership Interest (Stocks, Excluding Diversified Mutual Funds):<br />
Merck, Pfizer. Speakers’ Bureau/Speaking/Teaching: NCME (Bristol-<br />
Myers Squibb), Pfizer, Forest Laboratories, Boehringer-Ingelheim.<br />
James B. Froehlich, MD, MPH<br />
Advisor/Consultant: Merck, San<strong>of</strong>i-Aventis. Speakers’ Bureau/Speaking/Teaching:<br />
Merck, Schering-Plough.<br />
Leonard M. Fromer, MD<br />
Trustee/Board Member/Committee Member: TransferMed, LLC.<br />
Jeffrey L. Garvin, PhD<br />
Grant/Research Support: National Institutes <strong>of</strong> Health.<br />
147
Faculty Disclosure Listing continued<br />
Haralambos Gavras, MD<br />
Advisor/Consultant: Medivation, Merck. Speakers’ Bureau/Speaking/<br />
Teaching: Novartis.<br />
F. Wilford Germino, MD<br />
I have no relationships to disclose.<br />
Thomas D. Giles, MD<br />
Advisor/Consultant: Amylin, Forest, NiCox. Grant/Research Support:<br />
Forest. Speakers’ Bureau/Speaking/Teaching: Forest. Member, <strong>ASH</strong><br />
Board <strong>of</strong> Directors. Chair, <strong>ASH</strong> Specialists <strong>Program</strong> Inc.<br />
Alan H. Gradman, MD<br />
Advisor/Consultant: Novartis, Forest, Takeda, Daiichi-Sankyo. Speakers’<br />
Bureau/Speaking/Teaching: Novartis, Forest, Takeda. Member,<br />
<strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Joey P. Granger, PhD<br />
I have no relationships to disclose.<br />
Richard H. Grimm, MD, PhD<br />
Advisor/Consultant: Abbott. Grant/Research Support: Roche. Speakers’<br />
Bureau/Speaking/Teaching: Merck.<br />
Yuan Guo, MD, MS<br />
I have no relationships to disclose.<br />
John E. Hall, PhD<br />
I have no relationships to disclose.<br />
Joel Handler, MD<br />
I have no relationships to disclose.<br />
David Harder, MD, PhD<br />
I have no relationships to disclose.<br />
Raymond C. Harris, MD<br />
I have no relationships to disclose.<br />
David G. Harrison, MD<br />
Grant/Research Support: National Institutes <strong>of</strong> Health.<br />
Joseph A. Hill, MD<br />
I have no relationships to disclose.<br />
Norman K. Hollenberg, MD, PhD<br />
Advisor/Consultant: Novartis, Merck, Vitae Pharmaceuticals. Grant/<br />
Research Support: Vitae Pharmaceuticals.<br />
Suzanne Hughes, MSN, RN<br />
I have no relationships to disclose.<br />
Joseph L. Izzo, Jr., MD<br />
Advisor/Consultant: Pharmacists Mutural, Boehringer-Ingelheim,<br />
Novartis, Curry Rockfeller, Thornton Medical, Daiichi-Sankyo, SCS<br />
Healthcare, Takeda, Maritz Travel Co. Grant/Research Support:<br />
Novartis, Daiichi-Sankyo. Speakers’ Bureau/Speaking/Teaching: Novartis,<br />
Daiichi-Sankyo, SCS Healthcare, Maritz Travel Co.<br />
Edgar A. Jaimes, MD<br />
Advisor/Consultant: Novartis.<br />
148
Faculty Disclosure Listing continued<br />
Kenneth A. Jamerson, MD<br />
Advisor/Consultant: Boehringer-Ingelheim, Eli Lily, Daiichi-Sankyo,<br />
Novartis. Trustee/Board Member/Committee Member: <strong>American</strong><br />
<strong>Society</strong> Of <strong>Hypertension</strong>, International <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong><br />
in Blacks. Grant/Research Support: National Institutes <strong>of</strong> Health,<br />
National Institute <strong>of</strong> Diabetes and Digestive and Kidney Diseases, National<br />
Heart, Lung, and Blood Institute, Novartis. Speakers’ Bureau/<br />
Speaking/Teaching: Daiichi-Sankyo.<br />
Julie A. Johnson, PharmD<br />
Advisor/Consultant: Medco.<br />
Richard J. Johnson, MD<br />
Grant/Research Support: National Institutes <strong>of</strong> Health. Other Relevant<br />
Financial Benefit or Relationship: Patent on the Use <strong>of</strong> Allopurinol to<br />
Treat <strong>Hypertension</strong>.<br />
Pedro A. Jose, MD<br />
Grant/Research Support: National Heart, Lung, and Blood Institute,<br />
National Institutes <strong>of</strong> Health, National Institute <strong>of</strong> Diabetes and<br />
Digestive and Kidney Diseases, BIAL. Ownership/Partnership or<br />
Principal <strong>of</strong> Non-Pr<strong>of</strong>it or for Pr<strong>of</strong>it Corporation: Hypogen, Inc.<br />
Luis I. Juncos, MD<br />
I have no relationships to disclose.<br />
Rae‐Ellen W. Kavey, MD, MPH<br />
I have no relationships to disclose.<br />
Donald E. Kohan, MD, PhD<br />
Advisor/Consultant: Abbott, Pfizer, Gilead, Bristol-Myers Squibb.<br />
Grant/Research Support: National Institutes <strong>of</strong> Health. VA, Gilead.<br />
David S. Kountz, MD<br />
I have no relationships to disclose.<br />
Lawrence R. Krak<strong>of</strong>f, MD<br />
I have no relationships to disclose.<br />
Henry Krum, MBBS<br />
Grant/Research Support: Ardian.<br />
Louis Kuritzky, MD<br />
Advisor/Consultant: Boehringer-Ingelheim, Takeda. Speakers’ Bureau/Speaking/Teaching:<br />
Boehringer-Ingelheim, Takeda.<br />
Theodore W. Kurtz, MD<br />
I have no relationships to disclose.<br />
Robert F. Kushner, MD<br />
I have no relationships to disclose.<br />
Daniel T. Lackland, DrPH<br />
Speakers’ Bureau/Speaking/Teaching: San<strong>of</strong>i-Aventis, Boehringer-<br />
Ingelheim. Member, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Edward G. Lakatta, MD<br />
I have no relationships to disclose.<br />
Babbette LaMarca, PhD<br />
Grant/Research Support: <strong>American</strong> Heart Association, National<br />
Institutes <strong>of</strong> Health.<br />
Marc B. Lande, MD, MPH<br />
Grant/Research Support: National Institutes <strong>of</strong> Health.<br />
149
Faculty Disclosure Listing continued<br />
Daniel Levy, MD<br />
Member, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Nita A. Lindi, PharmD, PhD, MSPH<br />
I have no relationships to disclose.<br />
Tianh Liu, MD<br />
Employment Income/Salary: Pi County People’s Hospital.<br />
Charles J. Lowenstein, MD<br />
I have no relationships to disclose.<br />
Jianfang Luo, MD<br />
I have no relationships to disclose.<br />
James M. Luther, MD<br />
I have no relationships to disclose.<br />
Giuseppe Mancia, MD<br />
Advisor/Consultant: Bayer, Boehringer-Ingelheim, MSD, Menaribni<br />
International, Novartis, Recordati, San<strong>of</strong>i-Aventis, Servier. Grant/<br />
Research Support: Gilead, Servier.<br />
Samuel J. Mann, MD<br />
Grant/Research Support: Forest. Speaker’s Bureau/Speaking/Teaching:<br />
Forest.<br />
Athanasios J. Manolis, MD, PhD<br />
Advisor/Consultant: Menarini, Abbott. Speakers’ Bureau/Speaking/<br />
Teaching: Menarini, Recordati.<br />
Allyn L. Mark, MD<br />
I have no relationships to disclose.<br />
Barry J. Materson, MD, MBA<br />
Grant/Research Support: Forest, Takeda, Merck.<br />
David L. Mattson, PhD<br />
I have no relationships to disclose.<br />
Richard J. McManus, MD<br />
Grant/Research Support: Omron Europe (potential).<br />
John Merenich, MD<br />
I have no relationships to disclose.<br />
Franz H. Messerli, MD<br />
Advisor/Consultant: Novartis, Daiichi-Sankyo, San<strong>of</strong>i-Aventis,<br />
Takeda, Abbott. Grant/Research Support: Forest, Daiichi-Sankyo,<br />
Boehringer-Ingelheim. Treasurer, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Nancy Houston Miller, RN, BSN<br />
Advisor/Consultant: Abbott, Gilead, Novartis.<br />
Mark E. Molitch, MD<br />
Advisor/Consultant: Novartis, Abbott. Grant/Research Support: Eli<br />
Lily.<br />
Krzyszt<strong>of</strong> Narkiewicz, MD, PhD<br />
Speakers’ Bureau/Speaking/Teaching: Berlin Chernie Menarini,<br />
Boehringer-Ingelheim, Daiichi-Sankyo, Krka, Novartis, Servier.<br />
150
Faculty Disclosure Listing continued<br />
L. Gabriel Navar, PhD<br />
Advisor/Consultant: Forest, Novartis, Nicor, Merck & Co., Boehringer-Ingelheim.<br />
Trustee/Board Member/Committee Member: <strong>American</strong><br />
Heart Association, <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inter<strong>American</strong><br />
<strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>. Grant/Research Support: National Heart,<br />
Lung and Blood Institute, NCRR, Merck, Forest. Ownership Interest<br />
(Stocks, Excluding Diversified Mutual Funds): Abbott, AstraZeneca,<br />
Baxter International, Merck & Co., Pfizer, Inc. Speakers’ Bureua/<br />
Speaking/Teaching: Merck & Co., Forest Pharmaceuticals.<br />
Shawna D. Nesbitt, MD, MS<br />
Advisor/Consultant: Daiichi-Sankyo. Speakers’ Bureau/Speaking/<br />
Teaching: Novartis, Gilead, Boehringer-Ingelheim.<br />
Joel M. Neutel, MD<br />
Speakers’ Bureau/Speaking/Teaching: Novartis, Forest, Bristol-Myers<br />
Squibb – San<strong>of</strong>i-Aventis, Takeda, Boehringer-Ingelheim, Daiichi-<br />
Sankyo.<br />
Susanne B. Nicholas, MD, PhD, MPH<br />
I have no relationships to disclose.<br />
Eoin O’Brien, MD<br />
I have no relationships to disclose.<br />
Gbenga Ogedegbe, MD, MPH, MS<br />
I have no relationships to disclose.<br />
Suzanne Oparil, MD<br />
Advisor/Consultant: Boehringer-Ingelheim, Daiichi-Sankyo, Eli Lily,<br />
Forest, NiCox, Novartis, Omron. Grant/Research Support: Amgen,<br />
Inc., Merck & Co. Speakers’ Bureau/Speaking/Teaching: Daiichi-<br />
Sankyo, Novartis, Pfizer.<br />
Julio A. Panza, MD<br />
I have no relationships to disclose.<br />
Vasilios Papademetriou, MD<br />
I have no relationships to disclose.<br />
Thomas A. Pearson, MD, PhD, MPH<br />
I have no relationships to disclose.<br />
Aldo J. Peixoto, MD<br />
I have no relationships to disclose.<br />
Robert A. Phillips, MD, PhD<br />
Member, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
F. Xavier Pi‐Sunyer, MD, MPH<br />
Advisor/Consultant: Novo Nordisk, AstraZeneca. Grant/Research<br />
Support: Novo Nordisk.<br />
Bertram Pitt, MD<br />
Advisor/Consultant: Relypsa. Ownership Interest (Stocks, Excluding<br />
Diversified Mutual Funds): Relypsa, BG-Medicine, Nile Therapeutics.<br />
Velvie A. Pogue, MD<br />
Employment Income/Salary: Columbia University Affiliation at the<br />
Harlem Hospital Center. Grant/Research Support: Amgen.<br />
David M. Pollock, PhD<br />
Advisor/Consultant: Abbott Laboratories.<br />
Howard J. Pratt, MD<br />
Grant/Research Support: National Institutes <strong>of</strong> Health.<br />
151
Faculty Disclosure Listing continued<br />
Henry A. Punzi, MD<br />
Advisor/Consultant: Daiichi-Sankyo, Boehringer-Ingelheim, Forest<br />
Pharamaceuticals. Grant/Research Support: Daiichi-Sankyo, Boehringer-Ingelheim,<br />
Forest Pharmaceuticals, Abbott. Speakers’ Bureau/<br />
Speaking/Teaching: Daiichi-Sankyo, Boehringer-Ingelheim, Forest<br />
Pharmaceuticals, Abbott.<br />
Leopoldo Raij, MD<br />
I have no relationships to disclose.<br />
C. Venkata S. Ram, MD<br />
Advisor/Consultant: Daiichi-Sankyo, Forest. Speakers’ Bureau/Speaking/Teaching:<br />
Peer Group Med Knowledge.<br />
James Rippe, MD<br />
Advisor/Consultant: ConAgra Foods, Corn Refiners Association.<br />
Grant/Research Support: ConAgra Foods, Corn Refiners Association.<br />
Talma Rosenthal, MD<br />
Royalties (Including Trademarks or Patents): Patent (2%) Allyl<br />
Mercaptocptopril), Weitzmann Institute. Trustee/Board Member/<br />
Committee Member: Tel-Aviv University Sackler School <strong>of</strong> Medicine.<br />
Grant/Research Support: Boehringer-Ingelheim. Speakers’ Bureau/<br />
Speaking/Teaching: Tel-Aviv University Sackler School <strong>of</strong> Medicine.<br />
Luis M. Ruilope, MD<br />
Advisor/Consultant: AstraZeneca, Novartis, Bayer, Servier, Daiichi-<br />
Sankyo, Takeda, Pfizer, Otsuka. Menarini, Bayer. Speakers’ Bureau/<br />
Speaking/Teaching: AstraZeneca, Novartis, Bayer, Servier, Daiichi-<br />
Sankyo, Takeda, Pfizer, Otsuka. Menarini, Bayer.<br />
Michael J. Ryan, PhD<br />
Grant/Research Support: National Institutes <strong>of</strong> Health/ National<br />
Heart, Lung and Blood Institute.<br />
Elijah Saunders, MD<br />
Advisor/Consultant: Pfizer, Novartis, Forest, Bristol-Myers Squibb-<br />
San<strong>of</strong>i-Aventis, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli<br />
Lilly. Grant/Research Support: Pfizer, Novartis, Forest, Bristol-Myers<br />
Squibb-San<strong>of</strong>i-Aventis. Speakers’ Bureau/Speaking/Teaching: Pfizer,<br />
Novartis, Forest, Bristol-Myers Squibb-San<strong>of</strong>i-Aventis, Boehringer-<br />
Ingelheim, Bristol-Myers Squibb, Eli Lilly.<br />
Ernesto L. Schiffrin, MD, PhD<br />
I have no relationships to disclose.<br />
Roland E. Schmieder, MD<br />
Grant/Research Support: Ardian.<br />
Antoinette Schoenthaler, EdD<br />
Advisor/Consultant: Harlem Hospital Stroke Center.<br />
Domenic A. Sica, MD<br />
Advisor/Consultant: Novartis, Takeda, Merck, Boehringer-Ingelheim,<br />
CVRx. Grant/Research Support: CVRx. Speakers’ Bureau/Speaking/<br />
Teaching: Takeda.<br />
Matthew Sorrentino, MD<br />
I have no relationships to disclose.<br />
Thomas A. Sos, MD<br />
Royalties (Including Trademarks or Patents): AngioDynamics, Cook<br />
Medical.<br />
152
Faculty Disclosure Listing continued<br />
James R. Sowers, MD<br />
Advisor/Consultant: Novartis Pharmaceuticals. Grant/Research Support:<br />
National Institutes <strong>of</strong> Health, VA Merit.<br />
Lesley A. Stevens, MD, MS<br />
I have no relationships to disclose.<br />
Allan D. Struthers, MD<br />
Royalties (Including Trademarks or Patents): Filed a patent on the<br />
use <strong>of</strong> xanthine oxidate inhibitors in angina.<br />
Laura P. Svetkey, MD<br />
I have no relationships to disclose.<br />
Sandra J. Taler, MD<br />
Vice President, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Ting Tao, MD<br />
I have no relationships to disclose.<br />
Addison A. Taylor, MD, PhD<br />
Employment Income/Salary: Baylor College <strong>of</strong> Medicine. Advisor/<br />
Consultant: National Association <strong>of</strong> Managed Care Physicians. Grant/<br />
Research Support: Bristol-Myers Squibb, Novartis, National Institues<br />
<strong>of</strong> Health. Speakers’ Bureau/Speaking/Teaching: Forest Pharmaceuticals,<br />
Novartis, The Methodist Hospital, University <strong>of</strong> Texas. Member,<br />
<strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Jens Titze, MD<br />
I have no relationships to disclose.<br />
Sheldon W. Tobe, MD<br />
Advisor/Consultant: Pfizer, Bristol-Myers Squibb, Merck, Abbott.<br />
Grant/Research Support: Pfizer, Novartis, Amgen. Speakers’ Bureau/<br />
Speaking/Teaching: Abbott,<br />
Bristol-Myers Squibb, Pfizer, Merck.<br />
Rhian M. Touyz, MD, PhD<br />
I have no relationships to disclose.<br />
Raymond R. Townsend, MD<br />
Royalties (Including Trademarks or Patents): UptoDate. Advisor/Consultant:<br />
GlaxoSmithKline, Merck, Novartis. Grant/Research Support:<br />
National Institutes <strong>of</strong> Health.<br />
Joseph A. Vassalotti, MD<br />
I have no relationships to disclose.<br />
Ronald G. Victor, MD<br />
Advisor/Consultant: Merck Research Laboratories. Grant/Research<br />
Support: Pfizer, Forest Research Laboratories.<br />
Hongyu Wang, MD, PhD<br />
I have no relationships to disclose.<br />
R. Clinton Webb, PhD<br />
I have no relationships to disclose.<br />
David J. Webb, MD<br />
Advisor/Consultant: Abbott, Pfizer. Grant/Research Support: Pfizer.<br />
Michael A. Weber, MD<br />
Advisor/Consultant: Bristol-Myers Squibb, Boehringer-Ingelheim,<br />
Takeda, Novartis, Daiichi-Sankyo. Trustee/Board Member/Committee<br />
Member: Center for Medicine in the Public Interest. Member,<br />
<strong>ASH</strong> Board <strong>of</strong> Directors. Editor-In-Chief, The Journal <strong>of</strong> Clinical<br />
<strong>Hypertension</strong> (JCH).<br />
153
Faculty Disclosure Listing continued<br />
Alan B. Weder, MD<br />
I have no relationships to disclose.<br />
Myron H. Weinberger, MD<br />
Employment Income/Salary: <strong>American</strong> <strong>Society</strong> Of <strong>Hypertension</strong><br />
(Editor-in-Chief, Journal <strong>of</strong> the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong><br />
(J<strong>ASH</strong>)). Member, <strong>ASH</strong> Board <strong>of</strong> Directors.<br />
Matthew R. Weir, MD<br />
Advisor/Consultant: Amgen, Daiichi-Sankyo. Member, <strong>ASH</strong> Board <strong>of</strong><br />
Directors.<br />
Adam Whaley‐Connell, DO<br />
I have no relationships to disclose.<br />
Andrew Whelton, MD<br />
Advisor/Consultant: Takeda. Speakers’ Bureau/Speaking/Teaching:<br />
Takeda.<br />
William B. White, MD<br />
Advisor/Consultant: Astellas, Forest, Novartis, Roche, Teva, Takeda.<br />
Grant/Research Support: Novartis. Other Relevant Financial Benefit<br />
or Relationship: Pfizer, Inc., DMC Consultant. President-Elect <strong>ASH</strong><br />
Board <strong>of</strong> Directors. <strong>ASH</strong> Scientific <strong>Program</strong> Committee Chair.<br />
Ian B. Wilkinson, MD<br />
Advisor/Consultant: GlaxoSmithKline, MSD. Grant/Research Support:<br />
GlaxoSmithKline.<br />
Bryan Williams, MD<br />
I have no relationships to disclose.<br />
Gordon H. Williams, MD<br />
I have no relationships to disclose.<br />
Peter F. Wilson, MD<br />
I have no relationships to disclose.<br />
Nathan D. Wong<br />
Advisor/Consultant: Abbott. Grant/Research Support: Merck, Bristol-<br />
Myers Squibb.<br />
Martin S. Zand, MD<br />
I have no relationships to disclose.<br />
154
<strong>ASH</strong> <strong>Hypertension</strong> Resource Pavilion<br />
Hilton New York • Americas Hall I • Third Floor<br />
Innovations Theater<br />
Americas Hall I<br />
(Third Floor)<br />
<strong>ASH</strong> Posters<br />
(Second Floor Promenade)<br />
<strong>ASH</strong><br />
Outreach<br />
Innovations Theater<br />
1600<br />
Takeda<br />
Pharmaceuticals<br />
North <strong>American</strong> Inc.<br />
1400<br />
1600<br />
<strong>ASH</strong><br />
Outreach<br />
TO AMERICAS HALL II<br />
ESCALATOR<br />
UP<br />
Daiichi Sankyo Inc.<br />
1200<br />
Novartis<br />
Pharmaceuticals<br />
1100<br />
Takeda<br />
Pharmaceuticals<br />
North <strong>American</strong> Inc.<br />
Wiley-Blackwell<br />
1400<br />
1202 1204<br />
Mortara<br />
HoMedics<br />
1105 1107<br />
Daiichi David Sankyo Inc. ISHIB<br />
Lerner<br />
1200<br />
1102 1103<br />
Elsevier Inc.<br />
AtCor Medical, Inc.<br />
1106<br />
Wiley-Blackwell<br />
1202 1204<br />
1104<br />
Mortara<br />
HoMedics<br />
Elsevier Inc.<br />
Ajinomoto<br />
AtCor Medical, Inc.<br />
Omron Healthcare Novartis Forest Lippincott 1105 1107 A & D<br />
SunTech<br />
Medical<br />
Medical<br />
Novartis<br />
David ISHIB<br />
1106<br />
1000 Pharmaceuticals 1004 1006 1008 Lerner 1010 1014<br />
1100<br />
1102 1103<br />
1104<br />
Ajinomoto<br />
National<br />
Kidney<br />
1206<br />
Woman<br />
Heart<br />
1110<br />
National<br />
Kidney<br />
1206<br />
Woman<br />
Heart<br />
1110<br />
ENTRANCE<br />
Omron Healthcare Novartis Forest Lippincott A & D<br />
Medical<br />
SunTech<br />
Medical<br />
1000 1004 1006 1008 1010 1014<br />
TED FIRE ALARMS<br />
TED FIRE EXITS<br />
155
<strong>ASH</strong> Exposition Guide<br />
Hilton New York • Americas Hall I • Third Floor<br />
Hours:<br />
Saturday, May 21, 4:30 PM – 7:30 PM<br />
Sunday, May 22, 10:00 AM – 1:00 PM, 3:30 PM – 6:30 PM<br />
Monday, May 23, 10:00 AM – 1:30 PM, 4:00 PM – 5:30 PM<br />
<strong>ASH</strong> <strong>Hypertension</strong> Resource Pavilion<br />
America’s Hall I – Third Floor<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong> Community<br />
Outreach<br />
Booth Number: 1600<br />
Controlling your blood pressure is a<br />
check away!<br />
Get your blood pressure checked<br />
today at our Outreach Booth!!<br />
In <strong>2011</strong>, we are proud to continue<br />
with our Fourth Annual <strong>Hypertension</strong><br />
Community Outreach <strong>Program</strong> in the<br />
Greater New York City area, Northern<br />
New Jersey, and Long Island, NY.<br />
View videos and photos <strong>of</strong> all <strong>of</strong> our<br />
past Outreach <strong>Program</strong>s from New<br />
Orleans (2008), San Francisco (2009),<br />
and New York (2010). Our recently<br />
released educational videos will also<br />
be on view. The <strong>ASH</strong> published “Blood<br />
Pressure and Your Health” patient<br />
information pamphlets are available<br />
here as well.<br />
Check it out!!—go to Times Square—<br />
42nd Street between 7th and 8th Avenues<br />
and look up at the CBS “Super<br />
Screen” and you will see the new <strong>ASH</strong><br />
Public Service Announcement shown<br />
18 times a day.<br />
A & D Medical<br />
Booth Number: 1010<br />
A&D Medical / LifeSource manufacturers<br />
blood pressure monitors and<br />
other home health care products for<br />
home and pr<strong>of</strong>essional use. Models include<br />
automatic, manual, ambulatory,<br />
kiosk style and accessories including<br />
stethoscopes.<br />
A&D Medical is a division <strong>of</strong> A&D<br />
Engineering, and is ISO 13485:2003<br />
certified. Since 1977, A&D Medical<br />
has manufactured and distributed a<br />
full line <strong>of</strong> advanced electronic blood<br />
pressure monitoring equipment and<br />
health care products for home and<br />
pr<strong>of</strong>essional use. The company has<br />
established itself as a leader in home<br />
health monitoring technology through<br />
the development and introduction<br />
<strong>of</strong> a variety <strong>of</strong> unique products.<br />
A&D’s LifeSource® blood pressure<br />
monitor line has garnered numerous<br />
industry awards. Recent product<br />
introductions include: the LifeSource®<br />
digital thermometers, personal scales,<br />
stethoscopes, and Ambulatory Blood<br />
Pressure Monitors.<br />
Ajinomoto USA, Inc.<br />
Booth Number: 1104<br />
Since 1909, Ajinomoto Co., a leader<br />
in the development <strong>of</strong> pharmaceutical<br />
quality amino acids and distributor<br />
<strong>of</strong> products that <strong>of</strong>fer a holistic,<br />
side-effect free solution to today’s top<br />
health concerns <strong>of</strong> weight management,<br />
sleep quality improvement and<br />
healthy blood pressure management.<br />
These products are Capsiate Natura®,<br />
a patented, side effect-free dietary<br />
supplement with natural capsinoids<br />
shown to boost the body’s metabolism;<br />
Glysom, a safe, effective and<br />
scientifically-proven amino acid-based<br />
solution for deeper, sounder and<br />
more satisfying sleep, and Natura<br />
Guard BP, a milk protein-derived<br />
nutraceutical to help maintain healthy<br />
blood pressure levels already within<br />
the normal range.<br />
For more information, visit<br />
www.capsiatenatura.com,<br />
www.glysom.com and<br />
www.naturaguardbp.com<br />
AtCor Medical, Inc. (USA)<br />
Booth Number: 1106<br />
AtCor Medical developed and markets<br />
SphygmoCor® systems, the global gold<br />
standard in noninvasive assessment<br />
<strong>of</strong> central blood pressure and arterial<br />
stiffness. Featured in over 600 published<br />
studies, SphygmoCor systems<br />
are used worldwide in leading medical<br />
centers, physicians’ <strong>of</strong>fices, in research<br />
and in pharmaceutical clinical trials.<br />
Daiichi Sankyo, Inc.<br />
Booth Number: 1200<br />
Daiichi Sankyo, Inc. (DSI), headquartered<br />
in Parsippany, NJ, is the<br />
U. S. subsidiary <strong>of</strong> Daiichi Sankyo<br />
Co., Ltd., a global pharmaceutical<br />
company. DSI was formed in 2006<br />
from the integration <strong>of</strong> two leading<br />
pharmaceutical companies, Sankyo<br />
Pharma, Inc. and Daiichi Pharmaceutical<br />
Corporation. Its team <strong>of</strong> nearly<br />
3,000 U.S. employees is dedicated to<br />
the creation and supply <strong>of</strong> innovative<br />
pharmaceutical products to address<br />
the diversified, unmet medical needs<br />
<strong>of</strong> patients. DSI concentrates in the<br />
therapy areas <strong>of</strong> hypertension, thrombosis,<br />
dyslipidemia, diabetes and<br />
acute coronary syndrome. Clinical<br />
development and regulatory activities<br />
are headquartered at Daiichi Sankyo<br />
Pharma Development in Edison, NJ.<br />
Visit www.dsi.com.<br />
David Lerner Associates<br />
Booth Number: 1102<br />
Financial Investments at David Lerner<br />
Associates<br />
We believe gambling and investing are<br />
not the same.<br />
We believe the stock market should make<br />
for interesting dinner conversation but<br />
should not be a matter <strong>of</strong> financial life<br />
or death.<br />
We believe we have an obligation to<br />
guide our investors in directions we feel<br />
will help them achieve their financial<br />
objectives.<br />
We believe investors should not be chasing<br />
financial rainbows.<br />
We do not run with the herd. We pursue<br />
these fundamental investment principles<br />
regardless <strong>of</strong> market conditions.<br />
While <strong>of</strong>fering a full range <strong>of</strong> investments,<br />
we feature those that we believe<br />
are based on real value and regularly pay<br />
dividends or interest.<br />
Elsevier<br />
Booth Number: 1204<br />
ELSEVIER, a premier worldwide health<br />
science publishing company, is proud<br />
to publish Journal <strong>of</strong> the AMERICAN<br />
SOCIETY OF HYPERTENSION, the<br />
<strong>of</strong>ficial journal <strong>of</strong> the <strong>American</strong> <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong>. Please stop by our booth<br />
to view the latest issue <strong>of</strong> the journal.<br />
Forest Pharmaceuticals, Inc.<br />
Booth Number: 1006<br />
Forest Pharmaceuticals, Inc welcomes<br />
you to New York! We invite you to visit<br />
our exhibit. Please visit our website at<br />
www.forestpharm.com<br />
Community Partner <strong>of</strong> the <strong>ASH</strong><br />
<strong>Hypertension</strong> Community Outreach<br />
<strong>Program</strong><br />
HoMedics<br />
Booth Number: 1107<br />
Since HoMedics was founded in 1987,<br />
they have become the #1 name in health<br />
and wellness with an extensive line <strong>of</strong><br />
products that allow you to take a proactive<br />
role in managing your health.<br />
HoMedics blood pressure monitors are<br />
clinically proven accurate and <strong>of</strong>fer a<br />
wide range <strong>of</strong> innovative features and<br />
technologies that make monitoring your<br />
blood pressure at home easier than ever.<br />
Select arm and wrist models <strong>of</strong>fer Voice<br />
Assist® Talking Function, Supersize<br />
Digits®, Risk Category Index, Easy One<br />
Button Operation, Dual User Memory<br />
and 2 cuffs to fit most arm sizes.<br />
Community Partner <strong>of</strong> the <strong>ASH</strong><br />
<strong>Hypertension</strong> Community Outreach<br />
<strong>Program</strong><br />
International <strong>Society</strong> on<br />
<strong>Hypertension</strong> in Blacks, Inc. (ISHIB)<br />
Booth Number: 1103<br />
Founded in 1986, ISHIB is a non-pr<strong>of</strong>it<br />
organization <strong>of</strong> healthcare pr<strong>of</strong>essions<br />
and leaders in cardiovascular disease<br />
and related disorders. Our mission is to<br />
improve the health and life expectancy <strong>of</strong><br />
ethnic minorities and eliminate racial and<br />
ethnic health disparities in cardiovascular<br />
disease through pr<strong>of</strong>essional and public<br />
education, targeted clinical research, and<br />
facilitation <strong>of</strong> the delivery <strong>of</strong> higher quality<br />
cardiovascular health care. We host<br />
an annual conference, membership and<br />
other programs.<br />
Lippincott, Williams & Wilkins, a<br />
Wolters Kluwer Health Company<br />
Booth Number: 1008<br />
Lippincott Williams & Wilkins, Wolters<br />
Kluwer Health Company, is the proud<br />
publisher <strong>of</strong> <strong>Hypertension</strong>, Journal <strong>of</strong><br />
the <strong>American</strong> Heart Association, and<br />
the Journal <strong>of</strong> <strong>Hypertension</strong>, Official<br />
Journal <strong>of</strong> the International <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong> and the European <strong>Society</strong><br />
<strong>of</strong> <strong>Hypertension</strong>. We <strong>of</strong>fer a full range<br />
<strong>of</strong> specialized books, journals, and electronic<br />
media. Visit us today!<br />
Mortara Instrument<br />
Booth Number: 1105<br />
Mortara Instrument is proud to <strong>of</strong>fer its<br />
Ambulo 2400 ambulatory blood pressure<br />
(ABPM) technology at the <strong>American</strong><br />
<strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>’s <strong>2011</strong> Annual<br />
Scientific Meeting and Exposition. Designed<br />
and made in the USA, the Ambulo<br />
2400 system allows clinicians, researchers<br />
and other health pr<strong>of</strong>essionals to better<br />
assess a patient’s blood pressure fluctuations<br />
throughout the 24-hour circadian<br />
rhythm.<br />
For over 25 years, Mortara Instrument<br />
has distinguished itself in the field <strong>of</strong><br />
non-invasive cardiology by providing<br />
ECG, Holter and stress systems to customers<br />
worldwide. We are excited to be<br />
adding thorough blood pressure assessment<br />
tools to our portfolio <strong>of</strong> products.<br />
National Kidney Foundation<br />
Booth Number: 1206<br />
NKF <strong>of</strong>fers the nephrology community<br />
the latest science through clinical<br />
practice guidelines, free kidney screening<br />
programs held around the world, and<br />
educational materials for patients and<br />
pr<strong>of</strong>essionals. Learn more about the<br />
soon-to-be published guidelines, including:<br />
KDIGO’s Acute Kidney Injury and<br />
the Update on CKD and Diabetes by<br />
KDOQI. Please visit the booth to signup<br />
to review KDIGO’s Clinical Practice<br />
Guideline on Blood Pressure in CKD.<br />
Novartis Pharmaceuticals<br />
Corporation<br />
Booth Number: 1100, 1004<br />
Novartis Pharmaceuticals is dedicated to<br />
discovering, developing, manufacturing<br />
and marketing prescription drugs that<br />
help meet our customers’ medical needs<br />
and improve their quality <strong>of</strong> life. Please<br />
visit the Novartis exhibit where our sales<br />
representatives will be available to discuss<br />
our products.<br />
Community Partner <strong>of</strong> the <strong>ASH</strong><br />
<strong>Hypertension</strong> Community Outreach<br />
<strong>Program</strong><br />
Omron Healthcare<br />
Booth Number: 1000<br />
Omron Healthcare, Inc., is the leading<br />
manufacturer and distributor <strong>of</strong> blood<br />
pressure monitors for home use. Omron<br />
Healthcare markets clinically proven<br />
products that provide accurate health<br />
information to consumers and physicians<br />
and support position lifestyle changes and<br />
health improvement.<br />
Community Partner <strong>of</strong> the <strong>ASH</strong><br />
<strong>Hypertension</strong> Community Outreach<br />
<strong>Program</strong><br />
SunTech Medical, Inc.<br />
Booth Number: 1014<br />
For over twenty years, SunTech Medical<br />
has been the preeminent supplier <strong>of</strong><br />
clinical grade blood pressure monitoring<br />
products and technologies. SunTech is the<br />
world’s foremost manufacturer <strong>of</strong> ambulatory<br />
blood pressure monitors, including<br />
the Oscar 2 ABPM system, now available<br />
with Pediatric ABPM Interpretation<br />
function, which automatically generates<br />
guidelines specific to analyzing the<br />
24-hour blood pressure data <strong>of</strong> pediatric<br />
patients. Additionally, SunTech <strong>of</strong>fers solutions<br />
for in-<strong>of</strong>fice BP measurement with<br />
the SunTech 247, the first clinical grade<br />
automated blood pressure device to <strong>of</strong>fer<br />
a manual back-up mode, as well as a complete<br />
line <strong>of</strong> blood pressure cuffs. Please<br />
visit our booth for more information.<br />
Takeda Pharmaceuticals North<br />
America, Inc.<br />
Booth Number: 1400<br />
Based in Deerfield, IL. Takeda Pharmaceuticals<br />
North America, Inc. and Takeda<br />
Global Research & Development Center,<br />
Inc. market oral diabetes, insomnia, rheumatology<br />
and gastroenterology treatments<br />
and seek to bring innovative products to<br />
patients through a pipeline that includes<br />
compounds in development for diabetes,<br />
cardiovascular disease, gastroenterology<br />
and neurology. www.tpna.com.<br />
Wiley-Blackwell<br />
Booth Number: 1202<br />
Wiley-Blackwell is the international<br />
scientific, technical, medical and scholarly<br />
publishing business <strong>of</strong> John Wiley & Sons,<br />
with strengths in every major academic<br />
and pr<strong>of</strong>essional field and partnerships<br />
with many <strong>of</strong> the world’s leading societies.<br />
Wiley-Blackwell publishes over 1,400<br />
peer-reviewed journals as well as 1,500+<br />
new books annually in print and online,<br />
as well as databases, major reference<br />
works and laboratory protocols. For more<br />
information, please visit<br />
www.wileyblackwell.com or<br />
http://onlinelibrary.wiley.com/<br />
WomenHeart<br />
Booth Number: 1110<br />
WomenHeart was founded by three<br />
women who had heart attacks while in<br />
their 40s. In addition to being faced with<br />
many obstacles, including misdiagnosis<br />
and social isolation, they were each<br />
amazed how little information about<br />
or services for women with heart<br />
disease were available and how the issue<br />
seemed invisible within the women’s<br />
health community. But in March 1999<br />
everything changed.<br />
156
<strong>2011</strong> <strong>ASH</strong> Innovations Theater<br />
Rhinelander Gallery – 2nd Floor<br />
Saturday, May 21, <strong>2011</strong> • 6:30 PM to 7:30 PM<br />
Daiichi Sankyo, Inc. presents,<br />
The Growing Need for Combination Antihypertensive Therapy<br />
“The Innovations Theater content and the views expressed<br />
therein are those <strong>of</strong> the presenting corporate entity and not <strong>of</strong><br />
the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. The content is not<br />
part <strong>of</strong> the <strong>ASH</strong> Annual Scientific Meeting as approved by the<br />
“Annual Scientific <strong>Program</strong> Committee.”<br />
Sunday, May 22, <strong>2011</strong> • 12:00 PM to 1:00 PM<br />
Takeda Pharmaceuticals, North <strong>American</strong>, Inc. presents,<br />
A Clinical Update in <strong>Hypertension</strong>.<br />
“The Innovations Theater content and the views expressed<br />
therein are those <strong>of</strong> the presenting corporate entity and not <strong>of</strong><br />
the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. The content is not<br />
part <strong>of</strong> the <strong>ASH</strong> Annual Scientific Meeting as approved by the<br />
“Annual Scientific <strong>Program</strong> Committee.”<br />
Sunday, May 22, <strong>2011</strong> • 5:30 PM to 6:30 PM<br />
Novartis Pharmaceuticals Corporation Presentation<br />
“The Innovations Theater content and the views expressed<br />
therein are those <strong>of</strong> the presenting corporate entity and not <strong>of</strong><br />
the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>, Inc. The content is not<br />
part <strong>of</strong> the <strong>ASH</strong> Annual Scientific Meeting as approved by the<br />
Annual Scientific <strong>Program</strong> Committee.”<br />
157
<strong>2011</strong> <strong>ASH</strong> Exhibitors<br />
<strong>ASH</strong> <strong>Hypertension</strong> Resource Pavilion • America’s Hall I – 3rd Floor<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong> Community Outreach<br />
Contact: Gilda Caputo-Hansen<br />
148 Madison Ave. 5th Floor<br />
New York, NY 10016<br />
Phone: 212-696-9099<br />
Fax: 212-696-0711<br />
Email: gcaputo@ash-us.org<br />
Website: www.ash-us.org<br />
Booth Number: 1600<br />
Controlling your blood pressure is a check away!<br />
Get your blood pressure checked today at our Outreach<br />
Booth!!<br />
In <strong>2011</strong>, we are proud to continue with our Fourth Annual<br />
<strong>Hypertension</strong> Community Outreach <strong>Program</strong> in the Greater<br />
New York City area, Northern New Jersey, and Long Island,<br />
NY. View videos and photos <strong>of</strong> all <strong>of</strong> our past Outreach<br />
<strong>Program</strong>s from New Orleans (2008), San Francisco (2009), and<br />
New York (2010). Our recently released educational videos will<br />
also be on view. The <strong>ASH</strong> published “Blood Pressure and Your<br />
Health” patient information pamphlets are available here as<br />
well.<br />
Check it out!!—go to Times Square—42nd Street between<br />
7th and 8th Avenues and look up at the CBS “Super Screen”<br />
and you will see the new <strong>ASH</strong> Public Service Announcement<br />
shown 18 times a day.<br />
158
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
A & D Medical<br />
Contact: Amit Ghia<br />
1756 Automation Parkway<br />
San Jose, CA 95131<br />
Phone: 408-263-5333<br />
Fax: 408-263-0119<br />
E-mail: aghia@andmedical.com<br />
Website: www.andmedical.com<br />
Booth Number: 1010<br />
A&D Medical / LifeSource manufacturers blood pressure<br />
monitors and other home health care products for home<br />
and pr<strong>of</strong>essional use. Models include automatic, manual,<br />
ambulatory, kiosk style and accessories including stethoscopes.<br />
A&D Medical is a division <strong>of</strong> A&D Engineering, and is<br />
ISO 13485:2003 certified. Since 1977, A&D Medical has<br />
manufactured and distributed a full line <strong>of</strong> advanced<br />
electronic blood pressure monitoring equipment and health<br />
care products for home and pr<strong>of</strong>essional use. The company<br />
has established itself as a leader in home health monitoring<br />
technology through the development and introduction <strong>of</strong> a<br />
variety <strong>of</strong> unique products. A&D’s LifeSource® blood pressure<br />
monitor line has garnered numerous industry awards.<br />
Recent product introductions include: the LifeSource® digital<br />
thermometers, personal scales, stethoscopes, and Ambulatory<br />
Blood Pressure Monitors.<br />
Ajinomoto USA, Inc.<br />
Contact: Junichi Tashiro<br />
400 Kelby Street<br />
Fort Lee, NJ 07024<br />
Phone: 201-292-3244<br />
Fax: 201-346-5639<br />
Email: tashiroj@ajiusa.com<br />
Booth Number: 1104<br />
Since 1909, Ajinomoto Co., a leader in the development<br />
<strong>of</strong> pharmaceutical quality amino acids and distributor <strong>of</strong><br />
products that <strong>of</strong>fer a holistic, side-effect free solution to today’s<br />
top health concerns <strong>of</strong> weight management, sleep quality<br />
improvement and healthy blood pressure management. These<br />
products are Capsiate Natura®, a patented, side effect-free<br />
dietary supplement with natural capsinoids shown to boost the<br />
body’s metabolism; Glysom, a safe, effective and scientificallyproven<br />
amino acid-based solution for deeper, sounder and<br />
more satisfying sleep, and Natura Guard BP, a milk proteinderived<br />
nutraceutical to help maintain healthy blood pressure<br />
levels already within the normal range.<br />
For more information, visit www.capsiatenatura.com,<br />
www.glysom.com and www.naturaguardbp.com<br />
159
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
AtCor Medical, Inc. (USA)<br />
Contact: Beth Boyer<br />
One Pierce Place, Suite 225W<br />
Itasca, IL 60143<br />
Phone: 630-228-8871<br />
Fax: 630-228-8872<br />
Email: info@atcormedical.com<br />
Website: www.atcormedical.com<br />
Booth Number: 1106<br />
AtCor Medical developed and markets SphygmoCor® systems,<br />
the global gold standard in noninvasive assessment <strong>of</strong> central<br />
blood pressure and arterial stiffness. Featured in over 600<br />
published studies, SphygmoCor systems are used worldwide in<br />
leading medical centers, physicians’ <strong>of</strong>fices, in research and in<br />
pharmaceutical clinical trials.<br />
Daiichi Sankyo, Inc.<br />
Contact: Ann Marie Bermudez<br />
2 Hilton Court<br />
Parsippany, NJ 07054<br />
Phone: 973-944-2600<br />
Fax: 973-944-2891<br />
Email: abermudez@dsi.com<br />
Website: www.dsi.com<br />
Booth Number: 1200<br />
Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ,<br />
is the U. S. subsidiary <strong>of</strong> Daiichi Sankyo Co., Ltd., a global<br />
pharmaceutical company. DSI was formed in 2006 from the<br />
integration <strong>of</strong> two leading pharmaceutical companies, Sankyo<br />
Pharma, Inc. and Daiichi Pharmaceutical Corporation.<br />
Its team <strong>of</strong> nearly 3,000 U.S. employees is dedicated to the<br />
creation and supply <strong>of</strong> innovative pharmaceutical products to<br />
address the diversified, unmet medical needs <strong>of</strong> patients. DSI<br />
concentrates in the therapy areas <strong>of</strong> hypertension, thrombosis,<br />
dyslipidemia, diabetes and acute coronary syndrome. Clinical<br />
development and regulatory activities are headquartered at<br />
Daiichi Sankyo Pharma Development in Edison, NJ. Visit<br />
www.dsi.com.<br />
160
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
David Lerner Associates<br />
Contact: James Faillace<br />
568 Yamato Road 3rd Floor<br />
Boca Raton FL 33431<br />
Phone: 561-226-4500<br />
Fax: 561-226-4598<br />
Email: jon.jarow@davidlerner.com<br />
Booth Number: 1102<br />
Financial Investments at David Lerner Associates<br />
We believe gambling and investing are not the same.<br />
We believe the stock market should make for interesting<br />
dinner conversation but should not be a matter <strong>of</strong> financial life<br />
or death.<br />
We believe we have an obligation to guide our investors<br />
in directions we feel will help them achieve their financial<br />
objectives.<br />
We believe investors should not be chasing financial rainbows.<br />
We do not run with the herd. We pursue these fundamental<br />
investment principles regardless <strong>of</strong> market conditions.<br />
While <strong>of</strong>fering a full range <strong>of</strong> investments, we feature those that<br />
we believe are based on real value and regularly pay dividends<br />
or interest.<br />
Elsevier<br />
Contact:<br />
Jeffrey Francis<br />
Elsevier, Inc.<br />
1600 JFK Blvd. Suite 1800<br />
Philadelphia, PA 19103<br />
Phone: 215-239-3491<br />
Fax: 215-239-3494<br />
Email: j.francis@elsevier.com<br />
Website: www.elsevierhealth.com<br />
Booth Number: 1204<br />
ELSEVIER, a premier worldwide health science publishing<br />
company, is proud to publish Journal <strong>of</strong> the <strong>American</strong> <strong>Society</strong><br />
<strong>of</strong> <strong>Hypertension</strong>, the <strong>of</strong>ficial journal <strong>of</strong> the <strong>American</strong> <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong>. Please stop by our booth to view the latest issue<br />
<strong>of</strong> the journal.<br />
161
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
Forest Pharmaceuticals, Inc.<br />
Contact: info@forestpharm.com<br />
13600 Shoreline Drive<br />
St. Louis, MO 63045<br />
Phone: 800-678-1605<br />
Fax: 314-493-7450<br />
Email: info@forestpharm.com<br />
Website: www.forestpharm.com<br />
Booth Number: 1006<br />
Forest Pharmaceuticals, Inc welcomes you to New York! We<br />
invite you to visit our exhibit. Please visit our website at<br />
www.forestpharm.com<br />
Community Partner <strong>of</strong> the <strong>ASH</strong> <strong>Hypertension</strong> Community<br />
Outreach <strong>Program</strong><br />
HoMedics<br />
Contact:<br />
Anthony Vigliotti<br />
3000 Pontiac Trail<br />
Commerce Township, MI 48390<br />
Phone: 248-863-3000<br />
Fax: 248-863-3103<br />
Email: anthony.vigliotti@homedics.com<br />
Website: www.HoMedics.com<br />
Booth Number: 1107<br />
Since HoMedics was founded in 1987, they have become the #1<br />
name in health and wellness with an extensive line <strong>of</strong> products<br />
that allow you to take a proactive role in managing your health.<br />
HoMedics blood pressure monitors are clinically proven<br />
accurate and <strong>of</strong>fer a wide range <strong>of</strong> innovative features and<br />
technologies that make monitoring your blood pressure at<br />
home easier than ever.<br />
Select arm and wrist models <strong>of</strong>fer Voice Assist® Talking<br />
Function, Supersize Digits®, Risk Category Index, Easy One<br />
Button Operation, Dual User Memory and 2 cuffs to fit most<br />
arm sizes.<br />
Community Partner <strong>of</strong> the <strong>ASH</strong> <strong>Hypertension</strong> Community<br />
Outreach <strong>Program</strong><br />
162
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
International <strong>Society</strong> on <strong>Hypertension</strong> in Blacks, Inc. (ISHIB)<br />
Contact: Terry E. Jackson<br />
2111 Wilson Boulevard, Suite 700<br />
Arlington, VA. 22201<br />
Phone: 703-351-5023<br />
Fax: 703-351-9292<br />
Email: terry-jackson@ishib.org<br />
Website: www.ishib.org<br />
Booth Number: 1103<br />
Founded in 1986, ISHIB is a non-pr<strong>of</strong>it organization <strong>of</strong><br />
healthcare pr<strong>of</strong>essions and leaders in cardiovascular disease<br />
and related disorders. Our mission is to improve the health<br />
and life expectancy <strong>of</strong> ethnic minorities and eliminate racial<br />
and ethnic health disparities in cardiovascular disease through<br />
pr<strong>of</strong>essional and public education, targeted clinical research,<br />
and facilitation <strong>of</strong> the delivery <strong>of</strong> higher quality cardiovascular<br />
health care. We host an annual conference, membership and<br />
other programs.<br />
Lippincott, Williams & Wilkins, a Wolters Kluwer Health<br />
Company<br />
Contact: Jeff Thompson (PSG)<br />
16522 Hunters Green Parkway<br />
Hagerstown, MD 21740 U.S.A.<br />
Phone: 1-800-638-3030 (North America)<br />
+44 (0) 20 7981 0525 (Europe)<br />
1-301-223-2300 (Rest <strong>of</strong> World)<br />
Fax: 1-301-223-2400 (North America)<br />
+44 (0) 20 7981 0535 (Europe)<br />
1-301-223-2400 (Rest <strong>of</strong> World)<br />
Email: Jeff.Thompson@wolterskluwer.com or<br />
customerservice@lww.com<br />
Website: www.lww.com<br />
Booth Number: 1008<br />
Lippincott Williams & Wilkins, Wolters Kluwer Health<br />
Company, is the proud publisher <strong>of</strong> <strong>Hypertension</strong>, Journal<br />
<strong>of</strong> the <strong>American</strong> Heart Association, and the Journal <strong>of</strong><br />
<strong>Hypertension</strong>, Official Journal <strong>of</strong> the International <strong>Society</strong> <strong>of</strong><br />
<strong>Hypertension</strong> and the European <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>. We<br />
<strong>of</strong>fer a full range <strong>of</strong> specialized books, journals, and electronic<br />
media. Visit us today!<br />
163
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
Mortara Instrument<br />
Contact: Cynthia Muise<br />
7865 N. 86th Street<br />
Milwaukee, WI 53224<br />
Phone: 414-354-1600 x7738<br />
Fax: 414-354-4760<br />
Email: Cynthia.muise@mortara.com<br />
Booth Number: 1105<br />
Mortara Instrument is proud to <strong>of</strong>fer its Ambulo 2400<br />
ambulatory blood pressure (ABPM) technology at the<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Hypertension</strong>’s <strong>2011</strong> Annual Scientific<br />
Meeting and Exposition. Designed and made in the USA, the<br />
Ambulo 2400 system allows clinicians, researchers and other<br />
health pr<strong>of</strong>essionals to better assess a patient’s blood pressure<br />
fluctuations throughout the 24-hour circadian rhythm.<br />
For over 25 years, Mortara Instrument has distinguished itself<br />
in the field <strong>of</strong> non-invasive cardiology by providing ECG,<br />
Holter and stress systems to customers worldwide. We are<br />
excited to be adding thorough blood pressure assessment tools<br />
to our portfolio <strong>of</strong> products.<br />
National Kidney Foundation<br />
Contact: David Rexroad<br />
30 East 33rd Street<br />
New York, NY 10016<br />
Phone: 212-889-2210<br />
Fax: 212-889-2310<br />
Email: davidr@kidney.org<br />
Website: www.kidney.org<br />
Booth Number: 1206<br />
NKF <strong>of</strong>fers the nephrology community the latest science<br />
through clinical practice guidelines, free kidney screening<br />
programs held around the world, and educational materials for<br />
patients and pr<strong>of</strong>essionals. Learn more about the soon-to-be<br />
published guidelines, including: KDIGO’s Acute Kidney Injury<br />
and the Update on CKD and Diabetes by KDOQI. Please<br />
visit the booth to sign-up to review KDIGO’s Clinical Practice<br />
Guideline on Blood Pressure in CKD.<br />
164
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
Novartis Pharmaceuticals Corporation<br />
Contact: Becca Baileys<br />
One Health Plaza<br />
East Hanover, NJ 07936<br />
Phone: 862-778-8300<br />
Email: rebecca.baileys@novartis.com<br />
Website: www.novartis.com<br />
Booth Number: 1100, 1004<br />
Novartis Pharmaceuticals is dedicated to discovering,<br />
developing, manufacturing and marketing prescription drugs<br />
that help meet our customers’ medical needs and improve their<br />
quality <strong>of</strong> life. Please visit the Novartis exhibit where our sales<br />
representatives will be available to discuss our products.<br />
Community Partner <strong>of</strong> the <strong>ASH</strong> <strong>Hypertension</strong> Community<br />
Outreach <strong>Program</strong><br />
Omron Healthcare<br />
Contact: Dan Aske<br />
1200 Lakeside Drive<br />
Bannockburn, IL 60015<br />
Phone: 847-680-6200<br />
Fax: 847-680-6269<br />
Email: info@omron.com<br />
Booth Number: 1000<br />
Omron Healthcare, Inc., is the leading manufacturer and<br />
distributor <strong>of</strong> blood pressure monitors for home use. Omron<br />
Healthcare markets clinically proven products that provide<br />
accurate health information to consumers and physicians and<br />
support position lifestyle changes and health improvement.<br />
Community Partner <strong>of</strong> the <strong>ASH</strong> <strong>Hypertension</strong> Community<br />
Outreach <strong>Program</strong><br />
165
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
SunTech Medical, Inc.<br />
Contact: Rod Thomson<br />
507 Airport Blvd.., Suite 117<br />
Morrisville, NC 27560<br />
Phone: +1 919 654 2300 x 355<br />
Fax: +1 919 654 2301<br />
Email: sales @suntechmed.com<br />
Website: www.SunTechMed.com<br />
Booth Number: 1014<br />
For over twenty years, SunTech Medical has been the<br />
preeminent supplier <strong>of</strong> clinical grade blood pressure<br />
monitoring products and technologies. SunTech is the<br />
world’s foremost manufacturer <strong>of</strong> ambulatory blood pressure<br />
monitors, including the Oscar 2 ABPM system, now available<br />
with Pediatric ABPM Interpretation function, which<br />
automatically generates guidelines specific to analyzing the<br />
24-hour blood pressure data <strong>of</strong> pediatric patients. Additionally,<br />
SunTech <strong>of</strong>fers solutions for in-<strong>of</strong>fice BP measurement with the<br />
SunTech 247, the first clinical grade automated blood pressure<br />
device to <strong>of</strong>fer a manual back-up mode, as well as a complete<br />
line <strong>of</strong> blood pressure cuffs. Please visit our booth for more<br />
information.<br />
Takeda Pharmaceuticals North America, Inc.<br />
Contact: One Takeda Parkway<br />
Deerfield, Il 60015<br />
Phone: 224-554-6500<br />
Website: www.tpna.com<br />
Booth Number: 1400<br />
Based in Deerfield, IL. Takeda Pharmaceuticals North<br />
America, Inc. and Takeda Global Research & Development<br />
Center, Inc. market oral diabetes, insomnia, rheumatology<br />
and gastroenterology treatments and seek to bring innovative<br />
products to patients through a pipeline that includes<br />
compounds in development for diabetes, cardiovascular<br />
disease, gastroenterology and neurology. www.tpna.com.<br />
166
<strong>2011</strong> <strong>ASH</strong> Exhibitors continued<br />
Wiley-Blackwell<br />
Contact: 350 Main Street<br />
Malden, MA 02148<br />
Phone: 781-388-8250<br />
Fax: 781-338-8250<br />
Website: www.wiley.com<br />
Booth Number: 1202<br />
Wiley-Blackwell is the international scientific, technical,<br />
medical and scholarly publishing business <strong>of</strong> John Wiley &<br />
Sons, with strengths in every major academic and pr<strong>of</strong>essional<br />
field and partnerships with many <strong>of</strong> the world’s leading<br />
societies. Wiley-Blackwell publishes over 1,400 peer-reviewed<br />
journals as well as 1,500+ new books annually in print and<br />
online, as well as databases, major reference works and<br />
laboratory protocols. For more information, please visit<br />
www.wileyblackwell.com or http://onlinelibrary.wiley.com/<br />
WomenHeart<br />
Contact: Mary McGowan, COO<br />
818 18th Street NW<br />
Washington DC 20006<br />
Phone: 202-464-8735<br />
Email: mmcgowan@womenheart.org<br />
Website: www.womenheart.org<br />
Booth Number: 1110<br />
WomenHeart was founded by three women who had heart<br />
attacks while in their 40s. In addition to being faced with many<br />
obstacles, including misdiagnosis and social isolation, they<br />
were each amazed how little information about or services for<br />
women with heart disease were available and how the issue<br />
seemed invisible within the women’s health community. But in<br />
March 1999 everything changed.<br />
167
Author Index<br />
A<br />
Abad, María, 133<br />
Abaunza, Ricardo, 102<br />
Abbey, Susan, 136<br />
Abdallah, Rany T., 101<br />
Abdellatifi, Ibrahim L., 142<br />
Abecasis, Goncalo R., 79<br />
Abraham, Nader G., 66, 122<br />
Abramson, Beth, 136<br />
Acelajado, Maria Czarina, 88, 108,<br />
138<br />
Acelajado, Maria Czarina M., 120<br />
Acelajado‐Valdenor, Ma Czarlota<br />
M., 120<br />
Achouba, Assya, 92, 127<br />
Adamczyk, Maciej, 142<br />
Adams, Kenneth F., 106<br />
Adams, Robert J., 100, 102, 134<br />
Adler, G., 97<br />
Agarwal, Rajiv, 60, 145<br />
Agarwal, Vikram, 66, 93, 117<br />
Agarwal, Vikram V., 87, 117<br />
Aggelis, A., 66, 91, 124<br />
Agnoletti, Davide, 112, 126, 128<br />
Aguilar, Francisco, 101<br />
Ajzen, Sérgio Aron, 102<br />
Albarran, Olga Gonzalez, 99<br />
Alcon, Jose, 101<br />
Alebiosu, Olutayo Christopher, 97<br />
Alessi, Sheila M., 136<br />
Almenar, Luis, 116<br />
Almiroudi, M., 92, 96, 102, 122,<br />
124, 126<br />
Alonso, Ana, 91, 98<br />
Alonso, Ignacio, 114, 129<br />
Altun, Bulent, 97, 121<br />
Alvarez, Carlos, 98<br />
Alvarez, Carmen, 139<br />
Alvarez, Julio, 101<br />
Ambalavanan, Namasivayam, 118,<br />
144<br />
Ambrosio, Giuseppe, 91<br />
Amdur, Richard, 96, 105<br />
Amin, M. Yousri K., 142<br />
Ammary, Ibtissam, 141<br />
Anastasopoulos, I., 128<br />
Andrews, L. M., 133, 140<br />
Andrikou, E., 122, 126<br />
Andrikou, I., 92, 102, 122<br />
Angelini, Luca, 120<br />
Antonino, Cassi, 137<br />
Anunciato, Iara F., 143<br />
Anunciato, Iara Felício, 132<br />
Aonuma, Takanori, 117<br />
Appel, Lawrence J., 82, 145<br />
Aragiannis, D., 102<br />
Aranda, Pedro, 101, 102<br />
Arbique, Debbie, 59<br />
Arici, Mustafa, 97<br />
Arinsoy, Turgay, 121<br />
Armando, Ines, 47, 97, 123<br />
Arnett, Donna K., 145<br />
Aronne, Luigi, 123<br />
Artinian, Nancy, 45, 145<br />
Asche, Stephen E., 89<br />
Ascione, Frank, 87<br />
Asico, Laureano, 97<br />
Asico, Laureano D., 47<br />
Aslam, S., 91<br />
Asmar, Ali, 78<br />
Assia, Ehud, 103<br />
Ates, Kenan, 121<br />
Atkinson, Hal, 61<br />
Atluri, Tej K., 117<br />
Aucott, Lorna, 137<br />
August, Phyllis, 43, 145<br />
Aviv, Abraham, 76, 145<br />
Axon, R. Neal, 105, 130<br />
Ayala, Carma, 129<br />
Ayala, Diana E., 60, 97, 98, 99, 108,<br />
110, 111, 114, 121, 129, 131<br />
Azar, Silvia H., 123<br />
B<br />
Baba, Yoshichika, 121<br />
Babazadeh, Simon, 98<br />
Baber, Nigel, 95<br />
Bachman, David L., 134<br />
Bae, Jong‐Hoa, 116<br />
Baek, InYoung, 130<br />
Bagrov, Alexei Y., 142, 143<br />
Bailey, M., 97<br />
Bajaj, Jennifer, 90<br />
Baker, Brian, 136<br />
Baker, William L., 109<br />
Bakhtar, Omid, 93<br />
Bakris, George, 67, 78, 99<br />
Bakris, George L., 44, 50, 58, 68, 75,<br />
76, 78, 112, 140, 145<br />
Bakris, G. L., 115<br />
Balbarini, Alberto, 116, 126<br />
Baldo, Manuela S., 87<br />
Baldwin, William, 100<br />
Balish, Marshal, 136<br />
Ballesteros, Maria Jose, 95<br />
Baltatzi, Maria, 111<br />
Bancr<strong>of</strong>t, T. J., 140<br />
Bandyopadhyay, Dipankar, 110<br />
Banegas, Jose R., 93, 123, 134<br />
Baraniuk, Sarah, 60<br />
Baranova, Elena I., 87<br />
Barbatelli, Paolo, 133<br />
Barbetseas, I., 61<br />
Barbosa, Loide, 96<br />
Bard, Robert L., 65, 129<br />
Barros, Jesús, 129<br />
Baschiera, Fabio, 130<br />
Basile, Jan, 98, 130<br />
Basile, Jan N., 49, 50, 64, 145<br />
Bastien, Carl, 127<br />
Bastos, Jose Mesquita, 129, 134<br />
Basu, Sanjib, 47, 113<br />
Batisky, Donald L., 40, 51, 145<br />
Batson, Bryan, 139<br />
Baur, Dorothee M., 95<br />
Bavisotto, Susan Harris, 140<br />
Baylis, Chris, 100<br />
Bayorh, Mohamed A., 107<br />
Bellavia, Diego, 116<br />
Bellner, Lars, 122<br />
Belyaeva, Olga D., 87<br />
Ben‐Dov, Iddo Z., 93<br />
Benedict, Patrick E., 141<br />
Benetos, Georgios N., 119<br />
Berenson, Abbey B., 95, 102<br />
Berenson, Gerald S., 93, 94, 127<br />
168
Author Index<br />
Berezina, Aelita V., 87<br />
Berkovich, Olga O., 87<br />
Berktas, Mehmet, 108<br />
Bernard, Gutin, 47<br />
Bernheim, Jacques, 131<br />
Bernstein, Ira, 142<br />
Berrios, Ronaldo Sevilla, 110<br />
Bertoquini, Susana, 129<br />
Bertoquini, Susana P., 137<br />
Bhabhe, Aditya S., 123, 132<br />
Bhaheetharan, Sujan, 110<br />
Bhandari, Simran, 67<br />
Bhandari, Simran K., 108<br />
Bianchini, Elisabetta, 91, 127<br />
Biggi, Almerina, 91<br />
Bisognano, John, 67<br />
Bisognano, John D., 40, 49, 67, 126,<br />
145<br />
Blacher, Jacques, 99, 112, 126, 128<br />
Black, Henry R., 40, 81, 145<br />
Bloch, Michael J., 50, 145<br />
Blom, Kimberly C., 136<br />
Blue, Amanda E., 101<br />
Blumenthal, James A., 131<br />
Boan, Andrea D., 102, 134<br />
Boateng, Frank K., 139<br />
Bobrie, Guillaume, 108<br />
Bochud, Murielle, 79<br />
Boden, William E., 44<br />
Boerrigter, Guido, 91<br />
Bolin, Paul, 124<br />
Bolondi, Luigi, 95<br />
Bolshakova, Olga O., 87<br />
Bolton, Charlotte, 128<br />
Bonartseva, Garina A., 108<br />
Bonartsev, Anton P., 108<br />
Borghi, Claudio, 93<br />
Bosi, Matteo, 130, 137<br />
Bougatsa, Vaia, 111<br />
Bowden, Charles, 78<br />
Boyaci, Bulent, 108<br />
Bracho, Mayela J., 87<br />
Brady, Tammy M., 101<br />
Brands, Michael W., 40, 72, 145<br />
Brashear, R. Jeffrey, 142<br />
Braucht, Drew, 101<br />
Braun‐Dullaeus, Rudiger C., 139<br />
Braun, Lynne T., 45, 145<br />
Bravo, Emmanuel, 50, 145<br />
Briasoulis, Alex, 93, 117<br />
Briasoulis, Alexandros, 87, 117<br />
Bridges, William, 102<br />
Brinson, Stephanie, 140<br />
Brook, Robert D., 65, 129<br />
Brosolo, Gabriele, 136<br />
Brough, Elizabeth, 90, 115<br />
Brown, Angela L., 49, 50, 146<br />
Brown, Michael D., 136, 138, 144<br />
Brown, Morris, 112<br />
Brown, Nancy J., 40, 146<br />
Brunel, Patrick, 130<br />
Bruno, Rosa Maria, 127<br />
Brzezinski, W. Adam, 130<br />
Bueno, Isabel, 129<br />
Buglioni, Alessia, 107<br />
Buren, Peter Van, 60<br />
Burnett, John C., 91, 116<br />
Burnett, Jr., John C., 47<br />
Burnett, Richard T., 129<br />
Burney, Basil, 99<br />
Burri, Philippe, 143<br />
Bursztyn, Michael, 93<br />
Bushinksy, David A., 146<br />
Bushinsky, David, 107<br />
Bushinsky, David A., 70<br />
Bustamante, Eduardo E., 138<br />
Buysman, E. K., 140<br />
Byun, Young‐Sup, 118, 119, 120<br />
C<br />
Cafazzo, Joseph, 132<br />
Caglar, Sali, 97<br />
Cai, Jingjing, 112<br />
Cain, Van, 118<br />
Calabrò, Raffaele, 123<br />
Calara, Federico, 67<br />
Calara, Federico B., 108<br />
Calderon, Berniza, 91<br />
Calderón, Berniza, 99<br />
Calhoun, David A., 88, 108, 138<br />
Callejas, Pedro A., 97, 131<br />
Calmon, Gustavo E., 87<br />
Calvo, Sara, 91<br />
Campbell, Norman R.C., 54, 146<br />
Campbell, Patrick T., 109, 136<br />
Campese, Vito M., 88<br />
Campoy, Jose, 98<br />
Camsari, Taner, 121<br />
Cañas, Juan, 129<br />
Cannone, Valentina, 47, 91<br />
Cano, Marta, 91, 99<br />
Cao, C., 115<br />
Cao, Charlie, 112<br />
Capobianco, Frine, 88<br />
Carlberg, Bo, 93<br />
Carnevale, Daniela, 134, 135<br />
Carrasco, Marta, 91, 99<br />
Carreño, Agustin, 95<br />
Carretero, Oscar A., 20, 76, 146<br />
Carter, Barry L., 45, 49, 146<br />
Carugo, S., 130<br />
Cassi, Antonino, 130<br />
Castillo, Zenaida, 127<br />
Castiñeira, Maria C., 99, 121<br />
Castresana, Elena, 91<br />
Cataliotti, Alessandro, 22, 47, 76, 91,<br />
116, 146<br />
Catena, Cristiana, 59, 88, 136<br />
Caulfield, Mark, 78<br />
Caulfield, Mark J., 79<br />
Celis, Susana I., 127<br />
Cerezo, Cesar, 67, 93, 96<br />
Chacko, Billy G., 117<br />
Chakravarti, Aravinda, 78, 79<br />
Chamarthi, B., 97<br />
Charney, Alan, 130<br />
Chasman, Daniel I., 79<br />
Chavanu, Kathleen J., 114, 115<br />
Chayan, Luisa, 60, 114, 129<br />
Chazova, I. E., 143<br />
Chazova, Irina E., 112<br />
Cheh, Christopher Newton, 79<br />
Cheng, Dunlei, 94<br />
Chen, W., 113<br />
Chen, Wei, 93, 94, 122<br />
169
Author Index<br />
Chen, Yiu‐Fai, 103, 118, 126, 144<br />
Cheruvu, Bharadwaj, 122<br />
Cheung, D. G., 113<br />
Childers, W. Kurtis, 47<br />
Chlapoutakis, G., 126<br />
Cho, Eun‐Joo, 88<br />
Choi, Kyu‐Young, 88<br />
Cho, Jin‐Man, 111, 116<br />
Chow, Josephine X., 87<br />
Christensen, Niels Juel, 78<br />
Christiano, Cindy, 124<br />
Chrysant, Steven G., 109, 111<br />
Chung, Wook‐Jin, 118, 119, 120<br />
Chung, Yeonseung, 132<br />
Cicero, Arrigo, 93<br />
Cifelli, Giuseppe, 134, 135<br />
Cinteza, Mircea, 143<br />
Cirillo, Chiara, 123<br />
Civitarese, Louis, 141<br />
Clark, Rebecca I., 127<br />
Clark, Sarah, 87<br />
Clar, Xavier, 105<br />
Clyburn, Benjamin, 130<br />
Cockcr<strong>of</strong>t, John R., 46, 95, 128, 138,<br />
146<br />
Coelho, Eduardo B., 143<br />
Cohen, Debbie L., 127<br />
Cohn, Jay N., 51, 116, 144, 146<br />
Cohn, Lisa, 87<br />
Colaco, Clinton, 107<br />
Colby, Chris, 89<br />
Coloma, Ramon, 129<br />
Colussi, Gian Luca, 59<br />
Colussi, GianLuca, 59, 88, 136<br />
Comisky, Lauren, 123<br />
Concilio, Claudia, 123<br />
Connell, Barry, 92<br />
Corlan, Alexandru, 143<br />
Cornelissen‐Guillaume, Germaine<br />
G., 137<br />
Cosentino, Eugenio Roberto, 93<br />
Cosentino, Francesco, 91<br />
Couch, Sarah C., 106<br />
Coulson, James M., 138<br />
Craft, Chanda, 102<br />
Credendino, Maria, 123<br />
Crespo, Juan J., 97, 98, 121, 131<br />
Crippa, Giuseppe, 130, 137<br />
Croghan, Carry, 129<br />
Crowley, Steven D., 40, 146<br />
Cuevas, Santiago, 97<br />
Cui, Rong, 112<br />
Cushman, W. C., 115<br />
Cushman, William C., 54, 62, 78,<br />
112, 146<br />
D<br />
d’Addato, Sergio, 93<br />
D’Agostino, Ralph B., 96<br />
Dahlström, John K. F., 93<br />
Daley, Matt F., 106<br />
Damasceno, Albertino, 96<br />
Daniels, Stephen R., 47, 106, 146<br />
Daoud, Yahya, 94<br />
Darabont, Roxana O., 143<br />
Dart, Richard A., 135<br />
DasMahapatra, Pronabesh, 93, 94<br />
Dastani, H. B., 140<br />
Davidson, Michael H., 44, 146<br />
Davis, Barry R., 60<br />
Day, Wesley, 78<br />
De Angulo, Guillermo A., 100<br />
Dean, Lacy, 124<br />
Debenham, Ellen, 100<br />
Deedwania, P., 113<br />
Deghedi, Akram A., 142<br />
de la Cruz, Jose Juan, 101, 102<br />
de la Cruz, Juan J., 93, 123, 133, 134<br />
de la Sierra, Alejandro, 102, 105,<br />
123, 133, 134<br />
de la Sierra, Alex, 101<br />
De la Torre, Nuria, 47, 91, 92, 98<br />
Delgado‐Leon, Antonio J., 127<br />
de Lis, Jesus Perez, 99<br />
Del Tío, Rocío, 129<br />
Derici, Ulver, 97<br />
De Rosa, Maria Leonarda, 113<br />
Desai, Tejas, 122, 124<br />
DeSouza, Christopher A., 92<br />
Dessì-Fulgheri, Paolo, 120<br />
Dessì‐Fulgheri, Paolo, 107, 133<br />
Destounis, Antonios, 134<br />
Destounis, Antonis, 105<br />
DeVries, Andrea, 122<br />
Dhaun, N., 97, 121<br />
Diaz, Edgar A., 132<br />
Diaz, Keith M., 136, 144<br />
Díaz, María T., 129<br />
Di Bello, Vitantonio, 116, 126<br />
Dimitriadis, K., 66, 91, 92, 124, 126,<br />
128<br />
Diogo, Domingos, 96<br />
Dionne, Janis M., 87<br />
Dixon, John, 139<br />
Djordjevic, Dragan, 120<br />
Dobrokhod, Anna S., 133<br />
Dochee, Jennifer D., 107<br />
Does, Alec V., 90<br />
Dolan, Lawrence M., 106<br />
Dolz, Luis Martínez, 116<br />
Dominguez, Maria J., 114, 129<br />
Dominguez‐Sardiña, Manuel, 98,<br />
111, 121, 131<br />
Dongre, Neelesh, 94, 112<br />
Dong, Yanbin, 47<br />
Dormi, Ada, 93<br />
Doumas, Michael, 94, 96, 136<br />
Dourliou, Vasiliki, 111<br />
Drawz, Paul E., 60<br />
Dresser, George K., 141<br />
Dresser, G. K., 89<br />
Dubiel, Robert, 114, 115<br />
Dudenbostel, Tanja, 88, 108, 138<br />
Duh, Mei Sheng, 110, 131, 133<br />
Duprez, Daniel, 73, 109, 116, 130,<br />
146<br />
Duprez, Daniel A., 144<br />
Dvonch, J. Timothy, 65<br />
Dworkin, Lance D., 56, 146<br />
E<br />
Eatman, Danita, 107<br />
Ecder, Tevfik, 121<br />
Eckeli, Alan L., 143<br />
Egan, Brent, 105, 110, 130, 134<br />
Egan, Brent M., 40, 49, 134, 140, 147<br />
170
Author Index<br />
Eguchi, Kazuo, 110, 132<br />
Ehret, Georg, 78<br />
Ehret, Georg B., 79<br />
Einhorn, Paula T., 49, 147<br />
Eiroa, Peregrina, 97, 131<br />
Eisenberg, Debra F., 122<br />
Eleftheriadou, I., 122<br />
Eliseyeva, Marietta, 117<br />
Elliott, Paul, 79<br />
Elliott, William J., 47, 50, 61, 73, 113,<br />
140, 147<br />
Ennis, Riley C., 122<br />
Entcheva, Miglena, 93, 94<br />
Epstein, Benjamin J., 115<br />
Epstein, Michael J., 133<br />
Epstein, Murray, 24, 70, 76, 77, 147<br />
Erbay, Bulent, 97<br />
Erdem, Yunus, 97<br />
Escano, Crisanto, 97<br />
Esis, Carlos E., 87<br />
Esler, Murray D., 77, 138, 147<br />
Espinosa, Emma, 133<br />
Esposito, A., 130<br />
Eto, Masahiko, 117<br />
Eto, Tanenao, 114<br />
Eunsil, Yim, 100<br />
Evans, Gregory, 61<br />
Evora, Paulo R. B., 143<br />
Exuzides, Alex, 89<br />
F<br />
Fabregate, Martin, 47, 91, 92, 98, 110<br />
Fabregate, Rosa, 47, 91, 92, 98, 110<br />
Faillace, Robert T., 140<br />
Faita, Francesco, 91, 127<br />
Falck, John R., 66<br />
Falkner, Bonita, 40, 147<br />
Falvey, Heather, 110, 131<br />
Familoni, Oluranti, 97<br />
Fang, Christy, 122<br />
Fang, Jing, 136<br />
Fares, Maria Luisa, 130<br />
Farooqi, Sadaf, 58, 147<br />
Faselis, Charles, 94, 96, 105, 136<br />
Fawzy, Abdelmoneim A., 142<br />
Feagan, B. G., 89<br />
Feagan, Brian G., 141<br />
Feairheller, Deboarh L., 144<br />
Feairheller, Deborah L., 136, 138<br />
Fedecostante, Massimiliano, 133<br />
Fedorova, Olga V., 142, 143<br />
Fedorov, Sergiy V., 92<br />
Fedrizzi, Stefania, 88<br />
Feibel, Hedy, 123<br />
Feig, Daniel I., 66, 106, 147<br />
Feig, Denice, 132<br />
Feldman, R. D., 89<br />
Feldman, Ross, 54, 147<br />
Feldman, Ross D., 141<br />
Ferdinand, Keith, 105, 109, 130<br />
Ferdinand, Keith C., 44, 62, 110, 113,<br />
114, 147<br />
Ference, Brain, 107<br />
Ference, Brian A., 93<br />
Fernandes, Regina M. R., 143<br />
Fernandez, Angelica, 47, 91, 98, 110<br />
Fernandez, Camilo, 93, 94, 127<br />
Fernandez, Jose Carlos, 101, 102<br />
Fernandez, Jose R., 60, 97, 99, 108,<br />
110, 111, 114, 121, 129, 131<br />
Fernandez, Olga, 98<br />
Fernandez, Rafael, 109<br />
Fernandez, Victor, 109, 111<br />
Ferrario, Carlos M., 89<br />
Ferreras, Amelia, 121<br />
Ferrero, David, 133<br />
Ferrero‐Martinez, Ana Isabel, 120<br />
Ferriolli, Eduardo, 132, 143<br />
Ferris, Maria, 122<br />
Figueiredo, José Nuno, 134<br />
Filatova, Elena A., 108<br />
Filho, Sebastião R., 123<br />
Fiorentini, Lucia, 137<br />
Fiquet, Béatrice, 140<br />
Fivush, Barbara A., 101<br />
Flack, John, 107, 141<br />
Flack, John M., 62, 93, 114, 147<br />
Fleg, Jerome L., 90<br />
Flessas, D., 66, 126<br />
Fletcher, Ross, 94, 136<br />
Fletcher, Ross D., 96, 105<br />
Florea, Natalia, 116<br />
Flori, Serena, 95<br />
Flynn, Joseph, 101<br />
Flynn, Joseph T., 40, 58, 101, 106,<br />
147<br />
Fogari, Roberto, 87, 88<br />
Fogg, Louis, 138<br />
Foiato, Tariane F., 87<br />
Fontao, Maria J., 60, 99, 110, 111,<br />
114, 121, 129, 131<br />
Forker, Alan, 139<br />
Forrest, Brian, 89, 140<br />
Fortunati, Marco, 120<br />
Fox, Caroline S., 117<br />
Fragasso, Gabriele, 116<br />
Franchi, Eliana, 107<br />
Francillon, Alain, 140<br />
Franklin, Stanley S., 46, 147<br />
Fraser, William D., 137<br />
Frassetto, Lynda A., 98<br />
Frazer, Lauren C., 123<br />
Frech‐Tamas, Feride, 133<br />
Freed, Gary, 87<br />
Freitas, Joao, 135, 138<br />
Frishman, William H., 64, 147<br />
Froehlich, James B., 49, 147<br />
Fromer, Leonard M., 50, 147<br />
Frome, Wayne L., 135<br />
Fujii, Kenji, 130<br />
Fujimoto, Tetsuya, 99<br />
Fu, Qi, 142<br />
G<br />
Gaciong, Zbigniew, 138<br />
Gaida, Susan, 93, 94<br />
Galbreath, M. Melyn, 142<br />
Galgo, Alberto, 98<br />
Gaman, Iryna O., 119<br />
Ganotakis, Emmanuel S., 100<br />
Garcia‐Donaire, Jose A., 67, 96<br />
García‐Ortiz, Luis, 133<br />
Garg, Suchita, 133<br />
Garoufalis, Stefanos H., 119<br />
Garrett, Andrew T., 95<br />
Garvin, Jeffrey L., 80, 147<br />
171
Author Index<br />
Gassman, Jennifer, 115<br />
Gavish, Dov, 124<br />
Gavras, Haralambos, 52, 148<br />
Gavrilov, I. Y., 143<br />
Gemignani, Vincenzo, 91, 127<br />
Georgiadis, Ioannis V., 119<br />
Georgiopoulos, Georgios E., 119<br />
Germino, F. W., 131<br />
Germino, F. Wilford, 49, 148<br />
Germino, Megan M., 131<br />
Ghannad, Emmanuel, 92, 127<br />
Ghiadoni, Lorenzo, 91, 127<br />
Giakoumis, M., 122, 126<br />
Gialernios, T., 94<br />
Giannini, Elena, 133<br />
Gibstein, Raz, 103<br />
Gijon, Teresa, 105<br />
Giles, Thomas D., 47, 127, 140, 148<br />
Giovas, Periklis, 106<br />
Giralt, Patricio, 95<br />
Girerd, Xavier, 140<br />
Glasser, Stephen P., 108<br />
Go, Alan S., 81<br />
Goddard, J., 121<br />
Godleski, John J., 132<br />
Golan, Eliezer, 131<br />
Goldberg, Ruthie, 131<br />
Gomara, Sonia M., 98, 99<br />
Gómez, Manuel, 133<br />
Gong, Kaizheng, 118, 126, 144<br />
Gongora, Maria C., 122<br />
Gonzalez‐Albarran, Olga, 91<br />
Gonzalez, Alicex C., 87<br />
Gonzalez, Olga, 98<br />
Gonzalez, Santiago Cuevas, 47<br />
Gonzalez, Waddy, 110<br />
Gopalakrishnan, Kathirvel, 137<br />
Gorostidi, Manuel, 101, 102, 105,<br />
123, 134<br />
Gradman, Alan H., 54, 110, 131, 148<br />
Graeme, Katelyn, 101<br />
Graff, Alan, 114, 115<br />
Granato, Chiara, 123<br />
Grandits, Gregory A., 144<br />
Granger, Joey P., 43, 77, 148<br />
Grant, Joshua, 93, 94<br />
Greco, Barbara A., 139<br />
Green, Kelley R., 140<br />
Greenway, Frank L., 137<br />
Greiner, Jared J., 92<br />
Grennberg, George, 103<br />
Grima, Esther Zorio, 116<br />
Grim, Clarence E., 107, 142<br />
Grimm, Jr., Richard H., 57<br />
Grimm, Richard H., 148<br />
Grosman, Ehud, 124<br />
Grossman, Ehud, 103<br />
Guedj, Dominique, 92, 127<br />
Guenoun, Maxime, 92, 127<br />
Guerra, Federico, 107, 120, 133<br />
Guerri, Asuncion, 47, 98, 110<br />
Gunawardhana, Lhanoo, 100<br />
Guo, Yuan, 53, 148<br />
Gupta, Alok K., 137<br />
Gutierrez, G., 95<br />
H<br />
Hadker, Nandini, 133<br />
Hage, Fadi, 118, 126<br />
Hage, Fadi G., 103<br />
Hailpern, Susan M., 101<br />
Halberg, Franz, 132<br />
Halfon, Sherin, 107<br />
Hall, Jennifer, 116<br />
Hall, John E., 43, 59, 148<br />
Halpern, Michael, 141<br />
Hamad, Mazen, 89<br />
Hames, Melanie, 124<br />
Hamilton, Bruce, 61<br />
Handler, Joel, 40, 90, 131, 140, 148<br />
Hansen, Kimberley J., 117<br />
Hans, Nidhi, 66, 117<br />
Haque, Tahir, 92, 110<br />
Harats, Dror, 124<br />
Harb, Mohamed A., 142<br />
Harder, David, 57, 148<br />
Harrison, David G., 57, 72, 76, 122,<br />
148<br />
Harris, Raymond C., 65, 148<br />
Hartmann, Camila, 87<br />
Hasanoglu, Enver, 97<br />
Hasegawa, Kenichi, 59<br />
Hatzitolios, Apostolos I., 111<br />
Hatzopoulos, Anastasios, 111<br />
Haun, Daniel W., 91<br />
Hayakawa, Manabu, 118<br />
Hebert, Christopher, 94<br />
Hedquist, Lowell, 93, 107<br />
Heilbraun, Jeffrey, 124<br />
Hermida, Ramon C., 60, 65, 97, 98,<br />
99, 108, 110, 111, 114, 121, 129,<br />
131<br />
Hernaiz, Susana, 99<br />
Heublein, Denise M., 91<br />
Heyrman, Reinilde, 109, 111<br />
Hill, Joseph A., 76, 148<br />
Hinderliter, Alan L., 131<br />
Hollenberg, Norman K., 76, 148<br />
Holmstedt, Christine A., 102<br />
Hongyo, Kazuhiro, 121<br />
Hopkins, P., 97<br />
Hoshide, Satoshi, 102, 110, 132<br />
Ho, Timothy, 131<br />
Houston Miller, Nancy, 40, 45, 150<br />
Howard, Barbara V., 90<br />
Hoyem, Ruby, 138<br />
Hsueh, Willa, 138<br />
Hsu, Stephen C., 142<br />
Htun, Wah Wah, 127<br />
Htyte, Nay, 110<br />
Huang, I.‐Zu, 107<br />
Huang, Zhijun, 112<br />
Hughes, Suzanne, 45, 148<br />
Hull, Pamela, 118<br />
Hunt, Barbara, 100<br />
Huntley, Brenda K., 91<br />
Husaini, Baqar, 118<br />
Hwang, Shih‐Jen, 117<br />
Hygia, Investigadores Proyecto, 97,<br />
98, 99, 111, 121, 131<br />
I<br />
Iaria, Pierre, 126<br />
Ibrahim, Mediha, 127<br />
Ichiki, Tomoko, 47<br />
IIonze, Onyedika John, 126<br />
172
Author Index<br />
Ikeda, Yasuhiro, 116<br />
Imamura, Takuro, 96<br />
Inrig, Jula K., 60, 121, 122<br />
Ioannidis, Antonios, 100, 115<br />
Irvine, Jane, 132, 136<br />
Ishikawa, Joji, 126, 132<br />
Ishikawa, Shizukiyo, 110, 126<br />
Ishizaka, Nobukazu, 59<br />
Ito, Sadayoshi, 67<br />
Iwakura, Yoshitugu, 67<br />
Izzo, Joseph, 109, 111<br />
Izzo, Joseph L., 111, 128<br />
Izzo, Jr., Joseph L., 61, 114, 148<br />
J<br />
Jackson, Sharron M., 101<br />
Jaffe, Marc G., 61<br />
Jaimes, Edgar A., 52, 113, 114, 148<br />
Jamerson, Kenneth, 90, 115<br />
Jamerson, Kenneth A., 62, 149<br />
Jang, Sung‐Won, 88<br />
Jarvis, Sara S., 142<br />
Jason, Yap, 122<br />
Jatte, Fernanda, 132<br />
Jauch, Edward C., 102<br />
Javier, Angelo Dave C., 120<br />
Jin, Eun‐Sun, 111, 116<br />
Joe, Bina, 137<br />
Johannsen, Darcy, 137<br />
Johnson, Andrew D., 79<br />
Johnson, Julie A., 42, 115, 149<br />
Johnson, Mary A., 101<br />
Johnson, Richard J., 66, 100, 149<br />
Johnson, Toby, 78, 79<br />
Johnson, William D., 137<br />
Jones, John E., 122, 123<br />
Jones, Ronald, 105<br />
Jose, Pedro A., 47, 51, 97, 122, 123,<br />
149<br />
Joshi, Nomita, 102<br />
Josse, Robert, 61<br />
Joyner, JaNae, 89, 139, 140, 141<br />
Juncos, Luis, 52<br />
Juncos, Luis I., 149<br />
Jurgens, Julie A., 122<br />
K<br />
Kaciroti, Niko, 65<br />
Kaeser, Martha A., 91<br />
Kagan, Alexander, 123<br />
Kahan, Jonathan, 107<br />
Kajii, Eiji, 117<br />
Kakinoki, Shigeo, 99<br />
Kalantar‐Zadeh, Kamyar, 108<br />
Kales, Stefanos N., 95<br />
Kallikazaros, I., 92<br />
Kalpatthi, Ram V., 101<br />
Kamal, Khalid M., 141<br />
Kambona, Joseph, 141<br />
Kamide, Kei, 95, 121<br />
Kamran, Haroon, 127, 128<br />
Kanda, Kouichi, 99<br />
Kanter, Michael, 131<br />
Kantola, Ilkka M., 114<br />
Karan, Shaila, 111, 114, 128<br />
Karatan, Oktay, 97<br />
Kario, Kazuomi, 96, 102, 110, 118,<br />
126, 132<br />
Karpanou, Eva, 61, 94, 135<br />
Karpettas, Nikolaos, 134<br />
Karpettas, Nikos, 105<br />
Karpov, Yuri A., 112<br />
Kartalis, Athanasios N., 119<br />
Kasiakogias, A., 92, 96, 124, 128<br />
Kato, Johji, 114<br />
Kavey, Rae‐Ellen W., 58, 149<br />
Kawai, Tatsuo, 121<br />
Kawakami, Tomoko, 122<br />
Kayaba, Kazunori, 126<br />
Keenan, Nora L., 129, 136<br />
Kefala, A., 124<br />
Kerby, Tessa J., 89<br />
Kereiakes, Dean J., 109, 111<br />
Kershaw, David, 87<br />
Kerwin, Todd, 116<br />
Kettner, Norman W., 91<br />
Kevorkov, Amayak, 117<br />
Khan, Bobby V., 92, 110<br />
Khan, Shahnaz, 141<br />
Kharbanda, Elyse O., 106<br />
Kheirbek, Raya, 94, 136<br />
Kheirbek, Rhea, 136<br />
Kheterpal, Sachin, 141<br />
Khosla, Shikha, 136<br />
Khoury, Philip R., 106<br />
Kimball, Thomas R., 106<br />
Kim, Catherine, 60, 121, 122<br />
Kim, Chong‐Jin, 111, 116<br />
Kim, Dong‐Bin, 88<br />
Kim, DongHyun, 66<br />
Kim, Jae‐Hyung, 88<br />
Kimura, Joe, 131<br />
Kintis, K., 92, 96, 102, 126<br />
Kirkineska, Lambrini, 111<br />
Kirpalani, Ashok L., 123, 132<br />
Kirpalani, Dilip A., 123, 132<br />
Kitamura, Kazuo, 96, 114<br />
Kita, Toshihiro, 114<br />
Kitzman, Dalane, 107<br />
Kizilirmak, Pinar, 108<br />
Kluth, D. C., 97<br />
Kobayashi, Takeshi, 99<br />
Kobayashi, Tatsuya, 130<br />
Kohan, Donald E., 80, 149<br />
Kokkinos, Peter, 94, 96, 136<br />
Kollias, Anastasios, 105, 106<br />
Kordalis, A., 96, 102, 122, 124, 128<br />
Koren‐Morag, Nira, 103<br />
Kostic, Svetlana, 116, 120<br />
Koulousios, Konstantinos, 111<br />
Kountz, David S., 82, 149<br />
Krak<strong>of</strong>f, Lawrence R., 47, 63, 149<br />
Kretzschmar, Jan, 136, 138, 144<br />
Kroner, Beverly, 90<br />
Krum, Henry, 67, 149<br />
Kudo, Masataka, 67<br />
Kudyakov, Rustam, 94<br />
Ku, Elaine, 88<br />
Kumada, Maki, 117<br />
Kumarasamy, Sivarajan, 137<br />
Kumar, Sanjay, 119<br />
Kupfer, S., 115<br />
Kupfer, Stuart, 78, 112<br />
Kuritzky, Louis, 49, 149<br />
Kuroki, Kazuo, 118<br />
Kurtz, Theodore W., 42, 149<br />
173
Author Index<br />
Kushner, Robert F., 40, 149<br />
Kuznetsov, N. S., 143<br />
Kwiatkowski, Janet L., 100<br />
Kwon, Beom‐June, 88<br />
Kyvelou, S., 66<br />
Kyvelou, Stella Maria, 61, 94, 135<br />
L<br />
Labarthe, Darwin, 137<br />
Lackland, Daniel, 89, 110, 130<br />
Lackland, Daniel T., 62, 100, 102,<br />
134, 149<br />
Lafeuille, Marie‐Hélène, 110, 131<br />
Laghi, Luca, 93<br />
Lai, Hsiao, 124<br />
Lainscak, Mitja, 107<br />
Lai, Wen‐Ter, 94<br />
Lakatta, Edward G., 46, 142, 143,<br />
149<br />
Laken, Marilyn, 130<br />
LaMarca, Babbette, 72, 149<br />
Lambert, Gavin W., 138<br />
Lamoureux, Denise P., 132<br />
Lancioni, Letizia, 133<br />
Lande, Marc B., 51, 149<br />
Landini, Linda, 132<br />
Landry, Daniel L., 139<br />
Lanza, Gaetano A., 91<br />
Latrella, Margaret, 140<br />
Latsios, G., 124, 128<br />
Lavange, L., 65<br />
Lawrence, Joy, 132<br />
Lawson, Andrew B., 134<br />
Lazarevic, Gordana, 120<br />
Lazar, Jason, 119, 127, 128<br />
Lazich, Ivana, 99<br />
Laz, Tabassum H., 95, 102<br />
Lazzari, Pierangelo, 87, 88<br />
Lebreiro, Ana, 135<br />
Ledezma, Mateo Levine, 89<br />
Lee, James, 109, 111<br />
Lee, John S., 132<br />
Lee, Jong Y., 123, 132<br />
Lee, Mary S., 132<br />
Lee, Sang‐Hak, 119<br />
Lee‐Son, Kathy K. Y., 87<br />
Lefebvre, Patrick, 110, 131<br />
Leiba, Adi, 95<br />
Leibovitz, Eyal, 124<br />
Leighton, Harmony, 116<br />
Leitão, Maria Fátima, 135<br />
Lembo, Giuseppe, 134, 135<br />
Leone, Aurelio, 95, 132<br />
Leoni, Simona, 95<br />
Leon‐Muñoz, Luz, 95<br />
Levine, Benjamin D., 142<br />
Levine, Robert, 118<br />
Levin, Linda, 106<br />
Levy, Bernard I., 99<br />
Levy, Daniel, 61, 78, 79, 96, 117, 150<br />
Levy, Pavel J., 117<br />
Levy, Phillip, 107, 141<br />
Levy, Phillip D., 93<br />
Lewin, Andrew, 115<br />
Lex, Lora, 133<br />
Liakos, M., 94<br />
Lian, Jean, 122<br />
Lieber, Ari, 126, 128<br />
Lieber, Ari L., 99<br />
Li, Hewang, 123<br />
Lijnen, Paul J., 135<br />
Li, Li, 122<br />
Lillestol, Michael, 98<br />
Lima, Jr., Emilton, 87<br />
Lima, Leandra Gonçalves, 132<br />
Lima, Nereida K. C., 143<br />
Lima, Nereida K. Costa, 132<br />
Limdi, Nita A., 42<br />
Limor, Rona, 100<br />
Lindholm, Lars‐Hjalmar, 93<br />
Lindi, Nita A., 150<br />
Lioni, L., 66, 122<br />
Lioudaki, Eirini, 100<br />
Li, Peng, 118, 126, 144<br />
Littlejohn, Thomas, 109, 111<br />
Littman, Stephen, 127<br />
Liu, Chunyu, 117<br />
Liu, In Lu, 67<br />
Liu, Tianh, 150<br />
Liu, Tianhu, 53<br />
Li, Wei, 114, 115<br />
Lloyd, Eric, 78<br />
Lobo, Romulo R., 143<br />
Logan, Alexander G., 132<br />
Loide, Barbosa, 137<br />
Lo, Joan C., 106<br />
Long, Laura, 141<br />
Long, Mark S., 132<br />
Lopez‐Garcia, Esther, 95<br />
Lorenzo, Sonia, 99, 131<br />
Lovic, Dragan, 120<br />
Lowenstein, Charles J., 59, 150<br />
Lucas, Caridad Turpin, 88, 109, 129<br />
Lucas, Stephanie, 90<br />
Lu, Chunzeng, 116, 126<br />
Luepke, Erik, 88, 109, 129<br />
Lu, Fei, 116, 126<br />
Luo, Jianfang, 53, 150<br />
Luo, Jiangming, 135<br />
Luo, Yingjin, 123<br />
Lurbe, Empar, 101<br />
Luther, James M., 59, 150<br />
Lu, Yee, 88<br />
Lyass, Asya, 96<br />
Lyn, Deborah, 107<br />
Lyutikova, L. N., 143<br />
M<br />
Maa, Jen‐Fue, 96, 115, 138<br />
Macdonald, Helen M., 137<br />
MacDonald, Patricia, 100<br />
MacDonald, Thomas, 112<br />
Macedo, Espiga, 138<br />
Machida, Maiko, 99<br />
Maciel, Maria Julia, 135<br />
MacIntyre, I., 121<br />
Maciosek, Michael V., 89<br />
Madede, T., 96<br />
Madruga, Felipe, 105<br />
Magarik, Jordan A., 102<br />
Magid, David J., 106<br />
Magness, Ronald, 142<br />
Mahina, Tatiana K., 108<br />
Mahon, Jeffrey L., 141<br />
Mahon, J. L., 89<br />
Maisaidi, M., 130<br />
174
Author Index<br />
Makani, Harikrishna, 107, 110<br />
Mancia, G., 130<br />
Mancia, Giuseppe, 75, 150<br />
Mancinelli, Lucia, 107, 120<br />
Manning, Alexis, 138<br />
Mann, Samuel J., 49, 111, 150<br />
Manolis, Athanasios, 136<br />
Manolis, Athanasios J., 75, 150<br />
Maraj, Ilir, 127<br />
Marasi, Gianluigi, 87, 88<br />
Marek, George, 100<br />
Margolis, Karen, 61<br />
Margolis, Karen L., 89, 106<br />
Marin, Elena, 92, 98<br />
Mark, Allyn L., 77, 80, 150<br />
Marquez, David X., 138<br />
Marquis, A., 65<br />
Martell, Nieves, 133<br />
Martinez, Cristina, 91, 92, 98<br />
Martínez, María M., 129<br />
Martinez, Marie F., 89<br />
Martinez, Santos J., 88<br />
Martin, Fernando L., 116<br />
Martins, Helia, 135<br />
Marzilli, Mario, 116, 126<br />
Mascio, Giada, 134, 135<br />
Masharani, Umesh, 98<br />
Masica, Andrew, 94<br />
Masuo, Kazuko, 138<br />
Matei, Ana Maria, 91, 99<br />
Materson, Barry J., 71, 150<br />
Mathur, Vandana, 107<br />
Matsell, Douglas G., 87<br />
Matsuda, Hirohisa, 59<br />
Matsumura, Yasuo, 59<br />
Mattingly, Phillip G., 142<br />
Mattson, David L., 72, 150<br />
Mavimbe, C., 96<br />
Mavrogeni, Helen, 100<br />
McCoy, Connie E., 106<br />
McCrory, Mark A., 103<br />
McDonnell, Barry J., 128<br />
McEniery, Carmel M., 95, 128<br />
McInnes, Gordon, 112<br />
McIsaac, Warren, 132<br />
McKie, Paul M., 47<br />
McManus, Chris, 105<br />
McManus, Richard J., 63, 150<br />
McRae, Steven, 100<br />
Medvegy, Mihaly, 134<br />
Meier, Rhonda L., 142<br />
Meijide, Luis, 98<br />
Melander, Olle, 143<br />
Melino, Michael, 109, 111<br />
Mellen, Philip, 139<br />
Mendelowitz, David, 142<br />
Merchant, Nadya, 92, 110<br />
Merenich, John, 81, 150<br />
Mesas, Arthur E., 95<br />
Mesirov, Claire, 140<br />
Messerli, Franz, 66<br />
Messerli, Franz H., 64, 65, 87, 93,<br />
107, 110, 117, 150<br />
Mestek, Michael L., 92<br />
Mete, Mihriye, 90<br />
Meyer, Peter M., 47, 113<br />
Michaelides, A., 91<br />
Miguel, Robinson, 142<br />
Mijalkovic, Dragan, 116<br />
Mikhailidis, Dimitri P., 100<br />
Miliou, A., 124<br />
Miskulin, Dana, 115<br />
Mitsnefes, Mark, 106<br />
M<strong>of</strong>fatt, Steven M., 133<br />
Mohammad, Saklayen, 122<br />
Mohyeldin, Yousri A., 142<br />
Mojon, Artemio, 60, 97, 98, 99, 108,<br />
110, 114, 121, 129, 131<br />
Molitch, Mark E., 74, 150<br />
Moñivas, Vanesa, 96<br />
Monsalvo, M. L., 140<br />
Monteiro, Agostinho, 138<br />
Moore, Michael, 89<br />
Moore, Michael A., 89<br />
Mora, Carmen, 95<br />
Moreira, Nadia, 135<br />
Moreno, Carlos, 91<br />
Moreno, Jennifer, 127<br />
Moriguti, Julio C., 143<br />
Moriguti, Júlio Cesar, 132<br />
Morimoto, Ryo, 67<br />
Morishita, Masako, 65<br />
Morita, Kiyoshi, 122<br />
Mori, Tatsuhiko, 59<br />
Morris, Ken, 140<br />
Morris, Martha Clare, 138<br />
Moschouris, Panagiotis M., 119<br />
Mota, Victoria, 129<br />
Mounier‐Vehier, Claire, 92, 127<br />
Mousa, Tarek M., 116<br />
Moya, Ana, 97, 98, 99, 121<br />
Mpafakis, I., 92, 102, 126<br />
Mpekiari, Eleni, 99<br />
Mugellini, Amedeo, 87, 88<br />
Muiesan, Maria Lorenza, 91<br />
Munnery, Iain, 128<br />
Munnery, Margaret M., 128<br />
Munroe, Patricia, 78<br />
Munroe, Patricia B., 79<br />
Munshi, Mohamed, 127<br />
Myers, Martin, 136<br />
Myshkina, Vera L., 108<br />
N<br />
Nadim, Mitra, 67<br />
Nadkarni, Girish, 117<br />
Nadkarni, Girish N., 93, 117<br />
Nakamura, Yoshikazu, 117<br />
Naqvi, Syed U., 117<br />
Narkiewicz, Krzyszt<strong>of</strong>, 75, 150<br />
Nasothimiou, Efthimia G., 134<br />
Nasser, Samar A., 93<br />
Nastac, Iulian, 128<br />
Natale, Francesco, 123<br />
Nautiyal, Amit, 119<br />
Navar, L. Gabriel, 52, 77, 151<br />
Navarro‐Ibáñez, Vicente, 90<br />
Naveen, Saxena, 102<br />
Nelson, S. A. E., 89<br />
Nelson, Sigrid A., 141<br />
Nesbitt, Shawna D., 62, 151<br />
Neumann, Claas L., 133<br />
Neutel, Joel M., 54, 138, 151<br />
Newton‐Cheh, Christopher, 78<br />
Nguyen, Phuong‐son, 132<br />
175
Author Index<br />
Nicholas, Joyce S., 134<br />
Nicholas, Susanne B., 47, 151<br />
Nichols, Wilmer W., 115<br />
Nieto, Javier, 95<br />
Nobre, Fernando, 143<br />
Nomura, Akikazu, 99<br />
Norsk, Peter, 78<br />
Notario, Patricia M., 123<br />
Novack, Victor, 103<br />
Nov, Ori, 103<br />
Nuñez, Ana Galdamez, 88, 129<br />
Nylen, Eric, 136<br />
O<br />
Obasare, Edinrin Rae, 127<br />
O’Brien, Eoin, 56, 151<br />
O’Connor, Patrick, 61<br />
O’Connor, Patrick J., 89, 106<br />
O’Donnell, Jennifer, 141<br />
Odusan, Olatunde, 97<br />
Oefelein, Michael, 139<br />
Ogedegbe, Gbenga, 45, 49, 63, 90,<br />
151<br />
Ogihara, Toshio, 138<br />
Ogunsemi, Olawale, 97<br />
Ogura, Toshihiko, 130<br />
Ohishi, Mitsuru, 95, 121<br />
Okada, Yoshiyuki, 142<br />
Okafor, H., 118<br />
Okayama, Masanobu, 117<br />
Okerson, Ted, 139<br />
Oliva, Raymond, 99<br />
Oliveras, Anna, 133<br />
Onishi, Miyuki, 95, 121<br />
Ono, Yoshikiyo, 67<br />
Onuigbo, Nwamaka, 128<br />
Oparil, Suzanne, 53, 65, 78, 88, 103,<br />
105, 109, 111, 118, 126, 138, 144,<br />
151<br />
Orak, John K., 101<br />
Oron, Yoram, 100<br />
Orynchak, Mariya A., 116, 119<br />
Osmond, Peter J., 111, 128<br />
Otero, Alfonso, 97, 111, 121, 131<br />
Owen, E. L., 97<br />
P<br />
Palaciao, Ryan, 116<br />
Palermo, Lisa, 61<br />
Paletas, Konstantinos, 99<br />
Pandey, Kailash N., 117<br />
Panjabi, Sumeet, 89, 141<br />
Pan, Nan, 135<br />
Pannu, Varinderpal, 100<br />
Panza, Julio A., 65, 151<br />
Papadakis, John A., 100<br />
Papademetriou, V., 91, 92, 124<br />
Papademetriou, Vasilios, 71, 94, 96,<br />
105, 136, 151<br />
Papagiannis, Nikolaos V., 119<br />
Papaioannou, T., 102<br />
Papapostolou, Vasileios, 132<br />
Papst, Cheraz Cherif, 98, 112, 139<br />
Paran, Esther, 103<br />
Parati, Gianfranco, 63<br />
Paredes‐Galan, Emilio, 120<br />
Parikh, Neal S., 111<br />
Parikh, Samip J., 47<br />
Parisé, Hélène, 110, 131<br />
Park, Chang‐Bum, 111, 116<br />
Parker, Emily D., 106<br />
Parker, Karen, 124<br />
Park, Jae Hong, 119<br />
Park, Jeong‐Euy, 94<br />
Park, Jinhee, 122, 133<br />
Patel, Rinkesh, 127<br />
Patel, Seema, 116<br />
Pavlidis, Athinodoros, 111<br />
Pavlyuk, Evhenia A., 133<br />
Pearson, Thomas A., 44, 151<br />
Pedrinelli, Roberto, 116<br />
Pego, Guilherme Augusto<br />
Mariano, 135<br />
Pego, João Bernardo, 135<br />
Peixoto, Aldo J., 60, 73, 151<br />
Pelazza, Bruno B., 123<br />
Pemba, Senga, 141<br />
Pencina, Michael, 96<br />
Perez de Lis, Jesus, 111<br />
Pérez, Javier, 129<br />
Pérez, Miguel Palencia, 116<br />
Perkins, Nancy, 136<br />
Peroz, Julie, 99, 126, 128<br />
Persson, Mats, 93<br />
Peterson, Jessica A., 100<br />
Petry, Nancy M., 136<br />
Phillips, Robert A., 40, 61, 126, 151<br />
Pickering, Thomas, 90<br />
Pierce, Caleb, 103<br />
Piñeiro, Luis, 121<br />
Pinol, Ramon, 142<br />
Pisoni, Roberto, 88, 108, 138<br />
Pi‐Sunyer, F. Xavier, 58, 151<br />
Pittaras, Andreas, 136<br />
Pitt, Bertram, 71, 107, 151<br />
Plavnik, Frida Liane, 102<br />
Podjarny, Eduardo, 131<br />
Pogue, Velvie A., 74, 151<br />
Pollock, David M., 51, 151<br />
Pollock, Norman K., 47<br />
Polonia, Jorge, 96, 129, 134<br />
Polonia, Jorge J., 137<br />
Popov, E. G., 143<br />
Potapova, Galina N., 143<br />
Poulakis, M., 124, 126<br />
Pousa, Lorenzo, 99, 111<br />
Pratt, Howard J., 151<br />
Pratt, J. Howard, 59<br />
Pressler, Susan, 90, 115<br />
Primak, Galina F., 133<br />
Priore, Emanuela Lo, 123<br />
Pritchard, Sheila L., 87<br />
Protogerou, Athanase D., 126<br />
Providência, Luis Augusto, 135<br />
Pruden, James, 140<br />
Pruette, Cozumel S., 101<br />
Pstay, Bruce M., 79<br />
Punzi, Henry A., 64, 96, 115, 152<br />
Purakal, John, 141<br />
Puri, Nitin, 66, 122<br />
Purkayastha, Das, 109, 113, 114<br />
Pyun, Wook Bum, 119<br />
Pyun, Wook‐Bum, 118, 120<br />
Q<br />
Quéré, Stéphane, 92, 127, 140<br />
R<br />
176
Author Index<br />
Rabelink, Ton J., 93<br />
Raheja, Prafull, 59<br />
Rahman, Mahboob, 60<br />
Rahman, Mahbubur, 95, 102<br />
Rahman, Syed T., 110<br />
Raij, Leopoldo, 52, 152<br />
Rajagopalan, Sanjay, 65<br />
Rajagopal, Desikan, 92<br />
Rajpal, Minesh, 111, 128<br />
Rakugi, Hiromi, 95, 121, 138<br />
Ramamurthy, Priyanka, 133<br />
Ram, C. Venkata S., 40, 73, 152<br />
Rana, Hamza, 117<br />
Ranieri, Alessandro, 123<br />
Rantamaula, Laura, 114<br />
Rapoport, Jayson, 123<br />
Rarra, Vagia, 134<br />
Rasgon, Scott, 67<br />
Rasgon, Scott A., 89, 108<br />
Rash, Carla J., 136<br />
Ratner, Robert E., 90<br />
Ravussin, Eric, 137<br />
Rebelo, Irene, 138<br />
Rechtman, Ehud, 103<br />
Reddy, Maithri, 90<br />
Reddy, Podduturu S., 90<br />
Reddy, Sushma, 90<br />
Reid, David M., 137<br />
Rekovets, Oksana L., 133<br />
Reyes, Andres, 92, 98<br />
Rey, Jose Manuel Del, 98<br />
Reynolds, Kristi, 131, 140<br />
Rezzani, Rita, 122<br />
Rho, Tae‐Ho, 88<br />
Rice, Kenneth, 78<br />
Rice, Kenneth M., 79<br />
Rich, Steven, 116<br />
Rieken, Eike M., 133<br />
Rim, Se‐Joong, 118, 119, 120<br />
Rios, Maria T., 98, 111<br />
Ríos, María T., 129<br />
Rippe, James, 82, 152<br />
Roberts, A., 115<br />
Roberts, Andrew, 78, 112<br />
Rocchini, Albert, 87<br />
Rodriguez, Arantxa, 47, 91, 92, 98,<br />
110<br />
Rodriguez‐Artalejo, Fernando, 95<br />
Rodríguez‐Artalejo, Fernando, 120<br />
Rodriguez‐Pascual, Carlos, 120<br />
Rogelio, Gregorio G., 139<br />
Roig‐Espert, Belén, 90<br />
Rojas, Jose M., 127<br />
Rollins-Hairston, Aisha, 107<br />
Roman, Mary J., 90<br />
Romero, Jorge, 107, 110<br />
Rosa, César S., 123<br />
Rosenthal, Talma, 100, 105, 152<br />
Rosman, Yosi, 103<br />
Rossi, Filippo, 137<br />
Rothwell, Peter M., 56<br />
Rousos, D., 124, 128<br />
Roussias, Leonidas, 106<br />
Roussias, Leonidas G., 134<br />
Routledge, Faye S., 131<br />
Rudich, Assaf, 103<br />
Rughani, Govind, 102<br />
Ruilope, Luis M., 60, 67, 70, 93, 96,<br />
105, 123, 133, 134, 152<br />
Ruilope, Luis Maria, 101, 102<br />
Ruiz, Santiago Garcia, 88, 109<br />
Russell, Holly Ann, 123<br />
Russell, Marie, 90<br />
Russo, Andrea, 136<br />
Russo, Kristen M., 123<br />
Russo, Maria Giovanna, 123<br />
Ryabikina, G. V., 143<br />
Ryan, Michael J., 23, 76, 152<br />
Ryu, Sung‐Kee, 118, 119, 120<br />
S<br />
Saban‐Ruiz, Jose, 47, 91, 92, 98, 110<br />
Sabharwal, Manpreet S., 93, 117<br />
Saelens, Brian E., 106<br />
Saez, Ana Osa, 116<br />
Safar, Michel E., 99, 112, 126, 128<br />
Sakata, Koji, 96<br />
Salciccioli, Louis, 127, 128<br />
Saldaña, Manuel Aguilera, 88, 129<br />
Saleh, Tarek M., 92<br />
Salgado, Jose L., 99, 131<br />
Salvi, Paolo, 128<br />
Samad, Zahid, 118<br />
Sampson, U., 118<br />
Samuel, Rita, 109<br />
Sanada, Hironobo, 123<br />
Sanchez, Luis, 67<br />
Sanchez, Olivia, 91, 98, 110<br />
Sander, Gary E., 127<br />
Sandu, Oana, 128<br />
Sangaralingham, S. Jeson, 47<br />
Sansone, Torry Mark, 140<br />
Santos, Jose Nobre, 134<br />
Santos, Rosa M., 138<br />
Sanz, Antonio Salvador, 116<br />
Sarafidis, Pantelis A., 99<br />
Sarda, Sujata P., 133<br />
Sarigianni, Maria, 99<br />
Sarmento, Priscilla Lopes, 102<br />
Sarzani, Riccardo, 107, 120, 133<br />
Sas, David J., 101<br />
Satoh, Fumitoshi, 67<br />
Saul, Sara, 116<br />
Saul, Sara M., 144<br />
Saunders, Elijah, 40, 152<br />
Sauter, Kathleen, 140<br />
Sautin, Yuri Y., 100<br />
Savopoulos, Christos, 111<br />
Schiffrin, Ernesto L., 72, 152<br />
Schmidlin, Olga, 98<br />
Schmieder, Roland E., 67, 152<br />
Schneider, Edward, 88<br />
Schneider, Stephanie C., 90<br />
Schoenthaler, Antoinette, 45, 152<br />
Schreiner, Susan, 90<br />
Schulz, Egbert G., 133<br />
Schwartz, Ann, 61<br />
Schwartz, Faina, 117<br />
Schwartz, Joseph, 90<br />
Schwartzman, Michal L., 66<br />
Scisney‐Matlock, Margaret, 90, 115<br />
Scott, Graham A., 141<br />
Sebastian, Anthony, 98<br />
Sechi, Leonardo A., 59, 88, 136<br />
Secombes, Karen R., 137<br />
177
Author Index<br />
Segev, Shlomo, 103<br />
Segura, Julian, 67, 93, 96, 101, 102,<br />
105, 123, 134<br />
Segura, Julián, 133<br />
Selassie, Anbesaw, 130<br />
Sen, Amanda, 90, 115<br />
Seo, Hye‐Sun, 118, 120<br />
Serdengecti, Kamil, 121<br />
Seredyuk, Nestor M., 92, 119<br />
Seredyuk, Vitaliy N., 92<br />
Sergakova, L. M., 143<br />
Serio, Ilaria, 95<br />
Severin, Thomas, 98, 139<br />
Seyoum, Berhane, 107<br />
Sgourakis, Panagiotis D., 119<br />
Shaftman, Stephanie, 110<br />
Shah, Arpit, 110<br />
Shahawy, Mahfouz El, 93, 94<br />
Shah, Hardik K., 123, 132<br />
Shah, Niren K., 115<br />
Shanks, Amy M., 141<br />
Shapiro, Joseph I., 142<br />
Sharabi, Yehonatan, 103<br />
Sharma, Abhishek, 128<br />
Shatat, Ibrahim F., 101<br />
Shea, J., 113<br />
Sheremeta, Oleg M., 119<br />
Sheriff, Helen, 136<br />
Sherrill, Beth, 141<br />
Sherwood, Andrew, 131<br />
Sherwood, Nancy E., 106<br />
Shibata, Shigeki, 142<br />
Shi, Jiaxiao, 67<br />
Shi, Jiaxiao M., 108<br />
Shilova, Victoria Y., 142<br />
Shimada, Kazuyuki, 102, 110, 118,<br />
132<br />
Shimaoka, Izumi, 121<br />
Shimizu, Motohiro, 110<br />
Shin, Hwashin H., 129<br />
Shin, Sung‐Hee, 118, 120<br />
Shi, Victor, 101<br />
Shlyakhto, Evgeny V., 87<br />
Shojaee, Ali, 96, 115, 138<br />
Shoval, Ishay, 123<br />
Shrabi, Yonatan, 124<br />
Shull, Cyndi, 141<br />
Shustov, Sergey B., 139<br />
Sica, D., 115<br />
Sica, Domenic, 67, 78, 112<br />
Sica, Domenic A., 40, 67, 70, 152<br />
Siciliano, Alessandro, 123<br />
Silva, Jose A., 96, 137<br />
Silverman, Angela, 90<br />
Sim, John, 67<br />
Sim, John J., 108<br />
Simmons, Debra, 61, 89<br />
Simonyi, Gabor, 134<br />
Simpson, William G., 137<br />
Sinaiko, Alan R., 106<br />
Sindel, Sukru, 97<br />
Sineiro, Elvira, 99, 121<br />
Sion‐Vrdy, Netta, 103<br />
Sirenko, Yuriy M., 133<br />
Siu, Kin Lung, 122<br />
Skoumas, I., 135<br />
Skrypnyk, Nadiya V., 119<br />
Slama, Gerard, 99<br />
Smith, Albert V., 79<br />
Smith, Jr., Sidney, 81<br />
Smith, Rick, 88<br />
Smith, Ronald D., 89<br />
Smith, Steven M., 115<br />
Smith, William, 139<br />
Smyrnioudis, Nikolaos E., 119<br />
Soboleva, Galina M., 108<br />
Sodhi, Komal, 66<br />
Sohn, Il‐Suk, 111, 116<br />
Solari, D., 130<br />
Solar‐Yohay, Susan, 101<br />
Soldatos, N., 96<br />
Sole, Ricardo M. Cabrera, 88, 109,<br />
129<br />
Soriano, Joaquin Rueda, 116<br />
Sorrentino, Matthew, 40, 152<br />
Sos, Thomas A., 56, 152<br />
Sousa, Alexandra, 135<br />
Sowers, James R., 74, 153<br />
SperlHillen, JoAnn M., 89<br />
Sridharan, Kanaka, 113, 114<br />
Srikakarlapudi, Sirisha, 111, 128<br />
Srinivasan, Sathanur R., 94<br />
Staffileno, Beth A., 138<br />
Stagni, Barbara, 95<br />
Stallmann-Jorgensen, Inger, 47<br />
Stasiv, Yuri, 107<br />
Stauffer, Brian L., 92<br />
Stefanadi, E., 66<br />
Stefanadis, C., 61, 66, 91, 92, 94, 96,<br />
102, 122, 124, 126, 128, 135<br />
Steigerwalt, Susan, 90, 115<br />
Stergiou, George S., 105, 106, 134<br />
Sterling, Kevin A., 127<br />
Stern, Naftali, 100<br />
Steven, Bendel D., 109<br />
Stevens, Lesley A., 68, 153<br />
Strano, Talita R., 87<br />
Strimike, Carolyn, 140<br />
Struthers, Allan D., 66, 153<br />
Sturgeon, Kathleen M., 136, 138, 144<br />
Stylianou, Mario, 90<br />
Suárez, Carmen, 133<br />
Suleymanlar, Gultekin, 121<br />
Sun, B., 97<br />
Sun, Fengzhu, 117<br />
Svetkey, Laura P., 49, 153<br />
Symonides, Bartosz, 138<br />
Syros, George, 93<br />
Syrseloudis, D., 92, 102, 124, 128<br />
Szalai, Alexander J., 103<br />
Szendro, Gabriel, 103<br />
T<br />
Tabassome, Simon, 92, 127<br />
Taddei, Stefano, 91<br />
Takahashi, Toru, 122<br />
Takechi, Shigeru, 99<br />
Takeya, Yasushi, 95, 121<br />
Taler, Sandra J., 73, 153<br />
Tamarit‐García, Juan José, 90<br />
Tangney, Christy, 138<br />
Tao, Jun, 128<br />
Tao, Ting, 53, 153<br />
Tasic, Ivan, 116, 120<br />
Tatara, Yuji, 95, 121<br />
178
Author Index<br />
Tatsis, I., 92, 124<br />
Taylor, Addison A., 47, 64, 153<br />
Taylor‐Zapata, Perdita, 101<br />
Teixeira, Tiago, 134<br />
Tejera, Eduardo, 138<br />
Tello, Susana, 47, 91, 92, 98, 110<br />
Terrone, Deborah, 140<br />
Tewksbury, Duane A., 135<br />
Thangaratnavel, Revathy, 127<br />
Thies, Frank, 137<br />
Thomopoulos, C., 92, 96, 122, 128<br />
Thopy, Amanda, 106<br />
Thrun, Jan‐Marc Schmidt, 133<br />
Tiawana, Simrandeep K., 89<br />
Tiktin, Margaret, 61<br />
Tisler, Andras, 132<br />
Titze, Jens, 77, 80, 153<br />
Tobe, Sheldon W., 54, 136, 153<br />
Tobin, Jonathan, 90<br />
Tomiyama, Hir<strong>of</strong>umi, 130<br />
Tong, Xin, 129<br />
Tonne, Jason M., 116<br />
Topouchian, Jirar, 128<br />
Torrente‐Carballido, Marta, 120<br />
Torro, Isabel, 101<br />
Toto, Robert, 60, 121<br />
Toto, Robert D., 74, 82, 122<br />
Touyz, Rhian M., 43, 65, 153<br />
Townsend, Raymond R., 46, 127,<br />
139, 153<br />
Tsapas, Apostolos, 99<br />
Tsiachris, D., 92, 124, 128<br />
Tsioufis, C., 66, 91, 92, 96, 102, 122,<br />
124, 126, 128<br />
Tsioufis, Costas, 96<br />
Tsounis, Dimitrios, 100, 115<br />
Turgan, Cetin, 97<br />
Turk, Aquilla S., 102<br />
Tutor, Elena, 91, 98<br />
Tyszkiewicz, Jerzy T., 138<br />
Tzamouranis, Dimitrios, 134<br />
Tzamouranis, Dimitris, 105<br />
Tziomalos, Konstantinos, 111<br />
U<br />
Uehara, Ritei, 117<br />
Ugalde, Arturo, 98<br />
Umans, Jason G., 90<br />
Underwood, P., 97<br />
Urbina, Elaine M., 106<br />
Uribarri, Jaime, 128<br />
Utas, Cengiz, 121<br />
V<br />
Vakalyuk, Igor P., 92, 116<br />
Vakalyuk, Iryna I., 116, 119<br />
Van Buren, Peter N., 121, 122<br />
Vandervoort, Margaret K., 141<br />
Vandervoort, M. K., 89<br />
van Duijn, Cornelia M., 79<br />
van Duin, Cornelia, 78<br />
Vanella, Luca, 66, 122<br />
VanGundy, Tiffany B., 142<br />
van Pelt, Jos F., 135<br />
Vansomphone, Southida S., 140<br />
Varis, Juha, 114<br />
Vasan, Ramachandran S., 117<br />
Vasan, R. S., 96<br />
Vaschilko, Alla S., 133<br />
Vassalotti, Joseph A., 68, 153<br />
Vecchione, Carmine, 134<br />
Veerabhadrappa, Praveen, 136, 138,<br />
144<br />
Velhas, Moncho, 129<br />
Venner-Jones, Kinda, 127<br />
Veronesi, Maddalena, 93<br />
Verri‐Junior, Waldiceu A., 143<br />
Vette, Alan, 129<br />
Victor, Ronald G., 40, 67, 153<br />
Vigdorchik, Alexey V., 112<br />
Vigil, Luis, 133<br />
Vilches‐Moraga, Arturo, 120<br />
Villafruela, Juanjo, 91<br />
Villar, Van Anthony M., 122, 123<br />
Vinereanu, Dragos, 143<br />
Vinita, Srivastava, 102<br />
Vittingh<strong>of</strong>f, Eric, 61<br />
Vives, Miguel Angel Arnau, 116<br />
Vongpatanasin, Wanpen, 59, 142<br />
Vrentzos, George E., 100<br />
Vyssoulis, Gregory, 61, 94, 135<br />
W<br />
Wagner, C., 110<br />
Wagner, C. Shaun, 130, 134<br />
Wang, Guijing, 137<br />
Wang, Hongyu, 53, 153<br />
Wang, Jackson, 94<br />
Wang, Si‐Tien, 133<br />
Wang, Zhijun, 59<br />
Ward, Rachel, 124<br />
Watkins, Shannon B., 144<br />
Waverczak, William F., 96, 115, 138<br />
Webb, David J., 65, 153<br />
Webb, D. J., 97, 121<br />
Webb, R. Clinton, 43, 153<br />
Weber, M. A., 115<br />
Weber, Michael, 78<br />
Weber, Michael A., 40, 112, 153<br />
Weder, Alan B., 42, 73, 141, 154<br />
Weil, Brian R., 92<br />
Weinberger, Myron H., 47, 154<br />
Weir, Matthew R., 74, 90, 96, 115,<br />
154<br />
Wei, Robert, 133<br />
Weitzman, Richard, 98, 113, 114<br />
Welch, Robert, 141<br />
Welch, W. Pete, 101<br />
Wells, Ann M., 90<br />
Wever‐Pinzon, Omar, 107<br />
Whalen, J. J., 113<br />
Whaley‐Connell, Adam, 68, 154<br />
Whelton, Andrew, 66, 100, 154<br />
White, W. B., 65, 115<br />
White, William B., 56, 58, 63, 75, 78,<br />
109, 112, 136, 154<br />
Wilbur, JoEllen, 138<br />
Wilcox, C., 91<br />
Wilkinson, Ian B., 46, 95, 128, 154<br />
Williams, Bryan, 56, 61, 74, 154<br />
Williams, Eric, 141<br />
Williams, G., 97<br />
Williams, Gordon H., 40, 154<br />
Williams, J., 97<br />
Williams‐Johnson, Jean, 141<br />
Williamson, Sheara, 136<br />
Williamson, Sheara M., 144<br />
179
Author Index<br />
Williamson, Sheara T., 138<br />
Williams, Ron, 129<br />
Wilson, Peter F., 154<br />
Wilson, Peter W. F., 44, 96<br />
Winborne, Courtland, 124<br />
Winkler, Amber, 141<br />
Wohlgemuth, William K., 131<br />
Wolak, Talya, 103<br />
Wolf, Philip A., 96<br />
Wong, Cindy J., 141<br />
Wong, C. J., 89<br />
Wong, Nathan D., 44, 154<br />
Wood, Adrian D., 137<br />
Wright, Richard F., 109<br />
Wymer, David, 100<br />
X<br />
Xavier, Ana C., 100<br />
Xing, Dongqi, 103, 118, 126, 144<br />
Y<br />
Yadao, Anthony, 139<br />
Yakovlev, Sergey A., 108<br />
Yamamoto‐Hanasaki, Hiroko, 121<br />
Yamashina, Akira, 130<br />
Yang, Qiong, 117<br />
Yang, Wenya, 101<br />
Yang, Yu, 47, 123<br />
Yang, Zhen, 128<br />
Yano, Yuichiro, 96, 102, 118<br />
Yan, Shi Du, 135<br />
Yatsyshyn, Natalya G., 97<br />
Yatsyshyn, Roman I., 97<br />
Yokota, Naoto, 114<br />
Yoon, Esther, 87<br />
Yoo, Sandra A., 90<br />
Young, Joseph D., 61<br />
Youn, Ho‐Joong, 88<br />
Younis, Firas, 100<br />
Yuan, Hong, 112<br />
Yu‐Isenberg, Kristina, 110<br />
Z<br />
Zacker, Christopher, 141<br />
Zager, Philip, 115<br />
Zajicek, Anne, 101<br />
Zamadio, Stacy, 142<br />
Zand, Martin S., 60, 154<br />
Zazulina, Antonina Y., 112<br />
Zeniodi, Maria‐Helen, 100<br />
Zhang, J., 140<br />
Zhang, Jack, 112, 139<br />
Zhang, Jie, 141<br />
Zhang, Shiling, 107<br />
Zhang, Wei, 103, 118<br />
Zhang, Yanrong, 47, 97<br />
Zhang, Yi, 112, 126, 128<br />
Zhang, Ying, 101<br />
Zhao, Yumin, 105, 130<br />
Zhong, Wei, 144<br />
Zhu, Haidong, 47<br />
Zoppi, Annalisa, 87, 88<br />
Zou, Guang Y., 141<br />
Zou, G. Y., 89<br />
180
Hilton New York Floor Plans<br />
Second Floor<br />
181
Hilton New York Floor Plans<br />
Thrid Floor<br />
182
Hilton New York Floor Plans<br />
Fourth Floor Concourse<br />
183
Notes<br />
184
Tekamlo (aliskiren and amlodipine) tablets<br />
Initial U.S. Approval: 2010<br />
BRIEF SUMMARY: Please see package insert for full prescribing information.<br />
WARNING: AVOID USE IN PREGNANCY<br />
When pregnancy is detected, discontinue Tekamlo as soon as possible. Drugs<br />
that act directly on the renin-angiotensin-aldosterone system can cause injury<br />
and even death to the developing fetus. [See Warnings and Precautions (5.1)<br />
and Use in Specific Populations (8.1)].<br />
1 INDICATIONS AND USAGE<br />
Tekamlo is indicated for the treatment <strong>of</strong> hypertension, alone or with other antihypertensive<br />
agents.<br />
Initial Therapy<br />
Use Tekamlo as initial therapy in patients who are likely to need multiple drugs<br />
to achieve their blood pressure goals.<br />
Base the choice <strong>of</strong> Tekamlo as initial therapy on an assessment <strong>of</strong> potential benefits<br />
and risks.<br />
Add-On Therapy<br />
Switch a patient whose blood pressure is not adequately controlled with aliskiren<br />
alone or amlodipine besylate (or another dihydropyridine calcium channel<br />
blocker) to combination therapy with Tekamlo.<br />
Replacement Therapy<br />
Tekamlo may be substituted for its titrated components.<br />
Patients with moderate or severe hypertension are at a relatively high risk for<br />
cardiovascular events (such as strokes, heart attacks, and heart failure), kidney<br />
failure, and vision problems, so prompt treatment is clinically relevant. Individualize<br />
the decision to use a combination as initial therapy by weighing factors<br />
such as baseline blood pressure, the target goal, and the incremental likelihood<br />
<strong>of</strong> achieving goal with a combination compared to monotherapy. Individual<br />
blood pressure goals may vary based upon the patient’s risk.<br />
Data from the high-dose multifactorial study [see Clinical Studies (14) in the full<br />
prescribing information] provide estimates <strong>of</strong> the probability <strong>of</strong> reaching a target<br />
blood pressure with Tekamlo compared to aliskiren or amlodipine monotherapy.<br />
The figures below provide estimates <strong>of</strong> the likelihood <strong>of</strong> achieving systolic or<br />
diastolic blood pressure control with Tekamlo 300 mg/10 mg, based upon baseline<br />
systolic or diastolic blood pressure. The curve <strong>of</strong> each treatment group was<br />
estimated by logistic regression modeling. The estimated likelihood at the right<br />
tail <strong>of</strong> each curve is less reliable because <strong>of</strong> a small number <strong>of</strong> subjects with<br />
high baseline blood pressures.<br />
Figure 1: Probability <strong>of</strong> Achieving Systolic Blood Pressure (SBP)
Figure 2: Probability <strong>of</strong> Achieving Diastolic Blood Pressure (DBP)
25% (systolic) and 27% (diastolic) [see Dosage and Administration (2) and<br />
Clinical Studies (14) in the full prescribing information].<br />
4 CONTRAINDICATIONS<br />
None.<br />
5 WARNINGS AND PRECAUTIONS<br />
5.1 Fetal/Neonatal Morbidity and Mortality<br />
The use <strong>of</strong> drugs that act directly on the renin-angiotensin-aldosterone system<br />
during pregnancy can cause fetal and neonatal morbidity and death. No animal<br />
studies were conducted with Tekamlo; however, decreased fetal birth weight was<br />
observed in animal studies with aliskiren and intrauterine deaths were observed<br />
in animal studies with amlodipine. Tekamlo can cause fetal harm when administered<br />
to a pregnant woman. When pregnancy is detected, discontinue Tekamlo as<br />
soon as possible. If Tekamlo is used during pregnancy, or if a patient becomes<br />
pregnant while taking this drug, apprise the patient <strong>of</strong> the potential hazard to the<br />
fetus [see Use in Specific Populations (8.1)].<br />
5.2 Head and Neck Angioedema<br />
Aliskiren<br />
Angioedema <strong>of</strong> the face, extremities, lips, tongue, glottis and/or larynx has been<br />
reported in patients treated with aliskiren and has necessitated hospitalization<br />
and intubation. This may occur at any time during treatment and has occurred<br />
in patients with and without a history <strong>of</strong> angioedema with ACE inhibitors or<br />
angiotensin receptor antagonists. If angioedema involves the throat, tongue,<br />
glottis or larynx, or if the patient has a history <strong>of</strong> upper respiratory surgery, airway<br />
obstruction may occur and be fatal. Patients who experience these effects,<br />
even without respiratory distress, require prolonged observation, since treatment<br />
with antihistamines and corticosteroids may not be sufficient to prevent<br />
respiratory involvement. Prompt administration <strong>of</strong> subcutaneous epinephrine<br />
solution 1:1000 (0.3 to 0.5 ml) and measures to ensure a patent airway may be<br />
necessary.<br />
Discontinue Tekamlo immediately in patients who develop angioedema and do<br />
not readminister.<br />
5.3 Hypotension<br />
An excessive fall in blood pressure (hypotension) was rarely seen (0.2%) in<br />
patients with uncomplicated hypertension treated with Tekamlo in controlled<br />
trials.<br />
In patients with an activated renin-angiotensin-aldosterone system, such as volumeand/or<br />
salt-depleted patients receiving high doses <strong>of</strong> diuretics, symptomatic<br />
hypotension may occur in patients receiving renin-angiotensin-aldosterone<br />
system (RAAS) blockers. Correct these conditions prior to administration <strong>of</strong><br />
Tekamlo, or start the treatment under close medical supervision.<br />
If an excessive fall in blood pressure occurs with Tekamlo, place the patient in<br />
the supine position and, if necessary, give an intravenous infusion <strong>of</strong> normal<br />
saline. A transient hypotensive response is not a contraindication to further<br />
treatment, which usually can be continued without difficulty once the blood<br />
pressure has stabilized.<br />
5.4 Risk <strong>of</strong> Myocardial Infarction or Increased Angina<br />
Rarely, initiation or change to the dose <strong>of</strong> a calcium channel blocker has resulted<br />
in the development <strong>of</strong> documented increased frequency, duration or severity<br />
<strong>of</strong> angina or acute myocardial infarction, particularly in patients with severe<br />
obstructive coronary artery disease. The mechanism <strong>of</strong> this effect has not been<br />
elucidated.<br />
5.5 Impaired Renal Function<br />
Tekamlo<br />
Clinical trials with Tekamlo in hypertension excluded patients with severe renal<br />
impairment.<br />
Aliskiren<br />
Clinical trials <strong>of</strong> aliskiren in hypertension excluded patients with severe renal<br />
dysfunction (creatinine 1.7 mg/dL for women and 2.0 mg/dL for men and/or<br />
estimated GFR
should be exercised when administering Tekamlo to patients with severe hepatic<br />
impairment.<br />
5.7 Patients with Congestive Heart Failure<br />
Amlodipine besylate<br />
Amlodipine (5-10 mg per day) has been studied in a placebo-controlled trial <strong>of</strong><br />
1153 patients with NYHA Class III or IV heart failure on stable doses <strong>of</strong> ACE<br />
inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean <strong>of</strong><br />
about 14 months. There was no overall adverse effect on survival or cardiac<br />
morbidity (as defined by life-threatening arrhythmia, acute myocardial infarction,<br />
or hospitalization for worsened heart failure). Amlodipine has been compared to<br />
placebo in four 8-12 week studies <strong>of</strong> patients with NYHA Class II/III heart failure,<br />
involving a total <strong>of</strong> 697 patients. In these studies, there was no evidence <strong>of</strong><br />
worsened heart failure based on measures <strong>of</strong> exercise tolerance, NYHA classification,<br />
symptoms, or left ventricular ejection fraction.<br />
5.8 Renal Artery Stenosis<br />
No data are available on the use <strong>of</strong> Tekamlo or aliskiren in patients with unilateral<br />
or bilateral renal artery stenosis or stenosis <strong>of</strong> the artery to a solitary kidney.<br />
However, in studies <strong>of</strong> ACE inhibitors in hypertensive patients with unilateral or<br />
bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen<br />
have been reported.<br />
5.9 Cyclosporine or Itraconazole<br />
Aliskiren<br />
When aliskiren was given with cyclosporine or itraconazole, the blood concentrations<br />
<strong>of</strong> aliskiren were significantly increased. Avoid concomitant use <strong>of</strong><br />
aliskiren with cyclosporine or itraconazole [see Drug Interactions (7)].<br />
6 ADVERSE REACTIONS<br />
6.1 Clinical Studies Experience<br />
The following serious adverse reactions are discussed in greater detail in other<br />
sections <strong>of</strong> the label:<br />
• Risk <strong>of</strong> fetal/neonatal morbidity and mortality [see Warnings and Precautions<br />
(5.1)]<br />
• Head and neck angioedema [see Warnings and Precautions (5.2)]<br />
• Hypotension [see Warnings and Precautions (5.3)]<br />
Because clinical trials are conducted under widely varying conditions, adverse<br />
reaction rates observed in the clinical trials <strong>of</strong> a drug cannot be directly compared<br />
to rates in clinical trials <strong>of</strong> another drug and may not reflect the rates<br />
observed in practice.<br />
Tekamlo<br />
Tekamlo has been evaluated for safety in more than 2800 patients, including 372<br />
patients for 1 year or longer.<br />
In a placebo-controlled study, there were 51% males, 62% Caucasians, 20%<br />
Blacks, 18% Hispanics, and 17% who were over 65 years <strong>of</strong> age. In this study,<br />
the overall incidence <strong>of</strong> adverse events on therapy with Tekamlo was similar to<br />
the individual components. Discontinuation <strong>of</strong> therapy due to a clinical adverse<br />
event in this study occurred in 1.7% <strong>of</strong> patients treated with Tekamlo (2.2% in<br />
the highest dose group) versus 1.5% <strong>of</strong> patients given placebo.<br />
Peripheral edema is a known, dose-dependent adverse effect <strong>of</strong> amlodipine. The<br />
incidence <strong>of</strong> peripheral edema for Tekamlo in short-term double-blind placebocontrolled<br />
studies was lower than or equal to that <strong>of</strong> the corresponding amlodipine<br />
doses.<br />
The adverse event in a placebo-controlled trial that occurred in at least 2% <strong>of</strong><br />
patients treated with Tekamlo and at a higher incidence than placebo was peripheral<br />
edema (6.2% versus 1.0%). The incidence rate <strong>of</strong> peripheral edema at high<br />
dose was 8.9%.<br />
In a long-term safety trial, the safety pr<strong>of</strong>ile <strong>of</strong> adverse events was similar to that<br />
seen in the short-term controlled trials.<br />
Aliskiren<br />
Aliskiren has been evaluated for safety in 6460 patients, including 1740 treated<br />
for longer than 6 months, and 1250 for longer than 1 year. In placebo-controlled<br />
clinical trials, discontinuation <strong>of</strong> therapy because <strong>of</strong> a clinical adverse event,<br />
including uncontrolled hypertension, occurred in 2.2% <strong>of</strong> patients treated with<br />
aliskiren versus 3.5% <strong>of</strong> patients given placebo.
Two cases <strong>of</strong> angioedema with respiratory symptoms were reported with<br />
aliskiren use in the clinical studies. Two other cases <strong>of</strong> periorbital edema without<br />
respiratory symptoms were reported as possible angioedema and resulted in<br />
discontinuation. The rate <strong>of</strong> these angioedema cases in the completed studies<br />
was 0.06%.<br />
In addition, 26 other cases <strong>of</strong> edema involving the face, hands, or whole body<br />
were reported with aliskiren use, including 4 leading to discontinuation.<br />
In the placebo-controlled studies, however, the incidence <strong>of</strong> edema involving the<br />
face, hands, or whole body was 0.4% with aliskiren compared with 0.5% with<br />
placebo. In a long-term active-controlled study with aliskiren and HCTZ arms,<br />
the incidence <strong>of</strong> edema involving the face, hands, or whole body was 0.4% in<br />
both treatment arms.<br />
Aliskiren produces dose-related gastrointestinal (GI) adverse reactions. Diarrhea<br />
was reported by 2.3% <strong>of</strong> patients at 300 mg, compared to 1.2% in placebo<br />
patients. In women and the elderly (age ≥65) increases in diarrhea rates were<br />
evident starting at a dose <strong>of</strong> 150 mg daily, with rates for these subgroups at<br />
150 mg similar to those seen at 300 mg for men or younger patients (all rates<br />
about 2%). Other GI symptoms included abdominal pain, dyspepsia, and gastro -<br />
esophageal reflux, although increased rates for abdominal pain and dyspepsia<br />
were distinguished from placebo only at 600 mg daily. Diarrhea and other<br />
GI symptoms were typically mild and rarely led to discontinuation.<br />
Aliskiren was associated with a slight increase in cough in the placebo-controlled<br />
studies (1.1% for any aliskiren use versus 0.6% for placebo). In active-controlled<br />
trials with ACE inhibitor (ramipril, lisinopril) arms, the rates <strong>of</strong> cough for the<br />
aliskiren arms were about one-third to one-half the rates in the ACE inhibitor arms.<br />
Other adverse reactions with increased rates for aliskiren compared to placebo<br />
included rash (1% versus 0.3%), elevated uric acid (0.4% versus 0.1%), gout<br />
(0.2% versus 0.1%), and renal stones (0.2% versus 0%).<br />
Single episodes <strong>of</strong> tonic-clonic seizures with loss <strong>of</strong> consciousness were<br />
reported in two patients treated with aliskiren in the clinical trials. One patient<br />
had predisposing causes for seizures and had a negative electroencephalogram<br />
(EEG) and cerebral imaging following the seizures; for the other patient, EEG and<br />
imaging results were not reported. Aliskiren was discontinued and there was no<br />
rechallenge in either case.<br />
No clinically meaningful changes in vital signs or in ECG (including QTc interval)<br />
were observed in patients treated with aliskiren.<br />
Amlodipine besylate<br />
Amlodipine (Norvasc ® ) has been evaluated for safety in more than 11,000<br />
patients in U.S. and foreign clinical trials. Other adverse events that have been<br />
reported 0.1% <strong>of</strong> patients in controlled clinical trials or under conditions<br />
<strong>of</strong> open trials or marketing experience where a causal relationship is<br />
uncertain were:<br />
Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation),<br />
brady cardia, chest pain, peripheral ischemia, syncope, postural hypo -<br />
tension, vasculitis<br />
Central and Peripheral Nervous System: neuropathy peripheral, paresthesia,<br />
tremor, vertigo<br />
Gastrointestinal: anorexia, constipation, dyspepsia,** dysphagia, diarrhea, flatulence,<br />
pancreatitis, vomiting, gingival hyperplasia<br />
General: allergic reaction, asthenia,** back pain, hot flushes, malaise, pain, rigors,<br />
weight gain, weight decrease<br />
Musculoskeletal System: arthralgia, arthrosis, muscle cramps,** myalgia<br />
Psychiatric: sexual dysfunction (male** and female), insomnia, nervousness,<br />
depression, abnormal dreams, anxiety, depersonalization<br />
Respiratory System: dyspnea, epistaxis<br />
Skin and Appendages: angioedema, erythema multiforme, pruritus,** rash,**<br />
rash erythem atous, rash maculopapular<br />
**These events occurred in less than 1% in placebo-controlled trials, but the<br />
incidence <strong>of</strong> these side effects was between 1% and 2% in all multiple dose studies.<br />
Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus<br />
Urinary System: micturition frequency, micturition disorder, nocturia
Autonomic Nervous System: dry mouth, sweating increased<br />
Metabolic and Nutritional: hyperglycemia, thirst<br />
Hemopoietic: leukopenia, purpura, thrombocytopenia<br />
Other events reported with amlodipine at a frequency <strong>of</strong> ≤0.1% <strong>of</strong> patients<br />
include: cardiac failure, pulse irregularity, extrasystoles, skin discoloration,<br />
urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia,<br />
hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis,<br />
increased appetite, loose stools, rhinitis, dysuria, polyuria, parosmia, taste<br />
perversion, abnormal visual accommodation, and xerophthalmia. Other reactions<br />
occurred sporadically and cannot be distinguished from medications or concurrent<br />
disease states such as myocardial infarction and angina.<br />
6.2 Clinical Laboratory Test Abnormalities<br />
RBC count, hemoglobin and hematocrit: Small mean changes from baseline<br />
were seen in RBC count, hemoglobin and hematocrit in patients treated with<br />
both Tekamlo and aliskiren monotherapy. This effect is also seen with other<br />
agents acting on the renin angiotensin system. In aliskiren monotherapy trials<br />
these decreases led to slight increases in rates <strong>of</strong> anemia compared to placebo<br />
(0.1% for any aliskiren use, 0.3% for aliskiren 600 mg daily, vs. 0% for<br />
placebo). No patients discontinued due to anemia.<br />
Blood Urea Nitrogen (BUN)/Creatinine: Elevations in BUN (>40 mg/dL) and creat -<br />
inine (>2.0 mg/dL) in patients treated with Tekamlo were 5.5 mEq/L were infrequent in<br />
patients with essential hypertension treated with both Tekamlo and aliskiren<br />
monotherapy (0.9% compared to 0.6% with placebo). However, when aliskiren<br />
was used in combination with an angiotensin-converting enzyme inhibitor (ACEI)<br />
in a diabetic population, increases in serum potassium were more frequent<br />
(5.5%). Monitor electrolytes and renal function in this population.<br />
6.3 Post-marketing Experience<br />
The following adverse reactions have been identified during postapproval use <strong>of</strong><br />
either aliskiren or amlodipine. Because these reactions are reported voluntarily<br />
from a population <strong>of</strong> uncertain size, it is not always possible to estimate their<br />
frequency or establish a causal relationship to drug exposure:<br />
Hypersensitivity: angioedema requiring airway management and hospitalization<br />
Aliskiren: Peripheral edema, blood creatinine increased<br />
Amlodipine: The following postmarketing event has been reported infrequently<br />
where a causal relationship is uncertain: gynecomastia. In postmarketing experience,<br />
jaundice and hepatic enzyme elevations (mostly consistent with cholestasis<br />
or hepatitis), in some cases severe enough to require hospitalization, have<br />
been reported in association with use <strong>of</strong> amlodipine.<br />
7 DRUG INTERACTIONS<br />
No drug interaction studies have been conducted with Tekamlo and other drugs,<br />
although studies with the individual aliskiren and amlodipine besylate components<br />
are described below.<br />
Aliskiren<br />
Cyclosporine: Avoid co-administration <strong>of</strong> cyclosporine with aliskiren.<br />
Itraconazole: Avoid co-administration <strong>of</strong> itraconazole with aliskiren.<br />
[See Clinical Pharmacology (12.3) in the full prescribing information.]<br />
Amlodipine besylate<br />
In clinical trials, amlodipine has been safely administered with thiazide diuretics,<br />
beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates,<br />
sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory<br />
drugs, antibiotics, and oral hypoglycemic drugs.<br />
Cimetidine: Co-administration <strong>of</strong> amlodipine with cimetidine did not alter the<br />
pharmacokinetics <strong>of</strong> amlodipine.<br />
Grapefruit juice: Co-administration <strong>of</strong> 240 mL <strong>of</strong> grapefruit juice with a single<br />
oral dose <strong>of</strong> amlodipine 10 mg in 20 healthy volunteers had no significant effect<br />
on the pharmacokinetics <strong>of</strong> amlodipine.<br />
Maalox ® (antacid): Co-administration <strong>of</strong> the antacid Maalox with a single dose <strong>of</strong><br />
amlodipine had no significant effect on the pharmacokinetics <strong>of</strong> amlodipine.<br />
Sildenafil: A single 100 mg dose <strong>of</strong> sildenafil in subjects with essential hyper -<br />
tension had no effect on the pharmacokinetic parameters <strong>of</strong> amlodipine. When
amlodipine and sildenafil were used in combination, each agent independently<br />
exerted its own blood pressure lowering effect.<br />
Atorvastatin: Co-administration <strong>of</strong> multiple 10 mg doses <strong>of</strong> amlodipine with 80 mg<br />
<strong>of</strong> atorvastatin resulted in no significant change in the steady-state pharmaco -<br />
kinetic param eters <strong>of</strong> atorvastatin.<br />
Digoxin: Co-administration <strong>of</strong> amlodipine with digoxin did not change serum<br />
digoxin levels or digoxin renal clearance in normal volunteers.<br />
Ethanol (alcohol): Single and multiple 10 mg doses <strong>of</strong> amlodipine had no significant<br />
effect on the pharmacokinetics <strong>of</strong> ethanol.<br />
Warfarin: Co-administration <strong>of</strong> amlodipine with warfarin did not change the<br />
warfarin prothrombin response time.<br />
8 USE IN SPECIFIC POPULATIONS<br />
8.1 Pregnancy<br />
Pregnancy Category D [See Warnings and Precautions Section]<br />
The use <strong>of</strong> drugs that act directly on the renin-angiotensin-aldosterone system<br />
during the second and third trimesters <strong>of</strong> pregnancy can cause fetal and neo -<br />
natal morbidity and death. In addition, first trimester use <strong>of</strong> ACE inhibitors has<br />
been associated with birth defects in retrospective data. No animal studies were<br />
conducted with Tekamlo; however, decreased fetal birth weight was observed in<br />
animal studies with aliskiren and intrauterine deaths were observed in animal<br />
studies with amlodipine. Tekamlo can cause fetal harm when administered to a<br />
pregnant woman. When pregnancy is detected, discontinue Tekamlo as soon as<br />
possible. If Tekamlo is used during pregnancy, or if the patient becomes pregnant<br />
while taking this drug, the patient should be apprised <strong>of</strong> the potential hazard<br />
to the fetus.<br />
Human Data and Clinical Considerations<br />
Maternal hypertension is associated with increased risks for preterm delivery,<br />
intrauterine growth restriction, placental abruption, preeclampsia, and perinatal<br />
mortality. Appropriate management <strong>of</strong> maternal hypertension during pregnancy<br />
is important to optimize outcomes for both mother and fetus. Renin inhibitors<br />
(like aliskiren), angiotensin II receptor antagonists and angiotensin converting<br />
enzyme (ACE) inhibitors exert similar effects on the renin-angiotensin-aldosterone<br />
system. Based on several dozen published cases, ACE inhibitor use during the<br />
second and third trimesters <strong>of</strong> pregnancy is associated with fetal and neonatal<br />
injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or<br />
irreversible renal failure, and death. Decreased fetal renal function may result in<br />
oligohydramnios and associated with fetal limb contractures, crani<strong>of</strong>acial deformation,<br />
and hypoplastic lung development. Prematurity, intrauterine growth<br />
retardation, and patent ductus arteriosus have been reported in women using<br />
these drugs, but it is not clear whether these occurrences were due to drug<br />
exposure. Limited data are conflicting about whether first trimester use <strong>of</strong> ACE<br />
inhibitors is associated with an increased risk <strong>of</strong> birth defects, but the drugs’<br />
mechanism <strong>of</strong> action raises a theoretical concern.<br />
When pregnancy occurs in a patient using Tekamlo, the physician should discontinue<br />
Tekamlo treatment as soon as possible. Inform the patient about potential<br />
risks to the fetus based on the time <strong>of</strong> gestational exposure to Tekamlo (first<br />
trimester only or later). If exposure occurs beyond the first trimester, perform an<br />
ultrasound examination.<br />
In rare cases when another antihypertensive agent cannot be used to treat the<br />
pregnant patient, serial ultrasound examinations should be used to assess the<br />
intraamniotic environment. Routine fetal testing with non-stress tests, biophysical<br />
pr<strong>of</strong>iles, and/or contraction stress tests may be appropriate based on gestational<br />
age and standards <strong>of</strong> care in the community. If oligohydramnios occurs in<br />
these situations, individualized decisions about continuing or discontinuing<br />
Tekamlo treatment and about pregnancy management should be made by the<br />
patient and her physicians. Patients and physicians should be aware that oligohydramnios<br />
may not appear until after the fetus has sustained irreversible injury.<br />
Infants exposed to Tekamlo in-utero should be closely observed for hypotension,<br />
oliguria, and hyperkalemia. If oliguria occurs, these infants may require blood<br />
pressure and renal perfusion support. Exchange transfusion or dialysis may be<br />
required to reverse hypotension and/or support decreased renal function.
Animal Data<br />
No reproductive toxicity studies have been conducted with the combination <strong>of</strong><br />
aliskiren and amlodipine besylate. However, these studies have been conducted<br />
for aliskiren and amlodipine besylate alone.<br />
Aliskiren<br />
In developmental toxicity studies, pregnant rats and rabbits received oral<br />
aliskiren hemifumarate during organogenesis at doses up to 20 and 7 times<br />
the maximum recommended human dose (MRHD) based on body surface<br />
area (mg/m 2 ), respectively, in rats and rabbits. (Actual animal doses were up<br />
to 600 mg/kg/day in rats and up to 100 mg/kg/day in rabbits.) No teratogenicity<br />
was observed; however, fetal birth weight was decreased in rabbits at<br />
doses 3.2 times the MRHD based on body surface area (mg/m 2 ). Aliskiren<br />
was present in placentas, amniotic fluid and fetuses <strong>of</strong> pregnant rabbits.<br />
Amlodipine<br />
In developmental toxicity studies, pregnant rats and rabbits received oral<br />
amlodipine maleate during organogenesis at doses approximately 10 and 20<br />
times the maximum recommended human dose (MRHD) based on body surface<br />
area (mg/m 2 ), respectively, in rats and rabbits. (Actual animal doses<br />
were up to 10 mg/kg/day.) No evidence <strong>of</strong> teratogenicity or other embryo fetal<br />
toxicity was observed. However, litter size was decreased approximately 50%<br />
and the num ber <strong>of</strong> intrauterine deaths was increased approximately 5-fold for<br />
rats receiving amlodipine maleate at doses approximately 10 times the MRHD<br />
based on body surface area (mg/m 2 ) for 14 days before mating and throughout<br />
mating and gestation. Amlodipine maleate has been shown to prolong<br />
both the gestation period and the duration <strong>of</strong> labor in rats at this dose.<br />
8.3 Nursing Mothers<br />
It is not known whether aliskiren or amlodipine is excreted in human milk.<br />
Both aliskiren and amlodipine are secreted in the milk <strong>of</strong> lactating rats.<br />
Because <strong>of</strong> the potential for serious adverse reactions in human milk-fed<br />
infants from Tekamlo, a decision should be made whether to discontinue<br />
nursing or discontinue Tekamlo, taking into account the importance <strong>of</strong> the<br />
drug to the mother.<br />
8.4 Pediatric Use<br />
Safety and effectiveness <strong>of</strong> Tekamlo in pediatric patients have not been<br />
established.<br />
8.5 Geriatric Use<br />
Tekamlo<br />
In the short-term controlled clinical trials <strong>of</strong> Tekamlo, 17% <strong>of</strong> patients treated<br />
with Tekamlo were ≥65 years. No overall differences in safety or effectiveness<br />
were observed between these subjects and younger subjects. Other reported<br />
clinical experience has not identified differences in responses between the<br />
elderly and younger patients, but greater sensitivity <strong>of</strong> some older individuals<br />
cannot be ruled out.<br />
Aliskiren<br />
Impact <strong>of</strong> aging on aliskiren pharmacokinetics has been assessed, when<br />
compared to young adults (18-40 years), aliskiren mean AUC and C max in<br />
elderly subjects (>65 years) are increased by 57% and 28%, respectively.<br />
However, differences in efficacy and safety between the elderly and younger<br />
populations were minor, indicating that differences in exposure due to age do<br />
not significantly alter the clinical effect <strong>of</strong> the drug. Therefore, no starting<br />
dose adjustment in geriatric population is required.<br />
Amlodipine<br />
Other reported clinical experience has not identified differences in responses<br />
between the elderly and younger patients. However, elderly patients have<br />
decreased clearance <strong>of</strong> amlodipine with a resulting increase <strong>of</strong> AUC <strong>of</strong> approx -<br />
imately 40-60%. In general dose selection for an elderly patient should be<br />
cautious, usually starting at the low end <strong>of</strong> the dosing range, reflecting the<br />
greater frequency <strong>of</strong> decreased hepatic, renal or cardiac function, and <strong>of</strong> concomitant<br />
disease or other drug therapy.<br />
10 OVERDOSAGE<br />
Aliskiren<br />
Limited data are available related to overdosage in humans. The most likely<br />
manifestation <strong>of</strong> overdosage would be hypotension. If symptomatic hypotension<br />
should occur, provide supportive treatment.
Amlodipine besylate<br />
Single oral doses <strong>of</strong> amlodipine maleate equivalent to 40 mg amlodipine/kg<br />
and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single<br />
oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg<br />
or higher in dogs (11 or more times the maximum recommended human<br />
dose on a mg/m 2 basis) caused a marked peripheral vasodilation and<br />
hypotension.<br />
Overdosage might be expected to cause excessive peripheral vasodilation<br />
with marked hypotension and possibly a reflex tachycardia. In humans,<br />
experience with intentional overdosage <strong>of</strong> amlodipine is limited. Reports <strong>of</strong><br />
intentional overdosage include a patient who ingested 250 mg and was<br />
asymptomatic and was not hospitalized; another (120 mg) was hospitalized,<br />
underwent gastric lavage and remained normotensive; the third (105 mg) was<br />
hospitalized and had hypotension (90/50 mmHg) which normalized following<br />
plasma expansion. A case <strong>of</strong> accidental drug overdose has been documented<br />
in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg).<br />
During the emergency room presentation, vital signs were stable with no evidence<br />
<strong>of</strong> hypotension, but a heart rate <strong>of</strong> 180 bpm. Ipecac was administered<br />
3.5 hours after ingestion and on subsequent observation (overnight) no<br />
sequelae were noted.<br />
If massive overdose should occur, active cardiac and respiratory monitoring<br />
should be instituted. Frequent blood pressure measurements are essential.<br />
Should hypotension occur, cardiovascular support including elevation <strong>of</strong> the<br />
extremities and the judicious administration <strong>of</strong> fluids should be initiated. If<br />
hypotension remains unresponsive to these conservative mea sures, administration<br />
<strong>of</strong> vasopressors (such as phenylephrine) should be considered with<br />
attention to circulating volume and urine output. Intravenous calcium gluco -<br />
nate may help to reverse the effects <strong>of</strong> calcium entry blockade. As amlodipine<br />
is highly protein bound, hemodialysis is not likely to be <strong>of</strong> benefit.<br />
Distributed by:<br />
Novartis Pharmaceuticals Corporation<br />
East Hanover, New Jersey 07936<br />
T<strong>2011</strong>-52<br />
March <strong>2011</strong><br />
©Novartis
Get to know TEKAMLO<br />
at booth 1100<br />
Ask our sales representative how to<br />
obtain pr<strong>of</strong>essional samples.*<br />
150/5 mg 300/5 mg 300/10 mg<br />
150/10 mg dose not shown.<br />
*Samples are not available at booth 1100.<br />
Please see brief summary <strong>of</strong> Prescribing Information,<br />
including Boxed WARNING, on adjacent pages.<br />
Tekamlo<br />
(aliskiren and amlodipine) tablets<br />
150/5mg • 150/10mg • 300/5mg • 300/10mg<br />
Novartis Pharmaceuticals Corporation<br />
East Hanover, New Jersey 07936-1080<br />
© <strong>2011</strong> Novartis Printed in USA 4/11 TKT-1053803